e10vk
UNITED STATES SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
Form 10-K
|
|
|
þ
|
|
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
|
|
|
FOR THE FISCAL YEAR ENDED
DECEMBER 31, 2008
|
|
|
OR
|
o
|
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
|
001-32410
(Commission File Number)
CELANESE CORPORATION
(Exact Name of Registrant as
Specified in its Charter)
|
|
|
Delaware
(State or Other Jurisdiction
of
Incorporation or Organization)
|
|
98-0420726
(I.R.S. Employer
Identification No.)
|
|
|
|
1601 West LBJ Freeway, Dallas, TX
(Address of Principal
Executive Offices)
|
|
75234-6034
(Zip
Code)
|
(972) 443-4000
(Registrants telephone
number, including area code)
Securities registered pursuant to Section 12(b) of the
Act
|
|
|
|
|
Name of Each Exchange
|
Title of Each Class
|
|
on Which Registered
|
|
Series A Common Stock, par value $0.0001 per share
|
|
New York Stock Exchange
|
4.25% Convertible Perpetual Preferred Stock, par value
$0.01 per share (liquidation preference $25.00
per share)
|
|
New York Stock Exchange
|
Securities registered pursuant to Section 12(g) of the
Act
None
Indicate by check mark if the registrant is a well-known
seasoned issuer, as defined in Rule 405 of the Securities
Act. Yes þ No o
Indicate by check mark if the registrant is not required to file
reports pursuant to Section 13 or Section 15(d) of the
Act. Yes o No þ
Indicate by check mark whether the registrant (1) has filed
all reports required to be filed by Section 13 or 15
(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has
been subject to such filing requirements for the past
90 days. Yes þ No o
Indicate by check mark if disclosure of delinquent filers
pursuant to Item 405 of
Regulation S-K
is not contained herein and will not be contained, to the best
of the Registrants knowledge, in definitive proxy or
information statements incorporated by reference in
Part III of this
Form 10-K
or any amendment to this
Form 10-K. o
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated
filer, or a smaller reporting company. See the definitions of
large accelerated filer, accelerated
filer and smaller reporting company in
Rule 12b-2 of the Exchange Act. (Check one):
|
|
|
|
|
|
|
Large accelerated
filer þ
|
|
Accelerated
filer o
|
|
Non-accelerated
filer o
|
|
Smaller reporting
company o
|
|
|
|
|
(Do not check if a smaller reporting company)
|
|
|
Indicate by check mark whether the registrant is a shell company
(as defined in
Rule 12-b2
of the
Act). Yes o No þ
The aggregate market value of the registrants common stock
held by non-affiliates as of June 30, 2008 (the last
business day of the registrants most recently completed
second fiscal quarter) was $6,927,608,530.
The number of outstanding shares of the registrants
Series A Common Stock, $0.0001 par value, as of
February 6, 2009 was 143,505,708.
DOCUMENTS
INCORPORATED BY REFERENCE
Certain portions of the registrants Definitive Proxy
Statement relating to the 2009 annual meeting of shareholders,
to be filed with the Securities and Exchange Commission, are
incorporated by reference into Part III.
CELANESE
CORPORATION
Form 10-K
For the
Fiscal Year Ended December 31, 2008
TABLE OF CONTENTS
2
Special
Note Regarding Forward-Looking Statements
Certain statements in this Annual Report are forward-looking in
nature as defined in the Private Securities Litigation Reform
Act of 1995. These statements, and other written and oral
forward-looking statements made by the Company from time to
time, may relate to, among other things, such matters as planned
and expected capacity increases and utilization; anticipated
capital spending; environmental matters; legal proceedings;
exposure to, and effects of hedging of, raw material and energy
costs and foreign currencies; global and regional economic,
political, and business conditions; expectations, strategies,
and plans for individual assets and products, segments, as well
as for the whole Company; cash requirements and uses of
available cash; financing plans; pension expenses and funding;
anticipated restructuring, divestiture, and consolidation
activities; cost reduction and control efforts and targets and
integration of acquired businesses. These plans and expectations
are based upon certain underlying assumptions, and are in turn
based upon internal estimates and analyses of current market
conditions and trends, management plans and strategies, economic
conditions, and other factors. Actual results could differ
materially from expectations expressed in the forward-looking
statements if one or more of the underlying assumptions and
expectations proves to be inaccurate or is unrealized. Certain
important factors that could cause actual results to differ
materially from those in the forward-looking statements are
included with such forward-looking statements and in
Managements Discussion and Analysis of Financial
Condition and Results of Operations Forward-Looking
Statements May Prove Inaccurate.
Basis of
Presentation
In this Annual Report on
Form 10-K,
the term Celanese refers to Celanese Corporation, a
Delaware corporation, and not its subsidiaries. The terms the
Company, we, our and
us refer to Celanese and its subsidiaries on a
consolidated basis. The term Celanese US refers to
our subsidiary, Celanese US Holdings LLC, a Delaware limited
liability company, formerly known as BCP Crystal US Holdings
Corp., a Delaware corporation, and not its subsidiaries. The
term Purchaser refers to our subsidiary, Celanese
Europe Holding GmbH & Co. KG, formerly known as BCP
Crystal Acquisition GmbH & Co. KG, a German limited
partnership, and not its subsidiaries, except where otherwise
indicated.
Overview
Celanese Corporation was formed in 2004 when affiliates of The
Blackstone Group purchased 84% of the ordinary shares of
Celanese GmbH, formerly known as Celanese AG, a diversified
German chemical company. Celanese Corporation was incorporated
in 2005 under the laws of the state of Delaware and its shares
are traded on the New York Stock Exchange under the symbol
CE. During the period from
2005-2007,
Celanese Corporation purchased the remaining 16% interest in
Celanese GmbH.
We are a leading global integrated producer of chemicals and
advanced materials. We are one of the worlds largest
producers of acetyl products, which are intermediate chemicals
for nearly all major industries, as well as a leading global
producer of high performance engineered polymers that are used
in a variety of high-value end-use applications. As an industry
leader, we hold geographically balanced global positions and
participate in diversified end-use markets. Our operations are
primarily located in North America, Europe and Asia. We combine
a demonstrated track record of execution, strong performance
built on our principles and objectives, and a clear focus on
growth and value creation.
Our large and diverse global customer base primarily consists of
major companies in a broad array of industries. For the year
ended December 31, 2008, approximately 28% of our net sales
were to customers located in North America, 43% to customers in
Europe and Africa, 26% to customers in Asia and Australia and 3%
to customers in South America. We have property, plant and
equipment in the United States of $732 million and outside
the United States of $1,739 million. For more information
regarding our property, plant and equipment, see Note 9 and
Note 25 to the consolidated financial statements.
Market
Industry
This Annual Report on
Form 10-K
includes industry data obtained from industry publications and
surveys as well as our own internal company surveys. Third-party
industry publications, surveys and forecasts generally state
that the information contained therein has been obtained from
sources believed to be reliable. The statements
3
regarding Celaneses market position in this document are
based on information derived from, among others, the 2008
Stanford Research Institute International Chemical Economics
Handbook, CMAI 2008 World Methanol Analysis, Tecnon
OrbiChem Acetic Acid and Vinyl Acetate World Survey third
quarter 2008 report and Synthetic Latex Polymer Reports from
Kline and Co.
Segment
Overview
We operate principally through four business segments: Advanced
Engineered Materials, Consumer Specialties, Industrial
Specialties and Acetyl Intermediates. For further details on our
business segments, see Note 25 to the consolidated
financial statements. The table below illustrates each
segments net sales to external customers for the year
ended December 31, 2008, as well as each segments
major products and end-use markets.
|
|
|
|
|
|
|
|
|
|
|
Advanced
|
|
|
|
|
|
|
|
|
Engineered Materials
|
|
Consumer Specialties
|
|
Industrial Specialties
|
|
Acetyl Intermediates
|
|
2008 Net
Sales(1)
|
|
$1,061 million
|
|
$1,155 million
|
|
$1,406 million
|
|
$3,199 million
|
|
|
|
|
|
|
|
|
|
Key Products
|
|
Polyacetal products (POM)
Ultra-high molecular weight polyethylene (GUR®)
Liquid crystal polymers (LCP)
Polyphenylene sulfide (PPS)
Polybutylene terephthalate (PBT)
Polyethylene terephthalate (PET)
Long fiber reinforced thermoplastics (LFRT)
|
|
Acetate tow
Acetate flake
Sunett® sweetener
Sorbates
|
|
Polyvinyl alcohol (PVOH)
Polyvinyl acetate
Conventional emulsions
Vinyl acetate ethylene emulsions
Low-density polyethylene resins (LDPE)
Ethylene vinyl acetate (EVA) resins and compounds
|
|
Acetic acid
Vinyl acetate monomer (VAM)
Acetic anhydride
Acetaldehyde
Ethyl acetate
Butyl acetate
Formaldehyde
|
|
|
|
|
|
|
|
|
|
Major End-Use Markets
|
|
Fuel system components
Conveyor belts
Battery separators
Electronics
Seat belt mechanisms
Other automotive
Appliances and electronics
Filtrations
Coatings
Medical Devices
Telecommunications
|
|
Filter products
Beverages
Confections
Baked goods
Pharmaceuticals
|
|
Paints
Coatings
Adhesives
Building products
Glass fibers
Textiles
Paper
Flexible packaging
Lamination products
Medical tubing
Automotive parts
|
|
Paints
Coatings
Adhesives
Lubricants
Detergents
Pharmaceuticals
Films
Textiles
Inks
Plasticizers
Esters
Solvents
|
|
|
|
(1) |
|
Consolidated net sales of $6,823 million for the year ended
December 31, 2008 also includes $2 million in net
sales from Other Activities, which is attributable to our
captive insurance companies. Acetyl Intermediates net
sales exclude inter-segment sales of $676 million for the
year ended December 31, 2008. |
Advanced
Engineered Materials
Our Advanced Engineered Materials segment develops, produces and
supplies a broad portfolio of high performance technical
polymers for application in automotive and electronics products,
as well as other consumer and industrial applications. Together
with our strategic affiliates, we are a leading participant in
the global technical polymers industry. The primary products of
Advanced Engineered Materials are POM, PPS, LFRT, PBT, PET,
GUR®
and LCP. POM, PPS, LFRT, PBT and PET are used in a broad range
of products including automotive components, electronics,
appliances and industrial applications.
GUR®
is used in battery separators, conveyor belts, filtration
equipment, coatings and medical devices. Primary end markets for
LCP are electrical and electronics.
4
Consumer
Specialties
Our Consumer Specialties segment consists of our Acetate
Products and Nutrinova businesses. Our Acetate Products business
primarily produces and supplies acetate tow, which is used in
the production of filter products. We also produce acetate flake
which is processed into acetate fiber in the form of a tow band.
Our Nutrinova business produces and sells
Sunett®,
a high intensity sweetener, and food protection ingredients,
such as sorbates, for the food, beverage and pharmaceuticals
industries.
Industrial
Specialties
Our Industrial Specialties segment includes our Emulsions, PVOH
and AT Plastics businesses. Our Emulsions business is a global
leader which produces a broad product portfolio, specializing in
vinyl acetate ethylene emulsions, and is a recognized authority
on low VOC (volatile organic compounds), an
environmentally-friendly technology. As a global leader, our
PVOH business produces a broad portfolio of performance PVOH
chemicals engineered to meet specific customer requirements. Our
emulsions and PVOH products are used in a wide array of
applications including paints and coatings, adhesives, building
and construction, glass fiber, textiles and paper. AT Plastics
offers a complete line of low-density polyethylene and specialty
ethylene vinyl acetate resins and compounds. AT Plastics
products are used in many applications including flexible
packaging films, lamination film products, hot melt adhesives,
medical tubing, automotive carpeting and solar cell
encapsulation films.
Acetyl
Intermediates
Our Acetyl Intermediates segment produces and supplies acetyl
products, including acetic acid, VAM, acetic anhydride and
acetate esters. These products are generally used as starting
materials for colorants, paints, adhesives, coatings, medicines
and more. Other chemicals produced in this segment are organic
solvents and intermediates for pharmaceutical, agricultural and
chemical products.
Competitive
Strengths
We benefit from a number of competitive strengths, including the
following:
Leading
Market Positions
We believe that we are a leading global integrated producer of
acetyl, acetate and vinyl emulsion products. Advanced Engineered
Materials and our strategic affiliates, Polyplastics Co., Ltd.
(Polyplastics) and Korea Engineering Plastics Co.,
Ltd. (KEPCO), are leading producers and suppliers of
engineered polymers in North America, Europe and the
Asia/Pacific region. Our leadership positions are based on our
large share of global production capacity, operating
efficiencies, proprietary technology and competitive cost
structures in our major product lines.
Proprietary
Production Technology and Operating Expertise
Our production of acetyl products employs industry-leading
proprietary and licensed technologies, including our proprietary
AOPlustm
technology for the production of acetic acid and
VAntagetm
and VAntage
Plustm
vinyl acetate monomer technology.
AOPlustm
enables increased raw material efficiencies, lower operating
costs and the ability to expand plant capacity with minimal
investment.
VAntagetm
and VAntage
Plustm
enable significant increases in production efficiencies, lower
operating costs and increases in capacity at ten to fifteen
percent of the cost of building a new plant.
Low
Cost Producer
Our competitive cost structures are based on production and
purchasing economies of scale, vertical integration, technical
expertise and the use of advanced technologies.
Global
Reach
We operate thirty-two production facilities throughout the
world. We participate in strategic alliances which operate nine
additional facilities. Our infrastructure of manufacturing
plants, terminals, warehouses and sales offices provides us with
a competitive advantage in anticipating and meeting the needs of
our global and local customers in well-established and growing
markets, while our geographic diversity reduces the potential
impact of
5
volatility in any individual country or region. We have a
strong, growing presence in Asia, particularly in China, and we
have a defined strategy to continue this growth. For more
information regarding our financial information with respect to
our geographic areas, see Note 25 to the consolidated
financial statements.
Growth
We aggressively align with our customers and their markets to
capture growth. We are quickly expanding in Asia, the
fastest-growing region in the world, in order to meet increasing
demand for our products. As part of our strategy, we also
continue to develop new products and industry-leading production
technologies that deliver value-added solutions for our
customers.
Strategic
Investments
Our strategic investments have enabled us to gain access,
minimize costs and accelerate growth in new markets, while also
generating significant cash flow and earnings. Our equity
investments and cost investments represent an important
component of our growth strategy. See Note 8 to the
consolidated financial statements and the
Investments subheading of Item 1 for additional
information on our equity and cost investments.
Diversified
Products and End-Use Markets
We offer our customers a broad range of products in a wide
variety of end-use markets. Our diversified product lines
include paints and coatings, textiles, automotive applications,
consumer and medical applications, performance industrial
applications, filter media, paper and packaging, chemical
additives, construction, consumer and industrial adhesives, and
food and beverage applications. This product and market
diversity reduces the potential impact of volatility in any
individual market segment.
Business
Strategies
Our strategic foundation is based on the following four pillars
which are focused on increasing operating cash flows, improving
profitability, delivering high return on investments and
increasing shareholder value:
Focus
We focus on businesses where we have a sustainable and proven
competitive advantage. We continue to optimize our business
portfolio in order to achieve market, cost and technology
leadership while expanding our product mix into higher
value-added products.
Investment
We leverage and build on advantaged positions that optimize our
portfolio of products. In order to increase our competitive
advantage, we have invested in our core group of businesses
through acquisitions; growth in Asia bolstered by our integrated
chemical complex in Nanjing, China; and new applications of our
advanced engineered polymers products.
Redeployment
We divest non-core assets and revitalize underperforming
businesses. We have divested or exited businesses where we no
longer maintain a competitive advantage. We also continue to
make key strategic decisions to revitalize businesses that have
significant potential for improved performance and enhanced
efficiency.
Underlying all of these strategies is a culture of execution and
productivity. We continually seek ways to reduce costs, increase
productivity and improve process technology. Our commitment to
operational excellence is an integral part of our strategy to
maintain our cost advantage and productivity leadership.
Business
Segments
Advanced
Engineered Materials
Our Advanced Engineered Materials segment develops, produces and
supplies a broad portfolio of high-performance technical
polymers.
6
Advanced Engineered Materials technical polymers have
chemical and physical properties enabling them, among other
things, to withstand extreme temperatures, resist chemical
reactions with solvents and withstand fracturing or stretching.
These products are used in a wide range of performance-demanding
applications in the automotive and electronics sectors as well
as in other consumer and industrial goods.
Advanced Engineered Materials works in concert with its
customers to enable innovations and develop new or enhanced
products. Advanced Engineered Materials focuses its efforts on
developing new markets and applications for its product lines,
often developing custom formulations to satisfy the technical
and processing requirements of a customers applications.
For example, Advanced Engineered Materials has collaborated with
fuel system suppliers to develop an acetal copolymer with the
chemical and impact resistance necessary to withstand exposure
to hot diesel fuels in the new generation of common rail diesel
engines. The product can also be used in automotive fuel sender
units where it remains stable at the high operating temperatures
present in direct-injection diesel engines and can meet the
requirements of the new generation of bio fuels.
Advanced Engineered Materials customer base consists
primarily of a large number of plastic molders and component
suppliers, which typically supply original equipment
manufacturers (OEMs). Advanced Engineered Materials
works with these molders and component suppliers as well as
directly with the OEMs to develop and improve specialized
applications and systems.
Prices for most of these products, particularly specialized
product grades for targeted applications, generally reflect the
value added in complex polymer chemistry, precision formulation
and compounding, and the extensive application development
services provided. These specialized product lines are not
typically susceptible to cyclical swings in pricing.
Key
Products
POM is sold under the trademark
Hostaform®
in all regions but North America, where it is sold under the
trademark
Celcon®.
Polyplastics and KEPCO are leading suppliers of POM and other
engineering resins in the Asia/Pacific region. POM is used for
mechanical parts, including door locks and seat belt mechanisms,
in automotive applications and in electrical, consumer and
medical applications such as drug delivery systems and gears for
large appliances.
The primary raw material for POM is formaldehyde, which is
manufactured from methanol. Advanced Engineered Materials
currently purchases formaldehyde in the United States from our
Acetyl Intermediates segment and, in Europe, manufactures
formaldehyde from purchased methanol.
GUR®
is an engineered material used in heavy-duty automotive and
industrial applications such as car battery separator panels and
industrial conveyor belts, as well as in specialty medical and
consumer applications, such as sports equipment and prostheses.
GUR®
micro powder grades are used for high-performance filters,
membranes, diagnostic devices, coatings and additives for
thermoplastics and elastomers.
GUR®
fibers are also used in protective ballistic applications.
Celstran®
and
Compel®
are long fiber reinforced thermoplastics, which impart extra
strength and stiffness, making them more suitable for larger
parts than conventional thermoplastics and are used in
automotive, transportation and industrial applications.
Polyesters such as
Celanex®
PBT,
Celanex®
PET,
Vandar®,
a series of PBT-polyester blends and
Riteflex®,
a thermoplastic polyester elastomer, are used in a wide variety
of automotive, electrical and consumer applications, including
ignition system parts, radiator grilles, electrical switches,
appliance and sensor housings, light emitting diodes
(LEDs) and technical fibers. Raw materials for
polyesters vary. Base monomers, such as dimethyl terephthalate
and purified terephthalic acid (PTA), are widely
available with pricing dependent on broader polyester fiber and
packaging resins market conditions. Smaller volume specialty
co-monomers for these products are typically supplied by a
limited number of companies.
Liquid crystal polymers, such as
Vectra®,
are used in electrical and electronics applications and for
precision parts with thin walls and complex shapes or on
high-heat cookware applications.
7
Fortron®,
a PPS product, is used in a wide variety of automotive and other
applications, especially those requiring heat
and/or
chemical resistance, including fuel system parts, radiator pipes
and halogen lamp housings, often replacing metal. Other possible
application fields include non-woven filtration devices such as
coal fired power plants.
Fortron®
is manufactured by Fortron Industries LLC, Advanced Engineered
Materials 50% owned strategic venture with Kureha
Corporation of Japan.
Facilities
Advanced Engineered Materials has polymerization, compounding
and research and technology centers in Germany, Brazil, China
and the United States.
Markets
The following table illustrates the destination of the net sales
of the Advanced Engineered Materials segment by geographic
region for the years ended December 31, 2008, 2007 and 2006.
Net Sales
to External Customers by Destination Advanced
Engineered Materials
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
|
|
|
|
% of
|
|
|
|
|
|
% of
|
|
|
|
|
|
% of
|
|
|
|
$
|
|
|
Segment
|
|
|
$
|
|
|
Segment
|
|
|
$
|
|
|
Segment
|
|
|
|
(In millions, except percentages)
|
|
|
North America
|
|
|
365
|
|
|
|
34
|
%
|
|
|
388
|
|
|
|
38
|
%
|
|
|
311
|
|
|
|
34
|
%
|
Europe/Africa
|
|
|
553
|
|
|
|
52
|
%
|
|
|
517
|
|
|
|
50
|
%
|
|
|
500
|
|
|
|
55
|
%
|
Asia/Australia
|
|
|
106
|
|
|
|
10
|
%
|
|
|
88
|
|
|
|
8
|
%
|
|
|
55
|
|
|
|
6
|
%
|
South America
|
|
|
37
|
|
|
|
4
|
%
|
|
|
37
|
|
|
|
4
|
%
|
|
|
49
|
|
|
|
5
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
1,061
|
|
|
|
|
|
|
|
1,030
|
|
|
|
|
|
|
|
915
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Advanced Engineered Materials sales in the Asian market
are made directly and through its strategic affiliates.
Polyplastics, KEPCO and Fortron Industries are accounted for
under the equity method and therefore not included in Advanced
Engineered Materials consolidated net sales. If Advanced
Engineered Materials portion of the sales made by these
strategic affiliates were included in the table above, the
percentage of sales sold in Asia/Australia would be
substantially higher. A number of Advanced Engineered
Materials POM customers, particularly in the appliance,
electrical components and certain sections of the
electronics/telecommunications fields, have moved tooling and
molding operations to Asia, particularly southern China. In
addition to our Advanced Engineered Materials affiliates, we
directly service Asian demand offering our customers global
solutions.
Advanced Engineered Materials principal customers are
consumer product manufacturers and suppliers to the automotive
industry. These customers primarily produce engineered products,
and Advanced Engineered Materials collaborates with its
customers to assist in developing and improving specialized
applications and systems. Advanced Engineered Materials has
long-standing relationships with most of its major customers,
but also uses distributors for its major products, as well as a
number of electronic marketplaces to reach a larger customer
base. For most of Advanced Engineered Materials product
lines, contracts with customers typically have a term of one to
two years.
Competition
Advanced Engineered Materials principal competitors
include BASF AG (BASF), E. I. DuPont de Nemours and
Company (DuPont), DSM N.V., Sabic Innovative
Plastics and Solvay S.A. Smaller regional competitors include
Asahi Kasei Corporation, Mitsubishi Gas Chemicals, Inc., Chevron
Phillips Chemical Company, L.P., Braskem S.A., Lanxess AG,
Teijin, Sumitomo, Inc. and Toray Industries Inc.
Consumer
Specialties
The Consumer Specialties segment consists of our Acetate
Products and Nutrinova businesses. Our Acetate Products business
primarily produces and supplies acetate tow, which is used in
the production of filter products. We
8
also produce acetate flake which is processed into acetate fiber
in the form of a tow band. Our Nutrinova business produces and
sells
Sunett®,
a high intensity sweetener, and food protection ingredients,
such as sorbates, for the food, beverage and pharmaceutical
industries.
Key
Products
Acetate tow is used primarily in cigarette filters. We produce
acetate flake by processing wood pulp with acetic anhydride. We
purchase wood pulp that is made from reforested trees from major
suppliers and produce acetic anhydride internally. The acetate
flake is then further processed into acetate fiber in the form
of a tow band. According to the 2008 Stanford Research Institute
International Chemical Economics Handbook, we are the
worlds leading producer of acetate tow, including
production of our China ventures.
Sales of acetate tow amounted to approximately 12%, 11% and 9%
of our consolidated net sales for the years ended
December 31, 2008, 2007 and 2006, respectively.
We have an approximate 30% interest in three manufacturing China
ventures, which are accounted for as cost method investments
(Note 8) that produce acetate flake and tow. Our partner in
each of the ventures is the Chinese
state-owned
tobacco entity, China National Tobacco Corporation. In addition,
approximately 10% of our 2008 acetate tow sales were sold
directly to China, the largest single market for acetate tow in
the world.
Acesulfame potassium, a high intensity sweetener marketed under
the trademark
Sunett®,
is used in a variety of beverages, confections and dairy
products throughout the world.
Sunett®
pricing for targeted applications reflects the value added by
Nutrinova, through consistent product quality and reliable
supply. Nutrinovas strategy is to be the most reliable and
highest quality producer of this product, to develop new product
applications and expand into new markets.
Nutrinovas food ingredients business consists of the
production and sale of food protection ingredients, such as
sorbic acid and sorbates, and high intensity sweeteners
worldwide. Nutrinovas food protection ingredients are
mainly used in foods, beverages and personal care products. The
primary raw materials for these products are ketene and
crotonaldehyde. Sorbates pricing is extremely sensitive to
demand and industry capacity and is not necessarily dependent on
the prices of raw materials.
Facilities
Acetate Products has production sites in the United States,
Mexico, the United Kingdom and Belgium, and participates in
three manufacturing ventures in China.
Nutrinova has production facilities in Germany, as well as sales
and distribution facilities in all major world markets.
Markets
The following table illustrates the destination of the net sales
of the Consumer Specialties segment by geographic region for the
years ended December 31, 2008, 2007 and 2006.
Net Sales
to External Customers by Destination Consumer
Specialties
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
|
|
|
|
% of
|
|
|
|
|
|
% of
|
|
|
|
|
|
% of
|
|
|
|
$
|
|
|
Segment
|
|
|
$
|
|
|
Segment
|
|
|
$
|
|
|
Segment
|
|
|
|
(In millions, except percentages)
|
|
|
North America
|
|
|
194
|
|
|
|
17
|
%
|
|
|
201
|
|
|
|
18
|
%
|
|
|
204
|
|
|
|
23
|
%
|
Europe/Africa
|
|
|
497
|
|
|
|
43
|
%
|
|
|
427
|
|
|
|
39
|
%
|
|
|
248
|
|
|
|
28
|
%
|
Asia/Australia
|
|
|
413
|
|
|
|
36
|
%
|
|
|
437
|
|
|
|
39
|
%
|
|
|
395
|
|
|
|
45
|
%
|
South America
|
|
|
51
|
|
|
|
4
|
%
|
|
|
46
|
|
|
|
4
|
%
|
|
|
29
|
|
|
|
4
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
1,155
|
|
|
|
|
|
|
|
1,111
|
|
|
|
|
|
|
|
876
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9
Sales of acetate tow are principally to the major tobacco
companies that account for a majority of worldwide cigarette
production. Our contracts with most of our customers are entered
into on an annual basis.
Nutrinova primarily markets
Sunett®
to a limited number of large multinational and regional
customers in the beverage and food industry under long-term and
annual contracts. Nutrinova markets food protection ingredients
primarily through regional distributors to small and medium
sized customers and directly through regional sales offices to
large multinational customers in the food industry.
Competition
Acetate Products principal competitors include Daicel
Chemical Industries Ltd. (Daicel), Eastman Chemical
Corporation (Eastman) and Rhodia S.A.
The principal competitors for Nutrinovas
Sunett®
sweetener are Holland Sweetener Company, The NutraSweet Company,
Ajinomoto Co., Inc., Tate & Lyle PLC and several
Chinese manufacturers. In sorbates, Nutrinova competes with
Nantong AA, Daicel, Yu Yao/Ningbo, Yancheng AmeriPac and other
Chinese manufacturers of sorbates.
Industrial
Specialties
Our Industrial Specialties segment includes our Emulsions, PVOH
and AT Plastics businesses. Our Emulsions business is a global
leader which produces a broad product portfolio, specializing in
vinyl acetate ethylene emulsions and is a recognized authority
on low VOC, an environmentally-friendly technology. As a global
leader, our PVOH business produces and sells a broad portfolio
of performance PVOH chemicals engineered to meet specific
customer requirements. AT Plastics offers a complete line of
low-density polyethylene and specialty, ethylene vinyl acetate
resins and compounds.
Key
Products
The products in our Emulsions business include conventional
vinyl and acrylate based emulsions and high-pressure vinyl
acetate ethylene emulsions. Emulsions are made from VAM,
acrylate esters and styrene. Our Emulsions business is a leading
producer of polyvinyl acetate and vinyl acetate ethylene
emulsions in Europe. These products are a key component of
water-based architectural coatings, adhesives, non-wovens,
textiles, glass fiber and other applications.
Sales from the Emulsions business amounted to approximately 13%,
14% and 14% of our consolidated net sales for the years ended
December 31, 2008, 2007 and 2006, respectively.
PVOH is used in adhesives, building products, paper coatings,
films and textiles. The primary raw material to produce PVOH is
VAM, while acetic acid is produced as a by-product. Products are
sold on a global basis and prices vary depending on industry
segment and end-use application. According to industry sources
on PVOH, we are the largest North American producer of PVOH and
the third largest producer in the world.
AT Plastics produces low-density polyethylene and EVA resins and
compounds that are used in the manufacture of hot melt
adhesives, automotive carpeting, lamination film products,
flexible packaging films, medical tubing and solar cell
encapsulation films. EVA resins and compounds are produced in
high-pressure reactors from ethylene and VAM.
Facilities
Emulsions has production sites in the United States, Canada,
China, Spain, Sweden, the Netherlands and Germany. PVOH has
production sites in the United States and Spain along with sales
and distribution facilities in Europe, Asia and South America.
During 2008, we shut down our Slovenia and United Kingdom
facilities. AT Plastics has a production facility in Edmonton,
Alberta, Canada.
10
Markets
The following table illustrates the destination of the net sales
of the Industrial Specialties segment by geographic region for
years ended December 31, 2008, 2007 and 2006.
Net Sales
to External Customers by Destination Industrial
Specialties
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
|
|
|
|
% of
|
|
|
|
|
|
% of
|
|
|
|
|
|
% of
|
|
|
|
$
|
|
|
Segment
|
|
|
$
|
|
|
Segment
|
|
|
$-
|
|
|
Segment
|
|
|
|
(In millions, except percentages)
|
|
|
North America
|
|
|
617
|
|
|
|
44
|
%
|
|
|
583
|
|
|
|
43
|
%
|
|
|
605
|
|
|
|
47
|
%
|
Europe/Africa
|
|
|
684
|
|
|
|
48
|
%
|
|
|
674
|
|
|
|
50
|
%
|
|
|
601
|
|
|
|
47
|
%
|
Asia/Australia
|
|
|
81
|
|
|
|
6
|
%
|
|
|
69
|
|
|
|
5
|
%
|
|
|
58
|
|
|
|
5
|
%
|
South America
|
|
|
24
|
|
|
|
2
|
%
|
|
|
20
|
|
|
|
2
|
%
|
|
|
17
|
|
|
|
1
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
1,406
|
|
|
|
|
|
|
|
1,346
|
|
|
|
|
|
|
|
1,281
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Industrial Specialties products are sold to a diverse
group of regional and multinational customers. Customers for
emulsions are manufacturers of water-based paints and coatings,
adhesives, paper, building and construction products, glass
fiber, non-wovens and textiles. The customers of the PVOH
business, who purchase mainly under multi-year contracts, are
primarily engaged in the production of adhesives, paper, films,
building products and textiles. Customers of AT Plastics are
primarily engaged in the manufacture of adhesives, automotive
components, packaging materials, print media and solar energy
products.
Competition
Principal competitors in the Emulsions business include The Dow
Chemical Company (Dow), Rohm & Haas
Company, BASF, Dairen, Wacker and several smaller regional
manufacturers.
Principal competitors in the PVOH business include Kuraray Co.,
Ltd., DuPont, Chang Chun Petrochemical Co., Ltd., The Nippon
Synthetic Chemical Industry Co., Ltd. and several Chinese
manufacturers.
Principal competitors for the AT Plastics EVA resins and
compounds business include DuPont, ExxonMobil Chemical, Arkema
and several Asian manufacturers.
Acetyl
Intermediates
Our Acetyl Intermediates segment produces and supplies acetyl
products, including acetic acid, VAM, acetic anhydride and
acetate esters. Other chemicals produced in this segment are
organic solvents and intermediates for pharmaceutical,
agricultural and chemical products.
Key
Products
Acetyls. Acetyls products include acetic acid,
VAM, acetic anhydride and acetaldehyde. Acetic acid is primarily
used to manufacture VAM, PTA and other acetyl derivatives. VAM
is used in a variety of adhesives, paints, films, coatings and
textiles. Acetic anhydride is a raw material used in the
production of cellulose acetate, detergents and pharmaceuticals.
Acetaldehyde is a major feedstock for the production of polyols.
Acetaldehyde is also used in other organic compounds such as
pyridines, which are used in agricultural products. We
manufacture acetic acid, VAM and acetic anhydride for our own
use, as well as for sale to third parties.
Acetic acid and VAM, our basic acetyl intermediates products,
are impacted by global supply/demand fundamentals and are
cyclical in nature. The principal raw materials in these
products are ethylene, which we purchase from numerous sources;
carbon monoxide, which we purchase under long-term contracts;
and methanol, which we purchase under long-term and short-term
contracts. With the exception of carbon monoxide, these raw
materials are commodity products available from a wide variety
of sources.
11
Our production of acetyl products employs leading proprietary
and licensed technologies, including our proprietary
AOPlustm
technology for the production of acetic acid and
VAntagetm
and VAntage
Plustm
vinyl acetate monomer technology.
Solvents and Derivatives. Solvents and
derivatives products include a variety of solvents, formaldehyde
and other chemicals, which in turn are used in the manufacture
of paints, coatings, adhesives and other products.
Many solvents and derivatives products are derived from our
production of acetic acid. Primary products are:
|
|
|
|
|
Ethyl acetate, an acetate ester that is a solvent used in
coatings, inks and adhesives and in the manufacture of
photographic films and coated papers; and
|
|
|
|
Butyl acetate, an acetate ester that is a solvent used in inks,
pharmaceuticals and perfume.
|
Formaldehyde and formaldehyde derivative products are
derivatives of methanol and are made up of the following
products:
|
|
|
|
|
Formaldehyde, paraformaldehyde and formcels are primarily used
to produce adhesive resins for plywood, particle board,
coatings, POM engineering resins and a compound used in making
polyurethane;
|
|
|
|
Amines such as methyl amines, monisopropynol amines and butyl
amines are used in agrochemicals, herbicides and the treatment
of rubber and water; and
|
|
|
|
Special solvents, such as crotonaldehyde, which are used by the
Nutrinova business line for the production of sorbates, as well
as raw materials for the fragrance and food ingredients industry.
|
Solvents and derivatives are commodity products characterized by
cyclicality in pricing. The principal raw materials used in
solvents and derivatives products are acetic acid, various
alcohols, methanol, ethylene and ammonia. We manufacture many of
these raw materials for our own use as well as for sales to
third parties, including our competitors in the solvents and
derivatives business. We purchase ethylene from a variety of
sources. We manufacture acetaldehyde in Europe for our own use,
as well as for sale to third parties.
Sales from acetyl products amounted to approximately 35%, 34%
and 33% of our consolidated net sales for the years ended
December 31, 2008, 2007 and 2006, respectively. Sales from
solvents and derivatives products amounted to approximately 12%,
12% and 13% of our consolidated net sales for the years ended
December 31, 2008, 2007 and 2006, respectively.
Facilities
Acetyl Intermediates has production sites in the United States,
China, Mexico, Singapore, Spain, France and Germany. We also
participate in a strategic venture in Saudi Arabia that produces
methanol and methyl tertiary-butyl ether (MTBE).
Over the last few years, we have continued to shift our
production capacity to lower cost production facilities while
expanding in growth markets, such as China.
12
Markets
The following table illustrates net sales by destination of the
Acetyl Intermediates segment by geographic region for the years
ended December 31, 2008, 2007 and 2006.
Net Sales
to External Customers by Destination Acetyl
Intermediates
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
|
|
|
|
% of
|
|
|
|
|
|
% of
|
|
|
|
|
|
% of
|
|
|
|
$
|
|
|
Segment
|
|
|
$
|
|
|
Segment
|
|
|
$
|
|
|
Segment
|
|
|
|
(In millions, except percentages)
|
|
|
North America
|
|
|
743
|
|
|
|
23
|
%
|
|
|
685
|
|
|
|
23
|
%
|
|
|
685
|
|
|
|
26
|
%
|
Europe/Africa
|
|
|
1,198
|
|
|
|
37
|
%
|
|
|
1,183
|
|
|
|
40
|
%
|
|
|
1,075
|
|
|
|
40
|
%
|
Asia/Australia
|
|
|
1,142
|
|
|
|
36
|
%
|
|
|
968
|
|
|
|
33
|
%
|
|
|
814
|
|
|
|
30
|
%
|
South America
|
|
|
116
|
|
|
|
4
|
%
|
|
|
119
|
|
|
|
4
|
%
|
|
|
110
|
|
|
|
4
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total(1)
|
|
|
3,199
|
|
|
|
|
|
|
|
2,955
|
|
|
|
|
|
|
|
2,684
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Excludes inter-segment sales of $676 million, $660 million and
$667 million for the years ended December 31, 2008, 2007
and 2006, respectively. |
Acetyl Intermediates markets its products both directly to
customers and through distributors.
Acetic acid, VAM and acetic anhydride are global businesses
which have several large customers. Generally, we supply these
global customers under multi-year contracts. The customers of
acetic acid, VAM and acetic anhydride produce polymers used in
water-based paints, adhesives, paper coatings, polyesters, film
modifiers, pharmaceuticals, cellulose acetate and textiles. We
have long-standing relationships with most of these customers.
Solvents and derivatives are sold to a diverse group of regional
and multinational customers both under multi-year contracts and
on the basis of long-standing relationships. The customers of
solvents and derivatives are primarily engaged in the production
of paints, coatings and adhesives. We manufacture formaldehyde
for our own use as well as for sale to a few regional customers
that include manufacturers in the wood products and chemical
derivatives industries. The sale of formaldehyde is based on
both long and short-term agreements. Specialty solvents and
amines are sold globally to a wide variety of customers,
primarily in the coatings and resins and the specialty products
industries. These products serve global markets in the synthetic
lubricant, agrochemical, rubber processing and other specialty
chemical areas.
Competition
Our principal competitors in the Acetyl Intermediates segment
include Atofina S.A., BASF, British Petroleum PLC, Chang Chun
Petrochemical Co., Ltd., Daicel, Dow, Eastman, DuPont,
LyondellBasell Industries, Nippon Gohsei, Perstorp Inc.,
Rohm & Haas Company, Jiangsu Sopo Corporation (Group)
Ltd., Showa Denko K.K., and Kuraray Co. Ltd.
Other
Activities
Other Activities primarily consists of corporate center costs,
including financing and administrative activities such as legal,
accounting and treasury functions, interest income and expense
associated with our financing activities, and our captive
insurance companies. Our two wholly-owned captive insurance
companies are a key component of our global risk management
program, as well as a form of self-insurance for our property,
liability and workers compensation risks. The captive insurance
companies issue insurance policies to our subsidiaries to
provide consistent coverage amid fluctuating costs in the
insurance market and to lower long-term insurance costs by
avoiding or reducing commercial carrier overhead and regulatory
fees. The captive insurance companies retain risk at levels
approved by management and obtain reinsurance coverage from
third parties to limit the net risk retained. One of the captive
insurance companies also insures certain third-party risks.
13
Investments
We have a significant portfolio of strategic investments,
including a number of ventures in Asia, North America and
Europe. In aggregate, these strategic investments enjoy
significant sales, earnings and cash flow. We have entered into
these strategic investments in order to gain access to local
markets, minimize costs and accelerate growth in areas we
believe have significant future business potential. See
Note 8 to the consolidated financial statements for
additional information.
The table below represents our significant strategic ventures as
of December 31, 2008:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Location
|
|
Ownership
|
|
|
Segment
|
|
Partner(s)
|
|
Year Entered
|
|
|
Equity Method Investments
|
KEPCO
|
|
South Korea
|
|
|
50%
|
|
|
Advanced Engineered
Materials
|
|
Mitsubishi Gas Chemical Company, Inc./Mitsubishi Corporation
|
|
|
1999
|
|
Polyplastics Co., Ltd.
|
|
Japan
|
|
|
45%
|
|
|
Advanced Engineered
Materials
|
|
Daicel Chemical Industries Ltd.
|
|
|
1964
|
|
Fortron Industries LLC
|
|
US
|
|
|
50%
|
|
|
Advanced Engineered
Materials
|
|
Kureha Corporation
|
|
|
1992
|
|
Cost Method Investments
|
National Methanol Co.
|
|
Saudi Arabia
|
|
|
25%
|
|
|
Acetyl Intermediates
|
|
Saudi Basic Industries Corporation (SABIC)/
CTE Petrochemicals
|
|
|
1981
|
|
Kunming Cellulose Fibers Co. Ltd.
|
|
China
|
|
|
30%
|
|
|
Consumer Specialties
|
|
China National
Tobacco Corporation
|
|
|
1993
|
|
Nantong Cellulose Fibers Co. Ltd.
|
|
China
|
|
|
31%
|
|
|
Consumer Specialties
|
|
China National
Tobacco Corporation
|
|
|
1986
|
|
Zhuhai Cellulose Fibers Co. Ltd.
|
|
China
|
|
|
30%
|
|
|
Consumer Specialties
|
|
China National
Tobacco Corporation
|
|
|
1993
|
|
Major
Equity Method Investments
Korea Engineering Plastics Co. Ltd. Founded in
1987, KEPCO is the leading producer of polyacetal in South
Korea. Mitsubishi Gas Chemical Company, Inc. owns 40% and
Mitsubishi Corporation owns 10% of KEPCO. KEPCO operates a POM
plant in Ulsan, South Korea and participates with Polyplastics
and Mitsubishi Gas Chemical Company, Inc. in a world-scale POM
facility in Nantong, China.
Polyplastics Co., Ltd. Polyplastics is a
leading supplier of engineered plastics in the Asia-Pacific
region. Polyplastics principal production facilities are
located in Japan, Taiwan, Malaysia and China. We believe
Polyplastics is the largest producer and marketer of POM in the
Asia-Pacific region.
Fortron Industries LLC. Fortron Industries LLC
is a leading global producer of PPS. Production facilities are
located in Wilmington, North Carolina. We believe Fortron has
the leading technology in linear polymer applications.
Major
Cost Method Investments
National Methanol Co. (Ibn
Sina). With production facilities in Saudi
Arabia, National Methanol Co. represents approximately 2% of the
worlds methanol production capacity and is the
worlds eighth largest producer of MTBE. Methanol and MTBE
are key global commodity chemical products. We indirectly own a
25% interest in National Methanol Co. through CTE
Petrochemicals, a joint venture with Texas Eastern Arabian
Corporation Ltd., with the remainder held by SABIC (50%). SABIC
has responsibility for all product marketing.
China Acetate Products ventures. We hold
approximately 30% ownership interests (50% board representation)
in three separate Acetate Products production entities in China:
the Nantong, Kunming and Zhuhai Cellulose Fiber Companies. In
each instance, the Chinese state-owned tobacco entity, China
National Tobacco Corporation controls the remainder. The China
ventures fund operations using operating cash flows.
These cost investments where we own greater than a 20% ownership
interest are accounted for under the cost method of accounting
because we cannot exercise significant influence over these
entities. We determined that we
14
cannot exercise significant influence over these entities due to
local government investment in and influence over these
entities, limitations on our involvement in the day-to-day
operations and the present inability of the entities to provide
timely financial information prepared in accordance with US
generally accepted accounting principles.
Other
Equity Investments
InfraServs. We hold ownership interests in
several InfraServ entities located in Germany. InfraServs own
and develop industrial parks and provide
on-site
general and administrative support to tenants. The table below
represents our equity investments in InfraServ ventures as of
December 31, 2008:
|
|
|
|
|
Company
|
|
Ownership %
|
|
|
InfraServ GmbH & Co. Gendorf KG
|
|
|
39.0
|
%
|
InfraServ GmbH & Co. Knapsack KG
|
|
|
28.2
|
%
|
InfraServ GmbH & Co. Hoechst KG
|
|
|
31.2
|
%
|
Raw
Materials and Energy
We purchase a variety of raw materials and energy from sources
in many countries for use in our production processes. We have a
policy of maintaining, when available, multiple sources of
supply for materials. However, some of our individual plants may
have single sources of supply for some of their raw materials,
such as carbon monoxide, steam and acetaldehyde. Although we
have been able to obtain sufficient supplies of raw materials,
there can be no assurance that unforeseen developments will not
affect our raw material supply. Even if we have multiple sources
of supply for a raw material, there can be no assurance that
these sources can make up for the loss of a major supplier.
There cannot be any guarantee that profitability will not be
affected should we be required to qualify additional sources of
supply to our specifications in the event of the loss of a sole
supplier. In addition, the price of raw materials varies, often
substantially, from year to year.
A substantial portion of our products and raw materials are
commodities whose prices fluctuate as market supply/demand
fundamentals change. Our production facilities rely largely on
fuel oil, natural gas and electricity for energy. Most of the
raw materials for our European operations are centrally
purchased by one of our subsidiaries, which also buys raw
materials on behalf of third parties. We manage our exposure
through forward purchase contracts, long-term supply agreements
and multi-year purchasing and sales agreements. During 2008, we
did not enter into any commodity financial derivative contracts.
See Note 2 and Note 22 to the consolidated financial
statements for additional information.
We also currently purchase and lease supplies of various
precious metals, such as rhodium, used as catalysts for the
manufacture of Acetyl Intermediates products. For precious
metals, the leases are distributed between a minimum of three
lessors per product and are divided into several contracts.
Research
and Development
All of our businesses conduct research and development
activities to increase competitiveness. Our businesses are
innovation-oriented and conduct research and development
activities to develop new, and optimize existing, production
technologies, as well as to develop commercially viable new
products and applications. We consider the amount spent during
each of the last three fiscal years on research and development
activities to be adequate to drive our strategic initiatives.
Intellectual
Property
We attach great importance to patents, trademarks, copyrights
and product designs in order to protect our investment in
research and development, manufacturing and marketing. Our
policy is to seek the widest possible protection for significant
product and process developments in our major markets. Patents
may cover products, processes, intermediate products and product
uses. We also seek to register trademarks extensively as a means
of protecting the brand names of our products, which brand names
become more important once the corresponding patents have
expired. We protect our trademarks vigorously against
infringement and also seek to register design protection where
appropriate.
In most industrial countries, patent protection exists for new
substances and formulations, as well as for unique applications
and production processes. However, we do business in regions of
the world where intellectual property
15
protection may be limited and difficult to enforce. We maintain
strict information security policies and procedures wherever we
do business. Such information security policies and procedures
include data encryption, controls over the disclosure and
safekeeping of confidential information, as well as employee
awareness training. Moreover, we monitor our competitors and
vigorously challenge patent and trademark infringement. For
example, Acetyl Intermediates maintains a strict patent
enforcement strategy, which has resulted in favorable outcomes
in a number of patent infringement matters in Europe, Asia and
the United States. We are currently pursuing a number of matters
relating to the infringement of our acetic acid patents. Some of
our earlier acetic acid patents expired in 2007; other patent
applications covering acetic acid are presently pending.
Neither our business as a whole nor any particular segment is
materially dependent upon any one particular patent, trademark,
copyright or trade secret.
Trademarks
AOPlustm,
VAntagetm,
VAntage
Plustm,
BuyTiconaDirecttm,
Celanex®,
Celcon®,
Celstran®,
Celvol®,
Celvolit®,
Compel®,
Erkol®,
GUR®,
Hostaform®,
Impet®,
Impet-HI®,
Mowilith®,
Nutrinova®,
Riteflex®,
Sunett®,
Vandar®,
Vectra®,
Vinamul®,
EcoVAEtm,
Duroset®,,
Acetex®
and certain other products and services named in this document
are registered trademarks and service marks of Celanese.
Fortron®
is a registered trademark of Fortron Industries LLC, a venture
of Celanese.
Environmental
and Other Regulation
Matters pertaining to environmental and other regulations are
discussed in Item 1A. Risk Factors, Item 7.
Managements Discussion and Analysis of Financial Condition
and Results of Operations, and Note 16 and Note 23 to
the consolidated financial statements.
Employees
As of December 31, 2008, we had approximately
8,350 employees worldwide from continuing operations,
compared to 8,400 as of December 31, 2007. This represents
a decrease of less than 1%. The following table sets forth the
approximate number of employees on a continuing basis as of
December 31, 2008, 2007 and 2006.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Employees as of December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
North America
|
|
|
4,100
|
|
|
|
4,350
|
|
|
|
4,700
|
|
thereof US
|
|
|
3,050
|
|
|
|
3,200
|
|
|
|
3,300
|
|
thereof Canada
|
|
|
250
|
|
|
|
250
|
|
|
|
500
|
|
thereof Mexico
|
|
|
800
|
|
|
|
900
|
|
|
|
900
|
|
Europe
|
|
|
3,500
|
|
|
|
3,500
|
|
|
|
3,900
|
|
thereof Germany
|
|
|
1,700
|
|
|
|
1,700
|
|
|
|
2,600
|
|
Asia
|
|
|
700
|
|
|
|
500
|
|
|
|
250
|
|
Rest of World
|
|
|
50
|
|
|
|
50
|
|
|
|
50
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Employees
|
|
|
8,350
|
|
|
|
8,400
|
|
|
|
8,900
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Many of our employees are unionized, particularly in Germany,
Canada, Mexico, Brazil, Belgium and France. However, in the
United States, less than one quarter of our employees are
unionized. Moreover, in Germany and France, wages and general
working conditions are often the subject of centrally negotiated
collective bargaining agreements. Within the limits established
by these agreements, our various subsidiaries negotiate directly
with the unions and other labor organizations, such as
workers councils, representing the employees. Collective
bargaining agreements between the German chemical employers
associations and unions relating to remuneration generally have
a term of one year, while in the United States a three year term
for collective bargaining agreements is typical. We offer
comprehensive benefit plans for employees and their families and
believe our relations with employees are satisfactory.
16
Backlog
We do not consider backlog to be a significant indicator of the
level of future sales activity. In general, we do not
manufacture our products against a backlog of orders. Production
and inventory levels are based on the level of incoming orders
as well as projections of future demand. Therefore, we believe
that backlog information is not material to understanding our
overall business and should not be considered a reliable
indicator of our ability to achieve any particular level of
revenue or financial performance.
Available
Information Securities and Exchange Commission
(SEC) Filings and Corporate Governance
Materials
We make available free of charge, through our internet website
(www.celanese.com), our annual reports on
Form 10-K,
quarterly reports on
Form 10-Q,
current reports on
Form 8-K
and amendments to those reports filed or furnished pursuant to
Section 13(a) or 15(d) of the Securities Exchange Act of
1934, as soon as reasonably practicable after electronically
filing such material with, or furnishing it to, the SEC. The SEC
maintains an Internet site that contains reports, proxy and
information statements, and other information regarding issuers,
including Celanese Corporation, that electronically file with
the SEC at
http://www.sec.gov.
We also make available free of charge, through our internet
website, our Corporate Governance Guidelines of our Board of
Directors and the charters of each of the committees of the
Board. Such materials are also available in print upon the
written request of any shareholder to Celanese Corporation,
1601 West LBJ Freeway, Dallas, Texas,
75234-6034,
Attention: Investor Relations.
Many factors could have an effect on our financial condition,
cash flows and results of operations. We are subject to various
risks resulting from changing economic, environmental,
political, industry, business and financial conditions. The
factors described below represent our principal risks.
Risks
Related to Our Business
The
worldwide economic downturn and difficult conditions in the
global capital and credit markets have affected and may continue
to adversely affect our business, as well as the industries of
many of our customers and suppliers, which are cyclical in
nature. We do not expect these conditions to improve in the near
future.
Some of the markets in which our end-use customers participate,
such as the automotive, electrical, construction and textile
industries, are cyclical in nature, thus posing a risk to us
which is beyond our control. These markets are highly
competitive, to a large extent driven by end-use markets, and
may experience overcapacity, all of which may affect demand for
and pricing of our products.
Recent declines in consumer and business confidence and
spending, together with severe reductions in the availability
and cost of credit and volatility in the capital and credit
markets, have adversely affected the business and economic
environment in which we operate and the profitability of our
business. Our business is exposed to risks associated with the
creditworthiness of our key suppliers, customers and business
partners. In particular, we are exposed to risks associated with
the ongoing decline of the automotive, textile and housing
markets. These conditions have resulted in financial instability
or other adverse effects at many of our suppliers, customers or
business partners. The consequences of such adverse effects
could include the interruption of production at the facilities
of our customers, the reduction, delay or cancellation of
customer orders, delays in or the inability of customers to
obtain financing to purchase our products, delays or
interruptions of the supply of raw materials we purchase and
bankruptcy of customers, suppliers or other creditors. Any of
these events may adversely affect our cash flow, profitability
and financial condition.
Moreover, the current worldwide financial crisis has reduced the
availability of liquidity and credit to fund or support the
continuation and expansion of business operations worldwide.
Many lenders and institutional investors have reduced and, in
some cases, ceased to provide funding to borrowers. Continued
disruption of the credit markets has affected and could continue
to adversely affect our customers access to credit which
supports the continuation
17
and expansion of their businesses worldwide and could result in
contract cancellations or suspensions, payment delays or
defaults by our customers.
We are
a company with operations around the world and are exposed to
general economic, political and regulatory conditions and risks
in the countries in which we have significant
operations.
We operate in the global market and have customers in many
countries. We have major facilities primarily located in North
America, Europe and Asia, and hold interests in ventures that
operate in Germany, China, Japan, South Korea and Saudi Arabia.
Our principal customers are similarly global in scope, and the
prices of our most significant products are typically world
market prices. Consequently, our business and financial results
are affected, directly and indirectly, by world economic,
political and regulatory conditions.
In addition to the worldwide economic downturn, conditions such
as the uncertainties associated with war, terrorist activities,
epidemics, pandemics or political instability in any of the
countries in which we operate could affect us by causing delays
or losses in the supply or delivery of raw materials and
products, as well as increasing security costs, insurance
premiums and other expenses. These conditions could also result
in or lengthen economic recession in the United States, Europe,
Asia or elsewhere.
Moreover, changes in laws or regulations, such as unexpected
changes in regulatory requirements (including import or export
licensing requirements), or changes in the reporting
requirements of the United States, German or European Union
(EU) governmental agencies, could increase the cost
of doing business in these regions. Any of these conditions may
have an effect on our business and financial results as a whole
and may result in volatile current and future prices for our
securities, including our stock.
In particular, we have invested significant resources in China
and other Asian countries. This regions growth has slowed
and we may fail to realize the anticipated benefits associated
with our investment there and our financial results may be
adversely impacted.
We are
subject to risks associated with the increased volatility in the
prices and availability of key raw materials and
energy.
We purchase significant amounts of natural gas, ethylene and
methanol from third parties for use in our production of basic
chemicals in the Acetyl Intermediates segment, principally
formaldehyde, acetic acid and VAM. We use a portion of our
output of these chemicals, in turn, as inputs in the production
of further products in all our segments. We also purchase
significant amounts of wood pulp for use in our production of
cellulose acetate in the Consumer Specialties segment. The price
of many of these items is dependent on the available supply of
such item and may increase significantly as a result of
production disruptions or strikes. For example, the unplanned
shutdown of our Clear Lake, Texas facility together with other
tight supply conditions caused a shortage of acetic acid and
increased the price for such product during 2007.
We are exposed to any volatility in the prices of our raw
materials and energy. Although we have agreements providing for
the supply of natural gas, ethylene, wood pulp, electricity and
fuel oil, the contractual prices for these raw materials and
energy vary with market conditions and may be highly volatile.
Factors which have caused volatility in our raw material prices
in the past and which may do so in the future include:
|
|
|
|
|
Shortages of raw materials due to increasing demand, e.g., from
growing uses or new uses;
|
|
|
|
Capacity constraints, e.g., due to construction delays, strike
action or involuntary shutdowns;
|
|
|
|
The general level of business and economic activity; and
|
|
|
|
The direct or indirect effect of governmental regulation.
|
If we are not able to fully offset the effects of higher energy
and raw material costs, or if such commodities were unavailable,
it could have a significant adverse effect on our financial
results.
18
Failure
to develop new products and production technologies or to
implement productivity and cost reduction initiatives
successfully may harm our competitive position.
Our operating results, especially in our Consumer Specialties
and Advanced Engineered Materials segments, depend significantly
on the development of commercially viable new products, product
grades and applications, as well as production technologies. If
we are unsuccessful in developing new products, applications and
production processes in the future, our competitive position and
operating results may be negatively affected. Likewise, we have
undertaken and are continuing to undertake initiatives in all
segments to improve productivity and performance and to generate
cost savings. These initiatives may not be completed or
beneficial or the estimated cost savings from such activities
may not be realized.
Recent
federal regulations aimed at increasing security at certain
chemical production plants and similar legislation that may be
proposed in the future could, if passed into law, require us to
relocate certain manufacturing activities and require us to
alter or discontinue our production of certain chemical
products, thereby increasing our operating costs and causing an
adverse effect on our results of operations.
Regulations have recently been issued by the Department of
Homeland Security (DHS) aimed at decreasing the
risk, and effects, of potential terrorist attacks on chemical
plants located within the United States. Pursuant to these
regulations, these goals would be accomplished in part through
the requirement that certain high-priority facilities develop a
prevention, preparedness, and response plan after conducting a
vulnerability assessment. In addition, companies may be required
to evaluate the possibility of using less dangerous chemicals
and technologies as part of their vulnerability assessments and
prevention plans and implementing feasible safer technologies in
order to minimize potential damage to their facilities from a
terrorist attack. We have registered certain of our sites with
DHS in accordance with these regulations, and are conducting
vulnerability assessments for our sites and until that is done
we cannot state with certainty the costs associated with any
security plans that DHS may require. These regulations may be
revised further, and additional legislation may be proposed in
the future on this topic. It is possible that such future
legislation could contain terms that are more restrictive than
what has recently been passed and which would be more costly to
us. We cannot predict the final form of currently pending
legislation, or other related legislation that may be passed and
can provide no assurance that such legislation will not have an
adverse effect on our results of operations in a future
reporting period.
Environmental
regulations and other obligations relating to environmental
matters could subject us to liability for fines,
clean-ups
and other damages, require us to incur significant costs to
modify our operations and increase our manufacturing and
delivery costs.
Costs related to our compliance with environmental laws and
regulations, and potential obligations with respect to
contaminated sites may have a significant negative impact on our
operating results. These include obligations related to sites
currently or formerly owned or operated by us, or where waste
from our operations was disposed. We also have obligations
related to the indemnity agreement contained in the demerger and
transfer agreement between Celanese GmbH and Hoechst, also
referred to as the demerger agreement, for environmental matters
arising out of certain divestitures that took place prior to the
demerger.
Our operations are subject to extensive international, national,
state, local and other supranational laws and regulations that
govern environmental and health and safety matters, including
the Comprehensive Environmental Response, Compensation and
Liability Act of 1980 (CERCLA) and the Resource
Conservation and Recovery Act of 1976 (RCRA). We
incur substantial capital and other costs to comply with these
requirements. If we violate them, we can be held liable for
substantial fines and other sanctions, including limitations on
our operations as a result of changes to or revocations of
environmental permits involved. Stricter environmental, safety
and health laws, regulations and enforcement policies could
result in substantial costs and liabilities to us or limitations
on our operations and could subject our handling, manufacture,
use, reuse or disposal of substances or pollutants to more
rigorous scrutiny than at present. Consequently, compliance with
these laws and regulations could result in significant capital
expenditures as well as other costs and liabilities, which could
cause our business and operating results to be less favorable
than expected.
19
We are also involved in several claims, lawsuits and
administrative proceedings relating to environmental matters. An
adverse outcome in any of them may negatively affect our
earnings and cash flows in a particular reporting period.
Changes
in environmental, health and safety regulations in the
jurisdictions where we manufacture and sell our products could
lead to a decrease in demand for our products.
New or revised governmental regulations and independent studies
relating to the effect of our products on health, safety and the
environment may affect demand for our products and the cost of
producing our products.
Canada recently included vinyl acetate monomer (VAM)
as one of approximately 200 chemicals being assessed as part of
the Canadian Governments Chemicals Management Plan under
the Canadian Environmental Protection Act (CEPA). On
May 16, 2008, Health Canada published a draft screening
risk assessment and draft risk management scope document for VAM
that concluded, using a precautionary approach, that
VAM be listed as a toxic substance under CEPA. On
January 27, 2009, after consideration of data submitted by
Celanese and other manufacturers and users of VAM and further
consideration of a risk assessment prepared by the European
Union, Health Canada published its final decision overruling its
May 16, 2008 draft assessment of VAM. Health Canada
concluded that VAM does not meet the regulatory requirements for
being listed as a toxic substance under CEPA.
The Registration, Evaluation, Authorization and Restriction of
Chemicals (REACh), which established a system to
register and evaluate chemicals manufactured in, or imported to,
the European Union, became effective on June 1, 2007. VAM
is one of the chemicals that the European Chemicals Agency
(ECHA) will regulate under REACh. ECHA will likely
rely on the work of the EU-Working group on classification and
labeling of dangerous substances. After extensive study, the
EU-Working Group agreed that VAM should be classified in the EU
as showing limited evidence of a carcinogenic effect. In
addition, a risk assessment was performed on VAM by the European
Chemicals Bureau of the European Commission. Risk reduction
strategies for human health and the environment were finalized
without the imposition of any restrictions or burdens atypical
to an industrial chemical. The EU-Working Group conclusion has
been reviewed and substantively approved by EU Scientific
Committee on Health and Environmental Risks.
We can provide no assurance that the EU classifications on VAM
will not be revised in the future, or that other chemicals we
produce will not be classified in a manner that would adversely
affect demand for such products. Such negative classifications
could have an adverse affect on our business and results of
operations.
We are a producer of formaldehyde and plastics derived from
formaldehyde. Several studies have investigated possible links
between formaldehyde exposure and various end points including
leukemia. The International Agency for Research on Cancer
(IARC), a private research agency, has reclassified
formaldehyde from Group 2A (probable human carcinogen) to Group
1 (known human carcinogen) based on studies linking formaldehyde
exposure to nasopharyngeal cancer, a rare cancer in humans. We
expect the results of IARCs review will be examined and
considered by government agencies with responsibility for
setting worker and environmental exposure standards and labeling
requirements. If such agencies give strong consideration to
IARCs findings in setting such standards and requirements,
it could have an adverse effect on our business.
Other pending initiatives will potentially require toxicological
testing and risk assessments of a wide variety of chemicals,
including chemicals used or produced by us. These initiatives
include the Voluntary Childrens Chemical Evaluation
Program, High Production Volume Chemical Initiative and Chemical
Assessment and Management Program (ChAMP) in the
United States, as well as various European Commission programs,
such as REACh.
The above-mentioned assessments in the United States, Canada and
Europe may result in heightened concerns about the chemicals
involved and additional requirements being placed on the
production, handling, labeling or use of the subject chemicals.
Such concerns and additional requirements could increase the
cost incurred by our customers to use our chemical products and
otherwise limit the use of these products, which could lead to a
decrease in demand for these products. Such a decrease in demand
would likely have an adverse impact on our business and results
of operations.
20
Our
production facilities handle the processing of some volatile and
hazardous materials that subject us to operating risks that
could have a negative effect on our operating
results.
Our operations are subject to operating risks associated with
chemical manufacturing, including the related storage and
transportation of raw materials, products and waste. These risks
include, among other things, pipeline and storage tank leaks and
ruptures, explosions and fires and discharges or releases of
toxic or hazardous substances.
These operating risks can cause personal injury, property damage
and environmental contamination, and may result in the shutdown
of affected facilities and the imposition of civil or criminal
penalties. The occurrence of any of these events may disrupt
production and have a negative effect on the productivity and
profitability of a particular manufacturing facility and our
operating results and cash flows.
Production
at our manufacturing facilities could be disrupted for a variety
of reasons, which could prevent us from producing enough of our
products to maintain our sales and satisfy our customers
demands.
A disruption in production at our manufacturing facilities could
have a material adverse effect on our business. Disruptions
could occur for many reasons, including fire, natural disasters,
weather, unplanned maintenance or other manufacturing problems,
disease, strikes, transportation interruption, government
regulation or terrorism. Alternative facilities with sufficient
capacity or capabilities may not be available, may cost
substantially more or may take a significant time to start
production, each of which could negatively affect our business
and financial performance. If one of our key manufacturing
facilities is unable to produce our products for an extended
period of time, our sales may be reduced by the shortfall caused
by the disruption and we may not be able to meet our
customers needs, which could cause them to seek other
suppliers. For example, during 2007, production was disrupted
for an extended period of time at our Clear Lake, Texas facility
that produces primarily acetic acid and VAM. The disruption was
caused by an unplanned outage of our acetic acid unit. Because
of this disruption, the volumes of our Acetyl Intermediates
segment were lower than we had expected for 2007 as we were
unable to fully offset the lost production. Similar outages
could occur in the future from unexpected disruptions at any of
our other manufacturing facilities of key products. Such outages
could have an adverse effect on our results of operations in
future reporting periods.
We may
experience unexpected difficulties in the relocation of our
Ticona plant from Kelsterbach to the Rhine Main area, which may
increase our costs, delay the transition or disrupt our ability
to supply our customers.
We have agreed with Frankfurt, Germany Airport
(Fraport) to relocate our Kelsterbach, Germany
business, resolving several years of legal disputes related to
the planned Frankfurt airport expansion. As a result of the
settlement, we will transition Ticonas operations from
Kelsterbach to another location in Germany by mid-2011. In July
2007, we announced that we would relocate the Kelsterbach,
Germany business to the Hoechst Industrial Park in the Rhine
Main area. Over a five-year period, Fraport agreed to pay Ticona
a total of 670 million to offset the costs associated
with the transition of the business from its current location
and the closure of the Kelsterbach plant. While the settlement
and related payment amount are meant to be cost-neutral and
represent the actual amount we will require to select a site,
build new production facilities, demolish old production
facilities and transition business activities according to
schedule and without any disruptions to customer supply, we may
encounter unexpected costs or other difficulties during the
relocation process that bring the total costs of the relocation
to an amount greater than the compensation provided by Fraport.
The relocation of these facilities represents a major logistical
undertaking, and we may have underestimated the amount that will
be required to carry out every aspect of the relocation. We may
lose the services of valuable experienced employees during the
transition if they decide not to work at the new location. The
construction of the new facilities may not be complete on time
or may face cost overruns. If our costs relating to the
relocation exceed the amount of payments from Fraport or if the
relocation causes other unexpected difficulties, our expenses
may increase or supplies to our customers may be disrupted.
If supply to our customers is disrupted for an extended period,
this could negatively impact the reputation of this business and
result in the loss of customers. Such effects could have an
adverse impact on our results of operations in future periods.
21
Our
significant non-US operations expose us to global exchange rate
fluctuations that could adversely impact our
profitability.
As we conduct a significant portion of our operations outside
the United States, fluctuations in currencies of other
countries, especially the Euro, may materially affect our
operating results. For example, changes in currency exchange
rates may decrease our profits in comparison to the profits of
our competitors on the same products sold in the same markets
and increase the cost of items required in our operations.
A substantial portion of our net sales is denominated in
currencies other than the US dollar. In our consolidated
financial statements, we translate our local currency financial
results into US dollars based on average exchange rates
prevailing during a reporting period or the exchange rate at the
end of that period. During times of a strengthening US dollar
our reported international sales, earnings, assets and
liabilities will be reduced because the local currency will
translate into fewer US dollars.
In addition to currency translation risks, we incur a currency
transaction risk whenever one of our operating subsidiaries
enters into either a purchase or a sales transaction using a
currency different from the operating subsidiarys
functional currency. Given the volatility of exchange rates, we
may not be able to manage our currency transaction and
translation risks effectively, and volatility in currency
exchange rates may expose our financial condition or results of
operations to a significant additional risk. Since a portion of
our indebtedness is and will be denominated in currencies other
than US dollars, a weakening of the US dollar could make it more
difficult for us to repay our indebtedness.
We use financial instruments to hedge our exposure to foreign
currency fluctuations, but we cannot guarantee that our hedging
strategies will be effective. Failure to effectively manage
these risks could have an adverse impact on our financial
position, results of operations and cash flows.
Significant
changes in pension fund investment performance or assumptions
relating to pension costs may have a material effect on the
valuation of pension obligations, the funded status of pension
plans and our pension cost.
The cost of our pension plans is incurred over long periods of
time and involve many uncertainties during those periods of
time. Our funding policy for pension plans is to accumulate plan
assets that, over the long run, will approximate the present
value of projected benefit obligations. Our pension cost is
materially affected by the discount rate used to measure pension
obligations, the level of plan assets available to fund those
obligations at the measurement date and the expected long-term
rate of return on plan assets. Significant changes in investment
performance or a change in the portfolio mix of invested assets
can result in corresponding increases and decreases in the
valuation of plan assets, particularly equity securities, or in
a change of the expected rate of return on plan assets. During
the previous fiscal year, the value of our plan assets declined
significantly due to the decline in the overall equity markets.
A change in the discount rate would result in a significant
increase or decrease in the valuation of pension obligations,
affecting the reported funded status of our pension plans as
well as the net periodic pension cost in the following fiscal
years. In recent years, an extended duration strategy in the
asset portfolio has been implemented to minimize the influence
of liability volatility due to interest rate movements.
Similarly, changes in the expected return on plan assets can
result in significant changes in the net periodic pension cost
for subsequent fiscal years. If the value of our pension
funds portfolio declines or does not perform as expected
or if our experience with the fund leads us to change our
assumptions regarding the fund, we may be required to contribute
additional capital to the fund.
Our
future success will depend in part on our ability to protect our
intellectual property rights. Our inability to enforce these
rights could reduce our ability to maintain our market position
and our profit margins.
We attach great importance to patents, trademarks, copyrights
and product designs in order to protect our investment in
research and development, manufacturing and marketing. Our
policy is to seek the widest possible protection for significant
product and process developments in our major markets. Patents
may cover products, processes, intermediate products and product
uses. Protection for individual products extends for varying
periods in accordance with the date of patent application filing
and the legal life of patents in the various countries. The
protection afforded, which may also vary from country to
country, depends upon the type of patent and its scope of
22
coverage. As patents expire, the products and processes
described and claimed in those patents become generally
available for use by the public. We also seek to register
trademarks extensively as a means of protecting the brand names
of our products, which brand names become more important once
the corresponding patents have expired. Our continued growth
strategy may bring us to regions of the world where intellectual
property protection may be limited and difficult to enforce. If
we are not successful in protecting our trademark or patent
rights, our revenues, results of operations and cash flows may
be adversely affected.
Provisions
in our second amended and restated certificate of incorporation
and second amended and restated bylaws, as well as any
shareholders rights plan, may discourage a takeover
attempt.
Provisions contained in our second amended and restated
certificate of incorporation and bylaws could make it more
difficult for a third party to acquire us, even if doing so
might be beneficial to our shareholders. Provisions of our
second amended and restated certificate of incorporation and
bylaws impose various procedural and other requirements, which
could make it more difficult for shareholders to effect certain
corporate actions. For example, our second amended and restated
certificate of incorporation authorizes our Board of Directors
to determine the rights, preferences, privileges and
restrictions of unissued series of preferred stock, without any
vote or action by our shareholders. Thus, our Board of Directors
can authorize and issue shares of preferred stock with voting or
conversion rights that could adversely affect the voting or
other rights of holders of our Series A common stock. These
rights may have the effect of delaying or deterring a change of
control of our company. In addition, a change of control of our
company may be delayed or deterred as a result of our having
three classes of directors (each class elected for a three year
term) or as a result of any shareholders rights plan that
our Board of Directors may adopt. These provisions could limit
the price that certain investors might be willing to pay in the
future for shares of our Series A common stock.
Risks
Related to the Acquisition of Celanese GmbH, formerly Celanese
AG
The
amounts of the fair cash compensation and of the guaranteed
annual payment offered under the domination and profit and loss
transfer agreement (Domination Agreement) may be
increased, which may further reduce the funds the Purchaser can
otherwise make available to us.
Several minority shareholders of Celanese GmbH have initiated
special award proceedings seeking the courts review of the
amounts of the fair cash compensation and of the guaranteed
annual payment offered under the Domination Agreement. On
March 14, 2005, the Frankfurt District Court dismissed on
grounds of inadmissibility the motions of all minority
shareholders regarding the initiation of these special award
proceedings. In January 2006, the Frankfurt Higher District
Court ruled that the appeals were admissible, and the
proceedings will therefore continue. On December 12, 2006,
the Frankfurt District Court appointed an expert to help
determine the value of Celanese GmbH. As a result of these
proceedings, the amounts of the fair cash compensation and of
the guaranteed annual payment could be increased by the court,
and the Purchaser would be required to make such payments within
two months after the publication of the courts ruling. Any
such increase may be substantial. All minority shareholders
would be entitled to claim the respective higher amounts. This
may reduce the funds the Purchaser can make available to us and,
accordingly, diminish our ability to make payments on our
indebtedness. See Note 23 to the consolidated financial
statements for further information.
The
Purchaser may be required to compensate Celanese GmbH for annual
losses, which may reduce the funds the Purchaser can otherwise
make available to us.
Under the Domination Agreement, the Purchaser is required, among
other things, to compensate Celanese GmbH for any annual loss
incurred, determined in accordance with German accounting
requirements, by Celanese GmbH at the end of the fiscal year in
which the loss was incurred. This obligation to compensate
Celanese GmbH for annual losses will apply during the entire
term of the Domination Agreement. If Celanese GmbH incurs losses
during any period of the operative term of the Domination
Agreement and if such losses lead to an annual loss of Celanese
GmbH at the end of any given fiscal year during the term of the
Domination Agreement, the Purchaser will be obligated to make a
corresponding cash payment to Celanese GmbH to the extent that
the respective annual loss is not fully compensated for by the
dissolution of profit reserves accrued at the level of Celanese
GmbH during the term of the Domination Agreement. The Purchaser
may be able to reduce or avoid cash payments to Celanese GmbH by
off-setting against such loss compensation claims by Celanese
GmbH any valuable counterclaims against
23
Celanese GmbH that the Purchaser may have. If the Purchaser is
obligated to make cash payments to Celanese GmbH to cover an
annual loss, we may not have sufficient funds to make payments
on our indebtedness when due and, unless the Purchaser is able
to obtain funds from a source other than annual profits of
Celanese GmbH, the Purchaser may not be able to satisfy its
obligation to fund such shortfall. See Note 23 to the
consolidated financial statements.
We and
two of our subsidiaries have taken on certain obligations with
respect to the Purchasers obligation under the Domination
Agreement and intercompany indebtedness to Celanese GmbH, which
may diminish our ability to make payments on our
indebtedness.
Our subsidiaries, Celanese International Holdings Luxembourg
S.à r.l. (CIH), formerly Celanese Caylux
Holdings Luxembourg S.C.A., and Celanese US, have each agreed to
provide the Purchaser with financing so that the Purchaser is at
all times in a position to completely meet its obligations
under, or in connection with, the Domination Agreement. In
addition, Celanese has guaranteed (i) that the Purchaser
will meet its obligation under the Domination Agreement to
compensate Celanese GmbH for any annual loss incurred by
Celanese GmbH during the term of the Domination Agreement; and
(ii) the repayment of all existing intercompany
indebtedness of Celaneses subsidiaries to Celanese GmbH.
Further, under the terms of Celaneses guarantee, in
certain limited circumstances Celanese GmbH may be entitled to
require the immediate repayment of some or all of the
intercompany indebtedness owed by Celaneses subsidiaries
to Celanese GmbH. If CIH
and/or
Celanese US are obligated to make payments under their
obligations to the Purchaser or Celanese GmbH, as the case may
be, or if the intercompany indebtedness owed to Celanese GmbH is
accelerated, we may not have sufficient funds for payments on
our indebtedness when due.
Risks
Related to Our Indebtedness
See also Managements Discussion and Analysis of
Financial Condition and Results of Operations
Liquidity and Capital Resources
Liquidity Contractual Obligations.
Our
level of indebtedness could diminish our ability to raise
additional capital to fund our operations, limit our ability to
react to changes in the economy or the chemicals industry and
prevent us from meeting obligations under our
indebtedness.
Our total indebtedness is approximately $3.5 billion as of
December 31, 2008.
Our debt could have important consequences, including:
|
|
|
|
|
increasing vulnerability to general economic and industry
conditions including exacerbating any adverse business effects
that are determined to be material adverse effects under our
senior credit facility;
|
|
|
|
requiring a substantial portion of cash flow from operations to
be dedicated to the payment of principal and interest on
indebtedness, therefore reducing our ability to use our cash
flow to fund operations, capital expenditures and future
business opportunities;
|
|
|
|
exposing us to the risk of increased interest rates as certain
of our borrowings are at variable rates of interest;
|
|
|
|
limiting our ability to obtain additional financing for working
capital, capital expenditures, product development, debt service
requirements, acquisitions and general corporate or other
purposes; and
|
|
|
|
limiting our ability to adjust to changing market conditions and
placing us at a competitive disadvantage compared to our
competitors who have less debt.
|
A breach of a covenant or other provision in any debt instrument
governing our current or future indebtedness could result in a
default under that instrument and, due to cross-default
provisions, could result in a default under our senior credit
facility. Upon the occurrence of an event of default under the
senior credit facility, the lenders could elect to declare all
amounts outstanding to be immediately due and payable and
terminate all commitments to extend further credit. If we were
unable to repay those amounts, the lenders could proceed against
the collateral, if any, granted to them to secure the
indebtedness. If the lenders under the senior credit facility
were to accelerate the payment of the indebtedness, there is no
guarantee that our assets or cash flow would be sufficient to
repay in full our outstanding indebtedness.
24
Moreover, the terms of our existing debt do not fully prohibit
us or our subsidiaries from incurring substantial additional
indebtedness in the future. If new debt, including amounts
available under our senior credit agreement, is added to our
current debt levels, the related risks that we now face could
intensify. See also Managements Discussion and
Analysis of Financial Condition and Results of
Operations Liquidity and Capital
Resources Liquidity Contractual
Obligations.
Our
variable rate indebtedness subjects us to interest rate risk,
which could cause our debt service obligations to increase
significantly and affect our operating results.
Certain of our borrowings are at variable rates of interest and
expose us to interest rate risk. If interest rates were to
increase, our debt service obligations on our variable rate
indebtedness would increase, net of the impacts of hedges in
place. In April 2007, we, through certain of our
subsidiaries, entered into a senior credit agreement. The new
senior credit agreement consists of $2,280 million of US
dollar denominated and 400 million of Euro
denominated term loans due 2014, a $650 million revolving
credit facility terminating in 2013 and a $228 million
credit-linked revolving facility terminating in 2014. Borrowings
under the new senior credit agreement bear interest at a
variable interest rate based on LIBOR (for US dollars) or
EURIBOR (for Euros), as applicable, or, for US dollar
denominated loans under certain circumstances, a base rate, in
each case plus an applicable margin. The applicable margin for
the term loans and any loans under the credit-linked revolving
facility is 1.75%, subject to potential reductions as defined in
the new senior credit agreement. The term loans under the new
senior credit agreement are subject to amortization at 1% of the
initial principal amount per annum, payable quarterly,
commencing in July 2007. The remaining principal amount of the
term loans will be due on April 2, 2014.
An increase in interest rates could have an adverse impact on
our future results of operations and cash flows. See also
Quantitative and Qualitative Disclosures About Market
Risk Interest Rate Risk Management.
We may
not be able to generate sufficient cash to service our
indebtedness, and may be forced to take other actions to satisfy
obligations under our indebtedness, which may not be
successful.
Our ability to satisfy our cash needs depends on cash on hand,
receipt of additional capital, including possible additional
borrowings, and receipt of cash from our subsidiaries by way of
distributions, advances or cash payments.
Our ability to make scheduled payments on or to refinance our
debt obligations depends on the financial condition and
operating performance of our subsidiaries, which is subject to
prevailing economic and competitive conditions and to certain
financial, business and other factors beyond our control. We may
not be able to maintain a level of cash flows from operating
activities sufficient to permit us to pay the principal,
premium, if any, and interest on our indebtedness.
If our cash flows and capital resources are insufficient to fund
our debt service obligations, we may be forced to reduce or
delay capital expenditures, sell assets, seek additional capital
or restructure or refinance our indebtedness. These alternative
measures may not be successful and may not permit us to meet our
scheduled debt service obligations. In the absence of such
operating results and resources, we could face substantial
liquidity problems and might be required to dispose of material
assets or operations to meet our debt service and other
obligations. The senior credit agreement governing our
indebtedness restricts our ability to dispose of assets and use
the proceeds from the disposition. We may not be able to
consummate those dispositions or to obtain the proceeds which we
could realize from them and these proceeds may not be adequate
to meet any debt service obligations then due.
Restrictive
covenants in our debt instruments may limit our ability to
engage in certain transactions and may diminish our ability to
make payments on our indebtedness.
The senior credit agreement governing our indebtedness contains
various covenants that limit our ability to engage in specified
types of transactions. The covenants contained in the senior
credit agreement limit our ability to, among other things, incur
additional indebtedness, pay dividends on or make other
distributions on or repurchase capital stock or make other
restricted payments, make investments and sell certain assets.
Such restrictions in our debt instruments could result in us
having to obtain the consent of our lenders in order to take
certain actions. Recent disruptions in credit markets may
prevent us from or make it more difficult or more costly for us
to obtain such
25
consents from our lenders. Our ability to expand our business or
to address declines in our business may be limited if we are
unable to obtain such consents.
In addition, the senior credit agreement requires us to maintain
a maximum first lien senior secured leverage ratio no greater
than 3.90 to 1.00 if there are outstanding borrowings under the
revolving credit facility. Our ability to meet this financial
ratio can be affected by events beyond our control, and we may
not be able to meet this test at all.
A breach of any of these covenants could result in a default
under the senior credit agreement. Upon the occurrence of an
event of default under the senior credit agreement, the lenders
could elect to declare all amounts outstanding under the senior
credit agreement to be immediately due and payable and terminate
all commitments to extend further credit. If we were unable to
repay those amounts, the lenders under the senior credit
agreement could proceed against the collateral granted to them
to secure that indebtedness. Our subsidiaries have pledged a
significant portion of our assets as collateral under the senior
credit agreement. If the lenders under the senior credit
agreement accelerate the repayment of borrowings, we may not
have sufficient assets to repay amounts borrowed under the
senior credit agreement as well as their other indebtedness,
which could have a material adverse effect on the value of our
stock.
The
terms of our senior credit agreement limit the ability of BCP
Crystal and its subsidiaries to pay dividends or otherwise
transfer their assets to us.
Our operations are conducted through our subsidiaries and our
ability to pay dividends is dependent on the earnings and the
distribution of funds from our subsidiaries. However, the terms
of our senior credit agreement limit the ability of BCP Crystal
and its subsidiaries to pay dividends or otherwise transfer
their assets to us. Accordingly, our ability to pay dividends on
our stock is similarly limited.
|
|
Item 1B.
|
Unresolved
Staff Comments
|
None.
26
Description
of Property
As of December 31, 2008, we had numerous production and
manufacturing facilities throughout the world. We also own or
lease other properties, including office buildings, warehouses,
pipelines, research and development facilities and sales
offices. We continuously review and evaluate our facilities as a
part of our strategy to optimize our business portfolio. The
following table sets forth a list of our principal production
and other facilities throughout the world as of
December 31, 2008.
|
|
|
|
|
Site
|
|
Leased/Owned
|
|
Products/Functions
|
|
Corporate Offices
|
|
|
|
|
Budapest, Hungary
|
|
Leased
|
|
Administrative offices
|
Dallas, Texas, US
|
|
Leased
|
|
Corporate headquarters
|
Kronberg/Taunus, Germany
|
|
Leased
|
|
Administrative offices
|
Mexico City, Mexico
|
|
Leased
|
|
Administrative offices
|
Mexico City,
Mexico(1)
|
|
Owned
|
|
Administrative offices
|
Advanced Engineered Materials
|
|
|
|
|
Auburn Hills, Michigan, US
|
|
Leased
|
|
Automotive Development Center
|
Bishop, Texas, US
|
|
Owned
|
|
POM,
GUR®,
Compounding
|
Florence, Kentucky, US
|
|
Owned
|
|
Compounding
|
Kelsterbach, Germany
|
|
Owned
|
|
LFRT, POM, Compounding
|
Oberhausen,
Germany(5)
|
|
Leased
|
|
GUR®
|
Fuji City, Japan
|
|
Venture owned by Polyplastics Co., Ltd., a cost method investment
|
|
POM, PBT, LCP, Compounding
|
Kuantan, Malaysia
|
|
Venture owned by Polyplastics Co., Ltd., a cost method investment
|
|
POM, Compounding
|
Shelby, North Carolina, US
|
|
Owned
|
|
LCP, PBT, PET, Compounding
|
Suzano, Brazil
|
|
Owned
|
|
Compounding
|
Ulsan, South Korea
|
|
Venture owned by Korea Engineering Plastics Co., Ltd., an equity
method investment
|
|
POM
|
Wilmington, North Carolina, US
|
|
Venture owned by Fortron Industries LLC, an equity method
investment
|
|
PPS
|
Winona, Minnesota, US
|
|
Owned
|
|
LFRT
|
Nanjing,
China(3)
|
|
Leased
|
|
GUR®
|
Consumer Specialties
|
|
|
|
|
Kunming, China
|
|
Venture owned by Kunming Cellulose Fibers Co. Ltd., a cost
method investment
|
|
Acetate tow, Acetate flake
|
Lanaken, Belgium
|
|
Owned
|
|
Acetate tow
|
Nantong, China
|
|
Venture owned by Nantong Cellulose Fibers Co. Ltd., a cost
method investment
|
|
Acetate tow, Acetate flake
|
Narrows, Virginia, US
|
|
Owned
|
|
Acetate tow, Acetate flake
|
Ocotlán, Jalisco, Mexico
|
|
Owned
|
|
Acetate tow, Acetate flake
|
Spondon, Derby, UK
|
|
Owned
|
|
Acetate tow, Acetate flake
|
Frankfurt am Main,
Germany(4)
|
|
Venture owned by InfraServ GmbH & Co. Hoechst KG, an equity
method investment
|
|
Sorbates,
Sunett®
sweetener
|
Zhuhai, China
|
|
Venture owned by Zhuhai Cellulose Fibers Co. Ltd., a cost method
investment
|
|
Acetate tow, Acetate flake
|
Industrial Specialties
|
|
|
|
|
Boucherville, Quebec, Canada
|
|
Owned
|
|
Conventional emulsions
|
27
|
|
|
|
|
Site
|
|
Leased/Owned
|
|
Products/Functions
|
|
Calvert City, Kentucky,
US(5)
|
|
Leased
|
|
PVOH
|
Enoree, South Carolina, US
|
|
Owned
|
|
Conventional emulsions, Vinyl acetate ethylene emulsions
|
Edmonton, Alberta, Canada
|
|
Owned
|
|
LDPE, EVA
|
Frankfurt am Main,
Germany(4)
|
|
Venture owned by InfraServ GmbH & Co. Hoechst KG, an equity
method investment
|
|
Conventional emulsions, Vinyl acetate ethylene emulsions
|
Geleen, Netherlands
|
|
Owned
|
|
Vinyl acetate ethylene emulsions
|
Guardo,
Spain(6)
|
|
Owned
|
|
PVOH, Polyvinyl acetate
|
Meredosia, Illinois, US
|
|
Owned
|
|
Conventional emulsions, Vinyl acetate ethylene emulsions
|
Nanjing,
China(3)
|
|
Leased
|
|
Conventional emulsions, Vinyl acetate ethylene emulsions
|
Pasadena, Texas,
US(5)
|
|
Leased
|
|
PVOH
|
Koper,
Slovenia(6)
|
|
Owned
|
|
Conventional emulsions
|
Tarragona,
Spain(2)
|
|
Venture owned by Complejo Industrial Taqsa AIE, a cost method
investment
|
|
Conventional emulsions, Vinyl acetate ethylene emulsions, PVOH
|
Perstorp, Sweden
|
|
Owned
|
|
Conventional emulsions, Vinyl acetate ethylene emulsions
|
Warrington,
UK(6)
|
|
Owned
|
|
Conventional emulsions, Vinyl acetate ethylene emulsions
|
Acetyl Intermediates
|
|
|
|
|
Bay City, Texas, US
|
|
Leased
|
|
VAM
|
Bishop, Texas, US
|
|
Owned
|
|
Formaldehyde
|
Cangrejera, Veracruz,
Mexico(7)
|
|
Owned
|
|
Acetic anhydride, Ethyl acetate, VAM
|
Clear Lake, Texas, US
|
|
Owned
|
|
Acetic acid, VAM
|
Frankfurt am Main,
Germany(4)
|
|
Venture owned by InfraServ GmbH & Co. Hoechst KG, an equity
method investment
|
|
Acetaldehyde, VAM, Butyl acetate
|
Nanjing,
China(3)
|
|
Leased
|
|
Acetic acid, Acetic anhydride
|
Pampa, Texas,
US(6)
|
|
Owned
|
|
Acetic acid, Acetic anhydride, Ethyl acetate
|
Pardies, France
|
|
Owned
|
|
Acetic acid, VAM
|
Roussillon,
France(5)
|
|
Leased
|
|
Acetic anhydride
|
Jubail, Saudi Arabia
|
|
Venture owned by National Methanol Company (Ibn Sina), a cost
method investment
|
|
Methyl tertiary-butyl ether, Methanol
|
Jurong Island,
Singapore(5)
|
|
Leased
|
|
Acetic acid, Butyl acetate, Ethyl acetate, VAM
|
Tarragona,
Spain(2)
|
|
Venture owned by Complejo Industrial Taqsa AIE, a cost method
investment
|
|
VAM
|
|
|
|
(1) |
|
Site is no longer operational and is currently held for sale. |
|
(2) |
|
Multiple Celanese business segments conduct operations at the
Tarragona facility. Celanese owns its assets at the facility but
shares ownership in the land. Celaneses ownership
percentage in the land is 15%. |
28
|
|
|
(3) |
|
Multiple Celanese business segments conduct operations at the
Nanjing facility. Celanese owns the assets on this site, but
utilizes the land through the terms of a long-term land lease. |
|
(4) |
|
Multiple Celanese business segments conduct operations at the
Frankfurt facility. |
|
(5) |
|
Celanese owns the assets on this site, but utilizes the land
through the terms of a long-term land lease. |
|
(6) |
|
Site is no longer operating as of December 31, 2008. |
|
(7) |
|
The Company has announced its decision to shut down the
Cangrejera VAM production unit effective at the end of February
2009. |
We believe that our current facilities are adequate to meet the
requirements of our present and foreseeable future operations.
We continue to review our capacity requirements as part of our
strategy to maximize our global manufacturing efficiency.
See Note 8 to the consolidated financial statements for
more information on our cost and equity method investments.
For information on environmental issues associated with our
properties, see Business Environmental and
Other Regulation and Managements Discussion
and Analysis of Financial Condition and Results of
Operations Liquidity and Capital
Resources Environmental Matters. Additional
information with respect to our property, plant and equipment,
and leases is contained in Note 9 and Note 21 to the
consolidated financial statements.
|
|
Item 3.
|
Legal
Proceedings
|
We are involved in a number of legal proceedings, lawsuits and
claims incidental to the normal conduct of our business,
relating to such matters as product liability, antitrust, past
waste disposal practices and release of chemicals into the
environment. While it is impossible at this time to determine
with certainty the ultimate outcome of these proceedings,
lawsuits and claims, we believe, based on the advice of legal
counsel, that adequate provisions have been made and that the
ultimate outcomes will not have a material adverse effect on our
financial position, but may have a material adverse effect on
our results of operations or cash flows in any given accounting
period. See Note 23 to the consolidated financial
statements for a discussion of legal proceedings.
|
|
Item 4.
|
Submission
of Matters to a Vote of Security Holders
|
No matters were submitted to a vote of security holders during
the fourth quarter of 2008.
29
PART II
|
|
Item 5.
|
Market
for the Registrants Common Equity, Related Stockholder
Matters and Issuer Purchases of Equity Securities
|
Market
Information
Our Series A common stock has traded on the New York Stock
Exchange under the symbol CE since January 21,
2005. The closing sale price of our Series A common stock,
as reported by the New York Stock Exchange, on February 6,
2009 was $11.92. The following table sets forth the high and low
intraday sales prices per share of our common stock, as
reported by the New York Stock Exchange, for the periods
indicated.
|
|
|
|
|
|
|
|
|
|
|
Price Range
|
|
|
|
High
|
|
|
Low
|
|
|
2008
|
|
|
|
|
|
|
|
|
Quarter ended March 31, 2008
|
|
$
|
43.72
|
|
|
$
|
31.76
|
|
Quarter ended June 30, 2008
|
|
$
|
50.99
|
|
|
$
|
39.50
|
|
Quarter ended September 30, 2008
|
|
$
|
47.02
|
|
|
$
|
24.68
|
|
Quarter ended December 31, 2008
|
|
$
|
27.76
|
|
|
$
|
5.71
|
|
2007
|
|
|
|
|
|
|
|
|
Quarter ended March 31, 2007
|
|
$
|
32.00
|
|
|
$
|
24.50
|
|
Quarter ended June 30, 2007
|
|
$
|
39.43
|
|
|
$
|
30.59
|
|
Quarter ended September 30, 2007
|
|
$
|
42.49
|
|
|
$
|
30.70
|
|
Quarter ended December 31, 2007
|
|
$
|
44.77
|
|
|
$
|
35.16
|
|
Holders
No shares of Celaneses Series B common stock are
issued and outstanding. As of February 6, 2009, there were
72 holders of record of our Series A common stock, and one
holder of record of our perpetual preferred stock. By including
persons holding shares in broker accounts under street names,
however, we estimate our shareholder base to be approximately
56,000 as of February 6, 2009.
Dividend
Policy
Our Board of Directors adopted a policy of declaring, subject to
legally available funds, a quarterly cash dividend on each share
of our Series A common stock at an annual rate of $0.16 per
share unless our Board of Directors, in its sole discretion,
determines otherwise. Pursuant to this policy, we paid quarterly
dividends of $0.04 per share on February 1, 2008,
May 1, 2008, August 1, 2008 and November 1, 2008
and similar quarterly dividends during each quarter of 2007. The
annual cash dividend declared and paid during the years ended
December 31, 2008 and 2007 were $24 million and
$25 million, respectively. Dividends payable to holders of
our Series A common stock cannot be declared or paid nor
can any funds be set aside for the payment thereof, unless we
have paid or set aside funds for the payment of all accumulated
and unpaid dividends with respect to the shares of our preferred
stock, as described below. Our Board of Directors may, at any
time, modify or revoke our dividend policy on our Series A
common stock.
We are required under the terms of the preferred stock to pay
scheduled quarterly dividends, subject to legally available
funds. For so long as the preferred stock remains outstanding,
(1) we will not declare, pay or set apart funds for the
payment of any dividend or other distribution with respect to
any junior stock or parity stock and (2) neither we, nor
any of our subsidiaries, will, subject to certain exceptions,
redeem, purchase or otherwise acquire for consideration junior
stock or parity stock through a sinking fund or otherwise, in
each case unless we have paid or set apart funds for the payment
of all accumulated and unpaid dividends with respect to the
shares of preferred stock and any parity stock for all preceding
dividend periods. Pursuant to this policy, we paid quarterly
dividends of $0.265625 per share on our 4.25% convertible
perpetual preferred stock on February 1, 2008, May 1,
2008, August 1, 2008 and November 1, 2008 and similar
quarterly dividends during each quarter of 2007.
30
On January 5, 2009, we declared a cash dividend of
$0.265625 per share on our 4.25% convertible perpetual preferred
stock amounting to $3 million and a cash dividend of $0.04
per share on its Series A common stock amounting to
$6 million. Both cash dividends are for the period
November 1, 2008 to January 31, 2009 and were paid on
February 1, 2009 to holders of record as of
January 15, 2009.
Based on the number of outstanding shares as of
December 31, 2008, the cash dividends to be paid in 2009
are expected to result in annual dividend payments similar to
that paid in 2008.
The amount available to us to pay cash dividends is restricted
by our senior credit agreement. Any decision to declare and pay
dividends in the future will be made at the discretion of our
Board of Directors and will depend on, among other things, our
results of operations, cash requirements, financial condition,
contractual restrictions and other factors that our Board of
Directors may deem relevant.
Celanese
Purchases of its Equity Securities
The table below sets forth information regarding repurchases of
our Series A common stock during the three months ended
December 31, 2008:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Approximate Dollar
|
|
|
|
|
|
|
|
|
|
Total Number of
|
|
|
Value of Shares
|
|
|
|
Total Number
|
|
|
Average
|
|
|
Shares Purchased as
|
|
|
Remaining that may be
|
|
|
|
of Shares
|
|
|
Price Paid
|
|
|
Part of Publicly
|
|
|
Purchased Under
|
|
Period
|
|
Purchased(1)
|
|
|
per Share
|
|
|
Announced Program
|
|
|
the Program
|
|
|
October 1, 2008
|
|
|
44,221
|
|
|
$
|
26.71
|
|
|
|
|
|
|
$
|
122,300,000
|
|
|
|
|
(1) |
|
Relates to shares employees have elected to have withheld to
cover their minimum withholding requirements for personal income
taxes related to the vesting of restricted stock units. No
shares were purchased during the three months ended
December 31, 2008 under our previously announced stock
repurchase plan. |
31
Performance
Graph
The following Performance Graph and related information shall
not be deemed soliciting material or to be
filed with the SEC, nor shall such information be
incorporated by reference into any future filing under the
Securities Act of 1933 or Securities Exchange Act of 1934, each
as amended, except to the extent that we specifically
incorporate it by reference into such filing.
Comparison
of Cumulative Total Return
32
Equity
Compensation Plans
Securities
Authorized for Issuance Under Equity Compensation
Plans
The following information is provided as of December 31,
2008 with respect to equity compensation plans:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of Securities
|
|
|
|
|
|
|
|
|
|
Remaining Available for
|
|
|
|
Number of Securities to be
|
|
|
Weighted Average
|
|
|
Future Issuance Under
|
|
|
|
Issued upon Exercise of
|
|
|
Exercise Price of
|
|
|
Equity Compensation
|
|
|
|
Outstanding Options,
|
|
|
Outstanding Options,
|
|
|
Plans (excluding securities
|
|
Plan Category
|
|
Warrants and Rights
|
|
|
Warrants and Rights
|
|
|
reflected in column (a))
|
|
|
|
(a)
|
|
|
(b)
|
|
|
(c)
|
|
|
Equity compensation plans approved by security holders
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity compensation plans not approved by security holders:
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock options
|
|
|
7,015,759
|
|
|
$
|
19.35
|
|
|
|
285,517
|
|
Restricted stock units
|
|
|
1,603,766
|
|
|
|
|
|
|
|
285,517
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
8,619,525
|
|
|
|
|
|
|
|
285,517
|
|
Recent
Sales of Unregistered Securities
In December 2007, we adopted a deferred compensation plan
whereby we offered certain of our senior employees and directors
the opportunity to defer a portion of their compensation in
exchange for a future payment amount equal to their deferments
plus or minus certain amounts based upon the market-performance
of specified measurement funds selected by the participant.
These deferred compensation obligations may be considered
securities of Celanese. Participants were required to make
deferral elections under the plan prior to January 1 of the
year such deferrals will be withheld from their compensation. We
relied on the exemption from registration provided by
Section 4(2) of the Securities Act in making this offer to
a select group of employees, fewer than 35 of which were
non-accredited investors under the rules promulgated by the
Commission.
|
|
Item 6.
|
Selected
Financial Data
|
The balance sheet data shown below as of December 31, 2008
and 2007, and the statements of operations and cash flow data
for the years ended December 31, 2008, 2007 and 2006, all
of which are set forth below, are derived from the consolidated
financial statements included elsewhere in this document and
should be read in conjunction with those financial statements
and the notes thereto. The balance sheet data as of
December 31, 2006, 2005 and 2004 and as of March 31,
2004 and the statements of operations and cash flow data for the
year ended December 31, 2005, the nine months ended
December 31, 2004 and the three months ended March 31,
2004 shown below were derived from previously issued financial
statements, adjusted for applicable discontinued operations.
The balance sheet, statement of operations and cash flow data
for periods prior to April 1, 2004 in the tables below
represent the results of the Predecessor, which refers to
Celanese GmbH, formerly known as Celanese AG, and its
consolidated subsidiaries. The balance sheet, statement of
operations and cash flow data for periods subsequent to
April 1, 2004 in the tables below represent the results of
the Successor, which refers to Celanese Corporation and its
consolidated subsidiaries. The results of the Successor are not
comparable to the results of the Predecessor due to the
difference in the basis of presentation of purchase accounting
as compared to historical cost. Furthermore, the Successor and
the Predecessor have different accounting policies with respect
to certain matters.
33
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Successor
|
|
|
|
Predecessor
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months
|
|
|
|
Three Months
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ended
|
|
|
|
Ended
|
|
|
|
Year Ended December 31,
|
|
|
December 31,
|
|
|
|
March 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
2005
|
|
|
2004
|
|
|
|
2004
|
|
|
|
(In $ millions, except per share data)
|
|
Statement of Operations Data:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net sales
|
|
|
6,823
|
|
|
|
6,444
|
|
|
|
5,778
|
|
|
|
5,270
|
|
|
|
3,206
|
|
|
|
|
1,058
|
|
Other (charges) gains, net
|
|
|
(108
|
)
|
|
|
(58
|
)
|
|
|
(10
|
)
|
|
|
(61
|
)
|
|
|
(78
|
)
|
|
|
|
(28
|
)
|
Operating profit
|
|
|
440
|
|
|
|
748
|
|
|
|
620
|
|
|
|
486
|
|
|
|
17
|
|
|
|
|
39
|
|
Earnings (loss) from continuing operations before tax and
minority interests
|
|
|
434
|
|
|
|
447
|
|
|
|
526
|
|
|
|
276
|
|
|
|
(230
|
)
|
|
|
|
62
|
|
Earnings (loss) from continuing operations
|
|
|
372
|
|
|
|
336
|
|
|
|
319
|
|
|
|
214
|
|
|
|
(292
|
)
|
|
|
|
48
|
|
Earnings (loss) from discontinued operations
|
|
|
(90
|
)
|
|
|
90
|
|
|
|
87
|
|
|
|
63
|
|
|
|
39
|
|
|
|
|
30
|
|
Net earnings (loss)
|
|
|
282
|
|
|
|
426
|
|
|
|
406
|
|
|
|
277
|
|
|
|
(253
|
)
|
|
|
|
78
|
|
Earnings (loss) per share from continuing operations
basic
|
|
|
2.44
|
|
|
|
2.11
|
|
|
|
1.95
|
|
|
|
1.32
|
|
|
|
(2.94
|
)
|
|
|
|
0.97
|
|
Earnings (loss) per share from continuing operations
diluted
|
|
|
2.28
|
|
|
|
1.96
|
|
|
|
1.86
|
|
|
|
1.29
|
|
|
|
(2.94
|
)
|
|
|
|
0.97
|
|
Statement of Cash Flows Data:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by (used in):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating activities
|
|
|
586
|
|
|
|
566
|
|
|
|
751
|
|
|
|
701
|
|
|
|
(62
|
)
|
|
|
|
(102
|
)
|
Investing activities
|
|
|
(201
|
)
|
|
|
143
|
|
|
|
(268
|
)
|
|
|
(907
|
)
|
|
|
(1,811
|
)
|
|
|
|
91
|
|
Financing activities
|
|
|
(499
|
)
|
|
|
(714
|
)
|
|
|
(108
|
)
|
|
|
(144
|
)
|
|
|
2,686
|
|
|
|
|
(43
|
)
|
Balance Sheet Data (at the end of period):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Trade working
capital(1)
|
|
|
685
|
|
|
|
827
|
|
|
|
824
|
|
|
|
758
|
|
|
|
743
|
|
|
|
|
689
|
|
Total assets
|
|
|
7,166
|
|
|
|
8,058
|
|
|
|
7,895
|
|
|
|
7,445
|
|
|
|
7,410
|
|
|
|
|
6,613
|
|
Total debt
|
|
|
3,533
|
|
|
|
3,556
|
|
|
|
3,498
|
|
|
|
3,437
|
|
|
|
3,387
|
|
|
|
|
587
|
|
Shareholders equity (deficit)
|
|
|
182
|
|
|
|
1,062
|
|
|
|
787
|
|
|
|
235
|
|
|
|
(112
|
)
|
|
|
|
2,622
|
|
Other Financial Data:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
350
|
|
|
|
291
|
|
|
|
269
|
|
|
|
267
|
|
|
|
165
|
|
|
|
|
64
|
|
Capital
expenditures(3)
|
|
|
267
|
|
|
|
306
|
|
|
|
244
|
|
|
|
203
|
|
|
|
134
|
|
|
|
|
29
|
|
Cash basis dividends paid per common
share(2)
|
|
|
0.16
|
|
|
|
0.16
|
|
|
|
0.16
|
|
|
|
0.08
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Trade working capital is defined as trade accounts receivable
from third parties and affiliates net of allowance for doubtful
accounts, plus inventories, less trade accounts payable to third
parties and affiliates. Trade working capital is calculated in
the table below: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Successor
|
|
|
|
Predecessor
|
|
|
|
|
As of December 31,
|
|
|
|
March 31,
|
|
|
|
|
2008
|
|
|
|
2007
|
|
|
|
2006
|
|
|
|
2005
|
|
|
|
2004
|
|
|
|
2004
|
|
|
|
|
(In $ millions)
|
|
Trade receivables, net
|
|
|
|
631
|
|
|
|
|
1,009
|
|
|
|
|
1,001
|
|
|
|
|
919
|
|
|
|
|
866
|
|
|
|
|
810
|
|
Inventories
|
|
|
|
577
|
|
|
|
|
636
|
|
|
|
|
653
|
|
|
|
|
650
|
|
|
|
|
603
|
|
|
|
|
491
|
|
Trade payables
|
|
|
|
(523
|
)
|
|
|
|
(818
|
)
|
|
|
|
(830
|
)
|
|
|
|
(811
|
)
|
|
|
|
(726
|
)
|
|
|
|
(612
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Trade working capital
|
|
|
|
685
|
|
|
|
|
827
|
|
|
|
|
824
|
|
|
|
|
758
|
|
|
|
|
743
|
|
|
|
|
689
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(2) |
|
In the nine months ended December 31, 2004, Celanese GmbH
declared and paid a dividend of 0.12 ($0.14) per share for
the year ended December 31, 2003. Dividends paid to
Celanese and its consolidated subsidiaries eliminate in
consolidation. |
|
(3) |
|
Amounts include accrued capital expenditures. Amounts do not
include capital expenditures related to capital lease
obligations or capital expenditures related to the relocation of
our Ticona plant in Kelsterbach. See Note 24 and
Note 28 to the consolidated financial statements. |
34
|
|
Item 7.
|
Managements
Discussion and Analysis of Financial Condition and Results of
Operations
|
In this Annual Report on
Form 10-K,
the term Celanese refers to Celanese Corporation, a
Delaware corporation, and not its subsidiaries. The terms the
Company, we, our and
us refer to Celanese and its subsidiaries on a
consolidated basis. The term Celanese US refers to
our subsidiary Celanese US Holdings LLC, a Delaware limited
liability company, formally known as BCP Crystal US Holdings
Corp., a Delaware corporation, and not its subsidiaries. The
term Purchaser refers to our subsidiary, Celanese
Europe Holding GmbH & Co. KG, formerly known as BCP
Crystal Acquisition GmbH & Co. KG, a German limited
partnership, and not its subsidiaries, except where otherwise
indicated.
You should read the following discussion and analysis of the
financial condition and the results of operations together with
the consolidated financial statements and the accompanying notes
to the consolidated financial statements, which were prepared in
accordance with accounting principles generally accepted in the
United States of America (US GAAP).
Investors are cautioned that the forward-looking statements
contained in this section involve both risk and uncertainty.
Several important factors could cause actual results to differ
materially from those anticipated by these statements. Many of
these statements are macroeconomic in nature and are, therefore,
beyond the control of management. See Forward-Looking
Statements May Prove Inaccurate below.
Reconciliation of Non-US GAAP Measures: We
believe that using non-US GAAP financial measures to supplement
US GAAP results is useful to investors because such use provides
a more complete understanding of the factors and trends
affecting the business other than disclosing US GAAP results
alone. In this regard, we disclose net debt, which is a non-US
GAAP financial measure. Net debt is defined as total debt less
cash and cash equivalents. We use net debt to evaluate the
capital structure. Net debt is not a substitute for any US GAAP
financial measure. In addition, calculations of net debt
contained in this report may not be consistent with that of
other companies. The most directly comparable financial measure
presented in accordance with US GAAP in our financial statements
for net debt is total debt. For a reconciliation of net debt to
total debt, see Financial Highlights below.
Forward-Looking
Statements May Prove Inaccurate
Managements Discussion and Analysis of Financial Condition
and Results of Operations (MD&A) and other
parts of this Annual Report contain certain forward-looking
statements and information relating to us that are based on the
beliefs of our management as well as assumptions made by, and
information currently available to, us. When used in this
document, words such as anticipate,
believe, estimate, expect,
intend, plan and project and
similar expressions, as they relate to us are intended to
identify forward-looking statements. These statements reflect
our current views with respect to future events, are not
guarantees of future performance and involve risks and
uncertainties that are difficult to predict. Further, certain
forward-looking statements are based upon assumptions as to
future events that may not prove to be accurate. We assume no
obligation to revise or update any forward-looking statements
for any reason, except as required by law.
See the Risk Factors section under Part 1, Item 1A for
a description of risk factors that could significantly affect
our financial results. In addition, the following factors could
cause our actual results to differ materially from those
results, performance or achievements that may be expressed or
implied by such forward-looking statements. These factors
include, among other things:
|
|
|
|
|
changes in general economic, business, political and regulatory
conditions in the countries or regions in which we operate;
|
|
|
|
the length and depth of product and industry business cycles
particularly in the automotive, electrical, electronics and
construction industries;
|
|
|
|
changes in the price and availability of raw materials,
particularly changes in the demand for, supply of, and market
prices of ethylene, methanol, natural gas, wood pulp, fuel oil
and electricity;
|
|
|
|
the ability to pass increases in raw material prices on to
customers or otherwise improve margins through price increases;
|
35
|
|
|
|
|
the ability to maintain plant utilization rates and to implement
planned capacity additions and expansions;
|
|
|
|
the ability to reduce production costs and improve productivity
by implementing technological improvements to existing plants;
|
|
|
|
increased price competition and the introduction of competing
products by other companies;
|
|
|
|
changes in the degree of intellectual property and other legal
protection afforded to our products;
|
|
|
|
compliance costs and potential disruption or interruption of
production due to accidents or other unforeseen events or delays
in construction of facilities;
|
|
|
|
potential liability for remedial actions under existing or
future environmental regulations;
|
|
|
|
potential liability resulting from pending or future litigation,
or from changes in the laws, regulations or policies of
governments or other governmental activities in the countries in
which we operate;
|
|
|
|
changes in currency exchange rates and interest rates; and
|
|
|
|
various other factors, both referenced and not referenced in
this document.
|
Many of these factors are macroeconomic in nature and are,
therefore, beyond our control. Should one or more of these risks
or uncertainties materialize, or should underlying assumptions
prove incorrect, our actual results, performance or achievements
may vary materially from those described in this Annual Report
as anticipated, believed, estimated, expected, intended, planned
or projected. We neither intend nor assume any obligation to
update these forward-looking statements, which speak only as of
their dates.
Overview
During 2008, we made significant strides in strengthening our
competitive position. As detailed below, we advanced our
expansion efforts in Asia, successfully generated cash and used
it to deliver value for our shareholders, settled legacy
litigation matters, carried out our sustainability commitments
and fulfilled our role as a responsible corporate citizen.
2008 Highlights:
|
|
|
|
|
Opened a customer application development center in Shanghai,
China, to support growth in the region for Advanced Engineered
Materials engineering polymers business.
|
|
|
|
Our Board of Directors authorized us to repurchase up to
$500 million of our Series A common stock. During the
year ended December 31, 2008, we repurchased
9,763,200 shares of our Series A common stock for
$378 million pursuant to this authorization.
|
|
|
|
Signed an agreement to establish a 20,000 square-meter
integrated technology and marketing facility in Shanghai, China.
The facility will combine the headquarters for our Asia
businesses, customer application development and research and
development center.
|
|
|
|
Successfully started up our newly constructed 20,000 ton
ultra-high molecular weight polyethylene
(GUR®)
facility, 100,000 ton acetic anhydride facility and 300,000 ton
vinyl acetate monomer (VAM) facility, all located at
our integrated chemical complex in Nanjing, China.
|
|
|
|
Our Nutrinova business and BRAIN AG, a leading European
white biotech company, identified all-natural
compounds for high intensity sweeteners and sweetness enhancers.
|
|
|
|
Introduced
EcoVAEtm,
a new vinyl acetate/ethylene emulsion technology designed to
facilitate the manufacture of high quality, eco-friendly paints
for North America and Asia.
|
|
|
|
Resolved certain legacy litigation matters by entering into a
settlement agreement for $107 million related to sales by
the polyester staple fibers business, which Hoechst AG sold to
KoSa, Inc. in 1998. In addition, we paid 17 million
to settle Sorbates antitrust actions with the European
Commission.
|
36
|
|
|
|
|
Announced plans to build a new
Vectra®
liquid crystal polymer (LCP) production facility
co-located at our integrated chemical complex in Nanjing, China.
Construction for the LCP production facility and start-up dates
will depend on market conditions.
|
|
|
|
Began construction of the worlds largest polyacetal plant
in Hoechst Industrial Park. The state-of-the-art facility is
expected to be operational in 2011 and will replace
Ticonas existing production operations in Kelsterbach,
Germany.
|
|
|
|
Received Green Partner certification from Sony Corporation at
our Ticona plant in Shelby, North Carolina. The certification
recognizes suppliers cooperation of eco-friendly products
and their ability to meet established regulations for
environment-related substances found in components of products
that bear the Sony name.
|
|
|
|
Announced the shutdown of the VAM production unit in Cangrejera,
Mexico and the assessment of the potential closure of acetic
acid and vinyl acetate monomer (VAM) production in
Pardies, France and certain other actions.
|
|
|
|
Released our 2008 Sustainability Report, which details our
industry-leading commitment to safety, health and the
environment across our worldwide operations. The report also
highlights best practices driven by our employees around the
world.
|
|
|
|
Reached an agreement with the Frankfurt, Germany Airport to
receive an advance payment of 322 million associated
with the relocation of our Ticona business in Kelsterbach,
Germany. This advance payment will be in lieu of payments of
200 million and 140 million originally
scheduled to be paid in June 2009 and June 2010, respectively.
|
During the first half of 2008, the US and Europe began to
experience challenging economic conditions that resulted in
significant inflation in raw material and energy pricing.
Despite the challenges, we were able to implement higher pricing
on continued strong demand and higher volumes associated with
our growth strategy in Asia, all of which contributed to growth
in net sales during the period.
During the second half of 2008, recessionary trends stemming
from the US credit crisis quickly spread to other regions
of the world. This triggered an unexpected reduction in consumer
and industrial demand that caused our customers to sharply lower
their inventories during the last few months of the year. As a
result, demand for our products declined dramatically and we
aggressively managed our global production capacity to align
with the current environment. During this period of economic
uncertainty, we remained focused on executing our long-term
strategy to increase the value of Celanese.
2009
Outlook
We expect inventory destocking to diminish in 2009, but do not
foresee a short-term recovery in the global economic
environment. We expect earnings to improve from fourth quarter
levels throughout the year as the impact of destocking and the
negative effects of lower-of-cost or market and first-in,
first-out inventory accounting decrease.
We are taking aggressive actions in response to the expected
prolonged weak demand environment. These actions include an
assessment of our current manufacturing footprint and reductions
of our overall fixed cost structure. Initial fixed cost
reductions have been initiated and are estimated to result in
between $100 million and $120 million of cost savings
annually.
Expansion
in China
The Nanjing complex brings world-class scale to one site for the
production of acetic acid, VAM, acetic anhydride, emulsions,
Celstran®
long fiber reinforced thermoplastic (LFRT),
GUR®,
Vectra®
LCP and compounding. We believe the Nanjing complex will further
enhance our capabilities to better meet the growing needs of our
customers in a number of industries across Asia.
The acetic acid facility located in our Nanjing, China complex
achieved normal operations in June 2007 and we commenced
production of vinyl acetate emulsions at the complex during the
fourth quarter of 2007. During the
37
first quarter of 2008, we commissioned the startup of our LFRT
unit in Nanjing. Our newly constructed 20,000 ton
GUR®
facility, 100,000 ton acetic anhydride facility and 300,000 ton
VAM facility started up during the third quarter of 2008.
Operations for the compounding plant at the complex are expected
to begin during 2009.
In 2008, we announced our plans to build an LCP production
facility at our Nanjing complex. Construction for the LCP
production facility and start-up dates will depend on market
conditions.
Financial
Highlights
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
|
(In $ millions, except percentages)
|
|
|
Statement of Operations Data:
|
|
|
|
|
|
|
|
|
|
|
|
|
Net sales
|
|
|
6,823
|
|
|
|
6,444
|
|
|
|
5,778
|
|
Gross profit
|
|
|
1,256
|
|
|
|
1,445
|
|
|
|
1,309
|
|
Selling, general and administrative expenses
|
|
|
(540
|
)
|
|
|
(516
|
)
|
|
|
(536
|
)
|
Other (charges) gains, net
|
|
|
(108
|
)
|
|
|
(58
|
)
|
|
|
(10
|
)
|
Operating profit
|
|
|
440
|
|
|
|
748
|
|
|
|
620
|
|
Equity in net earnings of affiliates
|
|
|
54
|
|
|
|
82
|
|
|
|
76
|
|
Interest expense
|
|
|
(261
|
)
|
|
|
(262
|
)
|
|
|
(293
|
)
|
Refinancing expenses
|
|
|
|
|
|
|
(256
|
)
|
|
|
(1
|
)
|
Dividend income cost investments
|
|
|
167
|
|
|
|
116
|
|
|
|
79
|
|
Earnings (loss) from continuing operations before tax and
minority interests
|
|
|
434
|
|
|
|
447
|
|
|
|
526
|
|
Earnings (loss) from continuing operations
|
|
|
372
|
|
|
|
336
|
|
|
|
319
|
|
Earnings (loss) from discontinued operations
|
|
|
(90
|
)
|
|
|
90
|
|
|
|
87
|
|
Net earnings
|
|
|
282
|
|
|
|
426
|
|
|
|
406
|
|
Other Data:
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
350
|
|
|
|
291
|
|
|
|
269
|
|
Operating
margin(1)
|
|
|
6.4
|
%
|
|
|
11.6
|
%
|
|
|
10.7
|
%
|
Earnings from continuing operations before tax and minority
interests as a percentage of net sales
|
|
|
6.4
|
%
|
|
|
6.9
|
%
|
|
|
9.1
|
%
|
|
|
|
(1) |
|
Defined as operating profit divided by net sales. |
|
|
|
|
|
|
|
|
|
|
|
As of December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
|
(In $ millions)
|
|
|
Balance Sheet Data:
|
|
|
|
|
|
|
|
|
Short-term borrowings and current installments of long-term
debt third party and affiliates
|
|
|
233
|
|
|
|
272
|
|
Plus: Long-term debt
|
|
|
3,300
|
|
|
|
3,284
|
|
|
|
|
|
|
|
|
|
|
Total debt
|
|
|
3,533
|
|
|
|
3,556
|
|
Less: Cash and cash equivalents
|
|
|
676
|
|
|
|
825
|
|
|
|
|
|
|
|
|
|
|
Net debt
|
|
|
2,857
|
|
|
|
2,731
|
|
|
|
|
|
|
|
|
|
|
Summary
of Consolidated Results Year Ended December 31,
2008 compared with Year Ended December 31, 2007
The challenging economic environment in the United States and
Europe during the first half of 2008 resulted in higher raw
material and energy costs which enabled price increase
initiatives across all segments. During the second half of 2008,
the US credit crisis accelerated the economic slowdown and its
spread to other regions of the world. Despite the halt in
demand, we were able to maintain the majority of our enacted
price increases through the
38
remainder of 2008. As a result, increased prices improved net
sales by 8%. Favorable foreign currency impacts also had a
positive impact on net sales of 3%.
Net sales declined 5% due to decreased volumes. Lower volumes
were primarily a result of decreased demand stemming from the
global economic downturn. As demand declined, particularly
during the fourth quarter of 2008, our customers began
destocking to reduce their inventory levels. In response, we
aggressively managed our global production capacity to align
with the current environment. We expect destocking trends to
continue to a lesser extent into the first quarter of 2009.
Decreased volumes in our acetate flake and tow businesses were
not significantly impacted by the economic downturn. Rather,
decreased flake volumes were the result of our strategic
decision to shift our flake production to our China ventures,
which we account for as cost investments. The full impact of
this shift has been realized during 2008 and thus the resulting
trend of diminishing volumes is not expected to continue.
Gross profit declined as higher raw material, energy and freight
costs more than offset increases in net sales during the period.
The uncertain economic environment resulted in higher natural
gas, ethylene, methanol and other commodity prices during the
first nine months of the year. Our freight costs also increased,
primarily due to increased rates driven by higher energy prices.
Late in 2008, raw material and energy prices declined and we
expect that decline to positively impact gross profit during the
first quarter of 2009.
Other (charges) gains, net increased $50 million during
2008 as compared to 2007:
|
|
|
|
|
|
|
|
|
|
|
Year Ended
|
|
|
|
December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
|
(In $ millions)
|
|
|
Employee termination benefits
|
|
|
(21
|
)
|
|
|
(32
|
)
|
Plant/office closures
|
|
|
(7
|
)
|
|
|
(11
|
)
|
Deferred compensation triggered by Exit Event
|
|
|
|
|
|
|
(74
|
)
|
Insurance recoveries associated with plumbing cases
|
|
|
|
|
|
|
4
|
|
Insurance recoveries associated with Clear Lake, Texas
|
|
|
38
|
|
|
|
40
|
|
Resolution of commercial disputes with a vendor
|
|
|
|
|
|
|
31
|
|
Asset impairments
|
|
|
(115
|
)
|
|
|
(9
|
)(1)
|
Ticona Kelsterbach plant relocation
|
|
|
(12
|
)
|
|
|
(5
|
)
|
Sorbates antitrust actions
|
|
|
8
|
|
|
|
|
|
Other
|
|
|
1
|
|
|
|
(2
|
)
|
|
|
|
|
|
|
|
|
|
Total Other (charges) gains, net
|
|
|
(108
|
)
|
|
|
(58
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Includes $6 million of goodwill impairment |
Other charges increased in 2008 compared to 2007 and includes a
long-lived asset impairment loss of $92 million in
connection with the potential closure of our acetic acid and VAM
production facility in Pardies, France, our VAM production unit
in Cangrejera, Mexico and certain other facilities.
Consideration of this potential capacity reduction was
necessitated by the significant change in the global economic
environment and anticipated lower customer demand. Following the
initial assessment of this capacity reduction, we determined we
would shut down the Cangrejera VAM production unit effective at
the end of February 2009.
In addition, we recognized $23 million of long-lived asset
impairment losses and $13 million of employee termination
benefits in 2008 related to the shutdown of our Pampa, Texas
facility.
Selling, general and administrative expenses increased
$24 million during 2008 primarily due to business
optimization and finance improvement initiatives.
Operating profit decreased due to lower gross profit and higher
other charges and selling, general and administrative costs. The
absence of a $34 million gain on the sale of our Edmonton,
Alberta, Canada facility during 2007 also contributed to lower
operating profit in 2008 as compared to 2007.
Equity in net earnings of affiliates decreased $28 million
during 2008, primarily due to reduced earnings from our Advanced
Engineered Materials affiliates resulting from higher raw
material and energy costs and decreased demand.
39
Our effective income tax rate for 2008 was 15% compared to 25%
in 2007. The effective income tax rate decreased in 2008 due to:
1) a decrease in the valuation allowance 2) tax credits
generated on foreign jurisdictions and 3) the US tax impact of
foreign operations.
The loss from discontinued operations of $90 million during
2008 primarily relates to a legal settlement agreement we
entered into during 2008. Under the settlement agreement, we
agreed to pay $107 million to resolve certain legacy items.
Because the legal proceeding related to sales by the polyester
staple fibers business which Hoechst AG sold to KoSa, Inc. in
1998, the impact of the settlement is reflected within
discontinued operations in the current period. See the
Polyester Staple Antitrust Litigation section in
Note 23 of the consolidated financial statements.
Summary
of Consolidated Results Year Ended December 31,
2007 compared with Year Ended December 31, 2006
For the year ended December 31, 2007, net sales increased
by 12% to $6,444 million compared to the same period in
2006 as increases in pricing and favorable currency impacts more
than offset lower overall volumes. Overall pricing contributed
to a 6% increase in net sales primarily due to a tight global
supply of acetyl, PVOH and emulsion products, and higher acetate
tow and flake prices. Favorable currency impacts (particularly
related to the Euro) also contributed to a 4% increase in net
sales and the acquisition of Acetate Products Limited
(APL) in 2007 increased net sales by
$227 million. Strong volume increases due to increased
market penetration from several of Advanced Engineered
Materials key products and the successful startup of our
acetic acid unit in Nanjing, China helped to partially offset
the decreases in volumes in our Acetyl Intermediates and
Industrial Specialties segments resulting from the temporary
unplanned outage of the acetic acid unit at our Clear Lake,
Texas facility.
Gross profit as a percentage of net sales remained relatively
flat for the year ended December 31, 2007 (22.4%) compared
to the same period in 2006 (22.7%). The slight decrease was
primarily due to lower overall volumes and higher energy and raw
material costs more than offsetting the higher overall prices
and favorable currency impacts (particularly related to the
Euro).
Selling, general and administrative expenses decreased by
$20 million for the year ended December 31, 2007
compared to the same period in 2006. The decrease was primarily
due to the absence of executive severance and legal costs
associated with the Squeeze-Out of $23 million and
long-term incentive plan expenses of $20 million, both
recorded in 2006. Selling, general and administrative expenses
also decreased $5 million due to lower
stock-based
compensation expenses during the year ended December 31,
2007. The decreases were partially offset by $15 million of
additional expenses related to finance improvement initiatives
and $6 million related to the revised deferred compensation
plan expenses.
Other (charges) gains, net increased $48 million during
2007 as compared to 2006:
|
|
|
|
|
|
|
|
|
|
|
Year Ended
|
|
|
|
December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
|
(In $ millions)
|
|
|
Employee termination benefits
|
|
|
(32
|
)
|
|
|
(12
|
)
|
Plant/office closures
|
|
|
(11
|
)
|
|
|
1
|
|
Deferred compensation triggered by Exit Event
|
|
|
(74
|
)
|
|
|
|
|
Insurance recoveries associated with plumbing cases
|
|
|
4
|
|
|
|
5
|
|
Insurance recoveries associated with Clear Lake, Texas
|
|
|
40
|
|
|
|
|
|
Resolution of commercial disputes with a vendor
|
|
|
31
|
|
|
|
|
|
Asset impairments
|
|
|
(9
|
)(1)
|
|
|
|
|
Ticona Kelsterbach plant relocation
|
|
|
(5
|
)
|
|
|
|
|
Other
|
|
|
(2
|
)
|
|
|
(4
|
)
|
|
|
|
|
|
|
|
|
|
Total Other (charges) gains, net
|
|
|
(58
|
)
|
|
|
(10
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Includes $6 million of goodwill impairment |
40
Other charges for employee termination benefits and plant/office
closures include charges related to: 1) our plan to
simplify and optimize our Emulsions and PVOH businesses to
become a leader in technology and innovation and grow in both
new and existing markets and 2) charges related to the sale
of our Pampa, Texas facility. Additionally, we recorded a
$74 million deferred compensation charge in May 2007 as a
result of the triggering of an Exit Event, as defined in
Note 20 to the consolidated financial statements. Also
included in other charges are $40 million in insurance
recoveries we received during the fourth quarter of 2007 in
partial satisfaction of claims that we made based on losses
resulting from the temporary unplanned outage of the acetic acid
unit at our Clear Lake, Texas facility. In addition, during the
fourth quarter of 2007, we received $31 million as a
one-time payment in resolution of commercial disputes with a
vendor.
The net $128 million improvement in operating profit during
the year ended December 31, 2007 as compared to 2006 is a
result of higher net sales, lower selling, general and
administrative expenses and a $34 million gain recorded on
the sale of our Edmonton, Alberta, Canada facility during 2007,
offset by higher other charges, as discussed above.
Equity in net earnings of affiliates increased 8% in the year
ended December 31, 2007 compared to the same period in 2006
due primarily to improved performance from our InfraServ
affiliates.
Interest expense decreased $31 million for the year ended
December 31, 2007 compared to the same period in 2006. The
decrease was primarily related to lower interest rates on the
new senior credit agreement compared to the interest rates on
the senior discount notes and senior subordinated notes, which
were repaid in April 2007 in conjunction with the debt
refinancing (see Note 14 to the consolidated financial
statements for more information). These decreases were partially
offset by an increase in interest expense due to additional
China financing activities in 2007.
Refinancing expenses incurred during 2007 related to our debt
refinancing. As a result of the refinancing, we expensed
$207 million of premiums paid on early redemption of debt.
In addition, we expensed $33 million of unamortized
deferred financing costs and premiums related to the former
$2,454 million senior credit facility, senior discount
notes and senior subordinated notes and $16 million of debt
issuance and other refinancing expenses.
Income tax expense decreased by $93 million to
$110 million for the year ended December 31, 2007. The
effective tax rate for continuing operations for the year ended
December 31, 2007 was 25%, which is less than the combined
US federal and state statutory rate of 39%. The effective tax
rate for 2007 was favorably impacted by (1) an increase in
unrepatriated low-taxed earnings including tax holidays and
(2) the tax benefit related to German Tax Reform of
$39 million recorded during the year ended
December 31, 2007. These benefits are partially offset by
the accounting treatment of recent tax law changes in Mexico.
See Note 19 to the consolidated financial statements for
additional information.
Earnings from discontinued operations primarily relate to Acetyl
Intermediates sale of its oxo products and derivatives
businesses in February 2007, the shut down of its Edmonton,
Alberta, Canada methanol operations during the second quarter of
2007 and its pentaerythritol (PE) operations, which
were discontinued during the third quarter of 2006. As a result,
revenues and expenses related to these businesses and operations
are reflected as a component of discontinued operations.
41
Selected
Data by Business Segment Year Ended
December 31, 2008 Compared with Year Ended
December 31, 2007 and Year Ended December 31, 2007
Compared with Year Ended December 31, 2006
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
Year Ended December 31,
|
|
|
|
|
|
|
|
|
|
Change
|
|
|
|
|
|
|
|
|
Change
|
|
|
|
2008
|
|
|
2007
|
|
|
in $
|
|
|
2007
|
|
|
2006
|
|
|
in $
|
|
|
|
(In $ millions)
|
|
|
Net sales
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Advanced Engineered Materials
|
|
|
1,061
|
|
|
|
1,030
|
|
|
|
31
|
|
|
|
1,030
|
|
|
|
915
|
|
|
|
115
|
|
Consumer Specialties
|
|
|
1,155
|
|
|
|
1,111
|
|
|
|
44
|
|
|
|
1,111
|
|
|
|
876
|
|
|
|
235
|
|
Industrial Specialties
|
|
|
1,406
|
|
|
|
1,346
|
|
|
|
60
|
|
|
|
1,346
|
|
|
|
1,281
|
|
|
|
65
|
|
Acetyl Intermediates
|
|
|
3,875
|
|
|
|
3,615
|
|
|
|
260
|
|
|
|
3,615
|
|
|
|
3,351
|
|
|
|
264
|
|
Other Activities
|
|
|
2
|
|
|
|
2
|
|
|
|
|
|
|
|
2
|
|
|
|
22
|
|
|
|
(20
|
)
|
Inter-segment Eliminations
|
|
|
(676
|
)
|
|
|
(660
|
)
|
|
|
(16
|
)
|
|
|
(660
|
)
|
|
|
(667
|
)
|
|
|
7
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net sales
|
|
|
6,823
|
|
|
|
6,444
|
|
|
|
379
|
|
|
|
6,444
|
|
|
|
5,778
|
|
|
|
666
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other (charges) gains, net
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Advanced Engineered Materials
|
|
|
(29
|
)
|
|
|
(4
|
)
|
|
|
(25
|
)
|
|
|
(4
|
)
|
|
|
6
|
|
|
|
(10
|
)
|
Consumer Specialties
|
|
|
(2
|
)
|
|
|
(4
|
)
|
|
|
2
|
|
|
|
(4
|
)
|
|
|
|
|
|
|
(4
|
)
|
Industrial Specialties
|
|
|
(3
|
)
|
|
|
(23
|
)
|
|
|
20
|
|
|
|
(23
|
)
|
|
|
(11
|
)
|
|
|
(12
|
)
|
Acetyl Intermediates
|
|
|
(78
|
)
|
|
|
72
|
|
|
|
(150
|
)
|
|
|
72
|
|
|
|
|
|
|
|
72
|
|
Other Activities
|
|
|
4
|
|
|
|
(64
|
)
|
|
|
68
|
|
|
|
(64
|
)
|
|
|
(5
|
)
|
|
|
(59
|
)
|
Inter-segment Eliminations
|
|
|
|
|
|
|
(35
|
)
|
|
|
35
|
|
|
|
(35
|
)
|
|
|
|
|
|
|
(35
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other (charges) gains, net
|
|
|
(108
|
)
|
|
|
(58
|
)
|
|
|
(50
|
)
|
|
|
(58
|
)
|
|
|
(10
|
)
|
|
|
(48
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating profit
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Advanced Engineered Materials
|
|
|
32
|
|
|
|
133
|
|
|
|
(101
|
)
|
|
|
133
|
|
|
|
145
|
|
|
|
(12
|
)
|
Consumer Specialties
|
|
|
190
|
|
|
|
199
|
|
|
|
(9
|
)
|
|
|
199
|
|
|
|
165
|
|
|
|
34
|
|
Industrial Specialties
|
|
|
47
|
|
|
|
28
|
|
|
|
19
|
|
|
|
28
|
|
|
|
44
|
|
|
|
(16
|
)
|
Acetyl Intermediates
|
|
|
309
|
|
|
|
616
|
|
|
|
(307
|
)
|
|
|
616
|
|
|
|
456
|
|
|
|
160
|
|
Other Activities
|
|
|
(138
|
)
|
|
|
(228
|
)
|
|
|
90
|
|
|
|
(228
|
)
|
|
|
(190
|
)
|
|
|
(38
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating profit
|
|
|
440
|
|
|
|
748
|
|
|
|
(308
|
)
|
|
|
748
|
|
|
|
620
|
|
|
|
128
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings (loss) from continuing operations before tax and
minority interests
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Advanced Engineered Materials
|
|
|
69
|
|
|
|
189
|
|
|
|
(120
|
)
|
|
|
189
|
|
|
|
201
|
|
|
|
(12
|
)
|
Consumer Specialties
|
|
|
237
|
|
|
|
235
|
|
|
|
2
|
|
|
|
235
|
|
|
|
185
|
|
|
|
50
|
|
Industrial Specialties
|
|
|
47
|
|
|
|
28
|
|
|
|
19
|
|
|
|
28
|
|
|
|
43
|
|
|
|
(15
|
)
|
Acetyl Intermediates
|
|
|
434
|
|
|
|
694
|
|
|
|
(260
|
)
|
|
|
694
|
|
|
|
519
|
|
|
|
175
|
|
Other Activities
|
|
|
(353
|
)
|
|
|
(699
|
)
|
|
|
346
|
|
|
|
(699
|
)
|
|
|
(422
|
)
|
|
|
(277
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings (loss) from continuing operations before tax and
minority interests
|
|
|
434
|
|
|
|
447
|
|
|
|
(13
|
)
|
|
|
447
|
|
|
|
526
|
|
|
|
(79
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Advanced Engineered Materials
|
|
|
76
|
|
|
|
69
|
|
|
|
7
|
|
|
|
69
|
|
|
|
65
|
|
|
|
4
|
|
Consumer Specialties
|
|
|
53
|
|
|
|
51
|
|
|
|
2
|
|
|
|
51
|
|
|
|
39
|
|
|
|
12
|
|
Industrial Specialties
|
|
|
62
|
|
|
|
59
|
|
|
|
3
|
|
|
|
59
|
|
|
|
59
|
|
|
|
|
|
Acetyl Intermediates
|
|
|
150
|
|
|
|
106
|
|
|
|
44
|
|
|
|
106
|
|
|
|
101
|
|
|
|
5
|
|
Other Activities
|
|
|
9
|
|
|
|
6
|
|
|
|
3
|
|
|
|
6
|
|
|
|
5
|
|
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
350
|
|
|
|
291
|
|
|
|
59
|
|
|
|
291
|
|
|
|
269
|
|
|
|
22
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
42
Factors
Affecting Year Ended December 31, 2008 Segment Net Sales
Compared to Year Ended December 31, 2007
The tables below set forth the percentage increase (decrease) in
net sales attributable to each of the factors indicated in each
of our business segments.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Volume
|
|
|
Price
|
|
|
Currency
|
|
|
Other
|
|
|
Total
|
|
|
|
(In percentages)
|
|
|
Advanced Engineered Materials
|
|
|
(4
|
)
|
|
|
3
|
|
|
|
4
|
|
|
|
|
|
|
|
3
|
|
Consumer Specialties
|
|
|
(6
|
)
|
|
|
7
|
|
|
|
1
|
|
|
|
2
|
(b)
|
|
|
4
|
|
Industrial Specialties
|
|
|
(10
|
)
|
|
|
11
|
|
|
|
4
|
|
|
|
(1
|
)(c)
|
|
|
4
|
|
Acetyl Intermediates
|
|
|
(3
|
)
|
|
|
7
|
|
|
|
3
|
|
|
|
|
|
|
|
7
|
|
Total
Company(a)
|
|
|
(5
|
)
|
|
|
8
|
|
|
|
3
|
|
|
|
|
|
|
|
6
|
|
Factors
Affecting Year Ended December 31, 2007 Segment Net Sales
Compared to Year Ended December 31, 2006
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Volume
|
|
|
Price
|
|
|
Currency
|
|
|
Other
|
|
|
Total
|
|
|
|
(In percentages)
|
|
|
Advanced Engineered Materials
|
|
|
9
|
|
|
|
(1
|
)
|
|
|
5
|
|
|
|
|
|
|
|
13
|
|
Consumer Specialties
|
|
|
(4
|
)
|
|
|
4
|
|
|
|
1
|
|
|
|
26
|
(b)
|
|
|
27
|
|
Industrial Specialties
|
|
|
(1
|
)
|
|
|
2
|
|
|
|
5
|
|
|
|
(1
|
)(c)
|
|
|
5
|
|
Acetyl Intermediates
|
|
|
(5
|
)
|
|
|
9
|
|
|
|
4
|
|
|
|
|
|
|
|
8
|
|
Total
Company(a)
|
|
|
(2
|
)
|
|
|
6
|
|
|
|
4
|
|
|
|
4
|
|
|
|
12
|
|
|
|
|
(a) |
|
Includes the effects of the captive insurance companies. |
|
(b) |
|
Includes net sales from the APL acquisition. |
|
(c) |
|
Includes loss of sales related to the AT Plastics Films
business. |
Summary
by Business Segment Year Ended December 31,
2008 Compared with Year Ended December 31, 2007
Advanced
Engineered Materials
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
Change
|
|
|
|
2008
|
|
|
2007
|
|
|
in $
|
|
|
|
(In $ millions, except percentages)
|
|
|
Net sales
|
|
|
1,061
|
|
|
|
1,030
|
|
|
|
31
|
|
Net sales variance:
|
|
|
|
|
|
|
|
|
|
|
|
|
Volume
|
|
|
(4
|
)%
|
|
|
|
|
|
|
|
|
Price
|
|
|
3
|
%
|
|
|
|
|
|
|
|
|
Currency
|
|
|
4
|
%
|
|
|
|
|
|
|
|
|
Other
|
|
|
0
|
%
|
|
|
|
|
|
|
|
|
Operating profit
|
|
|
32
|
|
|
|
133
|
|
|
|
(101
|
)
|
Operating margin
|
|
|
3.0
|
%
|
|
|
12.9
|
%
|
|
|
|
|
Other (charges) gains, net
|
|
|
(29
|
)
|
|
|
(4
|
)
|
|
|
(25
|
)
|
Earnings (loss) from continuing operations before tax and
minority interests
|
|
|
69
|
|
|
|
189
|
|
|
|
(120
|
)
|
Depreciation and amortization
|
|
|
76
|
|
|
|
69
|
|
|
|
7
|
|
Our Advanced Engineered Materials segment develops, produces and
supplies a broad portfolio of high performance technical
polymers for application in automotive and electronics products,
as well as other consumer and industrial applications. Together
with our strategic affiliates, we are a leading participant in
the global technical polymers industry. The primary products of
Advanced Engineered Materials are POM, PPS, LFRT, PBT, PET,
43
GUR®
and LCP. POM, PPS, LFRT, PBT and PET are used in a broad range
of products including automotive components, electronics,
appliances and industrial applications.
GUR®
is used in battery separators, conveyor belts, filtration
equipment, coatings and medical devices. Primary end markets for
LCP are electrical and electronics.
Net sales increased 3% during 2008 as compared to 2007 primarily
as a result of implemented pricing increases combined with
favorable foreign currency impacts. Increases in net sales were
partially offset by lower volumes due to significant weakness in
the US and European automotive and housing industries. Extended
plant shutdowns enacted by major car manufacturers during the
fourth quarter of 2008 contributed significantly to the volume
decline.
Operating profit declined $101 million primarily due to
higher raw material, freight and energy costs. Raw material
costs increased on higher prices while freight costs increased
as a result of increased freight rates and larger shipments to
Asia. Raw material costs declined late in 2008 and we expect to
realize a benefit from the lower prices early in 2009 as our
higher-cost inventory levels diminish. Higher depreciation and
amortization expense and increased other charges also
contributed to lower operating profit. Depreciation and
amortization expense are higher in 2008 due to the
start-up of
the
GUR®
and LFRT units in Asia. Other charges consist primarily of a
$16 million long-lived asset impairment loss related to the
potential closure of certain Advanced Engineered Materials
facilities and $12 million related to the relocation of our
Ticona plant in Kelsterbach. See Ticona Kelsterbach Plant
Relocation below.
Earnings from continuing operations before tax and minority
interests decreased due to decreased operating profit and
decreased equity in net earnings of affiliates. Equity in net
earnings of affiliates decreased $18 million during 2008,
primarily due to reduced earnings from our Advanced Engineered
Materials affiliates resulting from higher raw material
and energy costs and decreased demand.
Ticona
Kelsterbach Plant Relocation
In 2007, we finalized a settlement agreement with the Frankfurt,
Germany Airport (Fraport) to relocate our
Kelsterbach, Germany, business, resolving several years of legal
disputes related to the planned Frankfurt airport expansion. As
a result of the settlement, we will transition Ticonas
operations from Kelsterbach to the Hoechst Industrial Park in
the Rhine Main area by mid-2011. Over a five-year period,
Fraport will pay Ticona a total of 670 million to
offset the costs associated with the transition of the business
from its current location and the closure of the Kelsterbach
plant. In June 2008, we received 200 million
($311 million) from Fraport under this agreement. Amounts
received from Fraport are accounted for as deferred proceeds and
are included in noncurrent other liabilities in the consolidated
balance sheets.
In February 2009, we announced the Fraport supervisory board
approved the acceleration of the 2009 and 2010 payments of
200 million and 140 million, respectively,
required by the settlement agreement signed in June 2007. On
February 5, 2009, we received a discounted amount of
approximately 322 million, excluding value-added tax
of 59 million.
Below is a summary of the cash flow activity and financial
statement impact associated with the Ticona plant relocation:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended
|
|
|
Total From
|
|
|
|
December 31,
|
|
|
Inception through
|
|
|
|
2008
|
|
|
2007
|
|
|
December 31, 2008
|
|
|
|
(In $ millions)
|
|
|
Proceeds received from Fraport
|
|
|
311
|
|
|
|
|
|
|
|
337
|
|
Costs expensed
|
|
|
12
|
|
|
|
5
|
|
|
|
17
|
|
Costs
capitalized(1)
|
|
|
202
|
|
|
|
40
|
|
|
|
243
|
|
|
|
|
(1) |
|
Includes an increase in accrued capital expenditures of
$17 million and $19 million during the years ended
December 31, 2008 and 2007, respectively. |
44
Consumer
Specialties
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
Change
|
|
|
|
2008
|
|
|
2007
|
|
|
in $
|
|
|
|
(In $ millions, except percentages)
|
|
|
Net sales
|
|
|
1,155
|
|
|
|
1,111
|
|
|
|
44
|
|
Net sales variance:
|
|
|
|
|
|
|
|
|
|
|
|
|
Volume
|
|
|
(6
|
)%
|
|
|
|
|
|
|
|
|
Price
|
|
|
7
|
%
|
|
|
|
|
|
|
|
|
Currency
|
|
|
1
|
%
|
|
|
|
|
|
|
|
|
Other
|
|
|
2
|
%
|
|
|
|
|
|
|
|
|
Operating profit
|
|
|
190
|
|
|
|
199
|
|
|
|
(9
|
)
|
Operating margin
|
|
|
16.4
|
%
|
|
|
17.9
|
%
|
|
|
|
|
Other (charges) gains, net
|
|
|
(2
|
)
|
|
|
(4
|
)
|
|
|
2
|
|
Earnings (loss) from continuing operations before tax and
minority interests
|
|
|
237
|
|
|
|
235
|
|
|
|
2
|
|
Depreciation and amortization
|
|
|
53
|
|
|
|
51
|
|
|
|
2
|
|
Our Consumer Specialties segment consists of our Acetate
Products and Nutrinova businesses. Our Acetate Products business
primarily produces and supplies acetate tow, which is used in
the production of filter products. We also produce acetate flake
which is processed into acetate fiber in the form of a tow band.
Our Nutrinova business produces and sells
Sunett®,
a high intensity sweetener, and food protection ingredients,
such as sorbates, for the food, beverage and pharmaceuticals
industries.
Net sales increased 4% to $1,155 million during the year
ended December 31, 2008 driven primarily by pricing actions
in our Acetate Products business and an additional month of
sales from our Acetate Products Limited (APL)
acquisition, which was acquired on January 31, 2007, offset
by lower volumes. Lower volumes are a direct result of our
strategic decision to shift acetate flake production to our
China ventures, which are accounted for as cost method
investments. The full impact of this shift has been realized
during 2008 and thus the resulting trend of diminishing volumes
is not expected to continue. Lower flake volumes were partially
offset by a 5% increase in tow volumes as we were able to
capture a portion of the growth in global tow demand.
The increase in net sales due to higher sales prices during 2008
was offset most significantly by higher energy costs, and to a
lesser extent, higher raw material and freight costs. Operating
profit, as compared to 2007, declined primarily due to the
absence of a $22 million gain on the sale of our Edmonton,
Alberta, Canada facility in 2007. Other charges during 2007
includes $3 million of deferred compensation plan expenses
and $5 million of other restructuring charges, offset by
insurance recoveries of $5 million for partial satisfaction
of the business interruption losses resulting from the temporary
unplanned outage of the acetic acid unit at our Clear Lake,
Texas facility.
Earnings from continuing operations before tax and minority
interests of $237 million increased from 2007 as increased
dividends from our China ventures more than offset the decline
in operating profit. Increased dividends are the result of
increased volumes and higher prices, as well as efficiency
improvements.
45
Industrial
Specialties
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
Change
|
|
|
|
2008
|
|
|
2007
|
|
|
in $
|
|
|
|
(In $ millions, except percentages)
|
|
|
Net sales
|
|
|
1,406
|
|
|
|
1,346
|
|
|
|
60
|
|
Net sales variance:
|
|
|
|
|
|
|
|
|
|
|
|
|
Volume
|
|
|
(10
|
)%
|
|
|
|
|
|
|
|
|
Price
|
|
|
11
|
%
|
|
|
|
|
|
|
|
|
Currency
|
|
|
4
|
%
|
|
|
|
|
|
|
|
|
Other
|
|
|
(1
|
)%
|
|
|
|
|
|
|
|
|
Operating profit
|
|
|
47
|
|
|
|
28
|
|
|
|
19
|
|
Operating margin
|
|
|
3.3
|
%
|
|
|
2.1
|
%
|
|
|
|
|
Other (charges) gains, net
|
|
|
(3
|
)
|
|
|
(23
|
)
|
|
|
20
|
|
Earnings (loss) from continuing operations before tax and
minority interests
|
|
|
47
|
|
|
|
28
|
|
|
|
19
|
|
Depreciation and amortization
|
|
|
62
|
|
|
|
59
|
|
|
|
3
|
|
Our Industrial Specialties segment includes our Emulsions, PVOH
and AT Plastics businesses. Our Emulsions business is a global
leader which produces a broad product portfolio, specializing in
vinyl acetate ethylene emulsions, and is a recognized authority
on low VOC (volatile organic compounds), an
environmentally-friendly technology. As a global leader, our
PVOH business produces a broad portfolio of performance PVOH
chemicals engineered to meet specific customer requirements. Our
emulsions and PVOH products are used in a wide array of
applications including paints and coatings, adhesives, building
and construction, glass fiber, textiles and paper. AT Plastics
offers a complete line of low-density polyethylene and specialty
ethylene vinyl acetate resins and compounds. AT Plastics
products are used in many applications including flexible
packaging films, lamination film products, hot melt adhesives,
medical tubing, automotive carpeting and solar cell
encapsulation films.
Net sales increased by 4% during 2008 as increased prices and
favorable foreign currency impacts more than offset volume
reductions. Pricing actions implemented by all business lines
late in 2007 and during 2008 contributed to the increase in net
sales. Volumes declined primarily on decreased demand across all
regions due to the global economic downturn combined with the
temporary shutdown of our AT Plastics plant late in 2008. The
overall volume decline was partially offset by increased
emulsions volumes at our Nanjing, China facility, which began
operating late in 2008.
Increased net sales were more than offset by higher raw material
and energy costs during 2008. The $19 million increase in
operating profit was primarily due to lower other charges and
the absence of the $7 million loss on the divestiture of
our AT Plastics Films business in 2007. During 2007, we
initiated a plan to simplify and optimize our Emulsions and PVOH
businesses to focus on technology and innovation. Other charges
during 2008 includes a charge of $3 million for employee
termination benefits and accelerated depreciation related to
this plan. Other charges during 2007 includes a charge of
$14 million for employee termination benefits,
$3 million for an impairment of long-lived assets and
$5 million of accelerated depreciation expense for our
shuttered United Kingdom plant related to this plan. Other
charges in 2007 also include $6 million of goodwill
impairment and receipt of $7 million in insurance
recoveries in partial satisfaction of the business interruption
losses resulting from the temporary unplanned outage of the
acetic acid unit at our Clear Lake, Texas facility.
46
Acetyl
Intermediates
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
Change
|
|
|
|
2008
|
|
|
2007
|
|
|
in $
|
|
|
|
(In $ millions, except percentages)
|
|
|
Net sales
|
|
|
3,875
|
|
|
|
3,615
|
|
|
|
260
|
|
Net sales variance:
|
|
|
|
|
|
|
|
|
|
|
|
|
Volume
|
|
|
(3
|
)%
|
|
|
|
|
|
|
|
|
Price
|
|
|
7
|
%
|
|
|
|
|
|
|
|
|
Currency
|
|
|
3
|
%
|
|
|
|
|
|
|
|
|
Other
|
|
|
0
|
%
|
|
|
|
|
|
|
|
|
Operating profit
|
|
|
309
|
|
|
|
616
|
|
|
|
(307
|
)
|
Operating margin
|
|
|
8.0
|
%
|
|
|
17.0
|
%
|
|
|
|
|
Other (charges) gains, net
|
|
|
(78
|
)
|
|
|
72
|
|
|
|
(150
|
)
|
Earnings (loss) from continuing operations before tax and
minority interests
|
|
|
434
|
|
|
|
694
|
|
|
|
(260
|
)
|
Depreciation and amortization
|
|
|
150
|
|
|
|
106
|
|
|
|
44
|
|
Our Acetyl Intermediates segment produces and supplies acetyl
products, including acetic acid, VAM, acetic anhydride and
acetate esters. These products are generally used as starting
materials for colorants, paints, adhesives, coatings, medicines
and more. Other chemicals produced in this segment are organic
solvents and intermediates for pharmaceutical, agricultural and
chemical products.
Net sales increased by 7% during 2008 primarily due to increased
prices and favorable foreign currency impacts, partially offset
by lower volumes. Our formula-based pricing arrangements
benefited from higher ethylene and methanol costs during the
first nine months of 2008. Market tightness in the Americas and
favorable foreign currency impacts in Europe also contributed to
the increase in net sales. Reduced volumes offset the increase
in net sales as the slowdown of the global economy caused
customers to slow production and diminish current inventory
levels, particularly in Asia during the fourth quarter. We
expect the impact of our customers destocking initiatives
to continue to a lesser extent during 2009. Ethylene and
methanol prices decreased during the fourth quarter of 2008 on
slowed global demand.
Operating profit declined $307 million primarily as a
result of higher ethylene, methanol and energy prices, increased
other charges, increased depreciation and amortization and the
absence of a $12 million gain on the sale of our Edmonton
facility in 2007. Other charges increased during 2008 partially
due to $76 million of long-lived asset impairment losses
recognized in 2008 related to the potential closure of our
acetic acid and VAM production facility in Pardies, France, our
VAM production unit in Cangrejera, Mexico (which we subsequently
decided to shut down effective at the end of February 2009) and
certain other facilities. Other charges in 2008 also includes
$23 million of long-lived asset impairment and
$13 million of severance and retention charges related to
the shutdown of our Pampa, Texas facility. Also contributing to
the increase was the absence of a one-time payment of
$31 million received in 2007 in resolution of commercial
disputes with a vendor and a $25 million decrease in
insurance recoveries received in partial satisfaction of the
losses resulting from the temporary outage of the acetic acid
unit at our Clear Lake, Texas facility. Increased depreciation
and amortization expense during 2008 is the result of
accelerated depreciation associated with the shutdown of our
Pampa, Texas facility and a full year of depreciation for our
acetic acid plant in Nanjing, China, which started up in
mid-2007.
Earnings from continuing operations before tax and minority
interest differs from operating profit primarily as a result of
dividend income from our cost investment, National Methanol Co.
(Ibn Sina). Increased dividend income of
$41 million during 2008 had a positive impact on earnings
from continuing operations before tax and minority interest. Ibn
Sina increased their dividends as a result of higher earnings
from expanding margins for methanol and methyl tertiary-butyl
ether.
47
Other
Activities
Other Activities primarily consists of corporate center costs,
including finance and administrative activities, and our captive
insurance companies.
Net sales remained flat in 2008 as compared to 2007. We do not
expect third-party revenues from our captive insurance companies
to increase significantly in the near future.
The operating loss for Other Activities improved
$90 million during 2008 as compared to 2007 due to lower
other charges, partially offset by higher selling, general and
administrative expenses. Other charges decreased principally due
to the release of reserves related to the Sorbates antitrust
actions settlement of $8 million and the absence of
$59 million of deferred compensation plan costs which were
incurred during 2007. Selling, general and administrative
expenses increased due to additional spending on business
optimization and finance improvement initiatives during 2008.
The loss from continuing operations before tax and minority
interests decreased $346 million during 2008. The
significant decrease was primarily due to the absence of
$256 million of refinancing costs incurred in 2007 and the
decrease in the operating loss discussed above.
Summary
by Business Segment Year Ended December 31,
2007 Compared with Year Ended December 31, 2006
Advanced
Engineered Materials
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
Change
|
|
|
|
2007
|
|
|
2006
|
|
|
in $
|
|
|
|
(In $ millions, except percentages)
|
|
|
Net sales
|
|
|
1,030
|
|
|
|
915
|
|
|
|
115
|
|
Net sales variance:
|
|
|
|
|
|
|
|
|
|
|
|
|
Volume
|
|
|
9
|
%
|
|
|
|
|
|
|
|
|
Price
|
|
|
(1
|
)%
|
|
|
|
|
|
|
|
|
Currency
|
|
|
5
|
%
|
|
|
|
|
|
|
|
|
Other
|
|
|
0
|
%
|
|
|
|
|
|
|
|
|
Operating profit
|
|
|
133
|
|
|
|
145
|
|
|
|
(12
|
)
|
Operating margin
|
|
|
12.9
|
%
|
|
|
15.8
|
%
|
|
|
|
|
Other (charges) gains, net
|
|
|
(4
|
)
|
|
|
6
|
|
|
|
(10
|
)
|
Earnings (loss) from continuing operations before tax and
minority interests
|
|
|
189
|
|
|
|
201
|
|
|
|
(12
|
)
|
Depreciation and amortization
|
|
|
69
|
|
|
|
65
|
|
|
|
4
|
|
Advanced Engineered Materials net sales increased 13% for
the year ended December 31, 2007 compared to the same
period in 2006 primarily due to volume growth in all major
business lines and favorable currency impacts partially offset
by a slight decline in pricing. Overall volume for the year
increased, principally driven by increased market penetration,
successful implementation of new projects and a continued strong
business environment, particularly in Europe. Advanced
Engineered Materials experienced a slight decline in average
pricing primarily driven by a larger mix of sales from lower
priced products.
Operating profit decreased to $133 million for the year
ended December 31, 2007 compared to $145 million for
the same period in 2006 as higher volumes and favorable currency
impacts were more than offset by higher energy costs, increased
other charges and slightly lower average pricing. Other charges
increased primarily due to $2 million of deferred
compensation plan expenses and $5 million of Kelsterbach
plant relocation costs, both incurred in 2007.
Earnings from continuing operations before tax and minority
interests decreased 6% to $189 million for the year ended
December 31, 2007 compared to the same period in 2006
primarily due to lower operating profits in 2007 driven by
increased other charges as discussed above.
48
Consumer
Specialties
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
Change
|
|
|
|
2007
|
|
|
2006
|
|
|
in $
|
|
|
|
(In $ millions, except percentages)
|
|
|
Net sales
|
|
|
1,111
|
|
|
|
876
|
|
|
|
235
|
|
Net sales variance:
|
|
|
|
|
|
|
|
|
|
|
|
|
Volume
|
|
|
(4
|
)%
|
|
|
|
|
|
|
|
|
Price
|
|
|
4
|
%
|
|
|
|
|
|
|
|
|
Currency
|
|
|
1
|
%
|
|
|
|
|
|
|
|
|
Other
|
|
|
26
|
%
|
|
|
|
|
|
|
|
|
Operating profit
|
|
|
199
|
|
|
|
165
|
|
|
|
34
|
|
Operating margin
|
|
|
17.9
|
%
|
|
|
18.8
|
%
|
|
|
|
|
Other (charges) gains, net
|
|
|
(4
|
)
|
|
|
|
|
|
|
(4
|
)
|
Earnings (loss) from continuing operations before tax and
minority interests
|
|
|
235
|
|
|
|
185
|
|
|
|
50
|
|
Depreciation and amortization
|
|
|
51
|
|
|
|
39
|
|
|
|
12
|
|
Consumer Specialties net sales increased 27% for the year
ended December 31, 2007 compared to the same period in 2006
primarily driven by additional net sales from the APL
acquisition completed on January 31, 2007. Net sales for
APL were $227 million during the year ended
December 31, 2007. Higher pricing for acetate tow and flake
products, higher
Sunett®
sweetener volumes and favorable currency impacts for the
Nutrinova business also contributed to the overall increase in
net sales. Higher
Sunett®
sweetener volumes reflected the continued growth in the global
beverage and confectionary markets. These increases were
partially offset by lower acetate flake volumes and
Nutrinovas exit of non-core lower margin trade business
during the fourth quarter of 2006. The decrease in acetate flake
volumes was due primarily to the shift in production of acetate
flake to our China ventures.
Operating profit increased $34 million for the year ended
December 31, 2007 compared to the same period in 2006.
Higher overall pricing more than offset increases in raw
material costs. Higher overall costs were primarily due to price
increases in wood pulp, acetyls (used as raw materials in
acetate flake production) and acetate flake as well as expenses
associated with the continued integration of APL. Other charges
during the year ended December 31, 2007 includes
$3 million of deferred compensation plan expenses,
$5 million of other restructuring charges and insurance
recoveries of $5 million for partial satisfaction of the
losses resulting from the temporary unplanned outage of the
acetic acid unit at our Clear Lake, Texas facility. Also
included in operating profit for the year ended
December 31, 2007 is a $22 million gain related to the
sale of our Edmonton, Alberta, Canada facility.
Earnings from continuing operations before tax and minority
interests increased $50 million to $235 million for
the year ended December 31, 2007 compared to the same
period in 2006. The increase was driven principally by the
changes in operating profit discussed above and an increase of
$16 million in dividends received from our China ventures
during the year ended December 31, 2007 compared to the
same period in 2006.
Depreciation and amortization increased $12 million to
$51 million for the year ended December 31, 2007
compared to the same period in 2006 primarily driven by the
acquisition of APL in 2007.
49
Industrial
Specialties
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
Change
|
|
|
|
2007
|
|
|
2006
|
|
|
in $
|
|
|
|
(In $ millions, except percentages)
|
|
|
Net sales
|
|
|
1,346
|
|
|
|
1,281
|
|
|
|
65
|
|
Net sales variance:
|
|
|
|
|
|
|
|
|
|
|
|
|
Volume
|
|
|
(1
|
)%
|
|
|
|
|
|
|
|
|
Price
|
|
|
2
|
%
|
|
|
|
|
|
|
|
|
Currency
|
|
|
5
|
%
|
|
|
|
|
|
|
|
|
Other
|
|
|
(1
|
)%
|
|
|
|
|
|
|
|
|
Operating profit
|
|
|
28
|
|
|
|
44
|
|
|
|
(16
|
)
|
Operating margin
|
|
|
2.1
|
%
|
|
|
3.4
|
%
|
|
|
|
|
Other (charges) gains, net
|
|
|
(23
|
)
|
|
|
(11
|
)
|
|
|
(12
|
)
|
Earnings (loss) from continuing operations before tax and
minority interests
|
|
|
28
|
|
|
|
43
|
|
|
|
(15
|
)
|
Depreciation and amortization
|
|
|
59
|
|
|
|
59
|
|
|
|
|
|
Industrial Specialties net sales for the year ended
December 31, 2007 increased 5% to $1,346 million
compared to the same period in 2006 primarily driven by pricing
increases and favorable currency impacts partially offset by a
slight decrease in volumes. Higher overall pricing, particularly
in our emulsions and PVOH products, was primarily due to market
tightness and increasing raw material costs which allowed for
upward movement in pricing across all regions. Lower volumes
were primarily driven by the tight supply of VAM, a major raw
material used in the production of emulsions products. This was
a result of the temporary unplanned outage of the acetic acid
unit at our Clear Lake, Texas facility and other global planned
and unplanned production outages in the chemical industry during
the year ended December 31, 2007. The increase in net sales
was partially offset by the absence of net sales from the AT
Plastics Films business, which was divested during the
third quarter of 2007.
Operating profit decreased $16 million to $28 million
for the year ended December 31, 2007 compared to the same
period in 2006. Higher prices and favorable currency impacts
were more than offset by the increase in other charges. Other
charges for the year ended December 31, 2007 included
$14 million of employee termination benefits,
$3 million for an impairment of long-lived assets and
$5 million of accelerated depreciation expense for our
shuttered United Kingdom plant. These increases were a result of
our plan to simplify and optimize our Emulsions and PVOH
businesses to become a leader in technology and innovation and
grow in both new and existing markets. Other charges for the
year ended December 31, 2007 also included $6 million
of goodwill impairment. The increase in other charges was
partially offset by insurance recoveries of $7 million for
partial satisfaction of the losses resulting from the temporary
unplanned outage of the acetic acid unit at our Clear Lake,
Texas facility. Additionally, operating profit decreased by
$7 million during the year ended December 31, 2007 as
a result of the loss on the divestiture of our AT Plastics
Films business.
Earnings from continuing operations before tax and minority
interests decreased $15 million to $28 million for the
year ended December 31, 2007 compared to the same period in
2006 principally driven by lower operating profits.
50
Acetyl
Intermediates
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended
|
|
|
|
|
|
|
December 31,
|
|
|
Change
|
|
|
|
2007
|
|
|
2006
|
|
|
in $
|
|
|
|
(In $ millions, except percentages)
|
|
|
Net sales
|
|
|
3,615
|
|
|
|
3,351
|
|
|
|
264
|
|
Net sales variance:
|
|
|
|
|
|
|
|
|
|
|
|
|
Volume
|
|
|
(5
|
)%
|
|
|
|
|
|
|
|
|
Price
|
|
|
9
|
%
|
|
|
|
|
|
|
|
|
Currency
|
|
|
4
|
%
|
|
|
|
|
|
|
|
|
Other
|
|
|
0
|
%
|
|
|
|
|
|
|
|
|
Operating profit
|
|
|
616
|
|
|
|
456
|
|
|
|
160
|
|
Operating margin
|
|
|
17.0
|
%
|
|
|
13.6
|
%
|
|
|
|
|
Other (charges) gains, net
|
|
|
72
|
|
|
|
|
|
|
|
72
|
|
Earnings (loss) from continuing operations before tax and
minority interests
|
|
|
694
|
|
|
|
519
|
|
|
|
175
|
|
Depreciation and amortization
|
|
|
106
|
|
|
|
101
|
|
|
|
5
|
|
Acetyl Intermediates net sales for the year ended
December 31, 2007 increased 8% to $3,615 million
compared to the same period in 2006 driven by pricing increases
and favorable currency impacts partially offset by lower
volumes. Tight supply of acetyl products caused by global
planned and unplanned production outages in the industry and
higher methanol and ethylene prices were the drivers of the
price increases. Lower volumes in 2007 were the result of lower
product availability due to the temporary unplanned outage of
the acetic acid unit at our Clear Lake, Texas facility. However,
the decrease in volumes from the Clear Lake, Texas facility was
partially offset by the successful startup of our acetic acid
plant in Nanjing, China and externally procured product.
Operating profit increased to $616 million for the year
ended December 31, 2007 compared to $456 million in
the same period in 2006. Higher pricing, favorable currency
impacts and an improvement in other charges were partially
offset by higher raw material costs. Other charges for the year
ended December 31, 2007 included $4 million of
employee termination benefits and $5 million of expenses
related to accelerated depreciation expense, both associated
with the shutdown of our Pampa, Texas plant, and
$10 million for deferred compensation plan expenses. These
charges were more than offset by $31 million related to a
one-time payment received in resolution of commercial disputes
with a vendor and insurance recoveries of $28 million for
partial satisfaction of the losses resulting from the temporary
unplanned outage of the acetic acid unit at our Clear Lake,
Texas facility. Acetyl Intermediates also received
$35 million of insurance recoveries from our captive
insurance companies relating to the unplanned outage of the
acetic acid unit at our Clear Lake, Texas facility. This amount
is included in Acetyl Intermediates other charges but is
properly eliminated in our consolidated statements of
operations. Operating profit also includes a gain on the sale of
our Edmonton facility of $12 million.
Earnings from continuing operations before tax and minority
interests increased $175 million to $694 million for
the year ended December 31, 2007 compared to the same
period in 2006 primarily driven by higher operating profit and
an increase in dividend income from our cost investments.
Dividend income from Ibn Sina cost investment increased
$24 million due to increased earnings for the year ended
December 31, 2007 compared to the same period in 2006.
Other
Activities
Net sales for Other Activities decreased to $2 million from
$22 million for the year ended December 31, 2007
compared to the same period in 2006. This decrease was
principally driven by the decrease in third-party revenues from
our captive insurance companies.
Operating loss increased to $228 million for the year ended
December 31, 2007 compared to $190 million in the same
period in 2006. This increase was principally driven by an
increase in other charges more than offsetting a decrease in
selling, general and administrative expenses. Other charges
increased primarily due to $59 million of deferred
compensation plan costs expensed in 2007. Selling, general and
administrative expenses decreased for the
51
year ended December 31, 2007 primarily due to the absence
of executive severance and legal costs associated with the
Squeeze-Out of $23 million and long-term incentive plan
expenses of $20 million recorded in 2006.
Loss from continuing operations before tax and minority
interests increased $277 million to $699 million for
the year ended December 31, 2007 compared to the same
period in 2006. The increase was primarily driven by the
increase in operating loss discussed above and higher
refinancing expenses incurred in 2007, partially offset by lower
interest expense. During the year ended December 31, 2007,
we incurred $256 million of refinancing expenses associated
with the April 2, 2007 debt refinancing. Interest expense
decreased $31 million during the year ended
December 31, 2007 compared to the same period in 2006
primarily related to lower interest rates on the new senior
credit agreement compared to the interest rates on the senior
discount notes and senior subordinated notes, which were repaid
in April 2007 in conjunction with the debt refinancing. In
addition, during the year ended December 31, 2007, we
incurred $26 million of mark-to-market loss on the cross
currency swap and the Euro denominated term loan that had been
used as a hedge of our net investment in our European
subsidiaries.
Liquidity
and Capital Resources
Our primary source of liquidity is cash generated from
operations, available cash and cash equivalents and dividends
from our portfolio of strategic investments. In addition, we
have a $650 million revolving credit facility and a
$228 million credit-linked revolving facility to assist, if
required, in meeting our working capital needs and other
contractual obligations. In excess of 20 lenders participate in
our revolving credit facility, each with a commitment of not
more than 10% of the $650 million commitment. Further,
Lehman Brothers Holdings, Inc., which filed for protection under
Chapter 11 of the United States Bankruptcy Code in
September 2008, is not a lender under our revolving credit
facility and we do not have any other material direct exposure
to Lehman Brothers Holdings, Inc.
While our contractual obligations, commitments and debt service
requirements over the next several years are significant, we
continue to believe we will have available resources to meet our
liquidity requirements, including debt service, for the
remainder of 2009. If our cash flow from operations is
insufficient to fund our debt service and other obligations, we
may be required to use other means available to us such as
increasing our borrowings, reducing or delaying capital
expenditures, seeking additional capital or seeking to
restructure or refinance our indebtedness. There can be no
assurance, however, that we will continue to generate cash flows
at or above current levels or that we will be able to maintain
our ability to borrow under our revolving credit facilities.
On a stand-alone basis, Celanese Corporation has no material
assets other than the stock of our subsidiaries and no
independent external operations of our own. As such, we
generally will depend on the cash flow of our subsidiaries to
meet our obligations under our preferred stock, our
Series A common stock and our senior credit agreement.
Cash
Flows
Cash and cash equivalents as of December 31, 2008 were
$676 million, which was a decrease of $149 million
from December 31, 2007. Cash and cash equivalents as of
December 31, 2007 were $825 million, which was an
increase of $34 million from December 31, 2006. See
below for details on the change in cash and cash equivalents
from December 31, 2007 to December 31, 2008 and the
change in cash and cash equivalents from December 31, 2006
to December 31, 2007.
Net Cash
Provided by Operating Activities
Cash flow provided by operating activities increased
$20 million to a cash inflow of $586 million in 2008
from a cash inflow of $566 million for the same period in
2007. Operating cash flows were favorably impacted by positive
trade working capital changes ($202 million), lower cash
taxes paid ($83 million) and the absence of adjustments to
cash for discontinued operations. Adjustments to cash for
discontinued operations of $84 million during 2007 related
primarily to working capital changes of the oxo products and
derivatives businesses and the shut down of our Edmonton,
Alberta, Canada methanol facility. Offsetting the increase in
cash flows were an increase in net cash interest paid
($78 million), cash spent on legal settlements
($134 million) and decreased operating profit during the
period.
Cash flow provided by operating activities decreased to a cash
inflow of $566 million in 2007 compared to a cash inflow of
$751 million for the same period in 2006. The decrease in
operating cash flows was primarily due to
52
adjustments to cash for discontinued operations and an increase
in working capital, partially offset by an increase in earnings
from continuing operations. Earnings from continuing operations
increased to $336 million during the year ended
December 31, 2007 compared with $319 million for the
same period in 2006.
Net Cash
Provided by/Used in Investing Activities
Net cash from investing activities decreased from a cash inflow
of $143 million in 2007 to a cash outflow of
$201 million in 2008. Net cash from investing activities
decreased primarily due to cash spent in settlement of our cross
currency swaps of $93 million (see Note 22 to the
consolidated financial statements) and the absence of proceeds
from the sale of our oxo products and derivatives businesses
during 2007. These amounts were offset by net cash received on
the sale of marketable securities ($111 million) and the
excess of cash received from Fraport over amounts spent in
connection with the Ticona Kelsterbach plant relocation.
Net cash from investing activities improved to a cash inflow of
$143 million in 2007 compared to a cash outflow of
$268 million in 2006. The increase in cash inflow was
primarily due to the proceeds from the sale of our oxo products
and derivatives businesses partially offset by the cash outflow
for the APL acquisition. Additionally, our cash outflow for
capital expenditures during the year ended December 31,
2007 was $44 million higher compared to the same period in
2006. During the year ended December 31, 2006, we increased
restricted cash by $42 million related to the anticipated
payment to minority shareholders for their remaining Celanese
GmbH, formerly Celanese AG, shares. During the year ended
December 31, 2007, as a result of the completion of the
Squeeze-Out (see Note 4 to the consolidated financial
statements) and the payment to minority shareholders for their
remaining Celanese GmbH shares, restricted cash decreased
$46 million.
Our cash outflow for capital expenditures were
$274 million, $288 million and $244 million for
the years ended December 31, 2008, 2007 and 2006,
respectively, excluding amounts related to the relocation of our
Ticona plant in Kelsterbach. Capital expenditures were primarily
related to major replacements of equipment, capacity expansions,
major investments to reduce future operating costs and
environmental, health and safety initiatives. Capital
expenditures in 2008, 2007 and 2006 included costs for the
expansion of our Nanjing, China site into an integrated chemical
complex. Cash outflows for capital expenditures are expected to
be approximately $175 million in 2009, excluding amounts
related to the relocation of our Ticona plant in Kelsterbach.
On February 5, 2009, we received approximately
322 million of cash from Fraport in connection with
the Ticona Kelsterbach plant relocation, excluding value-added
tax of 59 million. We anticipate related cash
outflows for capital expenditures in 2009 will range from $350
to $370 million.
Net Cash
Used in Financing Activities
Net cash from financing activities increased to a cash outflow
of $499 million in 2008 compared to a cash outflow of
$714 million during 2007. The increase primarily relates to
the absence of cash outflows attributable to the debt
refinancing in 2007. Also contributing to the increase, cash
spent to repurchase shares was $25 million less during 2008
than during 2007. Decreased cash received for stock option
exercises of $51 million partially offset the increase.
Net cash from financing activities decreased to a cash outflow
of $714 million in 2007 compared to a cash outflow of
$108 million in the same period in 2006. The decrease
primarily relates to the repurchase of shares of our
Series A common stock and the debt refinancing as discussed
in Note 17 and Note 14 to the consolidated financial
statements, respectively. This decrease was partially offset by
$69 million of proceeds received from the exercise of stock
options. Primarily as a result of the debt refinancing, we
incurred a net cash outflow of $119 million related to
repayments of our debt and $240 million for various
refinancing expenses during the year ended December 31,
2007. Furthermore, we paid a total of $403 million to
repurchase shares of our Series A common stock during the
year ended December 31, 2007.
In addition, exchange rate effects on cash and cash equivalents
decreased to an unfavorable currency effect of $35 million
in 2008 compared to a favorable impact of $39 million in
2007 and a favorable impact of $26 million in 2006.
53
Debt and
Other Obligations
As of December 31, 2008, we had total debt of
$3,533 million and cash and cash equivalents of
$676 million, resulting in net debt of $2,857 million,
a $126 million increase over December 31, 2007.
Decreased cash of $149 million and noncash increases in
debt of $102 million primarily resulting from new capital
lease obligations were partially offset by net cash paydowns on
debt of $98 million and favorable foreign currency impacts
of $27 million.
Senior
Credit Facilities
Our senior credit agreement consists of $2,280 million of
US dollar-denominated and 400 million of
Euro-denominated term loans due 2014, a $650 million
revolving credit facility terminating in 2013 and a
$228 million credit-linked revolving facility terminating
in 2014. As of December 31, 2008, there were no outstanding
borrowings or letters of credit issued under the revolving
credit facility; accordingly, $650 million remained
available for borrowing. As of December 31, 2008, there
were $91 million of letters of credit issued under the
credit-linked revolving facility and $137 million remained
available for borrowing. Our senior credit agreement requires us
to maintain a maximum first lien senior secured leverage ratio
not greater than 3.90 to 1.00 if there are outstanding
borrowings under the revolving credit facility. The first lien
senior secured leverage ratio is calculated as the ratio of
consolidated first lien senior secured debt to earnings before
interest, taxes, depreciation and amortization, subject to
adjustments identified in the credit agreement. See Note 14
to the consolidated financial statements for additional
information regarding our senior credit facilities.
Commitments
Relating to Share Capital
Our Board of Directors adopted a policy of declaring, subject to
legally available funds, a quarterly cash dividend on each share
of our Series A common stock at an annual rate of $0.16 per
share unless our Board of Directors in its sole discretion
determines otherwise. For the years ended December 31,
2008, 2007 and 2006, we paid $24 million, $25 million
and $26 million, respectively, in cash dividends on our
Series A common stock. On January 5, 2009, we declared
a $6 million cash dividend which was paid on
February 1, 2009.
Holders of our perpetual preferred stock are entitled to
receive, when, as and if declared by our Board of Directors, out
of funds legally available, quarterly cash dividends at the rate
of 4.25% per annum, or $0.265625 per share of liquidation
preference. Dividends on the preferred stock are cumulative from
the date of initial issuance. The preferred stock is
convertible, at the option of the holder, at any time into
approximately 1.26 shares of our Series A common
stock, subject to adjustments, per $25.00 liquidation preference
of the preferred stock. For the years ended December 31,
2008, 2007 and 2006, we paid $10 million annually of cash
dividends on our preferred stock. On January 5, 2009, we
declared a $3 million cash dividend on our convertible
perpetual preferred stock, which was paid on February 1,
2009.
Based upon the number of outstanding shares as of
December 31, 2008, the cash dividends to be paid in 2009
are expected to result in annual dividend payments similar to
that paid in 2008.
54
Contractual
Debt and Cash Obligations
The following table sets forth our fixed contractual debt and
cash obligations as of December 31, 2008.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expiration per Period
|
|
|
|
|
|
|
Less Than
|
|
|
|
|
|
|
|
|
After 5
|
|
Fixed Contractual Debt and Cash Obligations
|
|
Total
|
|
|
1 Year
|
|
|
Years 2 & 3
|
|
|
Years 4 & 5
|
|
|
Years
|
|
|
|
(In $ millions)
|
|
|
Term loans facility
|
|
|
2,794
|
|
|
|
28
|
|
|
|
57
|
|
|
|
57
|
|
|
|
2,652
|
|
Interest payments on
debt(1)
|
|
|
1,128
|
|
|
|
204
|
|
|
|
369
|
|
|
|
253
|
|
|
|
302
|
|
Capital lease obligations
|
|
|
211
|
|
|
|
11
|
|
|
|
41
|
|
|
|
23
|
|
|
|
136
|
|
Other
debt(2)
|
|
|
530
|
|
|
|
194
|
|
|
|
91
|
|
|
|
58
|
|
|
|
187
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fixed contractual debt obligations
|
|
|
4,663
|
|
|
|
437
|
|
|
|
558
|
|
|
|
391
|
|
|
|
3,277
|
|
Operating leases
|
|
|
140
|
|
|
|
45
|
|
|
|
48
|
|
|
|
25
|
|
|
|
22
|
|
Unconditional purchase obligations
|
|
|
2,291
|
|
|
|
527
|
|
|
|
717
|
|
|
|
399
|
|
|
|
648
|
|
FIN 48 obligations, including interest and
penalties(3)
|
|
|
218
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
218
|
|
Other contractual obligations
|
|
|
165
|
|
|
|
47
|
|
|
|
35
|
|
|
|
18
|
|
|
|
65
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fixed contractual debt and cash obligations
|
|
|
7,477
|
|
|
|
1,056
|
|
|
|
1,358
|
|
|
|
833
|
|
|
|
4,230
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Future interest expense is calculated using the rate in effect
on January 2, 2009. |
|
(2) |
|
Does not include a $2 million reduction due to purchase
accounting. |
|
(3) |
|
Due to uncertainties in the timing of the effective settlement
of tax positions with the respective taxing authorities, we are
unable to determine the timing of payments related to our
Financial Accounting Standards Board (FASB)
Interpretation No. 48, Accounting for Uncertainty
in Income Taxes, an interpretation of FASB Statement
No. 109 (FIN 48) obligations,
including interest and penalties. These amounts are therefore
reflected in After 5 Years. |
Other Debt. Other debt of $530 million is
primarily made up of fixed rate pollution control and industrial
revenue bonds, short-term borrowings from affiliated companies
and other bank obligations.
Unconditional Purchase
Obligations. Unconditional Purchase Obligations
include take or pay contracts. We do not expect to incur any
material losses under these contractual arrangements. In
addition, these contracts may include variable price components.
Other Contractual Obligations. Other
Contractual Obligations primarily includes committed capital
spending and fines associated with the US antitrust settlement
described in Note 23 to the consolidated financial
statements.
Contractual
Guarantees and Commitments
As of December 31, 2008, we have contractual guarantees and
commitments as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expiration per Period
|
|
|
|
|
|
|
Less Than
|
|
|
|
|
|
|
|
|
After 5
|
|
Contractual Guarantees and Commitments
|
|
Total
|
|
|
1 Year
|
|
|
Years 2 & 3
|
|
|
Years 4 & 5
|
|
|
Years
|
|
|
|
(In $ millions)
|
|
|
Financial guarantees
|
|
|
26
|
|
|
|
8
|
|
|
|
16
|
|
|
|
2
|
|
|
|
|
|
Standby letters of credit
|
|
|
91
|
|
|
|
91
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Contractual guarantees and commitments
|
|
|
117
|
|
|
|
99
|
|
|
|
16
|
|
|
|
2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
We are secondarily liable under a lease agreement which we
assigned to a third party. The lease expires on April 30,
2012. The lease liability for the period from January 1,
2009 to April 30, 2012 is estimated to be approximately
$26 million.
55
Standby letters of credit of $91 million outstanding as of
December 31, 2008 are irrevocable obligations of an issuing
bank that ensure payment to third parties in the event that
certain subsidiaries fail to perform in accordance with
specified contractual obligations. The likelihood is remote that
material payments will be required under these agreements.
Other
Obligations
Deferred Compensation. In April 2007, certain
participants in our 2004 deferred compensation plan elected to
participate in a revised program, which includes both cash
awards and restricted stock units. Under the revised program,
participants relinquished their cash awards of up to
$30 million that would have contingently accrued from
2007-2009
under the original plan. See additional discussion of the
revised program in Note 20 to the consolidated financial
statements. Based on current participation in the revised
program, the awards aggregate to approximately $27 million
plus notional earnings and will be recognized as expense through
December 31, 2010. We expensed $8 million and
$6 million during the years ended December 31, 2008
and 2007, respectively, related to the revised program.
In December 2008, we entered into time-vesting cash awards of
$22 million with Celaneses executive officers and
certain other key employees. Each award of cash vests 30% on
October 14, 2009, 30% on October 14, 2010 and 40% on
October 14, 2011. In its sole discretion, the compensation
committee of the Board of Directors may at any time convert all
or a portion of the cash award to an award of time-vesting
restricted stock units.
Pension and Other Postretirement
Obligations. Our contributions for pension and
postretirement benefits are preliminarily estimated to be
$40 million and $35 million, respectively, in 2009.
Domination Agreement. The domination and
profit and loss transfer agreement (the Domination
Agreement) was approved at the Celanese GmbH, formerly
known as Celanese AG, extraordinary shareholders meeting
on July 31, 2004. The Domination Agreement between Celanese
GmbH and the Purchaser became effective on October 1, 2004
and cannot be terminated by the Purchaser in the ordinary course
of business until September 30, 2009. Our subsidiaries,
Celanese International Holdings Luxembourg S.à r.l.
(CIH), formerly Celanese Caylux Holdings Luxembourg
S.C.A., and Celanese US, have each agreed to provide the
Purchaser with financing to strengthen the Purchasers
ability to fulfill its obligations under, or in connection with,
the Domination Agreement and to ensure that the Purchaser will
perform all of its obligations under, or in connection with, the
Domination Agreement when such obligations become due,
including, without limitation, the obligation to compensate
Celanese GmbH for any statutory annual loss incurred by Celanese
GmbH during the term of the Domination Agreement. If CIH
and/or
Celanese US are obligated to make payments under such guarantees
or other security to the Purchaser, we may not have sufficient
funds for payments on our indebtedness when due. We have not had
to compensate Celanese GmbH for an annual loss for any period
during which the Domination Agreement has been in effect.
Purchases
of Treasury Stock
In February 2008, our Board of Directors authorized the
repurchase of up to $400 million of our Series A
common stock. This authorization was increased to
$500 million in October 2008. The authorization gives
management discretion in determining the conditions under which
shares may be repurchased. This repurchase program does not have
an expiration date. During the year ended December 31,
2008, we repurchased 9,763,200 shares of our Series A
common stock at an average purchase price of $38.68 per share
for a total of approximately $378 million in connection
with this authorization.
These purchases reduced the number of shares outstanding and the
repurchased shares may be used by us for compensation programs
utilizing our stock and other corporate purposes. We account for
treasury stock using the cost method and include treasury stock
as a component of Shareholders equity.
Plumbing
Actions
We are involved in a number of legal proceedings and claims
incidental to the normal conduct of our business. As of
December 31, 2008 and 2007, there were reserves of
$64 million and $65 million, respectively, related to
plumbing action litigation. Although it is impossible at this
time to determine with certainty the ultimate outcome of these
matters, we believe, based on the advice of legal counsel, that
adequate provisions have been made and that the
56
ultimate outcome will not have a material adverse effect on our
financial position, but could have a material adverse effect on
our results of operations or cash flows in any given accounting
period.
Off-Balance
Sheet Arrangements
We have not entered into any material off-balance sheet
arrangements.
Market
Risks
Please see Quantitative and Qualitative Disclosure about
Market Risk under Item 7A of this
Form 10-K
for additional information about our Market Risks.
Critical
Accounting Policies and Estimates
Our consolidated financial statements are based on the selection
and application of significant accounting policies. The
preparation of consolidated financial statements in conformity
with US GAAP requires management to make estimates and
assumptions that affect the reported amounts of assets and
liabilities, disclosure of contingent assets and liabilities at
the date of the consolidated financial statements and the
reported amounts of revenues, expenses and allocated charges
during the reporting period. Actual results could differ from
those estimates. However, we are not currently aware of any
reasonably likely events or circumstances that would result in
materially different results.
We believe the following accounting polices and estimates are
critical to understanding the financial reporting risks present
in the current economic environment. These matters, and the
judgments and uncertainties affecting them, are also essential
to understanding our reported and future operating results. See
Note 2 to the consolidated financial statements for a more
comprehensive discussion of our significant accounting policies.
Recoverability
of Long-Lived Assets
We assess the recoverability of long-lived assets, excluding
goodwill and indefinite-lived intangible assets, whenever events
or circumstances indicate that the carrying value of the
long-lived asset may not be recoverable. Examples of a change in
events or circumstances include, but are not limited to, a
decrease in the market price of a long-lived asset, a history of
cash flow losses related to the use of the long-lived asset or a
significant adverse change in the extent or manner in which a
long-lived asset is being used. To assess the recoverability of
long-lived assets, excluding goodwill and indefinite-lived
intangible assets, we compare the carrying amount of the
long-lived asset or group of long-lived assets to the future net
undiscounted cash flows expected to be generated by the
long-lived asset or group of long-lived assets. If such
long-lived assets are considered impaired, the impairment
recognized is measured as the amount by which the carrying
amount of the long-lived assets exceeds the fair value of the
long-lived assets.
We assess the recoverability of the carrying value of our
goodwill and other indefinite-lived intangible assets annually
during the third quarter of our fiscal year using June 30
balances or whenever events or changes in circumstances indicate
that the carrying amount of the asset may not be fully
recoverable. Recoverability of goodwill and other
indefinite-lived intangible assets is measured using a
discounted cash flow model. We periodically engage a third-party
valuation consultant to assist us with this process.
The development of future net undiscounted cash flow projections
and the discounted cash flow projections require management
projections related to sales and profitability trends, other
future results of operations and discount rates. These
projections, which require significant judgment, are consistent
with projections we use to manage our operations internally. To
the extent that changes in the current business environment
result in adjusted management projections, impairment losses may
occur in future periods.
Income
Taxes
We regularly review our deferred tax assets for recoverability
and establish a valuation allowance based on historical taxable
income, projected future taxable income, applicable tax
strategies, and the expected timing of the reversals of existing
temporary differences. A valuation allowance is provided when it
is more likely than not that some portion or all of the deferred
tax assets will not be realized. Such evaluations require
significant management
57
judgments. Valuation allowances have been established primarily
on net operating loss carryforwards and other deferred tax
assets in the US, the United Kingdom and Canada.
We record accruals for income taxes and associated interest that
may become payable in future years as a result of audits by tax
authorities. We recognize tax benefits when it is more likely
than not (likelihood of greater than 50%), based on technical
merits, that the position will be sustained upon examination.
Tax positions that meet the more-likely-than-not threshold are
measured using a probability weighted approach as the largest
amount of tax benefit that is greater than 50% likely of being
realized upon settlement. Whether the more-likely-than-not
recognition threshold is met for a tax position is a matter of
judgment based on the individual facts and circumstances of that
position evaluated in light of all available evidence. The
actual outcome of the future tax consequence could differ from
our estimate due to changes in future circumstances and may have
a material impact on our consolidated results of operations,
financial position or cash flows.
Benefit
Obligations
We have pension and other postretirement benefit plans covering
substantially all employees who meet eligibility requirements.
With respect to its US qualified defined benefit pension plan,
minimum funding requirements are determined by the Employee
Retirement Income Security Act based on years of service
and/or
compensation. Various assumptions are used in the calculation of
the actuarial valuation of the employee benefit plans. These
assumptions include the weighted average discount rate,
compensation levels, expected long-term rates of return on plan
assets and trends in health care costs. In addition to the above
mentioned assumptions, actuarial consultants use subjective
factors such as withdrawal and mortality rates to estimate the
projected benefit obligation. The actuarial assumptions used may
differ materially from actual results due to changing market and
economic conditions, higher or lower withdrawal rates or longer
or shorter life spans of participants. These differences may
result in a significant impact to the amount of pension expense
recorded in future periods.
The amounts recognized in the consolidated financial statements
related to pension and other postretirement benefits are
determined on an actuarial basis. A significant assumption used
in determining our pension expense is the expected long-term
rate of return on plan assets. As of December 31, 2008, we
assumed an expected long-term rate of return on plan assets of
8.5% for the US qualified defined benefit pension plan, which
represents approximately 83% and 78% of our pension plan assets
and liabilities, respectively. On average, the actual return on
these plan assets over the long-term (15 to 20 years) has
exceeded 9.0%.
We estimate a 25 basis point decline in the expected
long-term rate of return for the US qualified defined benefit
pension plan to increase pension expense by an estimated
$5 million in 2008. Another estimate that affects our
pension and other postretirement benefit expense is the discount
rate used in the annual actuarial valuations of pension and
other postretirement benefit plan obligations. At the end of
each year, we determine the appropriate discount rate, used to
determine the present value of future cash flows currently
expected to be required to settle the pension and other
postretirement benefit obligations. The discount rate is
generally based on the yield on high-quality corporate
fixed-income securities. As of December 31, 2008, we
increased the discount rate to 6.50% from 6.30% as of
December 31, 2007 for the US plans. We estimate that a
50 basis point decline in our discount rate will decrease
our annual pension expenses by an estimated $1 million, and
increase our benefit obligations by approximately
$144 million for our US pension plan. In addition, the same
basis point decline in our discount rate will also increase our
annual expenses and benefit obligations by less than
$1 million and $8 million respectively, for our US
postretirement medical plans. We estimate that a 50 basis
point decline in the discount rate for the non-US pension and
postretirement medical plans will increase pension and other
postretirement benefit annual expenses by approximately
$1 million and less than $1 million, respectively, and
will increase our benefit obligations by approximately
$30 million and $2 million, respectively.
Other postretirement benefit plans provide medical and life
insurance benefits to retirees who meet minimum age and service
requirements. The key determinants of the accumulated
postretirement benefit obligation (APBO) are the
discount rate and the healthcare cost trend rate. The healthcare
cost trend rate has a significant effect on the reported amounts
of APBO and related expense. For example, increasing or
decreasing the healthcare cost trend rate by one percentage
point in each year would result in the APBO as of
December 31, 2008, and the 2008 postretirement benefit cost
to change by approximately $3 million and
$(3) million, respectively. See Note 15 to the
consolidated financial statements for additional information.
58
Accounting
for Commitments and Contingencies
We are subject to a number of legal proceedings, lawsuits,
claims, and investigations, incidental to the normal conduct of
our business, relating to and including product liability,
patent and intellectual property, commercial, contract,
antitrust, past waste disposal practices, release of chemicals
into the environment and employment matters, which are handled
and defended in the ordinary course of business. We routinely
assess the likelihood of any adverse judgments or outcomes to
these matters as well as ranges of probable and reasonably
estimable losses. Reasonable estimates involve judgments made by
us after considering a broad range of information including:
notifications, demands, settlements which have been received
from a regulatory authority or private party, estimates
performed by independent consultants and outside counsel,
available facts, identification of other potentially responsible
parties and their ability to contribute, as well as prior
experience. With respect to environmental liabilities, it is our
policy to accrue through fifteen years, unless we have
government orders or other agreements that extend beyond fifteen
years. A determination of the amount of loss contingency
required, if any, is assessed in accordance with FASB Statement
of Financial Accounting Standards No. 5,
Contingencies and Commitments, and recorded if probable
and estimable after careful analysis of each individual matter.
The required reserves may change in the future due to new
developments in each matter and as additional information
becomes available.
Financial
Reporting Changes
See Note 3 to the consolidated financial statements for
information regarding recent accounting pronouncements.
|
|
Item 7A.
|
Quantitative
and Qualitative Disclosures about Market Risk
|
Market
Risks
Our financial market risk consists principally of exposure to
currency exchange rates, interest rates and commodity prices.
Exchange rate and interest rate risks are managed with a variety
of techniques, including use of derivatives. We have in place
policies of hedging against changes in currency exchange rates,
interest rates and commodity prices as described below.
Contracts to hedge exposures are primarily accounted for under
Statement of Financial Accounting Standards
(SFAS) No. 133, Accounting for
Derivative Instruments and Hedging Activities
(SFAS No. 133) amended by
SFAS No. 138, Accounting for Certain Derivative
Instruments and Certain Hedging Activities and
SFAS No. 148, Amendment of Statement 133 on
Derivative Instruments and Hedging Activities.
Interest
Rate Risk Management
We use interest rate swap agreements to manage the interest rate
risk of our total debt portfolio and related overall cost of
borrowing. To reduce the interest rate risk inherent in our
variable rate debt, we utilize interest rate swap agreements to
convert a portion of our variable rate debt to a fixed rate
obligation. These interest rate swap agreements are designated
as cash flow hedges.
In March 2007, in anticipation of the April 2007 debt
refinancing, we entered into various US dollar and Euro interest
rate swap agreements, which became effective on April 2,
2007, with notional amounts of $1.6 billion and
150 million, respectively. The notional amount of the
$1.6 billion US dollar interest rate swaps decreased by
$400 million effective January 2, 2008 and decreased
by another $200 million effective January 2, 2009. To
offset the declines, we entered into US dollar interest rate
swaps with a combined notional amount of $400 million which
became effective on January 2, 2008 and an additional US
dollar interest rate swap with a notional amount of
$200 million which will become effective April 2, 2009.
As of December 31, 2008, we had $2.3 billion,
454 million and CNY 1.5 billion of variable rate
debt, of which $1.6 billion and 150 million is
hedged with interest rate swaps, which leaves $674 million,
304 million and CNY 1.5 billion of variable rate
debt subject to interest rate exposure. Accordingly, a 1%
increase in interest rates would increase annual interest
expense by approximately $13 million.
See Note 22 to the consolidated financial statements for
further discussion of our interest rate risk management and the
related impact on our financial position and results of
operations.
59
Foreign
Exchange Risk Management
The primary business objective of this hedging program is to
maintain an approximately balanced position in foreign
currencies so that exchange gains and losses resulting from
exchange rate changes, net of related tax effects, are
minimized. It is our policy to minimize currency exposures and
to conduct operations either within functional currencies or
using the protection of hedge strategies. Accordingly, we enter
into foreign currency forwards and swaps to minimize our
exposure to foreign currency fluctuations. From time to time we
may also hedge our currency exposure related to forecasted
transactions. Forward contracts are not designated as hedges
under SFAS No. 133.
The following table indicates the total US dollar equivalents of
net foreign exchange exposure related to (short) long foreign
exchange forward contracts outstanding by currency. All of the
contracts included in the table below will have approximately
offsetting effects from actual underlying payables, receivables,
intercompany loans or other assets or liabilities subject to
foreign exchange remeasurement.
|
|
|
|
|
|
|
2009 Maturity
|
|
|
|
(In $ millions)
|
|
|
Currency
|
|
|
|
|
Euro
|
|
|
145
|
|
British pound sterling
|
|
|
(115
|
)
|
Mexican peso
|
|
|
80
|
|
Singapore dollar
|
|
|
26
|
|
Canadian dollar
|
|
|
21
|
|
Japanese yen
|
|
|
9
|
|
Brazilian real
|
|
|
(7
|
)
|
Swedish krona
|
|
|
6
|
|
Hungarian forint
|
|
|
(5
|
)
|
Other
|
|
|
(3
|
)
|
|
|
|
|
|
Total
|
|
|
157
|
|
|
|
|
|
|
Additionally, a portion of our assets, liabilities, revenues and
expenses are denominated in currencies other than the US dollar,
principally the Euro. Fluctuations in the value of these
currencies against the US dollar, particularly the value of the
Euro, can have a direct and material impact on the business and
financial results. For example, a decline in the value of the
Euro versus the US dollar results in a decline in the US dollar
value of our sales and earnings denominated in Euros due to
translation effects. Likewise, an increase in the value of the
Euro versus the US dollar would result in an opposite effect.
To protect the foreign currency exposure of a net investment in
a foreign operation, we entered into cross currency swaps with
certain financial institutions in 2004. The cross currency swaps
and the Euro-denominated portion of the senior term loan were
designated as a hedge of a net investment of a foreign
operation. We dedesignated the net investment hedge due to the
debt refinancing in April 2007 and redesignated the cross
currency swaps and new senior EURO term loan in July 2007. As a
result, we recorded $26 million of
mark-to-market
losses related to the cross currency swaps and the new senior
Euro term loan during this period.
Under the terms of the cross currency swap arrangements, we paid
approximately 13 million in interest and received
approximately $16 million in interest on June 15 and
December 15 of each year. The fair value of the net obligation
under the cross currency swaps was included in current Other
liabilities in the consolidated balance sheets as of
December 31, 2007. Upon maturity of the cross currency swap
arrangements in June 2008, we owed 276 million
($426 million) and were owed $333 million. In
settlement of the obligation, we paid $93 million (net of
interest of $3 million) in June 2008.
During the year ended December 31, 2008, we dedesignated
385 million of the 400 million
euro-denominated portion of the term loan, previously designated
as a hedge of a net investment of a foreign operation. Prior to
this dedesignation, we had been using external derivative
contracts to offset foreign currency exposures on
60
intercompany loans. The foreign currency exposure resulting from
dedesignation of 385 million of the hedge of a net
investment of a foreign operation is expected to offset the
foreign currency exposure on certain intercompany loans,
decreasing the need for external derivative contracts and
reducing our exposure to external counterparties. The remaining
15 million euro-denominated portion of the term loan
continues to be designated as a hedge of a net investment of a
foreign operation.
See Note 22 to the consolidated financial statements for
further discussion of our foreign exchange risk management and
the related impact on our financial position and results of
operations.
Commodity
Risk Management
We have exposure to the prices of commodities in its procurement
of certain raw materials. We manage its exposure primarily
through the use of long-term supply agreements and derivative
instruments. We regularly assess our practice of purchasing a
portion of its commodity requirements forward and utilization of
other raw material hedging instruments, in addition to forward
purchase contracts, in accordance with changes in market
conditions. Forward purchases and swap contracts for raw
materials are principally settled through actual delivery of the
physical commodity. For qualifying contracts, we have elected to
apply the normal purchases and normal sales exception of
SFAS No. 133, as amended, as it was probable at the
inception and throughout the term of the contract that they
would not settle net and would result in physical delivery. As
such, realized gains and losses on these contracts are included
in the cost of the commodity upon the settlement of the contract.
In addition, we occasionally enter into financial derivatives to
hedge a component of a raw material or energy source. Typically,
these types of transactions do not qualify for hedge accounting.
These instruments are marked to market at each reporting period
and gains (losses) are included in Cost of sales in the
consolidated statements of operations. We recognized no gain or
loss from these types of contracts during the year ended
December 31, 2008 and less than $1 million during each
of the years ended December 31, 2007 and 2006,
respectively. As of December 31, 2008, we did not have any
open financial derivative contracts for commodities.
|
|
Item 8.
|
Financial
Statements and Supplementary Data
|
Our consolidated financial statements and supplementary data are
included in pages F-2 through of this Annual Report on
Form 10-K.
See accompanying Item 15. Exhibits and Financial Statement
Schedules and Index to the consolidated financial statements on
page F-1.
61
Quarterly
Financial Information
CELANESE
CORPORATION AND SUBSIDIARIES
CONSOLIDATED
STATEMENTS OF OPERATIONS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
March 31,
|
|
|
June 30,
|
|
|
September 30,
|
|
|
December 31,
|
|
|
|
2008
|
|
|
2008
|
|
|
2008
|
|
|
2008
|
|
|
|
(Unaudited)
|
|
|
|
(In $ millions, except per share data)
|
|
|
Net sales
|
|
|
1,846
|
|
|
|
1,868
|
|
|
|
1,823
|
|
|
|
1,286
|
|
Other (charges) gains, net
|
|
|
(16
|
)
|
|
|
(7
|
)
|
|
|
(1
|
)
|
|
|
(84
|
)
|
Operating profit (loss)
|
|
|
234
|
|
|
|
207
|
|
|
|
151
|
|
|
|
(152
|
)
|
Earnings (loss) from continuing operations before tax and
minority interests
|
|
|
218
|
|
|
|
247
|
|
|
|
152
|
|
|
|
(183
|
)
|
Earnings (loss) from continuing operations
|
|
|
145
|
|
|
|
203
|
|
|
|
164
|
|
|
|
(140
|
)
|
Earnings (loss) from discontinued operations
|
|
|
|
|
|
|
(69
|
)
|
|
|
(6
|
)
|
|
|
(15
|
)
|
Net earnings (loss)
|
|
|
145
|
|
|
|
134
|
|
|
|
158
|
|
|
|
(155
|
)
|
Earnings (loss) per share basic
|
|
|
0.93
|
|
|
|
0.87
|
|
|
|
1.05
|
|
|
|
(1.09
|
)
|
Earnings (loss) per share diluted
|
|
|
0.87
|
|
|
|
0.80
|
|
|
|
0.97
|
|
|
|
(1.09
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
March 31,
|
|
|
June 30,
|
|
|
September 30,
|
|
|
December 31,
|
|
|
|
2007
|
|
|
2007
|
|
|
2007
|
|
|
2007
|
|
|
|
(Unaudited)
|
|
|
|
(In $ millions, except per share data)
|
|
|
Net sales
|
|
|
1,555
|
|
|
|
1,556
|
|
|
|
1,573
|
|
|
|
1,760
|
|
Other (charges) gains, net
|
|
|
(1
|
)
|
|
|
(105
|
)
|
|
|
(12
|
)
|
|
|
60
|
|
Operating profit
|
|
|
206
|
|
|
|
71
|
|
|
|
147
|
|
|
|
324
|
|
Earnings (loss) from continuing operations before tax and
minority interests
|
|
|
171
|
|
|
|
(168
|
)
|
|
|
131
|
|
|
|
313
|
|
Earnings (loss) from continuing operations
|
|
|
122
|
|
|
|
(124
|
)
|
|
|
130
|
|
|
|
208
|
|
Earnings (loss) from discontinued operations
|
|
|
79
|
|
|
|
7
|
|
|
|
(2
|
)
|
|
|
6
|
|
Net earnings (loss)
|
|
|
201
|
|
|
|
(117
|
)
|
|
|
128
|
|
|
|
214
|
|
Earnings (loss) per share basic
|
|
|
1.25
|
|
|
|
(0.76
|
)
|
|
|
0.84
|
|
|
|
1.39
|
|
Earnings (loss) per share diluted
|
|
|
1.15
|
|
|
|
(0.76
|
)
|
|
|
0.76
|
|
|
|
1.27
|
|
For a discussion of material events affecting performance in
each quarter, see Item 7. Managements Discussion and
Analysis of Financial Condition and Results of Operations. All
amounts in the table above have been properly adjusted for the
effects of discontinued operations.
62
|
|
Item 9.
|
Changes
in and Disagreements with Accountants on Accounting and
Financial Disclosure
|
None.
|
|
Item 9A.
|
Controls
and Procedures
|
Under the supervision and with the participation of our
management, including the Chief Executive Officer and Chief
Financial Officer, we have evaluated the effectiveness of our
disclosure controls and procedures pursuant to Exchange Act
Rule 13a-15(b)
as of the end of the period covered by this report. Based on
that evaluation, as of December 31, 2008, the Chief
Executive Officer and Chief Financial Officer have concluded
that these disclosure controls and procedures are effective.
Changes
in Internal Control Over Financial Reporting
None.
REPORT OF
MANAGEMENT ON INTERNAL CONTROL OVER FINANCIAL
REPORTING
Our management is responsible for establishing and maintaining
adequate internal controls over financial reporting for the
Company. Internal control over financial reporting is a process
to provide reasonable assurance regarding the reliability of our
financial reporting for external purposes in accordance with
accounting principles generally accepted in the United States of
America. Internal control over financial reporting includes
maintaining records that in reasonable detail accurately and
fairly reflect our transactions; providing reasonable assurance
that transactions are recorded as necessary for preparation of
our consolidated financial statements; providing reasonable
assurance that receipts and expenditures of company assets are
made in accordance with management authorization; and providing
reasonable assurance that unauthorized acquisition, use or
disposition of company assets that could have a material effect
on our consolidated financial statements would be prevented or
detected on a timely basis. Because of its inherent limitations,
internal control over financial reporting is not intended to
provide absolute assurance that a misstatement of our
consolidated financial statements would be prevented or detected.
Management conducted an evaluation of the effectiveness of our
internal control over financial reporting based on the framework
in Internal Control Integrated Framework issued by
the Committee of Sponsoring Organizations of the Treadway
Commission. Based on this evaluation, management concluded that
the Companys internal control over financial reporting was
effective as of December 31, 2008. KPMG LLP has audited
this assessment of our internal control over financial
reporting; their report is included below.
63
REPORT OF
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The Board of Directors and Shareholders
Celanese Corporation:
We have audited Celanese Corporation and subsidiaries (the
Company) internal control over financial reporting
as of December 31, 2008, based on criteria established in
Internal Control Integrated Framework issued
by the Committee of Sponsoring Organizations of the Treadway
Commission (COSO). The Companys management is responsible
for maintaining effective internal control over financial
reporting and for its assessment of the effectiveness of
internal control over financial reporting, included in the
accompanying report of management on internal control over
financial reporting. Our responsibility is to express an opinion
on the Companys internal control over financial reporting
based on our audit.
We conducted our audit in accordance with the standards of the
Public Company Accounting Oversight Board (United States). Those
standards require that we plan and perform the audit to obtain
reasonable assurance about whether effective internal control
over financial reporting was maintained in all material
respects. Our audit included obtaining an understanding of
internal control over financial reporting, assessing the risk
that a material weakness exists, and testing and evaluating the
design and operating effectiveness of internal control based on
the assessed risk. Our audit also included performing such other
procedures as we considered necessary in the circumstances. We
believe that our audit provides a reasonable basis for our
opinion.
A companys internal control over financial reporting is a
process designed to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with
generally accepted accounting principles. A companys
internal control over financial reporting includes those
policies and procedures that (1) pertain to the maintenance
of records that, in reasonable detail, accurately and fairly
reflect the transactions and dispositions of the assets of the
company; (2) provide reasonable assurance that transactions
are recorded as necessary to permit preparation of financial
statements in accordance with generally accepted accounting
principles, and that receipts and expenditures of the company
are being made only in accordance with authorizations of
management and directors of the company; and (3) provide
reasonable assurance regarding prevention or timely detection of
unauthorized acquisition, use, or disposition of the
companys assets that could have a material effect on the
consolidated financial statements.
Because of its inherent limitations, internal control over
financial reporting may not prevent or detect misstatements.
Also, projections of any evaluation of effectiveness to future
periods are subject to the risk that controls may become
inadequate because of changes in conditions, or that the degree
of compliance with the policies or procedures may deteriorate.
In our opinion, Celanese Corporation and subsidiaries
maintained, in all material respects, effective internal control
over financial reporting as of December 31, 2008, based on
criteria established in Internal Control
Integrated Framework issued by the Committee of Sponsoring
Organizations of the Treadway Commission.
We also have audited, in accordance with the standards of the
Public Company Accounting Oversight Board (United States), the
consolidated balance sheets of Celanese Corporation and
subsidiaries as of December 31, 2008 and 2007, and the
related consolidated statements of operations,
shareholders equity and comprehensive income (loss), and
cash flows for each of the years in the three-year period ended
December 31, 2008, and our report dated February 12,
2009 expressed an unqualified opinion on those consolidated
financial statements.
Dallas, Texas
February 12, 2009
64
|
|
Item 9B.
|
Other
Information
|
None.
PART III
|
|
Item 10.
|
Directors,
Executive Officers and Corporate Governance
|
The information required by this Item 10 is incorporated
herein by reference from the section captioned Corporate
Governance, Our Management Team, and
Section 16(a) Beneficial Ownership Reporting
Compliance of the Companys definitive proxy
statement for the 2009 annual meeting of stockholders to be
filed not later than March 23, 2009 with the Securities and
Exchange Commission pursuant to Regulation 14A under the
Securities Exchange Act of 1934, as amended (the 2009
Proxy Statement).
|
|
Item 11.
|
Executive
Compensation
|
The information required by this Item 11 is incorporated by
reference from the section captioned Executive
Compensation of the 2009 Proxy Statement.
|
|
Item 12.
|
Security
Ownership of Certain Beneficial Owners and Management and
Related Stockholder Matters
|
The information required by this Item 12 is incorporated by
reference from the section captioned Stock Ownership
Information of the 2009 Proxy Statement. The information
required by Item 201(d) of
Regulation S-K
is submitted in a separate section of this
Form 10-K.
See Item 5 Market for Registrants
Common Equity, Related Stockholder Matters and Issuer Purchases
of Equity Securities, above.
|
|
Item 13.
|
Certain
Relationships and Related Transactions and Director
Independence
|
The information required by this Item 13 is incorporated by
reference from the section captioned Certain Relationships
and Related Party Transactions of the 2009 Proxy Statement.
|
|
Item 14.
|
Principal
Accounting Fees and Services
|
The information required by this Item 14 is incorporated by
reference from the section captioned Ratification of
Independent Auditors Audit and Related Fees of
the 2009 Proxy Statement.
PART IV
|
|
Item 15.
|
Exhibits
and Financial Statement Schedule
|
1. Financial Statements. The reports of our
independent registered public accounting firm and our
consolidated financial statements are listed below and begin on
page F-1
of this Annual Report on
Form 10-K.
|
|
|
|
|
Page Number
|
|
Report of Independent Registered Public Accounting Firm
|
|
F-2
|
Consolidated Statements of Operations
|
|
F-3
|
Consolidated Balance Sheets
|
|
F-4
|
Consolidated Statements of Shareholders Equity and
Comprehensive Income (Loss)
|
|
F-5
|
Consolidated Statements of Cash Flows
|
|
F-6
|
Notes to Consolidated Financial Statements
|
|
F-7
|
2. Financial Statement Schedule.
The financial statement schedule required by this item is
included as an Exhibit to this Annual Report on
Form 10-K.
3. Exhibit List.
65
See Index to Exhibits following our consolidated financial
statements contained in this Annual Report on
Form 10-K.
PLEASE NOTE: It is inappropriate for readers
to assume the accuracy of, or rely upon any covenants,
representations or warranties that may be contained in
agreements or other documents filed as Exhibits to, or
incorporated by reference in, this Annual Report. Any such
covenants, representations or warranties may have been qualified
or superseded by disclosures contained in separate schedules or
exhibits not filed with or incorporated by reference in this
Annual Report, may reflect the parties negotiated risk
allocation in the particular transaction, may be qualified by
materiality standards that differ from those applicable for
securities law purposes, and may not be true as of the date of
this Annual Report or any other date and may be subject to
waivers by any or all of the parties. Where exhibits and
schedules to agreements filed or incorporated by reference as
Exhibits hereto are not included in these exhibits, such
exhibits and schedules to agreements are not included or
incorporated by reference herein.
66
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the
Securities Exchange Act of 1934, the registrant has duly caused
the report to be signed on its behalf by the undersigned,
thereunto duly authorized.
CELANESE CORPORATION
Name: David N. Weidman
|
|
|
|
Title:
|
Chairman of the Board of
|
Directors and Chief Executive
Officer
Date: February 12, 2009
POWER OF
ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose
signature appears below constitutes and appoints Steven M.
Sterin, his true and lawful attorney-in-fact with power of
substitution and resubstitution to sign in his name, place and
stead, in any and all capacities, to do any and all things and
execute any and all instruments that such attorney may deem
necessary or advisable under the Securities Exchange Act of 1934
and any rules, regulations and requirements of the US Securities
and Exchange Commission in connection with the Annual Report on
Form 10-K
and any and all amendments hereto, as fully for all intents and
purposes as he might or could do in person, and hereby ratifies
and confirms said attorney-in-fact, acting alone, and his
substitute or substitutes, may lawfully do or cause to be done
by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of
1934, this report has been signed by the following persons in
the capacities and on the dates indicated.
|
|
|
|
|
|
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
|
/s/ David
N. Weidman
David
N. Weidman
|
|
Chairman of the Board of Directors, Chief Executive Officer
(Principal Executive Officer)
|
|
February 12, 2009
|
|
|
|
|
|
/s/ Steven
M. Sterin
Steven
M. Sterin
|
|
Senior Vice President, Chief Financial Officer (Principal
Financial Officer)
|
|
February 12, 2009
|
|
|
|
|
|
/s/ Miguel
A. Desdin
Miguel
A. Desdin
|
|
Vice President, Controller
(Principal Accounting Officer)
|
|
February 12, 2009
|
|
|
|
|
|
/s/ James
E. Barlett
James
E. Barlett
|
|
Director
|
|
February 12, 2009
|
|
|
|
|
|
/s/ David
F. Hoffmeister
David
F. Hoffmeister
|
|
Director
|
|
February 12, 2009
|
|
|
|
|
|
/s/ Martin
G. McGuinn
Martin
G. McGuinn
|
|
Director
|
|
February 12, 2009
|
67
|
|
|
|
|
|
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
|
/s/ Paul
H. ONeill
Paul
H. ONeill
|
|
Director
|
|
February 12, 2009
|
|
|
|
|
|
/s/ Mark
C. Rohr
Mark
C. Rohr
|
|
Director
|
|
February 12, 2009
|
|
|
|
|
|
/s/ Daniel
S. Sanders
Daniel
S. Sanders
|
|
Director
|
|
February 12, 2009
|
|
|
|
|
|
/s/ Farah
M. Walters
Farah
M. Walters
|
|
Director
|
|
February 12, 2009
|
|
|
|
|
|
/s/ John
K. Wulff
John
K. Wulff
|
|
Director
|
|
February 12, 2009
|
68
INDEX TO
CONSOLIDATED FINANCIAL STATEMENTS
|
|
|
|
|
|
|
Page
|
|
ANNUAL CELANESE CORPORATION CONSOLIDATED FINANCIAL STATEMENTS
|
|
|
|
|
|
|
|
F-2
|
|
|
|
|
F-3
|
|
|
|
|
F-4
|
|
|
|
|
F-5
|
|
|
|
|
F-6
|
|
|
|
|
|
|
|
|
|
F-7
|
|
|
|
|
F-7
|
|
|
|
|
F-12
|
|
|
|
|
F-14
|
|
|
|
|
F-16
|
|
|
|
|
F-18
|
|
|
|
|
F-18
|
|
|
|
|
F-19
|
|
|
|
|
F-21
|
|
|
|
|
F-21
|
|
|
|
|
F-22
|
|
|
|
|
F-23
|
|
|
|
|
F-23
|
|
|
|
|
F-24
|
|
|
|
|
F-26
|
|
|
|
|
F-31
|
|
|
|
|
F-34
|
|
|
|
|
F-35
|
|
|
|
|
F-37
|
|
|
|
|
F-41
|
|
|
|
|
F-45
|
|
|
|
|
F-45
|
|
|
|
|
F-49
|
|
|
|
|
F-56
|
|
|
|
|
F-56
|
|
|
|
|
F-60
|
|
|
|
|
F-61
|
|
|
|
|
F-61
|
|
|
|
|
F-62
|
|
|
|
|
F-62
|
|
F-1
REPORT OF
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The Board of Directors and Shareholders
Celanese Corporation:
We have audited the accompanying consolidated balance sheets of
Celanese Corporation and subsidiaries (the Company)
as of December 31, 2008 and 2007, and the related
consolidated statements of operations, shareholders equity
and comprehensive income (loss), and cash flows for each of the
years in the three-year period ended December 31, 2008.
These consolidated financial statements are the responsibility
of the Companys management. Our responsibility is to
express an opinion on these consolidated financial statements
based on our audits.
We conducted our audits in accordance with the standards of the
Public Company Accounting Oversight Board (United States). Those
standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are
free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in
the financial statements. An audit also includes assessing the
accounting principles used and significant estimates made by
management, as well as evaluating the overall financial
statement presentation. We believe that our audits provide a
reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred
to above present fairly, in all material respects, the financial
position of Celanese Corporation and subsidiaries as of
December 31, 2008 and 2007, and the results of their
operations and their cash flows for each of the years in the
three-year period ended December 31, 2008, in conformity
with US generally accepted accounting principles.
We also have audited, in accordance with the standards of the
Public Company Accounting Oversight Board (United States), the
Companys internal control over financial reporting as of
December 31, 2008, based on criteria established in
Internal Control Integrated Framework issued
by the Committee of Sponsoring Organizations of the Treadway
Commission (COSO), and our report dated February 12, 2009
expressed an unqualified opinion on the effectiveness of the
Companys internal control over financial reporting.
As discussed in Note 22 to the consolidated financial
statements, the Company adopted Statement of Financial
Accounting Standards No. 157, Fair Value
Measurements, during the year ended December 31, 2008.
As discussed in Note 19 to the consolidated financial
statements, the Company adopted Financial Accounting Standards
Board Interpretation No. 48, Accounting for Uncertainty
in Income Taxes, during the year ended December 31,
2007.
As discussed in Note 15 to the consolidated financial
statements, the Company adopted Statement of Financial
Accounting Standards No. 158, Employers Accounting
for Defined Benefit Pension and Other Postretirement Plans,
during the year ended December 31, 2006.
As discussed in Note 20 to the consolidated financial
statements, the Company adopted Statement of Financial
Accounting Standards No. 123 (revised 2004), Share-Based
Payment, during the year ended December 31, 2006.
Dallas, Texas
February 12, 2009
F-2
CELANESE
CORPORATION AND SUBSIDIARIES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
|
(In $ millions, except for share and per share data)
|
|
|
Net sales
|
|
|
6,823
|
|
|
|
6,444
|
|
|
|
5,778
|
|
Cost of sales
|
|
|
(5,567
|
)
|
|
|
(4,999
|
)
|
|
|
(4,469
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit
|
|
|
1,256
|
|
|
|
1,445
|
|
|
|
1,309
|
|
Selling, general and administrative expenses
|
|
|
(540
|
)
|
|
|
(516
|
)
|
|
|
(536
|
)
|
Amortization of intangible assets (primarily customer
relationships)
|
|
|
(76
|
)
|
|
|
(72
|
)
|
|
|
(66
|
)
|
Research and development expenses
|
|
|
(80
|
)
|
|
|
(73
|
)
|
|
|
(65
|
)
|
Other (charges) gains, net
|
|
|
(108
|
)
|
|
|
(58
|
)
|
|
|
(10
|
)
|
Foreign exchange gain (loss), net
|
|
|
(4
|
)
|
|
|
2
|
|
|
|
(3
|
)
|
Gain (loss) on disposition of businesses and assets, net
|
|
|
(8
|
)
|
|
|
20
|
|
|
|
(9
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating profit
|
|
|
440
|
|
|
|
748
|
|
|
|
620
|
|
Equity in net earnings of affiliates
|
|
|
54
|
|
|
|
82
|
|
|
|
76
|
|
Interest expense
|
|
|
(261
|
)
|
|
|
(262
|
)
|
|
|
(293
|
)
|
Refinancing expenses
|
|
|
|
|
|
|
(256
|
)
|
|
|
(1
|
)
|
Interest income
|
|
|
31
|
|
|
|
44
|
|
|
|
37
|
|
Dividend income cost investments
|
|
|
167
|
|
|
|
116
|
|
|
|
79
|
|
Other income (expense), net
|
|
|
3
|
|
|
|
(25
|
)
|
|
|
8
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings (loss) from continuing operations before tax and
minority interests
|
|
|
434
|
|
|
|
447
|
|
|
|
526
|
|
Income tax (provision) benefit
|
|
|
(63
|
)
|
|
|
(110
|
)
|
|
|
(203
|
)
|
Minority interests
|
|
|
1
|
|
|
|
(1
|
)
|
|
|
(4
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings (loss) from continuing operations
|
|
|
372
|
|
|
|
336
|
|
|
|
319
|
|
Earnings (loss) from operation of discontinued operations
|
|
|
(120
|
)
|
|
|
40
|
|
|
|
130
|
|
Gain (loss) on disposal of discontinued operations
|
|
|
6
|
|
|
|
52
|
|
|
|
5
|
|
Income tax (provision) benefit, discontinued operations
|
|
|
24
|
|
|
|
(2
|
)
|
|
|
(48
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings (loss) from discontinued operations
|
|
|
(90
|
)
|
|
|
90
|
|
|
|
87
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net earnings (loss)
|
|
|
282
|
|
|
|
426
|
|
|
|
406
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cumulative preferred stock dividend
|
|
|
(10
|
)
|
|
|
(10
|
)
|
|
|
(10
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net earnings (loss) available to common shareholders
|
|
|
272
|
|
|
|
416
|
|
|
|
396
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings (loss) per common share basic:
|
|
|
|
|
|
|
|
|
|
|
|
|
Continuing operations
|
|
|
2.44
|
|
|
|
2.11
|
|
|
|
1.95
|
|
Discontinued operations
|
|
|
(0.61
|
)
|
|
|
0.58
|
|
|
|
0.55
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net earnings (loss) basic
|
|
|
1.83
|
|
|
|
2.69
|
|
|
|
2.50
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings (loss) per common share diluted:
|
|
|
|
|
|
|
|
|
|
|
|
|
Continuing operations
|
|
|
2.28
|
|
|
|
1.96
|
|
|
|
1.86
|
|
Discontinued operations
|
|
|
(0.55
|
)
|
|
|
0.53
|
|
|
|
0.50
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net earnings (loss) diluted
|
|
|
1.73
|
|
|
|
2.49
|
|
|
|
2.36
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares basic
|
|
|
148,350,273
|
|
|
|
154,475,020
|
|
|
|
158,597,424
|
|
Weighted average shares diluted
|
|
|
163,471,873
|
|
|
|
171,227,997
|
|
|
|
171,807,599
|
|
See the accompanying notes to the consolidated financial
statements.
F-3
CELANESE
CORPORATION AND SUBSIDIARIES
CONSOLIDATED
BALANCE SHEETS
|
|
|
|
|
|
|
|
|
|
|
As of December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
|
(In $ millions, except
|
|
|
|
share amounts)
|
|
|
ASSETS
|
Current assets
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
|
676
|
|
|
|
825
|
|
Trade receivables third party and affiliates (net of
allowance for doubtful accounts 2008: $25; 2007: $18)
|
|
|
631
|
|
|
|
1,009
|
|
Non-trade receivables
|
|
|
328
|
|
|
|
437
|
|
Inventories
|
|
|
577
|
|
|
|
636
|
|
Deferred income taxes
|
|
|
24
|
|
|
|
70
|
|
Marketable securities, at fair value
|
|
|
6
|
|
|
|
46
|
|
Other assets
|
|
|
42
|
|
|
|
40
|
|
|
|
|
|
|
|
|
|
|
Total current assets
|
|
|
2,284
|
|
|
|
3,063
|
|
|
|
|
|
|
|
|
|
|
Investments in affiliates
|
|
|
789
|
|
|
|
814
|
|
Property, plant and equipment (net of accumulated
depreciation 2008: $1,141; 2007: $838)
|
|
|
2,472
|
|
|
|
2,362
|
|
Deferred income taxes
|
|
|
27
|
|
|
|
10
|
|
Marketable securities, at fair value
|
|
|
94
|
|
|
|
209
|
|
Other assets
|
|
|
357
|
|
|
|
309
|
|
Goodwill
|
|
|
779
|
|
|
|
866
|
|
Intangible assets, net
|
|
|
364
|
|
|
|
425
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
|
7,166
|
|
|
|
8,058
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND SHAREHOLDERS EQUITY
|
Current liabilities
|
|
|
|
|
|
|
|
|
Short-term borrowings and current installments of long-term
debt third party and affiliates
|
|
|
233
|
|
|
|
272
|
|
Trade payables third party and affiliates
|
|
|
523
|
|
|
|
818
|
|
Other liabilities
|
|
|
574
|
|
|
|
888
|
|
Deferred income taxes
|
|
|
15
|
|
|
|
30
|
|
Income taxes payable
|
|
|
24
|
|
|
|
23
|
|
|
|
|
|
|
|
|
|
|
Total current liabilities
|
|
|
1,369
|
|
|
|
2,031
|
|
|
|
|
|
|
|
|
|
|
Long-term debt
|
|
|
3,300
|
|
|
|
3,284
|
|
Deferred income taxes
|
|
|
122
|
|
|
|
265
|
|
Uncertain tax positions
|
|
|
218
|
|
|
|
220
|
|
Benefit obligations
|
|
|
1,167
|
|
|
|
696
|
|
Other liabilities
|
|
|
806
|
|
|
|
495
|
|
Minority interests
|
|
|
2
|
|
|
|
5
|
|
Commitments and contingencies
|
|
|
|
|
|
|
|
|
Shareholders equity:
|
|
|
|
|
|
|
|
|
Preferred stock, $0.01 par value, 100,000,000 shares
authorized (2008 and 2007: 9,600,000 issued and outstanding)
|
|
|
|
|
|
|
|
|
Series A common stock, $0.0001 par value,
400,000,000 shares authorized (2008: 164,107,394 issued and
143,505,708 outstanding; 2007: 162,941,287 issued and
152,102,801 outstanding)
|
|
|
|
|
|
|
|
|
Series B common stock, $0.0001 par value,
100,000,000 shares authorized (2008 and 2007: 0 shares
issued and outstanding)
|
|
|
|
|
|
|
|
|
Treasury stock, at cost (2008:
20,601,686 shares; 2007: 10,838,486 shares)
|
|
|
(781
|
)
|
|
|
(403
|
)
|
Additional paid-in capital
|
|
|
495
|
|
|
|
469
|
|
Retained earnings
|
|
|
1,047
|
|
|
|
799
|
|
Accumulated other comprehensive income (loss), net
|
|
|
(579
|
)
|
|
|
197
|
|
|
|
|
|
|
|
|
|
|
Total shareholders equity
|
|
|
182
|
|
|
|
1,062
|
|
|
|
|
|
|
|
|
|
|
Total liabilities and shareholders equity
|
|
|
7,166
|
|
|
|
8,058
|
|
|
|
|
|
|
|
|
|
|
See the accompanying notes to the consolidated financial
statements.
F-4
CELANESE
CORPORATION AND SUBSIDIARIES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
|
Shares
|
|
|
|
|
|
Shares
|
|
|
|
|
|
Shares
|
|
|
|
|
|
|
Outstanding
|
|
|
Amount
|
|
|
Outstanding
|
|
|
Amount
|
|
|
Outstanding
|
|
|
Amount
|
|
|
|
(In $ millions, except share data)
|
|
|
Preferred stock
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of the beginning of the period
|
|
|
9,600,000
|
|
|
|
|
|
|
|
9,600,000
|
|
|
|
|
|
|
|
9,600,000
|
|
|
|
|
|
Issuance of preferred stock
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of the end of the period
|
|
|
9,600,000
|
|
|
|
|
|
|
|
9,600,000
|
|
|
|
|
|
|
|
9,600,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Series A common stock
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of the beginning of the period
|
|
|
152,102,801
|
|
|
|
|
|
|
|
158,668,666
|
|
|
|
|
|
|
|
158,562,161
|
|
|
|
|
|
Issuance of Series A common stock
|
|
|
|
|
|
|
|
|
|
|
7,400
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock option exercises
|
|
|
1,056,368
|
|
|
|
|
|
|
|
4,265,221
|
|
|
|
|
|
|
|
106,505
|
|
|
|
|
|
Purchases of treasury stock
|
|
|
(9,763,200
|
)
|
|
|
|
|
|
|
(10,838,486
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock awards
|
|
|
109,739
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of the end of the period
|
|
|
143,505,708
|
|
|
|
|
|
|
|
152,102,801
|
|
|
|
|
|
|
|
158,668,666
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Treasury stock
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of the beginning of the period
|
|
|
10,838,486
|
|
|
|
(403
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchases of treasury stock, including related fees
|
|
|
9,763,200
|
|
|
|
(378
|
)
|
|
|
10,838,486
|
|
|
|
(403
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of the end of the period
|
|
|
20,601,686
|
|
|
|
(781
|
)
|
|
|
10,838,486
|
|
|
|
(403
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Additional paid-in capital
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of the beginning of the period
|
|
|
|
|
|
|
469
|
|
|
|
|
|
|
|
362
|
|
|
|
|
|
|
|
337
|
|
Indemnification of demerger liability
|
|
|
|
|
|
|
2
|
|
|
|
|
|
|
|
4
|
|
|
|
|
|
|
|
3
|
|
Stock-based compensation, net of tax
|
|
|
|
|
|
|
15
|
|
|
|
|
|
|
|
15
|
|
|
|
|
|
|
|
20
|
|
Stock option exercises, net of tax
|
|
|
|
|
|
|
10
|
|
|
|
|
|
|
|
88
|
|
|
|
|
|
|
|
2
|
|
Restricted stock unit withholding
|
|
|
|
|
|
|
(1
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of the end of the period
|
|
|
|
|
|
|
495
|
|
|
|
|
|
|
|
469
|
|
|
|
|
|
|
|
362
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Retained earnings
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of the beginning of the period
|
|
|
|
|
|
|
799
|
|
|
|
|
|
|
|
394
|
|
|
|
|
|
|
|
24
|
|
Net earnings (loss)
|
|
|
|
|
|
|
282
|
|
|
|
|
|
|
|
426
|
|
|
|
|
|
|
|
406
|
|
Series A common stock dividends
|
|
|
|
|
|
|
(24
|
)
|
|
|
|
|
|
|
(25
|
)
|
|
|
|
|
|
|
(26
|
)
|
Preferred stock dividends
|
|
|
|
|
|
|
(10
|
)
|
|
|
|
|
|
|
(10
|
)
|
|
|
|
|
|
|
(10
|
)
|
Adoption of FIN 48 (Note 19)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
14
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of the end of the period
|
|
|
|
|
|
|
1,047
|
|
|
|
|
|
|
|
799
|
|
|
|
|
|
|
|
394
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated other comprehensive income (loss), net
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of the beginning of the period
|
|
|
|
|
|
|
197
|
|
|
|
|
|
|
|
31
|
|
|
|
|
|
|
|
(126
|
)
|
Unrealized gain (loss) on securities
|
|
|
|
|
|
|
(23
|
)
|
|
|
|
|
|
|
17
|
|
|
|
|
|
|
|
13
|
|
Foreign currency translation
|
|
|
|
|
|
|
(130
|
)
|
|
|
|
|
|
|
70
|
|
|
|
|
|
|
|
5
|
|
Unrealized gain (loss) on interest rate swaps
|
|
|
|
|
|
|
(79
|
)
|
|
|
|
|
|
|
(41
|
)
|
|
|
|
|
|
|
2
|
|
Pension and postretirement benefits
|
|
|
|
|
|
|
(544
|
)
|
|
|
|
|
|
|
120
|
|
|
|
|
|
|
|
269
|
|
Adjustment to initially apply FASB Statement No. 158, net
of tax
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(132
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of the end of the period
|
|
|
|
|
|
|
(579
|
)
|
|
|
|
|
|
|
197
|
|
|
|
|
|
|
|
31
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total shareholders equity
|
|
|
|
|
|
|
182
|
|
|
|
|
|
|
|
1,062
|
|
|
|
|
|
|
|
787
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive income (loss)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net earnings (loss)
|
|
|
|
|
|
|
282
|
|
|
|
|
|
|
|
426
|
|
|
|
|
|
|
|
406
|
|
Other comprehensive income (loss), net of tax:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unrealized gain (loss) on securities
|
|
|
|
|
|
|
(23
|
)
|
|
|
|
|
|
|
17
|
|
|
|
|
|
|
|
13
|
|
Foreign currency translation
|
|
|
|
|
|
|
(130
|
)
|
|
|
|
|
|
|
70
|
|
|
|
|
|
|
|
5
|
|
Unrealized gain (loss) on interest rate swaps
|
|
|
|
|
|
|
(79
|
)
|
|
|
|
|
|
|
(41
|
)
|
|
|
|
|
|
|
2
|
|
Pension and postretirement benefits
|
|
|
|
|
|
|
(544
|
)
|
|
|
|
|
|
|
120
|
|
|
|
|
|
|
|
269
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total comprehensive income (loss), net of tax
|
|
|
|
|
|
|
(494
|
)
|
|
|
|
|
|
|
592
|
|
|
|
|
|
|
|
695
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See the accompanying notes to the consolidated financial
statements.
F-5
CELANESE
CORPORATION AND SUBSIDIARIES
CONSOLIDATED
STATEMENTS OF CASH FLOWS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
|
(In $ millions)
|
|
|
Operating activities
|
|
|
|
|
|
|
|
|
|
|
|
|
Net earnings (loss)
|
|
|
282
|
|
|
|
426
|
|
|
|
406
|
|
Adjustments to reconcile net earnings (loss) to net cash
provided by operating activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Other (charges) gains, net of amounts used
|
|
|
111
|
|
|
|
30
|
|
|
|
(34
|
)
|
Depreciation, amortization and accretion
|
|
|
360
|
|
|
|
311
|
|
|
|
323
|
|
Deferred income taxes, net
|
|
|
(69
|
)
|
|
|
23
|
|
|
|
125
|
|
(Gain) loss on disposition of businesses and assets, net
|
|
|
1
|
|
|
|
(74
|
)
|
|
|
(8
|
)
|
Refinancing expense
|
|
|
|
|
|
|
256
|
|
|
|
|
|
Other, net
|
|
|
35
|
|
|
|
(1
|
)
|
|
|
61
|
|
Operating cash provided by (used in) discontinued operations
|
|
|
3
|
|
|
|
(84
|
)
|
|
|
10
|
|
Changes in operating assets and liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Trade receivables third party and affiliates, net
|
|
|
339
|
|
|
|
(69
|
)
|
|
|
(9
|
)
|
Inventories
|
|
|
21
|
|
|
|
(27
|
)
|
|
|
19
|
|
Other assets
|
|
|
53
|
|
|
|
66
|
|
|
|
(5
|
)
|
Trade payables third party and affiliates
|
|
|
(265
|
)
|
|
|
(11
|
)
|
|
|
(22
|
)
|
Other liabilities
|
|
|
(285
|
)
|
|
|
(280
|
)
|
|
|
(115
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by operating activities
|
|
|
586
|
|
|
|
566
|
|
|
|
751
|
|
Investing activities
|
|
|
|
|
|
|
|
|
|
|
|
|
Capital expenditures on property, plant and equipment
|
|
|
(274
|
)
|
|
|
(288
|
)
|
|
|
(244
|
)
|
Acquisitions and related fees, net of cash acquired
|
|
|
|
|
|
|
(269
|
)
|
|
|
|
|
Proceeds from sale of businesses and assets, net
|
|
|
9
|
|
|
|
715
|
|
|
|
23
|
|
Proceeds from Ticona Kelsterbach plant relocation
|
|
|
311
|
|
|
|
|
|
|
|
26
|
|
Capital expenditures related to Ticona Kelsterbach plant
relocation
|
|
|
(185
|
)
|
|
|
(21
|
)
|
|
|
|
|
Proceeds from sale of marketable securities
|
|
|
202
|
|
|
|
69
|
|
|
|
95
|
|
Purchases of marketable securities
|
|
|
(91
|
)
|
|
|
(59
|
)
|
|
|
(65
|
)
|
Changes in restricted cash
|
|
|
|
|
|
|
46
|
|
|
|
(42
|
)
|
Settlement of cross currency swap agreements
|
|
|
(93
|
)
|
|
|
|
|
|
|
|
|
Investing cash provided by (used in) discontinued operations
|
|
|
|
|
|
|
|
|
|
|
(18
|
)
|
Other, net
|
|
|
(80
|
)
|
|
|
(50
|
)
|
|
|
(43
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by (used in) investing activities
|
|
|
(201
|
)
|
|
|
143
|
|
|
|
(268
|
)
|
Financing activities
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-term borrowings (repayments), net
|
|
|
(64
|
)
|
|
|
30
|
|
|
|
13
|
|
Proceeds from long-term debt
|
|
|
13
|
|
|
|
2,904
|
|
|
|
38
|
|
Repayments of long-term debt
|
|
|
(47
|
)
|
|
|
(3,053
|
)
|
|
|
(125
|
)
|
Refinancing costs
|
|
|
|
|
|
|
(240
|
)
|
|
|
|
|
Purchases of treasury stock, including related fees
|
|
|
(378
|
)
|
|
|
(403
|
)
|
|
|
|
|
Stock option exercises
|
|
|
18
|
|
|
|
69
|
|
|
|
2
|
|
Series A common stock dividends
|
|
|
(24
|
)
|
|
|
(25
|
)
|
|
|
(26
|
)
|
Preferred stock dividends
|
|
|
(10
|
)
|
|
|
(10
|
)
|
|
|
(10
|
)
|
Other, net
|
|
|
(7
|
)
|
|
|
14
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash used in financing activities
|
|
|
(499
|
)
|
|
|
(714
|
)
|
|
|
(108
|
)
|
Exchange rate effects on cash and cash equivalents
|
|
|
(35
|
)
|
|
|
39
|
|
|
|
26
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net increase (decrease) in cash and cash equivalents
|
|
|
(149
|
)
|
|
|
34
|
|
|
|
401
|
|
Cash and cash equivalents at beginning of period
|
|
|
825
|
|
|
|
791
|
|
|
|
390
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents at end of period
|
|
|
676
|
|
|
|
825
|
|
|
|
791
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See the accompanying notes to the consolidated financial
statements.
F-6
CELANESE
CORPORATION AND SUBSIDIARIES
|
|
1.
|
Description
of the Company
|
Celanese Corporation and its subsidiaries (collectively the
Company) is a leading global integrated chemical and
advanced materials company. The Companys business involves
processing chemical raw materials, such as methanol, carbon
monoxide and ethylene, and natural products, including wood
pulp, into value-added chemicals, thermoplastic polymers and
other chemical-based products.
Definitions
In this Annual Report on
Form 10-K,
the term Celanese refers to Celanese Corporation, a
Delaware corporation, and not its subsidiaries. The term
Celanese US refers to the Companys subsidiary,
Celanese US Holdings LLC, a Delaware limited liability company,
formerly known as BCP Crystal US Holdings Corp., a Delaware
corporation, and not its subsidiaries. The term
Purchaser refers to the Companys subsidiary,
Celanese Europe Holding GmbH & Co. KG, formerly known
as BCP Crystal Acquisition GmbH & Co. KG, a German
limited partnership, and not its subsidiaries, except where
otherwise indicated. The term Original Shareholders
refers, collectively, to Blackstone Capital Partners (Cayman)
Ltd. 1, Blackstone Capital Partners (Cayman) Ltd. 2, Blackstone
Capital Partners (Cayman) Ltd. 3 and BA Capital Investors
Sidecar Fund, L.P. The term Advisor refers to
Blackstone Management Partners, an affiliate of The Blackstone
Group.
Basis
of Presentation
The consolidated financial statements contained in this Annual
Report were prepared in accordance with accounting principles
generally accepted in the United States of America (US
GAAP) for all periods presented. The consolidated
financial statements and other financial information included in
this Annual Report, unless otherwise specified, have been
presented to separately show the effects of discontinued
operations.
|
|
2.
|
Summary
of Accounting Policies
|
Consolidation principles
The consolidated financial statements have been prepared in
accordance with US GAAP for all periods presented and include
the accounts of the Company and its majority owned subsidiaries
over which the Company exercises control. All significant
intercompany accounts and transactions have been eliminated in
consolidation.
Estimates and assumptions
The preparation of consolidated financial statements in
conformity with US GAAP requires management to make estimates
and assumptions that affect the reported amounts of assets and
liabilities, disclosure of contingent assets and liabilities at
the date of the consolidated financial statements and the
reported amounts of revenues, expenses and allocated charges
during the reporting period. Significant estimates pertain to
impairments of goodwill, intangible assets and other long-lived
assets, purchase price allocations, restructuring costs and
other (charges) gains, net, income taxes, pension and other
postretirement benefits, asset retirement obligations,
environmental liabilities and loss contingencies, among others.
Actual results could differ from those estimates.
Cash and cash equivalents
All highly liquid investments with original maturities of three
months or less are considered cash equivalents.
Inventories
Inventories, including stores and supplies, are stated at the
lower of cost or market. Cost for inventories is determined
using the
first-in,
first-out (FIFO) method. Cost includes raw
materials, direct labor and manufacturing overhead. Cost for
stores and supplies is primarily determined by the average cost
method.
Investments in marketable securities
The Company classifies its investments in debt and equity
securities as available-for-sale and reports those
investments at their fair market values in the consolidated
balance sheets as Marketable Securities, at fair value.
F-7
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Unrealized gains or losses, net of the related tax effect on
available-for-sale securities, are excluded from earnings and
are reported as a component of Accumulated other comprehensive
income (loss), net until realized. The cost of securities sold
is determined by using the specific identification method.
A decline in the market value of any available-for-sale security
below cost that is deemed to be other-than-temporary results in
a reduction in the carrying amount to fair value. The impairment
is charged to earnings and a new cost basis for the security is
established. To determine whether impairment is
other-than-temporary, the Company considers whether it has the
ability and intent to hold the investment until a market price
recovery and evidence indicating the cost of the investment is
recoverable outweighs evidence to the contrary. Evidence
considered in this assessment includes the reasons for the
impairment, the severity and duration of the impairment, changes
in value subsequent to year end and forecasted performance of
the investee.
Investments in affiliates
Accounting Principles Board (APB) Opinion
No. 18, The Equity Method of Accounting for Investments
in Common Stock, stipulates that the equity method should be
used to account for investments whereby an investor has
the ability to exercise significant influence over
operating and financial policies of an investee, but does
not exercise control. APB Opinion No. 18 generally
considers an investor to have the ability to exercise
significant influence when it owns 20% or more of the voting
stock of an investee. Financial Accounting Standards Board
(FASB) Interpretation No. 35, Criteria for
Applying the Equity Method of Accounting for Investments in
Common Stock, which was issued to clarify the criteria for
applying the equity method of accounting to 50% or less owned
companies, lists circumstances under which, despite 20%
ownership, an investor may not be able to exercise significant
influence. Certain investments where the Company owns greater
than a 20% ownership and cannot exercise significant influence
or control are accounted for under the cost method (Note 8).
The Company assesses the recoverability of the carrying value of
its investments whenever events or changes in circumstances
indicate a loss in value that is other than a temporary decline.
A loss in value of an equity-method or cost-method investment
which is other than a temporary decline will be recognized as
the difference between the carrying amount of the investment and
its fair value.
The Companys estimates of fair value are determined based
on a discounted cash flow model. The Company periodically
engages third-party valuation consultants to assist with this
process.
Property, plant and equipment, net
Land is recorded at historical cost. Buildings, machinery and
equipment, including capitalized interest, and property under
capital lease agreements, are recorded at cost less accumulated
depreciation. Depreciation is calculated on a straight-line
basis over the following estimated useful lives of depreciable
assets:
|
|
|
|
|
Land Improvements
|
|
|
20 years
|
|
Buildings and Building Improvements
|
|
|
30 years
|
|
Machinery and Equipment
|
|
|
20 years
|
|
Leasehold improvements are amortized over ten years or the
remaining life of the respective lease, whichever is shorter.
Accelerated depreciation is recorded when the estimated useful
life is shortened. Ordinary repair and maintenance costs,
including costs for planned maintenance turnarounds, that do not
extend the useful life of the asset are charged to earnings as
incurred. Fully depreciated assets are retained in property and
depreciation accounts until sold or otherwise disposed. In the
case of disposals, assets and related depreciation are removed
from the accounts, and the net amounts, less proceeds from
disposal, are included in earnings.
The Company also leases property, plant and equipment under
operating and capital leases. Rent expense for operating leases,
which may have escalating rentals or rent holidays over the term
of the lease, is recorded on a
F-8
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
straight-line basis over the lease term. Amortization of capital
lease assets is included as a component of depreciation expense.
Assets acquired in business combinations are recorded at their
fair values and depreciated over the assets remaining
useful lives or the Companys policy lives, whichever is
shorter.
The Company assesses the recoverability of the carrying amount
of its property, plant and equipment whenever events or changes
in circumstances indicate that the carrying amount of an asset
or asset group may not be recoverable. An impairment loss would
be assessed when estimated undiscounted future cash flows from
the operation and disposition of the asset group are less than
the carrying amount of the asset group. Asset groups have
identifiable cash flows and are largely independent of other
asset groups. Measurement of an impairment loss is based on the
excess of the carrying amount of the asset group over its fair
value. Fair value is measured using discounted cash flows or
independent appraisals, as appropriate. Impairment losses are
recorded in depreciation expense or Other (charges) gains, net
depending on the facts and circumstances.
Goodwill and other intangible assets
Trademarks and trade names, customer-related intangible assets
and other intangibles with finite lives are amortized on a
straight-line basis over their estimated useful lives. The
weighted average amortization period is 8 years. The excess
of the purchase price over fair value of net identifiable assets
and liabilities of an acquired business (goodwill)
and other indefinite-lived intangible assets are not amortized,
but rather tested for impairment, at least annually. The Company
tests for goodwill and indefinite-lived intangible asset
impairment during the third quarter of its fiscal year using
June 30 balances.
The Company assesses the recoverability of the carrying value of
goodwill at least annually or whenever events or changes in
circumstances indicate that the carrying amount of the goodwill
of a reporting unit may not be fully recoverable. Recoverability
is measured at the reporting unit level based on the provisions
of Statement of Financial Accounting Standards
(SFAS) No. 142, Goodwill and Other
Intangible Assets. The Companys estimates of fair
value are determined based on a discounted cash flow model. The
Company periodically engages third-party valuation consultants
to assist with this process. Impairment losses are recorded in
other operating expense or Other (charges) gains, net depending
on the facts and circumstances.
The Company assesses recoverability of other indefinite-lived
intangible assets at least annually or whenever events or
changes in circumstances indicate that the carrying amount of
the indefinite-lived intangible asset may not be fully
recoverable. Recoverability is measured by a comparison of the
carrying value of the indefinite-lived intangible asset over its
fair value. Any excess of the carrying value of the
indefinite-lived intangible asset over its fair value is
recognized as an impairment loss. The Companys estimates
of fair value are determined based on a discounted cash flow
model. The Company periodically engages third-party valuation
consultants to assist with this process. Impairment losses are
recorded in other operating expense or Other (charges) gains,
net depending on the facts and circumstances.
The Company assesses the recoverability of finite-lived
intangible assets in the same manner as for property, plant and
equipment as described above. Impairment losses are recorded in
amortization expense or Other (charges) gains, net depending on
the facts and circumstances.
Financial instruments
On January 1, 2008, the Company adopted the provisions of
SFAS No. 157, Fair Value Measurements
(SFAS No. 157) for financial assets
and liabilities. On January 1, 2009, the Company applied
the provisions of SFAS No. 157 for non-recurring fair
value measurements of non-financial assets and liabilities, such
as goodwill, indefinite-lived intangible assets, property, plant
and equipment and asset retirement obligations. The adoption of
SFAS No. 157 for non-recurring fair value measurements
of non-financial assets and liabilities did not have a material
impact on the Companys financial position, results of
operations or cash flows. SFAS No. 157 defines fair
value, and increases disclosures surrounding fair value
calculations.
F-9
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The Company manages its exposures to currency exchange rates,
interest rates and commodity prices through a risk management
program that includes the use of derivative financial
instruments (Note 22). The Company does not use derivative
financial instruments for speculative trading purposes. The fair
value of all derivative instruments is recorded as assets or
liabilities at the balance sheet date. Changes in the fair value
of these instruments are reported in income or Accumulated other
comprehensive income (loss), net, depending on the use of the
derivative and whether it qualifies for hedge accounting
treatment under the provisions of SFAS No. 133,
Accounting for Derivative Instruments and Hedging
Activities, as amended (SFAS No. 133).
Gains and losses on derivative instruments qualifying as cash
flow hedges are recorded in Accumulated other comprehensive
income (loss), net, to the extent the hedges are effective,
until the underlying transactions are recognized in income. To
the extent effective, gains and losses on derivative and
non-derivative instruments used as hedges of the Companys
net investment in foreign operations are recorded in Accumulated
other comprehensive income (loss), net as part of the cumulative
translation adjustment. The ineffective portions of cash flow
hedges and hedges of net investment in foreign operations, if
any, are recognized in income immediately. Derivative
instruments not designated as hedges are marked to market at the
end of each accounting period with the change in fair value
recorded in income.
Concentrations of credit risk
The Company is exposed to credit risk in the event of nonpayment
by customers and counterparties. The creditworthiness of
customers and counterparties is subject to continuing review,
including the use of master netting agreements, where the
Company deems appropriate. The Company minimizes concentrations
of credit risk through its global orientation in diverse
businesses with a large number of diverse customers and
suppliers. In addition, credit risks arising from derivative
instruments is not significant because the counterparties to
these contracts are primarily major international financial
institutions and, to a lesser extent, major chemical companies.
Where appropriate, the Company has diversified its selection of
counterparties. Generally, collateral is not required from
customers and counterparties and allowances are provided for
specific risks inherent in receivables.
Deferred financing costs
The Company capitalizes direct costs incurred to obtain debt
financings and amortizes these costs using a method that
approximates the effective interest rate method over the terms
of the related debt. Upon the extinguishment of the related
debt, any unamortized capitalized debt financing costs are
immediately expensed.
Environmental liabilities
The Company manufactures and sells a diverse line of chemical
products throughout the world. Accordingly, the Companys
operations are subject to various hazards incidental to the
production of industrial chemicals including the use, handling,
processing, storage and transportation of hazardous materials.
The Company recognizes losses and accrues liabilities relating
to environmental matters if available information indicates that
it is probable that a liability has been incurred and the amount
of loss can be reasonably estimated. Depending on the nature of
the site, the Company accrues through fifteen years, unless the
Company has government orders or other agreements that extend
beyond fifteen years. If the event of loss is neither probable
nor reasonably estimable, but is reasonably possible, the
Company provides appropriate disclosure in the notes to the
consolidated financial statements if the contingency is
considered material. The Company estimates environmental
liabilities on a
case-by-case
basis using the most current status of available facts, existing
technology, presently enacted laws and regulations and prior
experience in remediation of contaminated sites. Recoveries of
environmental costs from other parties are recorded as assets
when their receipt is deemed probable.
An environmental reserve related to cleanup of a contaminated
site might include, for example, a provision for one or more of
the following types of costs: site investigation and testing
costs, cleanup costs, costs related to soil and water
contamination resulting from tank ruptures and post-remediation
monitoring costs. These reserves do not take into account any
claims or recoveries from insurance. There are no pending
insurance claims for any
F-10
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
environmental liability that are expected to be material. The
measurement of environmental liabilities is based on the
Companys periodic estimate of what it will cost to perform
each of the elements of the remediation effort. The Company
utilizes third parties to assist in the management and
development of cost estimates for its sites. Changes to
environmental regulations or other factors affecting
environmental liabilities are reflected in the consolidated
financial statements in the period in which they occur
(Note 16).
Legal fees
The Company accrues for legal fees related to loss contingency
matters when the costs associated with defending these matters
can be reasonably estimated and are probable of occurring. All
other legal fees are expensed as incurred.
Revenue recognition
The Company recognizes revenue when title and risk of loss have
been transferred to the customer, generally at the time of
shipment of products, and provided that four basic criteria are
met: (1) persuasive evidence of an arrangement exists;
(2) delivery has occurred or services have been rendered;
(3) the fee is fixed or determinable; and
(4) collectibility is reasonably assured. Should changes in
conditions cause the Company to determine revenue recognition
criteria are not met for certain transactions, revenue
recognition would be delayed until such time that the
transactions become realizable and fully earned. Payments
received in advance of meeting the above revenue recognition
criteria are recorded as deferred revenue.
Research and development
The costs of research and development are charged as an expense
in the period in which they are incurred.
Insurance loss reserves
The Company has two wholly owned insurance companies (the
Captives) that are used as a form of self insurance
for property, liability and workers compensation risks. One of
the Captives also insures certain third-party risks. The
liabilities recorded by the Captives relate to the estimated
risk of loss which is based on management estimates and
actuarial valuations, and unearned premiums, which represent the
portion of the third-party premiums written applicable to the
unexpired terms of the policies in-force. Liabilities are
recognized for known claims when sufficient information has been
developed to indicate involvement of a specific policy and the
Company can reasonably estimate its liability. In addition,
liabilities have been established to cover additional exposure
on both known and unasserted claims. Estimates of the
liabilities are reviewed and updated regularly. It is possible
that actual results could differ significantly from the recorded
liabilities. Premiums written are recognized as revenue based on
the terms of the policies. Capitalization of the Captives is
determined by regulatory guidelines.
Reinsurance receivables
The Captives enter into reinsurance arrangements to reduce their
risk of loss. The reinsurance arrangements do not relieve the
Captives from their obligations to policyholders. Failure of the
reinsurers to honor their obligations could result in losses to
the Captives. The Captives evaluate the financial condition of
their reinsurers and monitor concentrations of credit risk to
minimize their exposure to significant losses from reinsurer
insolvencies and to establish allowances for amounts deemed
non-collectible.
Income taxes
The provision for income taxes has been determined using the
asset and liability approach of accounting for income taxes.
Under this approach, deferred income taxes reflect the net tax
effects of temporary differences between the carrying amounts of
assets and liabilities for financial reporting purposes and the
amounts used for income tax purposes and net operating loss and
tax credit carry forwards. The amount of deferred taxes on these
temporary differences is determined using the tax rates that are
expected to apply to the period when the asset is
F-11
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
realized or the liability is settled, as applicable, based on
tax rates and laws in the respective tax jurisdiction enacted as
of the balance sheet date.
The Company reviews its deferred tax assets for recoverability
and establishes a valuation allowance based on historical
taxable income, projected future taxable income, applicable tax
strategies, and the expected timing of the reversals of existing
temporary differences. A valuation allowance is provided when it
is more likely than not that some portion or all of the deferred
tax assets will not be realized.
The Company adopted the provisions of FASB Interpretation
No. 48, Accounting for Uncertainty in Income
Taxes an interpretation of FASB Statement
No. 109 (FIN 48) on January 1,
2007. The Company considers many factors when evaluating and
estimating its tax positions and tax benefits, which may require
periodic adjustments and which may not accurately anticipate
actual outcomes. Tax positions are recognized only when it is
more likely than not (likelihood of greater than 50%), based on
technical merits, that the positions will be sustained upon
examination. Tax positions that meet the more-likely-than-not
threshold are measured using a probability weighted approach as
the largest amount of tax benefit that is greater than 50%
likely of being realized upon settlement. Whether the
more-likely-than-not recognition threshold is met for a tax
position is a matter of judgment based on the individual facts
and circumstances of that position evaluated in light of all
available evidence.
Minority interests
Minority interests in the equity and results of operations of
the entities consolidated by the Company are shown as a separate
line item in the consolidated financial statements. The entities
included in the consolidated financial statements that have
minority interests are as follows:
|
|
|
|
|
|
|
|
|
|
|
Ownership Percentage
|
|
|
|
as of December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
Celanese Polisinteza d.o.o.
|
|
|
76
|
%
|
|
|
76
|
%
|
Synthesegasanlage Ruhr GmbH
|
|
|
50
|
%
|
|
|
50
|
%
|
The Company has a 60% voting interest and the right to appoint a
majority of the board of management of Synthesegasanlage Ruhr
GmbH, which results in the Company controlling this entity and,
accordingly, the Company is consolidating this entity in its
consolidated financial statements.
Accounting for purchasing agent agreements
A subsidiary of the Company acts as a purchasing agent on behalf
of the Company, as well as third parties. The entity arranges
sale and purchase agreements for raw materials on a commission
basis. Accordingly, the commissions earned on these third-party
sales are classified as a reduction to Selling, general and
administrative expenses.
Functional and reporting currencies
For the Companys international operations where the
functional currency is other than the US dollar, assets and
liabilities are translated using period-end exchange rates,
while the statement of operations amounts are translated using
the average exchange rates for the respective period.
Differences arising from the translation of assets and
liabilities in comparison with the translation of the previous
periods or from initial recognition during the period are
included as a separate component of Accumulated other
comprehensive income (loss), net.
Reclassifications
The Company has reclassified certain prior period amounts to
conform to the current year presentation.
|
|
3.
|
Recent
Accounting Pronouncements
|
In December 2007, the FASB issued SFAS No. 160,
Noncontrolling Interests in Consolidated Financial
Statements an amendment of ARB No. 51
(SFAS No. 160) to establish accounting
and reporting standards for
F-12
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
the noncontrolling interest in a subsidiary and for the
deconsolidation of a subsidiary. It clarifies that a
noncontrolling interest in a subsidiary is an ownership interest
in the consolidated entity that should be reported as equity in
the consolidated financial statements and establishes a single
method of accounting for changes in a parents ownership
interest in a subsidiary that does not result in
deconsolidation. The Company adopted SFAS No. 160 on
January 1, 2009. This standard had no material impact on
the Companys financial position, results of operations or
cash flows.
In December 2007, the FASB issued SFAS No. 141(R),
Business Combinations
(SFAS No. 141(R)).
SFAS No. 141(R) establishes principles and
requirements for how an acquirer recognizes and measures in its
financial statements the identifiable assets acquired, the
liabilities assumed, the goodwill acquired and any
non-controlling interest in the acquiree. This statement also
establishes disclosure requirements to enable the evaluation of
the nature of the financial effect of the business combination.
SFAS No. 141(R) is effective for all business
combinations for which the acquisition date is on or after the
beginning of the first fiscal year after December 15, 2008,
with the exception of the accounting for valuation allowances on
deferred taxes and acquired tax contingencies.
SFAS No. 141(R) amends SFAS No. 109,
Accounting for Income Taxes, such that adjustments made
to valuation allowances on deferred taxes and acquired tax
contingencies associated with acquisitions that closed prior to
the effective date of SFAS No. 141(R) would also apply
the provisions of SFAS No. 141(R). The Company adopted
SFAS No. 141(R) on January 1, 2009. Beginning in
2009, the Company will record adjustments to preacquisition tax
contingencies as a component of income tax expense in the
consolidated statement of operations.
In March 2008, the FASB issued SFAS No. 161,
Disclosures about Derivative Instruments and Hedging
Activities, an amendment of FASB Statement No. 133
(SFAS No. 161). SFAS No. 161
requires enhanced disclosures about a companys derivative
and hedging activities. These enhanced disclosures will discuss:
(a) how and why a company uses derivative instruments,
(b) how derivative instruments and related hedged items are
accounted for under FASB Statement No. 133 and its related
interpretations and (c) how derivative instruments and
related hedged items affect a companys financial position,
results of operations and cash flows. The Company adopted
SFAS No. 161 on January 1, 2009. This standard
had no impact on the Companys financial position, results
of operations or cash flows.
In April 2008, the FASB issued FASB Staff Position
(FSP)
FAS No. 142-3,
Determination of the Useful Life of Intangible Assets
(FSP
FAS No. 142-3).
FSP
FAS No. 142-3
amends the factors that should be considered in developing
renewal or extension assumptions used to determine the useful
life of a recognized intangible asset under
SFAS No. 142, Goodwill and Other Intangible
Assets. The intent of this FSP is to improve the consistency
between the useful life of a recognized intangible asset and the
period of expected cash flows used to measure the fair value of
the asset under SFAS No. 141 (revised 2007),
Business Combinations, and other US GAAP. The Company
adopted FSP
FAS No. 142-3
on January 1, 2009. This standard had no material impact on
the Companys financial position, results of operations or
cash flows.
In May 2008, the FASB issued SFAS No. 162, The
Hierarchy of Generally Accepted Accounting Principles,
(SFAS No. 162), which became effective
November 15, 2008. SFAS No. 162 identifies the
sources of accounting principles and the framework for selecting
the principles to be used in the preparation of financial
statements of nongovernmental entities that are presented in
conformity with US GAAP. This standard had no impact on the
Companys financial position, results of operations or cash
flows.
In September 2008, the EITF issued EITF
No. 08-6,
Equity Method Investment Accounting Considerations
(EITF 08-6).
EITF 08-6
addresses the effect of SFAS No. 141(R) and
SFAS No. 160 on the equity method of accounting. The
Company adopted
EITF 08-6
on January 1, 2009. This standard had no impact on the
Companys financial position, results of operations or cash
flows.
In October 2008, the FASB issued FSP FAS
No. 157-3,
Determining the Fair Value of a Financial Asset When the
Market for That Asset Is Not Active (FSP FAS
No. 157-3),
to provide guidance on determining the fair value of
F-13
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
financial instruments in inactive markets. FSP FAS
No. 157-3
became effective for the Company upon issuance. This standard
had no impact on the Companys financial position, results
of operations or cash flows.
|
|
4.
|
Acquisitions,
Ventures, Divestitures and Asset Sales
|
Acquisitions
On January 31, 2007, the Company completed the acquisition
of the cellulose acetate flake, tow and film business of Acetate
Products Limited (APL), a subsidiary of Corsadi B.V.
The purchase price for the transaction was approximately
£57 million ($112 million), in addition to direct
acquisition costs of approximately £4 million
($7 million). As contemplated prior to the closing of the
acquisition, the Company closed the acquired tow production
plant at Little Heath, United Kingdom in September 2007. In
accordance with the Companys sponsor services agreement
dated January 26, 2005, as amended, the Company paid the
Advisor $1 million in connection with the acquisition. The
acquired business is included in the Companys Consumer
Specialties segment.
On April 6, 2004, the Company acquired 84% of Celanese
GmbH. During 2005, the Company acquired an additional 14% of
Celanese GmbH. On May 30, 2006, Celanese GmbHs
shareholders approved a transfer to the Purchaser of all shares
owned by minority shareholders against payment of cash
compensation in the amount of 66.99 per share (the
Squeeze-Out). As a result of the effective
registration of the Squeeze-Out in the commercial register in
Germany in December 2006, the Company acquired the remaining 2%
of Celanese GmbH in January 2007. The Companys current
ownership percentage in Celanese GmbH is 100%.
Ventures
In March 2007, the Company entered into a strategic partnership
with Accsys Technologies PLC (Accsys), and its
subsidiary, Titan Wood, to become the exclusive supplier of
acetyl products to Titan Woods technology licensees for
use in wood acetylation. In connection with this partnership, in
May 2007, the Company acquired 8,115,883 shares of
Accsys common stock representing approximately 5.45% of
the total voting shares of Accsys for 22 million
($30 million). The investment was treated as an
available-for-sale security and was included in Marketable
securities on the Companys consolidated balance sheets. On
November 20, 2007, the Company and Accsys announced that
they agreed to amend their business arrangements so that each
company would have a nonexclusive at-will trading
and supply relationship to give both companies greater
flexibility. As part of this amendment, the Company subsequently
sold all of its shares of Accsys stock for approximately
20 million ($30 million), which resulted in a
cumulative loss of $3 million.
Divestitures
In July 2008, the Company sold its 55.46% interest in Derivados
Macroquimicos S.A. de C.V. (DEMACSA) for proceeds of
$3 million. DEMACSA produces cellulose ethers at an
industrial complex in Zacapu, Michoacan, Mexico and is included
in the Companys Acetyl Intermediates segment. In June
2008, the Company recorded an impairment loss of $1 million
to Cost of sales in the consolidated statements of operations.
As a result, the proceeds from the sale approximated the
carrying value of DEMACSA on the date of the sale. The Company
concluded the sale of DEMACSA is not a discontinued operation
due to certain forms of continuing involvement between the
Company and DEMACSA subsequent to the sale.
In August 2007, the Company sold its Films business of AT
Plastics, located in Edmonton and Westlock, Alberta, Canada, to
British Polythene Industries PLC (BPI) for
$12 million. The Films business manufactures products for
the agricultural, horticultural and construction industries. The
Company recorded a loss on the sale of $7 million during
the year ended December 31, 2007. The Company maintained
ownership of the Polymers business of AT Plastics, which
concentrates on the development and supply of specialty resins
and compounds. AT Plastics is included in the Companys
Industrial Specialties segment. The Company concluded that the
sale of the Films business of AT Plastics is not a discontinued
operation due to the level of continuing cash flows between the
Films business and AT Plastics Polymers business
subsequent to the sale. Under the terms of the purchase
F-14
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
agreement, the Company entered into a two year sales agreement
to continue selling product to BPI through August 2009.
In December 2006, the Company sold its preferred interest in
Pemeas GmbH, a venture formed in April 2004 to advance the
commercialization of the Companys fuel cell technology to
BASF AG. The Company received net proceeds from the sale of
9 million and recognized a gain of
8 million ($11 million). This amount is included
in Other income (expense), net in the consolidated statements of
operations.
In connection with the Companys strategy to optimize its
portfolio and divest non-core operations, the Company announced
on December 13, 2006 its agreement to sell its Acetyl
Intermediates segments oxo products and derivatives
businesses, including European Oxo GmbH (EOXO), a
50/50 venture between Celanese GmbH and Degussa AG
(Degussa), to Advent International, for a purchase
price of 480 million ($636 million) subject to
final agreement adjustments and the successful exercise of the
Companys option to purchase Degussas 50% interest in
EOXO. On February 23, 2007, the option was exercised and
the Company acquired Degussas interest in the venture for
a purchase price of 30 million ($39 million), in
addition to 22 million ($29 million) paid to
extinguish EOXOs debt upon closing of the transaction. The
Company completed the sale of its oxo products and derivatives
businesses, including the acquired 50% interest in EOXO, on
February 28, 2007. The sale included the oxo and
derivatives businesses at the Oberhausen, Germany, and Bay City,
Texas facilities as well as portions of its Bishop, Texas
facility. Also included were EOXOs facilities within the
Oberhausen and Marl, Germany plants. The former oxo products and
derivatives businesses acquired by Advent International was
renamed Oxea. Taking into account agreed deductions by the buyer
for pension and other employee benefits and various costs for
separation activities, the Company received proceeds of
approximately 443 million ($585 million) at
closing. The transaction resulted in the recognition of a
$47 million pre-tax gain, recorded to Gain (loss) on
disposal of discontinued operations, which includes certain
working capital and other adjustments, in 2007. Due to certain
lease-back arrangements between the Company and the buyer and
related environmental obligations of the Company, approximately
$51 million of the transaction proceeds attributable to the
fair value of the underlying land at Bay City ($1 million)
and Oberhausen (36 million) is included in deferred
proceeds in noncurrent Other liabilities, and divested land with
a book value of $14 million (10 million at
Oberhausen and $1 million at Bay City) remains in Property,
plant and equipment, net in the Companys consolidated
balance sheets.
Subsequent to closing, the Company and Oxea have certain site
service and product supply arrangements. The site services
include, but are not limited to, administrative, utilities,
health and safety, waste water treatment and maintenance
activities for terms which range up to fifteen years. Product
supply agreements contain initial terms of up to fifteen years.
The Company has no contractual ability through these agreements
or any other arrangements to significantly influence the
operating or financial policies of Oxea. The Company concluded,
based on the nature and limited projected magnitude of the
continuing business relationship between the Company and Oxea,
the divestiture of the oxo products and derivatives businesses
should be accounted for as a discontinued operation.
Third-party net sales include $5 million and
$35 million for the years ended December 31, 2007 and
2006, respectively, that would have been eliminated upon
consolidation were the divestiture not accounted for as a
discontinued operation. These amounts relate to sales from the
continuing operations of the Company to the divested businesses.
In accordance with the Companys sponsor services agreement
dated January 26, 2005, as amended, the Company paid the
Advisor $6 million in connection with the sale of the oxo
products and derivatives businesses.
During the third quarter of 2006, the Company discontinued its
pentaerythritol (PE) operations, which were included
in the Acetyl Intermediates segment. During the second quarter
of 2007, the Company discontinued its Edmonton, Alberta, Canada
methanol operations, which were included in the Acetyl
Intermediates segment. As a result, the earnings (loss) from
operations related to the Edmonton methanol and PE operations
are accounted for as discontinued operations.
F-15
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Asset
Sales
In May 2008, shareholders of the Companys Koper, Slovenia
legal entity voted to approve the April 2008 decision by the
Company to permanently shut down this emulsions production site.
The decision to shut down the site resulted in employee
severance of less than $1 million, which is included in
Other (charges) gains, net, in the consolidated statements of
operations during the year ended December 31, 2008.
Currently, the facility is idle and the existing fixed assets,
including machinery and equipment, buildings and land are being
marketed for sale. The Koper, Slovenia legal entity is included
in the Companys Industrial Specialties segment.
In December 2007, the Company sold the assets at its Edmonton,
Alberta, Canada facility to a real estate developer for
approximately $35 million. As part of the agreement, the
Company will retain certain environmental liabilities associated
with the site. The Company derecognized $16 million of
asset retirement obligations which were transferred to the
buyer. As a result of the sale, the Company recorded a gain of
$37 million for the year ended December 31, 2007, of
which a gain of $34 million was recorded to Gain (loss) on
disposition of businesses and assets, net in the consolidated
statements of operation.
In July 2007, the Company reached an agreement with
Babcock & Brown, a worldwide investment firm which
specializes in real estate and utilities development, to sell
the Companys Pampa, Texas, facility. The Company ceased
operations at the site in December 2008. Proceeds received upon
certain milestone events will be treated as deferred proceeds
and included in noncurrent Other liabilities in the
Companys consolidated balance sheets until the transaction
is complete (expected to be in 2010), as defined in the sales
agreement. These operations are included in the Companys
Acetyl Intermediates segment. During the second half of 2008,
the Company determined that two of the milestone events, which
are outside of the Companys control, were unlikely to be
achieved. The Company performed a discounted cash flow analysis
which resulted in a $23 million long-lived asset impairment
loss recorded to Other (charges) gains, net, in the consolidated
statements of operations during the year ended December 31,
2008 (Note 18).
|
|
5.
|
Securities
Available for Sale
|
The Companys captive insurance companies and
pension-related trusts hold available-for-sale securities for
capitalization and funding requirements, respectively. The
Company recorded a net realized gain (loss) of $0 million,
$1 million and $(1) million recorded to Other income
(expense), net in the consolidated statements of operations for
the years ended December 31, 2008, 2007 and 2006,
respectively.
F-16
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The amortized cost, gross unrealized gain, gross unrealized loss
and fair values for available-for-sale securities by major
security type were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross
|
|
|
Gross
|
|
|
|
|
|
|
Amortized
|
|
|
Unrealized
|
|
|
Unrealized
|
|
|
Fair
|
|
|
|
Cost
|
|
|
Gain
|
|
|
Loss
|
|
|
Value
|
|
|
|
(In $ millions)
|
|
|
As of December 31, 2008
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt securities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US government
|
|
|
35
|
|
|
|
17
|
|
|
|
|
|
|
|
52
|
|
US corporate
|
|
|
3
|
|
|
|
|
|
|
|
|
|
|
|
3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total debt securities
|
|
|
38
|
|
|
|
17
|
|
|
|
|
|
|
|
55
|
|
Equity securities
|
|
|
55
|
|
|
|
|
|
|
|
(13
|
)
|
|
|
42
|
|
Money market deposits and other securities
|
|
|
3
|
|
|
|
|
|
|
|
|
|
|
|
3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
96
|
|
|
|
17
|
|
|
|
(13
|
)
|
|
|
100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of December 31, 2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt securities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US government
|
|
|
67
|
|
|
|
5
|
|
|
|
|
|
|
|
72
|
|
US corporate
|
|
|
33
|
|
|
|
|
|
|
|
(1
|
)
|
|
|
32
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total debt securities
|
|
|
100
|
|
|
|
5
|
|
|
|
(1
|
)
|
|
|
104
|
|
Equity securities
|
|
|
78
|
|
|
|
26
|
|
|
|
|
|
|
|
104
|
|
Money market deposits and other securities
|
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
1
|
|
Mortgage-backed securities
|
|
|
46
|
|
|
|
|
|
|
|
|
|
|
|
46
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
225
|
|
|
|
31
|
|
|
|
(1
|
)
|
|
|
255
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fixed maturities as of December 31, 2008 by contractual
maturity are shown below. Actual maturities could differ from
contractual maturities because borrowers may have the right to
call or prepay obligations, with or without call or prepayment
penalties.
|
|
|
|
|
|
|
|
|
|
|
Amortized
|
|
|
Fair
|
|
|
|
Cost
|
|
|
Value
|
|
|
|
(In $ millions)
|
|
|
Within one year
|
|
|
6
|
|
|
|
6
|
|
From one to five years
|
|
|
|
|
|
|
|
|
From six to ten years
|
|
|
|
|
|
|
|
|
Greater than ten years
|
|
|
35
|
|
|
|
52
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
41
|
|
|
|
58
|
|
|
|
|
|
|
|
|
|
|
Proceeds received from fixed maturities that mature within one
year are expected to be reinvested into additional securities
upon such maturity.
F-17
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
|
|
|
|
|
|
|
|
|
As of
|
|
|
|
December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
|
(In $ millions)
|
|
|
Trade receivables third party and affiliates
|
|
|
656
|
|
|
|
1,027
|
|
Allowance for doubtful accounts third party and
affiliates
|
|
|
(25
|
)
|
|
|
(18
|
)
|
|
|
|
|
|
|
|
|
|
Trade receivables third party and affiliates, net
|
|
|
631
|
|
|
|
1,009
|
|
Non-trade receivables:
|
|
|
|
|
|
|
|
|
Reinsurance receivables
|
|
|
33
|
|
|
|
35
|
|
Income taxes receivable
|
|
|
88
|
|
|
|
73
|
|
Derivatives
|
|
|
54
|
|
|
|
29
|
|
Other
|
|
|
153
|
|
|
|
300
|
|
|
|
|
|
|
|
|
|
|
Receivables, net
|
|
|
959
|
|
|
|
1,446
|
|
|
|
|
|
|
|
|
|
|
As of December 31, 2008 and 2007, the Company had no
significant concentrations of credit risk since the
Companys customer base is dispersed across many different
industries and geographies.
|
|
|
|
|
|
|
|
|
|
|
As of
|
|
|
|
December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
|
(In $ millions)
|
|
|
Finished goods
|
|
|
434
|
|
|
|
500
|
|
Work-in-process
|
|
|
24
|
|
|
|
29
|
|
Raw materials and supplies
|
|
|
119
|
|
|
|
107
|
|
|
|
|
|
|
|
|
|
|
Inventories
|
|
|
577
|
|
|
|
636
|
|
|
|
|
|
|
|
|
|
|
During December 2008, the Company recorded a $14 million
charge to reduce its inventories to the lower-of-cost or market.
F-18
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Equity
Method
The Companys equity investments and ownership interests
are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share of Earnings (Loss)
|
|
|
|
|
|
Ownership Percentage
|
|
|
Carrying Value
|
|
|
Year Ended
|
|
|
|
|
|
as of December 31,
|
|
|
as of December 31,
|
|
|
December 31,
|
|
|
|
Segment
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
|
|
|
(In percentages)
|
|
|
(In $ millions)
|
|
|
European Oxo
GmbH(1)
|
|
Acetyl Intermediates
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2
|
|
|
|
10
|
|
Erfei, A.I.E.
|
|
Acetyl Intermediates
|
|
|
45.0
|
|
|
|
45.0
|
|
|
|
1
|
|
|
|
1
|
|
|
|
|
|
|
|
(1
|
)
|
|
|
|
|
|
|
Advanced Engineered
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fortron Industries LLC
|
|
Materials
|
|
|
50.0
|
|
|
|
50.0
|
|
|
|
77
|
|
|
|
73
|
|
|
|
4
|
|
|
|
16
|
|
|
|
14
|
|
Korea Engineering
|
|
Advanced Engineered
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Plastics Co., Ltd.
|
|
Materials
|
|
|
50.0
|
|
|
|
50.0
|
|
|
|
145
|
|
|
|
170
|
|
|
|
12
|
|
|
|
14
|
|
|
|
13
|
|
|
|
Advanced Engineered
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Polyplastics Co., Ltd.
|
|
Materials
|
|
|
45.0
|
|
|
|
45.0
|
|
|
|
189
|
|
|
|
170
|
|
|
|
19
|
|
|
|
25
|
|
|
|
26
|
|
|
|
Advanced Engineered
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Una SA
|
|
Materials
|
|
|
50.0
|
|
|
|
50.0
|
|
|
|
2
|
|
|
|
|
|
|
|
2
|
|
|
|
|
|
|
|
|
|
InfraServ GmbH & Co. Gendorf KG
|
|
Other Activities
|
|
|
39.0
|
|
|
|
39.0
|
|
|
|
28
|
|
|
|
30
|
|
|
|
4
|
|
|
|
5
|
|
|
|
4
|
|
InfraServ GmbH & Co. Hoechst KG
|
|
Other Activities
|
|
|
31.2
|
|
|
|
31.2
|
|
|
|
137
|
|
|
|
154
|
|
|
|
10
|
|
|
|
18
|
|
|
|
14
|
|
InfraServ GmbH & Co. Knapsack KG
|
|
Other Activities
|
|
|
28.2
|
|
|
|
28.2
|
|
|
|
22
|
|
|
|
23
|
|
|
|
4
|
|
|
|
4
|
|
|
|
1
|
|
Sherbrooke Capital Health and Wellness,
L.P.(2)
|
|
Consumer Specialties
|
|
|
10.0
|
|
|
|
10.0
|
|
|
|
4
|
|
|
|
4
|
|
|
|
(1
|
)
|
|
|
|
|
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
|
|
|
|
|
|
|
|
|
|
605
|
|
|
|
625
|
|
|
|
54
|
|
|
|
83
|
|
|
|
83
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
The Company divested this investment in February 2007
(Note 4). The share of earnings (loss) for this investment
is included in Earnings (loss) from operation of discontinued
operations on the consolidated statements of operations. |
|
(2) |
|
The Company accounts for its 10% ownership interest in
Sherbrooke Capital Health and Wellness, L.P. under the equity
method of accounting because the Company is able to exercise
significant influence. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
|
(In $ millions)
|
|
|
Affiliates totals:
|
|
|
|
|
|
|
|
|
|
|
|
|
Net earnings
|
|
|
121
|
|
|
|
204
|
|
|
|
197
|
|
Companys share:
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
earnings(1)
|
|
|
54
|
|
|
|
83
|
|
|
|
83
|
|
Dividends and other distributions
|
|
|
64
|
|
|
|
57
|
|
|
|
109
|
|
|
|
|
(1) |
|
Amount does not include a $1 million and a $3 million
liquidating dividend from Clear Lake Methanol Partners for the
years ended December 31, 2007 and 2006, respectively. |
F-19
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The total assets and liabilities associated with the
Companys equity method investments are as follows:
|
|
|
|
|
|
|
|
|
|
|
As of
|
|
|
|
December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
|
(In $ millions)
|
|
|
Total assets
|
|
|
3,163
|
|
|
|
2,916
|
|
Total liabilities
|
|
|
1,853
|
|
|
|
1,576
|
|
Cost
Method
The Companys investments accounted for under the cost
method of accounting are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ownership Percentage
|
|
|
Carrying Value as of
|
|
|
|
|
|
as of December 31,
|
|
|
December 31,
|
|
|
|
Segment
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
|
|
|
|
(In percentages)
|
|
|
(In $ millions)
|
|
|
National Methanol Company (Ibn Sina)
|
|
Acetyl Intermediates
|
|
|
25
|
|
|
|
25
|
|
|
|
54
|
|
|
|
54
|
|
Kunming Cellulose Fibers Co. Ltd.
|
|
Consumer Specialties
|
|
|
30
|
|
|
|
30
|
|
|
|
14
|
|
|
|
15
|
|
Nantong Cellulose Fibers Co. Ltd.
|
|
Consumer Specialties
|
|
|
31
|
|
|
|
31
|
|
|
|
77
|
|
|
|
77
|
|
Zhuhai Cellulose Fibers Co. Ltd.
|
|
Consumer Specialties
|
|
|
30
|
|
|
|
30
|
|
|
|
14
|
|
|
|
15
|
|
InfraServ GmbH & Co. Wiesbaden KG
|
|
Other Activities
|
|
|
8
|
|
|
|
8
|
|
|
|
6
|
|
|
|
6
|
|
Other
|
|
|
|
|
|
|
|
|
|
|
|
|
19
|
|
|
|
22
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
|
|
|
|
|
|
|
|
|
|
184
|
|
|
|
189
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Certain cost investments where the Company owns greater than a
20% ownership interest are accounted for under the cost method
of accounting because the Company cannot exercise significant
influence over these entities. The Company determined that it
cannot exercise significant influence over these entities due to
local government investment in and influence over these
entities, limitations on the Companys involvement in the
day-to-day operations and the present inability of the entities
to provide timely financial information prepared in accordance
with US GAAP.
During 2007, the Company wrote-off its remaining
1 million ($1 million) cost investment in
European Pipeline Development Company B.V. (EPDC)
and expensed 7 million ($9 million), included in
Other income (expense), net, associated with contingent
liabilities that became payable due to the Companys
decision to exit the pipeline development project. In June 2008,
the outstanding contingent liabilities were resolved and the
Company recognized a gain of 2 million
($2 million), included in Other income (expense), net, in
the consolidated statements of operations to remove the
remaining accrual. The investment in EPDC related to the
construction of a pipeline system, solely dedicated to the
transportation of propylene, which was to connect Rotterdam via
Antwerp, Netherlands, with the Companys Oberhausen and
Marl production facilities in Germany. However, on
February 15, 2007, EPDC shareholders voted to cease the
pipeline project as originally envisaged and go into
liquidation. The Company was a 12.5% shareholder of EPDC.
During 2007, the Company fully impaired its $5 million cost
investment in Elemica Corporation (Elemica). Elemica
is a network for the global chemical industry developed by 22 of
the leading chemical companies in the world for the benefit of
the entire industry. The Company is a 1.83% shareholder of
Elemica through its preferred share holdings. As part of
Elemicas planned capital reorganization in 2007, its board
of directors has proposed to convert all outstanding preferred
stock into shares of Elemicas common stock. Based on the
Companys analysis of
F-20
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Elemicas proposed capital reorganization, past earnings
performance and business prospects, the Company concluded that
its cost investment in Elemica was impaired. The impairment was
included in Other income (expense), net in the consolidated
statements of operations.
|
|
9.
|
Property,
Plant and Equipment, Net
|
|
|
|
|
|
|
|
|
|
|
|
As of
|
|
|
|
December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
|
(In $ millions)
|
|
|
Land
|
|
|
61
|
|
|
|
69
|
|
Land improvements
|
|
|
44
|
|
|
|
45
|
|
Buildings
|
|
|
362
|
|
|
|
353
|
|
Machinery and equipment
|
|
|
2,702
|
|
|
|
2,404
|
|
Construction in progress
|
|
|
444
|
|
|
|
329
|
|
|
|
|
|
|
|
|
|
|
Property, plant and equipment, gross
|
|
|
3,613
|
|
|
|
3,200
|
|
Less: accumulated depreciation
|
|
|
(1,141
|
)
|
|
|
(838
|
)
|
|
|
|
|
|
|
|
|
|
Property, plant and equipment, net
|
|
|
2,472
|
|
|
|
2,362
|
|
|
|
|
|
|
|
|
|
|
Assets under capital leases amounted to $233 million and
$112 million, less accumulated amortization of
$38 million and $7 million, as of December 31,
2008 and 2007, respectively. Interest costs capitalized were
$6 million, $9 million and $6 million during the
years ended December 31, 2008, 2007 and 2006, respectively.
Depreciation expense was $255 million, $209 million
and $191 million during the years ended December 31,
2008, 2007 and 2006, respectively.
At December 31, 2008, the Company had assets held for sale
with a net book value of $2 million.
During 2008, certain long-lived assets were impaired
(Note 18).
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Advanced
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Engineered
|
|
|
Consumer
|
|
|
Industrial
|
|
|
Acetyl
|
|
|
|
|
|
|
Materials
|
|
|
Specialties
|
|
|
Specialties
|
|
|
Intermediates
|
|
|
Total
|
|
|
|
(In $ millions)
|
|
|
Goodwill as of December 31, 2006
|
|
|
256
|
|
|
|
240
|
|
|
|
52
|
|
|
|
327
|
|
|
|
875
|
|
Acquisitions
|
|
|
1
|
|
|
|
19
|
|
|
|
|
|
|
|
3
|
|
|
|
23
|
|
Adjustments to preacquisition tax uncertainties
|
|
|
(12
|
)
|
|
|
(15
|
)
|
|
|
|
|
|
|
(14
|
)
|
|
|
(41
|
)
|
Sale of businesses
|
|
|
|
|
|
|
|
|
|
|
(1
|
)
|
|
|
(42
|
)
|
|
|
(43
|
)
|
Adoption of
FIN 48(1)
|
|
|
15
|
|
|
|
6
|
|
|
|
(1
|
)
|
|
|
(22
|
)
|
|
|
(2
|
)
|
Goodwill
impairment(2)
|
|
|
|
|
|
|
|
|
|
|
(6
|
)
|
|
|
|
|
|
|
(6
|
)
|
Exchange rate changes
|
|
|
17
|
|
|
|
14
|
|
|
|
3
|
|
|
|
26
|
|
|
|
60
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Goodwill as of December 31, 2007
|
|
|
277
|
|
|
|
264
|
|
|
|
47
|
|
|
|
278
|
|
|
|
866
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjustments to preacquisition tax uncertainties
|
|
|
(9
|
)
|
|
|
2
|
|
|
|
(12
|
)
|
|
|
(30
|
)
|
|
|
(49
|
)
|
Exchange rate changes
|
|
|
(10
|
)
|
|
|
(14
|
)
|
|
|
(1
|
)
|
|
|
(13
|
)
|
|
|
(38
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Goodwill as of December 31, 2008
|
|
|
258
|
|
|
|
252
|
|
|
|
34
|
|
|
|
235
|
|
|
|
779
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
See Note 19 for additional discussion of FIN 48. |
F-21
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
|
(2) |
|
In connection with the Companys annual goodwill impairment
test, the Company recorded an impairment of $6 million in
the polyvinyl alcohol (PVOH) reporting unit. The
PVOH reporting unit is included in the Industrial Specialties
segment. |
In connection with the Companys annual goodwill impairment
test, the Company did not record an impairment loss for goodwill
during the nine months ended September 30, 2008. In
addition, based on the significant adverse change in the US and
global business climate, the Company performed a goodwill
impairment test during the three months ended December 31,
2008. Based on the results of this goodwill impairment test, the
Company did not record an impairment loss for goodwill.
|
|
11.
|
Intangible
Assets, Net
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Customer-
|
|
|
|
|
|
Covenants
|
|
|
|
|
|
|
Trademarks
|
|
|
|
|
|
Related
|
|
|
|
|
|
not to
|
|
|
|
|
|
|
and
|
|
|
|
|
|
Intangible
|
|
|
Developed
|
|
|
Compete
|
|
|
|
|
|
|
Trade names
|
|
|
Licenses
|
|
|
Assets
|
|
|
Technology
|
|
|
and Other
|
|
|
Total
|
|
|
|
|
|
|
|
|
|
(In $ millions)
|
|
|
|
|
|
|
|
|
Gross Asset Value
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of December 31, 2006
|
|
|
79
|
|
|
|
|
|
|
|
523
|
|
|
|
13
|
|
|
|
12
|
|
|
|
627
|
|
Acquisitions
|
|
|
2
|
|
|
|
|
|
|
|
10
|
|
|
|
|
|
|
|
|
|
|
|
12
|
|
Divestitures
|
|
|
(1
|
)
|
|
|
|
|
|
|
(17
|
)
|
|
|
(1
|
)
|
|
|
|
|
|
|
(19
|
)
|
Exchange rate changes
|
|
|
5
|
|
|
|
|
|
|
|
46
|
|
|
|
|
|
|
|
|
|
|
|
51
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of December 31, 2007
|
|
|
85
|
|
|
|
|
|
|
|
562
|
|
|
|
12
|
|
|
|
12
|
|
|
|
671
|
|
Acquisitions(1)
|
|
|
|
|
|
|
28
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
28
|
|
Divestitures
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exchange rate changes
|
|
|
(3
|
)
|
|
|
1
|
|
|
|
(25
|
)
|
|
|
|
|
|
|
|
|
|
|
(27
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of December 31, 2008
|
|
|
82
|
|
|
|
29
|
|
|
|
537
|
|
|
|
12
|
|
|
|
12
|
|
|
|
672
|
|
Accumulated Amortization
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of December 31, 2006
|
|
|
(1
|
)
|
|
|
|
|
|
|
(149
|
)
|
|
|
(8
|
)
|
|
|
(6
|
)
|
|
|
(164
|
)
|
Current period amortization
|
|
|
|
|
|
|
|
|
|
|
(68
|
)
|
|
|
(1
|
)
|
|
|
(3
|
)
|
|
|
(72
|
)
|
Divestitures
|
|
|
1
|
|
|
|
|
|
|
|
5
|
|
|
|
|
|
|
|
|
|
|
|
6
|
|
Exchange rate changes
|
|
|
|
|
|
|
|
|
|
|
(16
|
)
|
|
|
|
|
|
|
|
|
|
|
(16
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of December 31, 2007
|
|
|
|
|
|
|
|
|
|
|
(228
|
)
|
|
|
(9
|
)
|
|
|
(9
|
)
|
|
|
(246
|
)
|
Current period amortization
|
|
|
|
|
|
|
(3
|
)
|
|
|
(71
|
)
|
|
|
(1
|
)
|
|
|
(1
|
)
|
|
|
(76
|
)
|
Exchange rate changes
|
|
|
|
|
|
|
|
|
|
|
14
|
|
|
|
|
|
|
|
|
|
|
|
14
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of December 31, 2008
|
|
|
|
|
|
|
(3
|
)
|
|
|
(285
|
)
|
|
|
(10
|
)
|
|
|
(10
|
)
|
|
|
(308
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Intangible assets, net as of December 31, 2008
|
|
|
82
|
|
|
|
26
|
|
|
|
252
|
|
|
|
2
|
|
|
|
2
|
|
|
|
364
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Acquisition of a sole and exclusive license to patents and
patent applications related to acetic acid. The license will be
amortized over 10 years. |
Estimated amortization expense for the succeeding five fiscal
years is approximately $73 million in 2009,
$64 million in 2010, $59 million in 2011,
$45 million in 2012 and $29 million in 2013. The
Companys trademarks and trade names have an indefinite
life. Accordingly, no amortization is recorded on these
intangible assets. As a result of the Companys annual
impairment test on indefinite-lived intangible assets, the
Company did not record an impairment loss for indefinite-lived
intangible assets during the year ended December 31, 2008.
F-22
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
12.
|
Current Other Liabilities
|
|
|
|
|
|
|
|
|
|
|
|
As of December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
|
(In $ millions)
|
|
|
Salaries and benefits
|
|
|
107
|
|
|
|
157
|
|
Environmental (Note 16)
|
|
|
19
|
|
|
|
19
|
|
Restructuring (Note 18)
|
|
|
32
|
|
|
|
40
|
|
Insurance
|
|
|
34
|
|
|
|
41
|
|
Sorbates litigation (Note 23)
|
|
|
1
|
|
|
|
170
|
|
Asset retirement obligations
|
|
|
9
|
|
|
|
16
|
|
Derivatives
|
|
|
65
|
|
|
|
129
|
|
Current portion of benefit obligations
|
|
|
57
|
|
|
|
56
|
|
Interest
|
|
|
56
|
|
|
|
60
|
|
Other
|
|
|
194
|
|
|
|
200
|
|
|
|
|
|
|
|
|
|
|
Current Other liabilities
|
|
|
574
|
|
|
|
888
|
|
|
|
|
|
|
|
|
|
|
|
|
13.
|
Noncurrent Other Liabilities
|
|
|
|
|
|
|
|
|
|
|
|
As of December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
|
(In $ millions)
|
|
|
Environmental (Note 16)
|
|
|
79
|
|
|
|
96
|
|
Insurance
|
|
|
85
|
|
|
|
78
|
|
Deferred revenue
|
|
|
56
|
|
|
|
71
|
|
Deferred proceeds (Note 4, Note 28)
|
|
|
370
|
|
|
|
93
|
|
Asset retirement obligations
|
|
|
40
|
|
|
|
31
|
|
Derivatives
|
|
|
76
|
|
|
|
37
|
|
Other
|
|
|
100
|
|
|
|
89
|
|
|
|
|
|
|
|
|
|
|
Noncurrent Other liabilities
|
|
|
806
|
|
|
|
495
|
|
|
|
|
|
|
|
|
|
|
Changes in asset retirement obligations are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
|
(In $ millions)
|
|
|
Balance at beginning of year
|
|
|
47
|
|
|
|
59
|
|
|
|
54
|
|
Additions
|
|
|
6
|
(2)
|
|
|
|
|
|
|
10
|
|
Accretion
|
|
|
3
|
|
|
|
5
|
|
|
|
3
|
|
Payments
|
|
|
(6
|
)
|
|
|
(6
|
)
|
|
|
(2
|
)
|
Divestitures
|
|
|
|
|
|
|
(16
|
)(1)
|
|
|
|
|
Purchase accounting adjustments
|
|
|
|
|
|
|
3
|
|
|
|
|
|
Revisions to cash flow estimates
|
|
|
1
|
|
|
|
(2
|
)
|
|
|
(7
|
)
|
Exchange rate changes
|
|
|
(2
|
)
|
|
|
4
|
|
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at end of year
|
|
|
49
|
|
|
|
47
|
|
|
|
59
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Relates to the sale of the Edmonton, Alberta, Canada plant
(Note 4). |
(2) |
|
Primarily relates to long-lived assets impaired during the year
ended December 31, 2008 (Note 18) which management no
longer considers to have an indeterminate life. |
F-23
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Included in the asset retirement obligations for each of the
years ended December 31, 2008, 2007 and 2006 is
$10 million related to a business acquired in 2005. The
Company has a corresponding receivable for this amount included
in noncurrent Other assets as of December 31, 2008.
The Company has identified but not recognized asset retirement
obligations related to certain of its existing operating
facilities. Examples of these types of obligations include
demolition, decommissioning, disposal and restoration
activities. Legal obligations exist in connection with the
retirement of these assets upon closure of the facilities or
abandonment of the existing operations. However, the Company
currently plans on continuing operations at these facilities
indefinitely and therefore a reasonable estimate of fair value
cannot be determined at this time. In the event the Company
considers plans to abandon or cease operations at these sites,
an asset retirement obligation will be reassessed at that time.
If certain operating facilities were to close, the related asset
retirement obligations could significantly affect the
Companys results of operations and cash flows.
|
|
|
|
|
|
|
|
|
|
|
As of December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
|
(In $ millions)
|
|
|
Short-term borrowings and current installments of long-term
debt third party and affiliates
|
|
|
|
|
|
|
|
|
Current installments of long-term debt
|
|
|
81
|
|
|
|
44
|
|
Short-term borrowings, principally comprised of amounts due to
affiliates
|
|
|
152
|
|
|
|
228
|
|
|
|
|
|
|
|
|
|
|
Short-term borrowings and current installments of long-term
debt third party and affiliates
|
|
|
233
|
|
|
|
272
|
|
|
|
|
|
|
|
|
|
|
Long-term debt
|
|
|
|
|
|
|
|
|
Senior Credit Facilities: Term Loan facility due 2014
|
|
|
2,794
|
|
|
|
2,855
|
|
Term notes 7.125%, due 2009
|
|
|
14
|
|
|
|
14
|
|
Pollution control and industrial revenue bonds, interest rates
ranging from 5.7% to 6.7%, due at various dates through 2030
|
|
|
181
|
|
|
|
181
|
|
Obligations under capital leases and other secured borrowings
due at various dates through 2024
|
|
|
211
|
|
|
|
110
|
|
Other bank obligations, interest rates ranging from 4.33% to
7.05%, due at various dates through 2014
|
|
|
181
|
|
|
|
168
|
|
|
|
|
|
|
|
|
|
|
Subtotal
|
|
|
3,381
|
|
|
|
3,328
|
|
Less: Current installments of long-term debt
|
|
|
81
|
|
|
|
44
|
|
|
|
|
|
|
|
|
|
|
Long-term debt
|
|
|
3,300
|
|
|
|
3,284
|
|
|
|
|
|
|
|
|
|
|
Senior
Credit Facilities
The Companys senior credit agreement consists of
$2,280 million of US dollar-denominated and
400 million of Euro-denominated term loans due 2014,
a $650 million revolving credit facility terminating in
2013 and a $228 million credit-linked revolving facility
terminating in 2014. Borrowings under the senior credit
agreement bear interest at a variable interest rate based on
LIBOR (for US dollars) or EURIBOR (for Euros), as applicable,
or, for US dollar-denominated loans under certain circumstances,
a base rate, in each case plus an applicable margin. The
applicable margin for the term loans and any loans under the
credit-linked revolving facility is 1.75%, subject to potential
reductions as defined in the senior credit agreement. As of
December 31, 2008, the applicable margin was 1.5% and
continues to be subject to potential adjustments as defined in
the senior credit agreement. The term loans
F-24
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
under the senior credit agreement are subject to amortization at
1% of the initial principal amount per annum, payable quarterly.
The remaining principal amount of the term loans is due on
April 2, 2014.
As of December 31, 2008, there were no outstanding
borrowings or letters of credit issued under the revolving
credit facility; accordingly, $650 million remained
available for borrowing. As of December 31, 2008, there
were $91 million of letters of credit issued under the
credit-linked revolving facility and $137 million remained
available for borrowing.
The senior credit agreement is guaranteed by Celanese Holdings
LLC, a subsidiary of Celanese Corporation, and certain domestic
subsidiaries of Celanese US, and is secured by a lien on
substantially all assets of Celanese US and such guarantors,
subject to certain agreed exceptions, pursuant to the Guarantee
and Collateral Agreement, dated as of April 2, 2007, by and
among Celanese Holdings LLC, Celanese US, certain subsidiaries
of Celanese US and Deutsche Bank AG, New York Branch, as
Administrative Agent and as Collateral Agent.
Our senior credit agreement requires us to maintain a maximum
first lien senior secured leverage ratio not greater than 3.90
to 1.00 if there are outstanding borrowings under the revolving
credit facility. The first lien senior secured leverage ratio is
calculated as the ratio of consolidated first lien senior
secured debt to earnings before interest, taxes, depreciation
and amortization, subject to adjustments identified in the
credit agreement. The Company is in compliance with all of the
covenants related to its debt agreements as of
December 31, 2008.
Debt
Refinancing
In April 2007, the Company, through certain of its subsidiaries,
entered into a new senior credit agreement. Proceeds from the
new senior credit agreement, together with available cash, were
used to retire the Companys $2,454 million amended
and restated (January 2005) senior credit facilities, which
consisted of $1,626 million in term loans due 2011, a
$600 million revolving credit facility terminating in 2009
and a $228 million credit-linked revolving facility
terminating in 2009, and to retire all of the Companys
9.625% senior subordinated notes due 2014 and
10.375% senior subordinated notes due 2014 (the
Senior Subordinated Notes) and 10% senior
discount notes due 2014 and 10.5% senior discount notes due
2014 (the Senior Discount Notes) as discussed below.
Substantially all of the Senior Discount Notes and Senior
Subordinated Notes were tendered in the first quarter of 2007.
The remaining outstanding Senior Discount Notes and Senior
Subordinated Notes not tendered in conjunction with the Tender
Offers were redeemed by the Company in May 2007 through optional
redemption allowed in the indentures.
As a result of the refinancing, the Company incurred premiums
paid on early redemption of debt, accelerated amortization and
other refinancing expenses. The components of refinancing
expenses are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
|
(In $ millions)
|
|
|
Premium paid on early redemption of debt
|
|
|
|
|
|
|
207
|
|
|
|
|
|
Accelerated amortization of premiums and deferred financing
costs on early redemption and prepayment of debt
|
|
|
|
|
|
|
33
|
|
|
|
1
|
|
Debt issuance costs and other
|
|
|
|
|
|
|
16
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Refinancing expenses
|
|
|
|
|
|
|
256
|
|
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
In connection with the refinancing, the Company recorded
deferred financing costs of $39 million related to the new
senior credit agreement, which are included in noncurrent Other
assets on the consolidated balance sheets and are being
amortized over the term of the new senior credit agreement. The
deferred financing costs consist of $23 million of costs
incurred to acquire the new senior credit agreement and
$16 million of debt issue costs existing prior to the
refinancing.
F-25
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
For the years ended December 31, 2008, 2007 and 2006, the
Company recorded amortization of deferred financing costs, which
is classified in Interest expense, of $7 million,
$8 million and $13 million, respectively. As of
December 31, 2008 and 2007, respectively, the Company had
$32 million and $39 million of net deferred financing
costs.
Principal payments scheduled to be made on the Companys
debt, including short-term borrowings, are as follows:
|
|
|
|
|
|
|
(In $ millions)
|
|
|
2009
|
|
|
233
|
|
2010
|
|
|
100
|
|
2011
|
|
|
89
|
|
2012
|
|
|
65
|
|
2013
|
|
|
73
|
|
Thereafter
|
|
|
2,973
|
|
|
|
|
|
|
Total
|
|
|
3,533
|
|
|
|
|
|
|
The Company adopted the provisions of SFAS No. 158,
Employers Accounting for Defined Benefit Pension and
Other Postretirement Plans an amendment of FASB Statements No.
87, 88, 106, and 132(R) (SFAS No. 158), on
December 31, 2006 which caused the Company to recognize the
unfunded status of its benefit plans of $113 million in the
December 31, 2006 consolidated balance sheet, with a
corresponding adjustment to Accumulated other comprehensive
income (loss), net. The Companys adoption of SFAS No. 158
had no impact to the consolidated statements of operations for
the year ended December 31, 2006.
Pension obligations. Pension obligations are
established for benefits payable in the form of retirement,
disability and surviving dependent pensions. The benefits
offered vary according to the legal, fiscal and economic
conditions of each country. The commitments result from
participation in defined contribution and defined benefit plans,
primarily in the US. Benefits are dependent on years of service
and the employees compensation. Supplemental retirement
benefits provided to certain employees are nonqualified for US
tax purposes. Separate trusts have been established for some
nonqualified plans. Pension costs under the Companys
retirement plans are actuarially determined.
The Company sponsors defined benefit pension plans in North
America, Europe and Asia. As of December 31, 2008, the
Companys US qualified pension plan represents
approximately 83% and 78% of the Companys pension plan
assets and liabilities, respectively. Independent trusts or
insurance companies administer the majority of these plans. The
US qualified defined benefit plans actual return on assets
for the year ended December 31, 2008 was a loss of 18%
versus an expected long-term rate of asset return assumption of
8.5%. The overall performance of the portfolio suffered due to
the significant declines in the global equity markets. The
returns on equity investments for this plan were negative while
the returns on fixed income investments were positive.
The Company sponsors various defined contribution plans in North
America, Europe and Asia covering certain employees. Employees
may contribute to these plans and the Company will match these
contributions in varying amounts. The Companys matching
contribution to the defined contribution plans are based on
specified percentages of employee contributions and aggregated
$13 million, $12 million and $11 million for the
years ended December 31, 2008, 2007 and 2006, respectively.
The Company participates in multiemployer defined benefit
pension plans in Europe covering certain employees. The
Companys contributions to the multiemployer defined
benefit pension plans are based on specified percentages of
employee contributions and aggregated $7 million, for each
of the years ended December 31, 2008, 2007 and 2006.
Other postretirement obligations. Certain
retired employees receive postretirement healthcare and life
insurance benefits under plans sponsored by the Company, which
has the right to modify or terminate these plans at any time.
The cost for coverage is shared between the Company and the
retiree. The cost of providing retiree
F-26
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
health care and life insurance benefits is actuarially
determined and accrued over the service period of the active
employee group. The Companys policy is to fund benefits as
claims and premiums are paid. The US plan was closed to new
participants effective January 1, 2006.
The following tables set forth the benefit obligations, the fair
value of the plan assets and the funded status of the
Companys pension and postretirement benefit plans; and the
amounts recognized in the Companys consolidated financial
statements:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Postretirement Benefits
|
|
|
|
Pension Benefits
|
|
|
as of
|
|
|
|
as of December 31,
|
|
|
December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
|
|
|
|
|
(In $ millions)
|
|
|
|
|
|
Change in projected benefit obligation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Projected benefit obligation at beginning of period
|
|
|
3,264
|
|
|
|
3,343
|
|
|
|
306
|
|
|
|
343
|
|
Service cost
|
|
|
31
|
|
|
|
38
|
|
|
|
2
|
|
|
|
2
|
|
Interest cost
|
|
|
195
|
|
|
|
187
|
|
|
|
17
|
|
|
|
19
|
|
Participant contributions
|
|
|
|
|
|
|
1
|
|
|
|
22
|
|
|
|
17
|
|
Plan amendments
|
|
|
|
|
|
|
4
|
|
|
|
2
|
|
|
|
|
|
Actuarial
gains(1)
|
|
|
(107
|
)
|
|
|
(123
|
)
|
|
|
(14
|
)
|
|
|
(18
|
)
|
Special termination benefits
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Divestitures
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Settlements
|
|
|
(19
|
)
|
|
|
(40
|
)
|
|
|
|
|
|
|
|
|
Benefits paid
|
|
|
(222
|
)
|
|
|
(215
|
)
|
|
|
(58
|
)
|
|
|
(66
|
)
|
Federal subsidy on Medicare Part D
|
|
|
|
|
|
|
|
|
|
|
6
|
|
|
|
6
|
|
Curtailments
|
|
|
(1
|
)
|
|
|
(1
|
)
|
|
|
(2
|
)
|
|
|
(1
|
)
|
Foreign currency exchange rate changes
|
|
|
(68
|
)
|
|
|
69
|
|
|
|
(6
|
)
|
|
|
4
|
|
Other
|
|
|
|
|
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Projected benefit obligation at end of period
|
|
|
3,073
|
|
|
|
3,264
|
|
|
|
275
|
|
|
|
306
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Change in plan assets
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair value of plan assets at beginning of period
|
|
|
2,875
|
|
|
|
2,802
|
|
|
|
|
|
|
|
|
|
Actual return on plan assets
|
|
|
(448
|
)
|
|
|
209
|
|
|
|
|
|
|
|
|
|
Employer contributions
|
|
|
48
|
|
|
|
48
|
|
|
|
35
|
|
|
|
49
|
|
Participant contributions
|
|
|
|
|
|
|
1
|
|
|
|
23
|
|
|
|
17
|
|
Settlements
|
|
|
(22
|
)
|
|
|
(28
|
)
|
|
|
|
|
|
|
|
|
Benefits paid
|
|
|
(222
|
)
|
|
|
(215
|
)
|
|
|
(58
|
)
|
|
|
(66
|
)
|
Foreign currency exchange rate changes
|
|
|
(61
|
)
|
|
|
57
|
|
|
|
|
|
|
|
|
|
Other
|
|
|
|
|
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair value of plan assets at end of period
|
|
|
2,170
|
|
|
|
2,875
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Funded status and net amounts recognized
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Plan assets less than benefit obligation
|
|
|
(903
|
)
|
|
|
(389
|
)
|
|
|
(275
|
)
|
|
|
(306
|
)
|
Unrecognized prior service cost
|
|
|
1
|
|
|
|
3
|
|
|
|
1
|
|
|
|
(1
|
)
|
Unrecognized actuarial (gain) loss
|
|
|
502
|
|
|
|
(53
|
)
|
|
|
(80
|
)
|
|
|
(71
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net amount recognized in the consolidated balance sheets
|
|
|
(400
|
)
|
|
|
(439
|
)
|
|
|
(354
|
)
|
|
|
(378
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amounts recognized in the consolidated balance sheets consist
of:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Noncurrent Other assets
|
|
|
8
|
|
|
|
7
|
|
|
|
|
|
|
|
|
|
Current Other liabilities
|
|
|
(22
|
)
|
|
|
(21
|
)
|
|
|
(35
|
)
|
|
|
(34
|
)
|
Pension obligations
|
|
|
(889
|
)
|
|
|
(375
|
)
|
|
|
(240
|
)
|
|
|
(272
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accrued benefit liability
|
|
|
(903
|
)
|
|
|
(389
|
)
|
|
|
(275
|
)
|
|
|
(306
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net actuarial (gain) loss
|
|
|
502
|
|
|
|
(53
|
)
|
|
|
(80
|
)
|
|
|
(71
|
)
|
Prior service (benefit) cost
|
|
|
1
|
|
|
|
3
|
|
|
|
1
|
|
|
|
(1
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other comprehensive (income)
loss(2)
|
|
|
503
|
|
|
|
(50
|
)
|
|
|
(79
|
)
|
|
|
(72
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net amount recognized in the consolidated balance sheets
|
|
|
(400
|
)
|
|
|
(439
|
)
|
|
|
(354
|
)
|
|
|
(378
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Primarily relates to change in discount rates. |
F-27
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
|
(2) |
|
Amount shown net of tax in the consolidated statements of
shareholders equity and comprehensive income (loss). See
Note 19 for the related tax associated with the pension and
postretirement benefit obligations. |
A summary of pension plans with projected benefit obligations in
excess of plan assets is shown below:
|
|
|
|
|
|
|
|
|
|
|
As of December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
|
(In $ millions)
|
|
|
Projected benefit obligation
|
|
|
2,924
|
|
|
|
3,146
|
|
Fair value of plan assets
|
|
|
2,014
|
|
|
|
2,750
|
|
Included in the above table are pension plans with accumulated
benefit obligations in excess of plan assets as detailed below:
|
|
|
|
|
|
|
|
|
|
|
As of December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
|
(In $ millions)
|
|
|
Accumulated benefit obligation
|
|
|
2,797
|
|
|
|
618
|
|
Fair value of plan assets
|
|
|
1,985
|
|
|
|
308
|
|
The accumulated benefit obligation for all defined benefit
pension plans was $2,967 million and $3,147 million as
of December 31, 2008 and 2007, respectively.
The following table sets forth the Companys net periodic
pension cost:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pension Benefits
|
|
|
Postretirement Benefits
|
|
|
|
Year Ended
|
|
|
Year Ended
|
|
|
|
December 31,
|
|
|
December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
|
|
|
|
|
|
|
(In $ millions)
|
|
|
|
|
|
|
|
|
Components of net periodic benefit cost
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Service cost
|
|
|
31
|
|
|
|
38
|
|
|
|
40
|
|
|
|
1
|
|
|
|
2
|
|
|
|
2
|
|
Interest cost
|
|
|
195
|
|
|
|
187
|
|
|
|
183
|
|
|
|
17
|
|
|
|
19
|
|
|
|
20
|
|
Expected return on plan assets
|
|
|
(218
|
)
|
|
|
(216
|
)
|
|
|
(207
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of prior service cost
|
|
|
|
|
|
|
|
|
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Recognized actuarial (gain) loss
|
|
|
1
|
|
|
|
1
|
|
|
|
2
|
|
|
|
(4
|
)
|
|
|
(2
|
)
|
|
|
|
|
Curtailment (gain) loss
|
|
|
(2
|
)
|
|
|
(1
|
)
|
|
|
1
|
|
|
|
|
|
|
|
(1
|
)
|
|
|
(1
|
)
|
Settlement (gain) loss
|
|
|
3
|
|
|
|
(12
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Special termination benefits
|
|
|
|
|
|
|
|
|
|
|
3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net periodic benefit cost
|
|
|
10
|
|
|
|
(3
|
)
|
|
|
23
|
|
|
|
14
|
|
|
|
18
|
|
|
|
21
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of the actuarial (gain) loss into net periodic cost
in 2009 is expected to be $1 million and $(5) million
for pension benefits and postretirement benefits, respectively.
Included in the pension obligations above are accrued
liabilities relating to supplemental retirement plans for
certain employees amounting to $224 million and
$230 million as of December 31, 2008 and 2007,
respectively. Pension expense relating to these plans included
in net periodic benefit cost totaled $15 million,
$14 million and $15 million for the years ended
December 31, 2008, 2007 and 2006, respectively. To fund
these obligations, nonqualified trusts were established which
hold marketable securities valued at $97 million and
$121 million as of December 31, 2008 and 2007,
respectively. In addition to holding marketable securities, the
nonqualified trusts hold investments in insurance contracts of
$67 million and $74 million as of December 31,
2008 and 2007, respectively, which are included in noncurrent
Other assets in the consolidated balance sheets.
F-28
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Valuation
The Company uses the corridor approach in the valuation of the
defined benefit plans and other postretirement benefits. The
corridor approach defers all actuarial gains and losses
resulting from variances between actual results and economic
estimates or actuarial assumptions. For defined benefit pension
plans, these unrecognized gains and losses are amortized when
the net gains and losses exceed 10% of the greater of the
market-related value of plan assets or the projected benefit
obligation at the beginning of the year. For other
postretirement benefits, amortization occurs when the net gains
and losses exceed 10% of the accumulated postretirement benefit
obligation at the beginning of the year. The amount in excess of
the corridor is amortized over the average remaining service
period to retirement date for active plan participants or, for
retired participants, the average remaining life expectancy.
The following tables set forth the principal weighted-average
assumptions used:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pension Benefits
|
|
|
Postretirement Benefits
|
|
|
|
as of
|
|
|
as of
|
|
|
|
December 31,
|
|
|
December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
|
|
(In percentages)
|
|
|
Weighted-average assumptions used to determine benefit
obligations
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Discount rate:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US plans
|
|
|
6.50
|
|
|
|
6.30
|
|
|
|
6.40
|
|
|
|
6.00
|
|
International plans
|
|
|
5.84
|
|
|
|
5.42
|
|
|
|
6.11
|
|
|
|
5.31
|
|
Combined
|
|
|
6.41
|
|
|
|
6.16
|
|
|
|
6.37
|
|
|
|
5.93
|
|
Rate of compensation increase:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US plans
|
|
|
4.00
|
|
|
|
4.00
|
|
|
|
N/A
|
|
|
|
N/A
|
|
International plans
|
|
|
3.24
|
|
|
|
3.15
|
|
|
|
N/A
|
|
|
|
N/A
|
|
Combined
|
|
|
3.90
|
|
|
|
3.66
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pension Benefits
|
|
|
Postretirement Benefits
|
|
|
|
Year Ended December 31,
|
|
|
Year Ended December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
|
(In percentages)
|
|
|
Weighted-average assumptions used to determine net cost
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Discount rate:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US plans
|
|
|
6.30
|
|
|
|
5.88
|
|
|
|
5.63
|
|
|
|
6.00
|
|
|
|
5.88
|
|
|
|
5.63
|
|
International plans
|
|
|
5.42
|
|
|
|
4.70
|
|
|
|
4.54
|
|
|
|
5.31
|
|
|
|
4.80
|
|
|
|
4.97
|
|
Combined
|
|
|
6.16
|
|
|
|
5.86
|
|
|
|
5.46
|
|
|
|
5.93
|
|
|
|
5.79
|
|
|
|
5.57
|
|
Expected return on plan assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US plans
|
|
|
8.50
|
|
|
|
8.50
|
|
|
|
8.50
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
International plans
|
|
|
5.68
|
|
|
|
6.59
|
|
|
|
6.30
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
Combined
|
|
|
8.05
|
|
|
|
8.20
|
|
|
|
8.17
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
Rate of compensation increase:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US plans
|
|
|
4.00
|
|
|
|
4.00
|
|
|
|
4.00
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
International plans
|
|
|
3.15
|
|
|
|
3.18
|
|
|
|
3.26
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
Combined
|
|
|
3.66
|
|
|
|
3.73
|
|
|
|
3.81
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
The expected rate of return assumptions for plan assets are
based mainly on historical performance achieved over a long
period of time (15 to 20 years) encompassing many business
and economic cycles. Adjustments, upward and
F-29
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
downward, may be made to those historical returns to reflect
future capital market expectations; these expectations are
typically derived from expert advice from the investment
community and surveys of peer company assumptions.
The Company determines its assumption for the discount rates to
be used for the purposes of computing annual service and
interest costs for its US plans based on the yields of high
quality corporate/government bonds with a duration appropriate
to the duration of the plan obligations.
The Company determines its discount rates in the Euro zone using
the iBoxx Euro Corporate AA Bond indices with appropriate
adjustments for the duration of the plan obligations. In other
international locations, the Company determines its discount
rates based on the yields of high quality government bonds with
a duration appropriate to the duration of the plan obligations.
On January 1, 2008, the Companys health care cost
trend assumption for US postretirement medical plans net
periodic benefit cost was 9% for the first two years declining
0.5% per year to an ultimate rate of 5%. On January 1,
2007, the health care cost trend rate was 8.5% per year
declining 1% per year to an ultimate rate of 5%.
Assumed health care cost trend rates have a significant effect
on the amounts reported for the health care plans. A
one-percentage-point increase or decrease in the assumed health
care cost trend rate would impact postretirement obligations by
$3 million and $(3) million, respectively. The effect
of a one percent increase or decrease in the assumed health care
cost trend rate would have a less than $1 million impact on
service and interest cost.
Plan
Assets
The following tables set forth the target asset allocation for
the Companys pension plans and the asset allocation:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
|
|
|
|
|
|
|
Average
|
|
|
Percentage of
|
|
|
|
Target
|
|
|
Plan Assets as of
|
|
|
|
Allocation
|
|
|
December 31,
|
|
Asset Category US
|
|
2009
|
|
|
2008
|
|
|
2007
|
|
|
Equity securities
|
|
|
72
|
%
|
|
|
56
|
%
|
|
|
68
|
%
|
Debt securities
|
|
|
28
|
%
|
|
|
44
|
%
|
|
|
30
|
%
|
Real estate and other
|
|
|
|
|
|
|
|
|
|
|
2
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
100
|
%
|
|
|
100
|
%
|
|
|
100
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
|
|
|
|
|
|
|
Average
|
|
|
Percentage of
|
|
|
|
Target
|
|
|
Plan Assets as of
|
|
|
|
Allocation
|
|
|
December 31,
|
|
Asset Category International
|
|
2009
|
|
|
2008
|
|
|
2007
|
|
|
Equity securities
|
|
|
21
|
%
|
|
|
17
|
%
|
|
|
39
|
%
|
Debt securities
|
|
|
74
|
%
|
|
|
72
|
%
|
|
|
48
|
%
|
Real estate and other
|
|
|
5
|
%
|
|
|
11
|
%
|
|
|
13
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
100
|
%
|
|
|
100
|
%
|
|
|
100
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The financial objectives of the qualified pension plans are
established in conjunction with a comprehensive review of each
plans liability structure. The Companys asset
allocation policy is based on a detailed asset/liability
analysis. In developing investment policy and financial goals,
consideration is given to the plans demographics, the
returns and risks associated with alternative investment
strategies, and the current and projected cash, expense and
funding ratios of the plan. The investment policy must also
comply with local statutory requirements as determined by each
country. A formal asset/liability mix study of the plan is
undertaken every 3 to 5 years or whenever there has been a
material change in plan demographics, benefit structure or
funding status and investment market. The Company has adopted a
long-term investment horizon such that the risk and duration of
investment losses are weighed against the long-term
F-30
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
potential for appreciation of assets. Although there cannot be
complete assurance that these objectives will be realized, it is
believed that the likelihood for their realization is reasonably
high, based upon the asset allocation chosen and the historical
and expected performance of the asset classes utilized by the
plans. The intent is for investments to be broadly diversified
across asset classes, investment styles, investment managers,
developed and emerging markets, business sectors and securities
in order to moderate portfolio volatility and risk. Investments
may be in separate accounts, commingled trusts, mutual funds and
other pooled asset portfolios provided they all conform to
fiduciary standards.
External investment managers are hired to manage the pension
assets. An investment consultant assists with the screening
process for each new manager hired. Over the long-term, the
investment portfolio is expected to earn returns that exceed a
composite of market indices that are weighted to match each
plans target asset allocation. Long-term is considered 3
to 5 years; however, incidences of underperformance are
analyzed. The portfolio return should also (over the long term)
meet or exceed the return used for actuarial calculations in
order to minimize future pension contributions and escalation in
pension expense.
Employer contributions for pension benefits and postretirement
benefits are preliminarily estimated to be $40 million and
$35 million, respectively, in 2009. The table below
reflects pension benefits expected to be paid from the plan or
from the Companys assets. The postretirement benefits
represent the Companys share of the benefit cost.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Postretirement
|
|
|
|
|
|
|
Benefit
|
|
|
|
Pension
|
|
|
|
|
|
Expected
|
|
|
|
Benefit
|
|
|
|
|
|
Federal
|
|
|
|
Payments(1)
|
|
|
Payments
|
|
|
Subsidy
|
|
|
|
(In $ millions)
|
|
|
2009
|
|
|
215
|
|
|
|
35
|
|
|
|
11
|
|
2010
|
|
|
210
|
|
|
|
28
|
|
|
|
7
|
|
2011
|
|
|
209
|
|
|
|
24
|
|
|
|
7
|
|
2012
|
|
|
209
|
|
|
|
21
|
|
|
|
8
|
|
2013
|
|
|
211
|
|
|
|
19
|
|
|
|
8
|
|
2014-2018
|
|
|
1,108
|
|
|
|
96
|
|
|
|
14
|
|
|
|
|
(1) |
|
Payments are expected to be made primarily from plan assets. |
Other
Obligations
The following table represents additional benefit liabilities
and other similar obligations:
|
|
|
|
|
|
|
|
|
|
|
As of December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
|
(In $ millions)
|
|
|
Long-term disability
|
|
|
33
|
|
|
|
36
|
|
Other
|
|
|
5
|
|
|
|
13
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
38
|
|
|
|
49
|
|
|
|
|
|
|
|
|
|
|
General
The Company is subject to environmental laws and regulations
worldwide which impose limitations on the discharge of
pollutants into the air and water and establish standards for
the treatment, storage and disposal of solid and hazardous
wastes. The Company believes that it is in substantial
compliance with all applicable environmental laws and
regulations. The Company is also subject to retained
environmental obligations specified in various
F-31
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
contractual agreements arising from the divestiture of certain
businesses by the Company or one of its predecessor companies.
For the years ended December 31, 2008, 2007 and 2006, the
Companys expenditures, including expenditures for legal
compliance, internal environmental initiatives and remediation
of active, orphan, divested and US Superfund sites (as defined
below) were $78 million, $83 million and
$71 million, respectively. The Companys capital
project-related environmental expenditures for the years ended
December 31, 2008, 2007 and 2006 were $13 million,
$14 million and $5 million, respectively.
Environmental reserves for remediation matters were
$98 million and $115 million as of December 31,
2008 and 2007, respectively, which represents the Companys
best estimate of its liability.
Remediation
Due to its industrial history and through retained contractual
and legal obligations, the Company has the obligation to
remediate specific areas on its own sites as well as on
divested, orphan or US Superfund sites. In addition, as part of
the demerger agreement between the Company and Hoechst, a
specified portion of the responsibility for environmental
liabilities from a number of Hoechst divestitures was
transferred to the Company. The Company provides for such
obligations when the event of loss is probable and reasonably
estimable.
For the years ended December 31, 2008, 2007 and 2006, the
total remediation efforts charged to Cost of sales in the
consolidated statements of operations were $3 million,
$4 million and $6 million, respectively. The Company
believes that environmental remediation costs will not have a
material adverse effect on the financial position of the
Company, but may have a material adverse effect on the results
of operations or cash flows in any given accounting period.
The Company did not record any insurance recoveries related to
these matters for the reported periods. There are no receivables
for insurance recoveries as of December 31, 2008 and 2007,
however, as of December 31, 2008, there is an
$8 million receivable from a former owner of an acquired
business.
German
InfraServs
On January 1, 1997, coinciding with a reorganization of the
Hoechst businesses in Germany, real estate service companies
(InfraServs) were created to own directly the land
and property and to provide various technical and administrative
services at each of the manufacturing locations. The Company has
manufacturing operations at the InfraServ location in Frankfurt
am Main-Hoechst, Germany and holds interests in the companies
which own and operate the former Hoechst sites in Gendorf,
Knapsack and Wiesbaden.
InfraServs are liable for any residual contamination and other
pollution because they own the real estate on which the
individual facilities operate. In addition, Hoechst, and its
legal successors, as the responsible party under German public
law, is liable to third parties for all environmental damage
that occurred while it was still the owner of the plants and
real estate. The contribution agreements entered into in 1997
between Hoechst and the respective operating companies, as part
of the divestiture of these companies, provide that the
operating companies will indemnify Hoechst, and its legal
successors, against environmental liabilities resulting from the
transferred businesses. Additionally, the InfraServs have agreed
to indemnify Hoechst, and its legal successors, against any
environmental liability arising out of or in connection with
environmental pollution of any site. Likewise, in certain
circumstances the Company could be responsible for the
elimination of residual contamination on a few sites that were
not transferred to InfraServ companies, in which case Hoechst,
and its legal successors, must reimburse the Company for
two-thirds of any costs so incurred.
The InfraServ partnership agreements provide that, as between
the partners, each partner is responsible for any contamination
caused predominantly by such partner. Any liability, which
cannot be attributed to an InfraServ partner and for which no
third party is responsible, is required to be borne by the
InfraServ partnership. In view of this potential obligation to
eliminate residual contamination, the InfraServs, primarily
relating to equity and cost affiliates which are not
consolidated by the Company, have reserves of $84 million
and $88 million as of December 31, 2008 and 2007,
respectively.
F-32
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
If an InfraServ partner defaults on its respective
indemnification obligations to eliminate residual contamination,
the owners of the remaining participation in the InfraServ
companies have agreed to fund such liabilities, subject to a
number of limitations. To the extent that any liabilities are
not satisfied by either the InfraServs or their owners, these
liabilities are to be borne by the Company in accordance with
the demerger agreement. However, Hoechst, and its legal
successors, will reimburse the Company for two-thirds of any
such costs. Likewise, in certain circumstances the Company could
be responsible for the elimination of residual contamination on
several sites that were not transferred to InfraServ companies,
in which case Hoechst, and its legal successors, must also
reimburse the Company for two-thirds of any costs so incurred.
The German InfraServs are owned partially by the Company, as
noted below, and the remaining ownership is held by various
other companies. The Companys ownership interest and
environmental liability participation percentages for such
liabilities which cannot be attributed to an InfraServ partner
were as follows as of December 31, 2008:
|
|
|
|
|
|
|
|
|
Company
|
|
Ownership %
|
|
|
Liability %
|
|
|
InfraServ GmbH & Co. Gendorf KG
|
|
|
39.0
|
%
|
|
|
10.0
|
%
|
InfraServ GmbH & Co. Knapsack KG
|
|
|
28.2
|
%
|
|
|
22.0
|
%
|
InfraServ GmbH & Co. Hoechst KG
|
|
|
31.2
|
%
|
|
|
40.0
|
%
|
InfraServ GmbH & Co. Wiesbaden KG
|
|
|
7.9
|
%
|
|
|
0.0
|
%
|
InfraServ Verwaltungs GmbH
|
|
|
100.0
|
%
|
|
|
0.0
|
%
|
US
Superfund Sites
In the US, the Company may be subject to substantial claims
brought by US federal or state regulatory agencies or private
individuals pursuant to statutory authority or common law. In
particular, the Company has a potential liability under the US
Federal Comprehensive Environmental Response, Compensation and
Liability Act of 1980, as amended, and related state laws
(collectively referred to as Superfund) for
investigation and cleanup costs at approximately 50 sites. At
most of these sites, numerous companies, including certain
companies comprising the Company, or one of its predecessor
companies, have been notified that the Environmental Protection
Agency, state governing bodies or private individuals consider
such companies to be potentially responsible parties
(PRP) under Superfund or related laws. The
proceedings relating to these sites are in various stages. The
cleanup process has not been completed at most sites and the
status of the insurance coverage for most of these proceedings
is uncertain. Consequently, the Company cannot accurately
determine its ultimate liability for investigation or cleanup
costs at these sites. As of December 31, 2008 and 2007, the
Company had provisions totaling $11 million and
$13 million, respectively, for US Superfund sites and
utilized $2 million, $1 million and $1 million of
these reserves during the years ended December 31, 2008,
2007 and 2006, respectively. Additional provisions and
adjustments recorded during the years ended December 31,
2008, 2007 and 2006 approximately offset these expenditures.
As events progress at each site for which it has been named a
PRP, the Company accrues, as appropriate, a liability for site
cleanup. Such liabilities include all costs that are probable
and can be reasonably estimated. In establishing these
liabilities, the Company considers its shipment of waste to a
site, its percentage of total waste shipped to the site, the
types of wastes involved, the conclusions of any studies, the
magnitude of any remedial actions that may be necessary and the
number and viability of other PRPs. Often the Company will join
with other PRPs to sign joint defense agreements that will
settle, among PRPs, each partys percentage allocation of
costs at the site. Although the ultimate liability may differ
from the estimate, the Company routinely reviews the liabilities
and revises the estimate, as appropriate, based on the most
current information available.
Hoechst
Liabilities
In connection with the Hoechst demerger, the Company agreed to
indemnify Hoechst, and its legal successors, for the first
250 million of future remediation liabilities for
environmental damages arising from 19 specified divested Hoechst
entities. As of December 31, 2008 and 2007, reserves of
$27 million and $27 million, respectively, for these
matters are included as a component of the total environmental
reserves. As of December 31, 2008 and
F-33
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
2007, the Company, has made total cumulative payments of
$48 million and $46 million, respectively. If such
future liabilities exceed 250 million, Hoechst, and
its legal successors, will bear such excess up to an additional
500 million. Thereafter, the Company will bear
one-third and Hoechst, and its legal successors, will bear
two-thirds of any further environmental remediation liabilities.
Where the Company is unable to reasonably determine the
probability of loss or estimate such loss under this
indemnification, the Company has not recognized any liabilities
relative to this indemnification.
Preferred
Stock
The Company has $240 million aggregate liquidation
preference of outstanding 4.25% convertible perpetual preferred
stock. Holders of the preferred stock are entitled to receive,
when, as and if, declared by the Companys Board of
Directors, out of funds legally available, cash dividends at the
rate of 4.25% per annum of liquidation preference, payable
quarterly in arrears, commencing on May 1, 2005. Dividends
on the preferred stock are cumulative from the date of initial
issuance. Accumulated but unpaid dividends accumulate at an
annual rate of 4.25%. The preferred stock is convertible, at the
option of the holder, at any time into approximately
1.26 shares of Series A common stock, subject to
adjustments, per $25.00 liquidation preference of preferred
stock and upon conversion will be recorded in the consolidated
statements of shareholders equity and comprehensive income
(loss).
During 2008 and 2007, the Company declared and paid
$10 million of cash dividends in each period on its 4.25%
convertible perpetual preferred stock.
Dividends
During 2005, the Companys Board of Directors adopted a
policy of declaring, subject to legally available funds, a
quarterly cash dividend on each share of the Companys
Series A common stock at an annual rate of $0.16 per
share unless the Companys Board of Directors, in its sole
discretion, determines otherwise. Further, such dividends
payable to holders of the Companys Series A common
stock cannot be declared or paid nor can any funds be set aside
for the payment thereof, unless the Company has paid or set
aside funds for the payment of all accumulated and unpaid
dividends with respect to the shares of the Companys
preferred stock, as described above. Additionally, the amount
available to pay cash dividends is restricted by our senior
credit agreement.
During 2008, 2007 and 2006, the Company declared and paid
$24 million, $25 million and $26 million,
respectively, of cash dividends to holders of its Series A
common stock.
Treasury
Stock
In conjunction with the April 2007 debt refinancing
(Note 14), the Company, through its wholly-owned subsidiary
CIH, repurchased 2,021,775 shares of its outstanding
Series A common stock in a modified Dutch
Auction tender offer from public shareholders, which
expired on April 3, 2007, at a purchase price of $30.50 per
share. The total price paid for these shares was
$62 million. The Company also separately purchased, through
its wholly-owned subsidiary CIH, 329,011 shares of the
Companys Series A common stock at $30.50 per share
from the investment funds associated with The Blackstone Group
L.P. The total price paid for these shares was $10 million.
In June 2007, the Companys Board of Directors authorized
the repurchase of up to $330 million of its Series A
common stock. During 2007, the Company repurchased
8,487,700 shares of its Series A common stock at an
average purchase price of $38.88 per share for a total of
$330 million pursuant to this authorization. The Company
completed repurchasing shares related to this authorization
during July 2007.
In February 2008, the Companys Board of Directors
authorized the repurchase of up to $400 million of the
Companys Series A common stock. This authorization
was increased to $500 million in October 2008. The
authorization gives management discretion in determining the
conditions under which shares may be repurchased.
F-34
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
During the year ended December 31, 2008, the Company
repurchased 9,763,200 shares of its Series A common
stock at an average purchase price of $38.68 per share for a
total of $378 million pursuant to this authorization.
These purchases reduced the number of shares outstanding and the
repurchased shares may be used by the Company for compensation
programs utilizing the Companys stock and other corporate
purposes. The Company accounts for treasury stock using the cost
method and includes treasury stock as a component of
Shareholders equity.
Accumulated
Other Comprehensive Income (Loss), Net
Accumulated other comprehensive income (loss), net, which is
displayed in the consolidated statements of shareholders
equity, represents net earnings (loss) plus the results of
certain shareholders equity changes not reflected in the
consolidated statements of operations. Such items include
unrealized gain (loss) on marketable securities, foreign
currency translation, certain pension and postretirement benefit
obligations and unrealized gain (loss) on interest rate swaps.
The after-tax components of Accumulated other comprehensive
income (loss), net are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated
|
|
|
|
Unrealized
|
|
|
|
|
|
|
|
|
Unrealized
|
|
|
Other
|
|
|
|
Gain (Loss) on
|
|
|
Foreign
|
|
|
Pension and
|
|
|
Gain (Loss)
|
|
|
Comprehensive
|
|
|
|
Marketable
|
|
|
Currency
|
|
|
Postretirement
|
|
|
on Interest
|
|
|
Income
|
|
|
|
Securities
|
|
|
Translation
|
|
|
Benefits
|
|
|
Rate Swaps
|
|
|
(Loss), Net
|
|
|
|
(In $ millions)
|
|
|
Balance as of December 31, 2005
|
|
|
(4
|
)
|
|
|
12
|
|
|
|
(136
|
)
|
|
|
2
|
|
|
|
(126
|
)
|
Current-period change
|
|
|
13
|
|
|
|
5
|
|
|
|
137
|
|
|
|
2
|
|
|
|
157
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of December 31, 2006
|
|
|
9
|
|
|
|
17
|
|
|
|
1
|
|
|
|
4
|
|
|
|
31
|
|
Current-period change
|
|
|
17
|
|
|
|
70
|
|
|
|
120
|
|
|
|
(41
|
)
|
|
|
166
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of December 31, 2007
|
|
|
26
|
|
|
|
87
|
|
|
|
121
|
|
|
|
(37
|
)
|
|
|
197
|
|
Current-period change
|
|
|
(23
|
)(1)
|
|
|
(130
|
)
|
|
|
(544
|
)
|
|
|
(79
|
)
|
|
|
(776
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of December 31, 2008
|
|
|
3
|
|
|
|
(43
|
)
|
|
|
(423
|
)
|
|
|
(116
|
)
|
|
|
(579
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Includes a net reclassification adjustment of ($2) million
to the consolidated statements of operations. |
|
|
18.
|
Other
(Charges) Gains, Net
|
Other (charges) gains, net includes provisions for restructuring
and other expenses and income incurred outside the normal course
of operations. Restructuring provisions represent costs related
to severance and other benefit programs related to major
activities undertaken to fundamentally redesign the business
operations, as well as costs incurred in connection with
decisions to exit non-strategic businesses. These measures are
based on formal management decisions, establishment of
agreements with employees representatives or individual
agreements with affected employees, as well as the public
announcement of the restructuring plan. The related reserves
reflect certain estimates, including those pertaining to
separation costs, settlements of contractual obligations and
other closure costs. The Company reassesses the reserve
requirements to complete each individual plan under existing
restructuring programs at the end of each reporting period.
Actual experience may be different from these estimates.
F-35
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The components of Other (charges) gains, net are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
|
(In $ millions)
|
|
|
Employee termination benefits
|
|
|
(21
|
)
|
|
|
(32
|
)
|
|
|
(12
|
)
|
Plant/office closures
|
|
|
(7
|
)
|
|
|
(11
|
)
|
|
|
1
|
|
Deferred compensation triggered by Exit Event (Note 20)
|
|
|
|
|
|
|
(74
|
)
|
|
|
|
|
Insurance recoveries associated with plumbing cases
|
|
|
|
|
|
|
4
|
|
|
|
5
|
|
Insurance recoveries associated with Clear Lake, Texas
(Note 29)
|
|
|
38
|
|
|
|
40
|
|
|
|
|
|
Resolution of commercial disputes with a vendor
|
|
|
|
|
|
|
31
|
|
|
|
|
|
Asset impairments
|
|
|
(115
|
)
|
|
|
(9
|
)(1)
|
|
|
|
|
Ticona Kelsterbach plant relocation (Note 28)
|
|
|
(12
|
)
|
|
|
(5
|
)
|
|
|
|
|
Sorbates antitrust actions (Note 23)
|
|
|
8
|
|
|
|
|
|
|
|
|
|
Other
|
|
|
1
|
|
|
|
(2
|
)
|
|
|
(4
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Other (charges) gains, net
|
|
|
(108
|
)
|
|
|
(58
|
)
|
|
|
(10
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Includes $6 million of goodwill impairment (Note 10). |
2008
Other (charges) gains, net for asset impairments includes
long-lived asset impairment losses of $92 million related
to the potential closure of the Companys acetic acid and
vinyl acetate monomer (VAM) production facility in
Pardies, France, the VAM production unit in Cangrejera, Mexico
(which the Company subsequently decided to shut down effective
at the end of February 2009) and certain other facilities. Of
the $92 million recorded in December 2008, $76 million
relates to the Acetyl Intermediates segment and $16 million
relates to the Advanced Engineered Materials segment.
Consideration of this potential capacity reduction was
necessitated by the significant change in the global economic
environment and anticipated lower customer demand.
Additionally, the Company recognized $23 million of
long-lived asset impairment losses related to the shutdown of
the Companys Pampa, Texas facility (Acetyl Intermediates
segment).
Other (charges) gains, net for employee termination benefits
includes severance and retention charges of $13 million
related to the sale of the Companys Pampa, Texas facility
and $8 million of severance and retention charges related
to other business optimization plans undertaken by the Company.
2007
Other (charges) gains, net for employee termination benefits and
plant/office closures include charges related to the
Companys plan to simplify and optimize its Emulsions and
PVOH businesses (Industrial Specialties segment) to become a
leader in technology and innovation and grow in both new and
existing markets. Other (charges) gains, net for employee
termination benefits and plant/office closures also includes
charges related to the sale of the Companys Pampa, Texas
facility. In addition, the Company recorded an impairment of
long-lived assets of $3 million during the year ended
December 31, 2007.
In December 2007, the Company received a one-time payment in
resolution of commercial disputes with a vendor.
2006
Other (charges) gains, net includes charges related to severance
associated with the relocation of corporate offices of
$4 million, severance payments in connection with the
lockout settlement at the Meredosia, Illinois plant of
$5 million and severance and relocation expenses related to
restructuring at AT Plastics (Industrial Specialties segment) of
$4 million.
F-36
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
These charges were offset by $5 million of income related
to insurance recoveries associated with plumbing cases.
The changes in the restructuring reserves by business segment
are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Advanced
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Engineered
|
|
|
Consumer
|
|
|
Industrial
|
|
|
Acetyl
|
|
|
|
|
|
|
|
|
|
Materials
|
|
|
Specialties
|
|
|
Specialties
|
|
|
Intermediates
|
|
|
Other
|
|
|
Total
|
|
|
|
(In $ millions)
|
|
|
Employee Termination Benefits
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restructuring reserve as of December 31, 2006
|
|
|
4
|
|
|
|
13
|
|
|
|
5
|
|
|
|
8
|
|
|
|
|
|
|
|
30
|
|
Restructuring additions
|
|
|
|
|
|
|
13
|
|
|
|
9
|
|
|
|
18
|
|
|
|
2
|
|
|
|
42
|
|
Cash payments
|
|
|
(2
|
)
|
|
|
(22
|
)
|
|
|
(3
|
)
|
|
|
(11
|
)
|
|
|
|
|
|
|
(38
|
)
|
Currency translation adjustment
|
|
|
|
|
|
|
1
|
|
|
|
1
|
|
|
|
1
|
|
|
|
|
|
|
|
3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restructuring reserve as of December 31, 2007
|
|
|
2
|
|
|
|
5
|
|
|
|
12
|
|
|
|
16
|
|
|
|
2
|
|
|
|
37
|
|
Restructuring additions
|
|
|
2
|
|
|
|
2
|
|
|
|
2
|
|
|
|
14
|
|
|
|
3
|
|
|
|
23
|
|
Cash payments
|
|
|
(2
|
)
|
|
|
(6
|
)
|
|
|
(6
|
)
|
|
|
(9
|
)
|
|
|
(4
|
)
|
|
|
(27
|
)
|
Currency translation adjustment
|
|
|
|
|
|
|
|
|
|
|
(2
|
)
|
|
|
(1
|
)
|
|
|
(1
|
)
|
|
|
(4
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restructuring reserve as of December 31, 2008
|
|
|
2
|
|
|
|
1
|
|
|
|
6
|
|
|
|
20
|
|
|
|
|
|
|
|
29
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Plant/Office Closures
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restructuring reserve as of December 31, 2006
|
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
2
|
|
|
|
2
|
|
|
|
5
|
|
Restructuring additions
|
|
|
|
|
|
|
1
|
|
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
2
|
|
Cash payments
|
|
|
|
|
|
|
(2
|
)
|
|
|
|
|
|
|
|
|
|
|
(1
|
)
|
|
|
(3
|
)
|
Currency translation adjustment
|
|
|
|
|
|
|
4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restructuring reserve as of December 31, 2007
|
|
|
1
|
|
|
|
3
|
|
|
|
1
|
|
|
|
2
|
|
|
|
1
|
|
|
|
8
|
|
Restructuring additions
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash payments
|
|
|
|
|
|
|
(1
|
)
|
|
|
(1
|
)
|
|
|
(1
|
)
|
|
|
(1
|
)
|
|
|
(4
|
)
|
Currency translation adjustment
|
|
|
|
|
|
|
(1
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restructuring reserve as of December 31, 2008
|
|
|
1
|
|
|
|
1
|
|
|
|
|
|
|
|
1
|
|
|
|
|
|
|
|
3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Restructuring reserves as of December 31, 2008
|
|
|
3
|
|
|
|
2
|
|
|
|
6
|
|
|
|
21
|
|
|
|
|
|
|
|
32
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings (loss) from continuing operations before tax and
minority interests by jurisdiction are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended
|
|
|
|
December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
|
(In $ millions)
|
|
|
US
|
|
|
135
|
|
|
|
(111
|
)
|
|
|
116
|
|
Foreign
|
|
|
299
|
|
|
|
558
|
|
|
|
410
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
434
|
|
|
|
447
|
|
|
|
526
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
F-37
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The income tax provision (benefit) consists of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended
|
|
|
|
December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
|
(In $ millions)
|
|
|
Current:
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
|
62
|
|
|
|
(9
|
)
|
|
|
38
|
|
Foreign
|
|
|
92
|
|
|
|
163
|
|
|
|
29
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total current
|
|
|
154
|
|
|
|
154
|
|
|
|
67
|
|
Deferred:
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
|
(37
|
)
|
|
|
17
|
|
|
|
80
|
|
Foreign
|
|
|
(54
|
)
|
|
|
(61
|
)
|
|
|
56
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total deferred
|
|
|
(91
|
)
|
|
|
(44
|
)
|
|
|
136
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income tax provision
|
|
|
63
|
|
|
|
110
|
|
|
|
203
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deferred income taxes reflect the net tax effects of temporary
differences between the carrying amounts of assets and
liabilities for financial reporting purposes and the amounts
used for income tax purposes. Significant components of the
consolidated deferred tax assets and liabilities were as follows:
|
|
|
|
|
|
|
|
|
|
|
As of
|
|
|
|
December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
|
(In $ millions)
|
|
|
Pension and postretirement obligations
|
|
|
304
|
|
|
|
229
|
|
Accrued expenses
|
|
|
195
|
|
|
|
92
|
|
Inventory
|
|
|
8
|
|
|
|
2
|
|
Net operating loss and tax credit carryforwards
|
|
|
279
|
|
|
|
214
|
|
Other
|
|
|
192
|
|
|
|
33
|
|
|
|
|
|
|
|
|
|
|
Subtotal
|
|
|
978
|
|
|
|
570
|
|
Valuation
allowance(1)
|
|
|
(652
|
)
|
|
|
(311
|
)
|
|
|
|
|
|
|
|
|
|
Deferred tax assets
|
|
|
326
|
|
|
|
259
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
322
|
|
|
|
384
|
|
Investments
|
|
|
41
|
|
|
|
26
|
|
Interest
|
|
|
|
|
|
|
7
|
|
Other
|
|
|
49
|
|
|
|
57
|
|
|
|
|
|
|
|
|
|
|
Deferred tax liabilities
|
|
|
412
|
|
|
|
474
|
|
|
|
|
|
|
|
|
|
|
Net deferred tax assets (liabilities)
|
|
|
(86
|
)
|
|
|
(215
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Includes deferred tax asset valuation allowances primarily for
the Companys deferred tax assets in the US, the United
Kingdom and China, as well as other foreign jurisdictions. These
valuation allowances relate primarily to net operating loss
carryforward benefits and other net deferred tax assets, all of
which may not be realizable. |
For the year ended December 31, 2008, the valuation
allowance increased by $341 million, consisting of:
(1) charges to income tax expense of $11 million for
continuing operations and discontinued operations, (2) an
increase of $223 million allocated to accumulated other
comprehensive income, (3) an increase of $41 million
F-38
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
related to CTA, (4) an increase of $16 million related
to additional paid in capital and (5) $50 million of
other increases related to preacquisition deferred tax assets,
FIN 48 and other adjustments to deferred taxes.
A reconciliation of the significant differences between the US
federal statutory tax rate of 35% and the effective income tax
rate on income from continuing operations is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended
|
|
|
|
December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
|
(In $ millions)
|
|
|
Income tax provision computed at US federal statutory tax rate
|
|
|
152
|
|
|
|
156
|
|
|
|
184
|
|
Increase (decrease) in taxes resulting from:
|
|
|
|
|
|
|
|
|
|
|
|
|
Change in valuation allowance
|
|
|
(5
|
)
|
|
|
9
|
|
|
|
4
|
|
Equity income and dividends
|
|
|
(17
|
)
|
|
|
8
|
|
|
|
5
|
|
Expenses not resulting in tax benefits
|
|
|
18
|
|
|
|
19
|
|
|
|
15
|
|
US tax effect of foreign earnings and dividends
|
|
|
(5
|
)
|
|
|
27
|
|
|
|
28
|
|
Other foreign tax rate
differentials(1)
|
|
|
(84
|
)
|
|
|
(98
|
)
|
|
|
(59
|
)
|
Legislative changes
|
|
|
3
|
|
|
|
(21
|
)
|
|
|
|
|
State income taxes and other
|
|
|
1
|
|
|
|
10
|
|
|
|
26
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income tax provision
|
|
|
63
|
|
|
|
110
|
|
|
|
203
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Includes impact of earnings from China and Singapore subject to
tax holidays which expire between 2008 and 2013. |
Federal and state income taxes have not been provided on
accumulated but undistributed earnings of $2.5 billion as
of December 31, 2008, as such earnings have been
permanently reinvested in the business. The determination of the
amount of the unrecognized deferred tax liability related to the
undistributed earnings is not practicable.
The effective tax rate for continuing operations for the year
ended December 31, 2008 was 15% compared to 25% for the
year ended December 31, 2007. The effective tax rate for
2008 was favorably impacted by: (1) an increase in
unrepatriated low-taxed earnings, including tax holidays,
(2) tax credits generated in foreign jurisdictions and
(3) the US tax impact of foreign operations.
The Company operates under tax holidays in various countries
which are effective through December 2013. In China, one of the
Companys entities has a tax holiday that provides for a
zero percent tax rate in 2007 and 2008. For 2009 through 2011,
the Companys tax rate will be 50% of the statutory rate,
or 12.5% based on the 2008 statutory rate of 25%. In Singapore,
one of the Companys entities has a tax holiday that
provides for a zero percent tax rate through 2010. For 2011
through 2013, the Companys tax rate will be 50% of the
statutory rate, or 9% based on the current statutory rate of
18%. The impact of these tax holidays decreased foreign taxes
$22 million for the year ended December 31, 2008.
The Corporate Tax Reform Act of 2008 was signed by the German
Federal President in August 2007. The Act reduced the
Companys combined corporate statutory tax rate from 40% to
30% while imposing limitations on the deductibility of certain
expenses, including interest expense. The Company recognized a
tax benefit of approximately $39 million in 2007 related to
the statutory rate reduction on its German net deferred tax
liabilities.
Mexico enacted the 2008 Fiscal Reform Bill on October 1,
2007. Effective January 1, 2008, the bill repealed the
existing asset-based tax and established a dual income tax
system consisting of a new minimum flat tax (the
IETU) and the existing regular income tax system.
The IETU system taxes companies on cash basis net income,
consisting only of certain specified items of revenue and
expense, at a rate of 16.5%, 17% and 17.5% for 2008, 2009
F-39
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
and 2010 forward, respectively. In general, companies must pay
the higher of the income tax or the IETU, although unlike the
previous asset tax, the IETU is not creditable against future
income tax liabilities. The Company has determined that it will
primarily be subject to the IETU in future periods, and as such
it has recorded tax expense of approximately $20 million in
2007 for the deferred tax effects of the new IETU system.
As of December 31, 2008, the Company had US federal net
operating loss carryforwards of approximately $298 million
which will begin to expire in 2021. Of this amount,
$53 million relates to the preacquisition period and is
subject to limitation. Of the remaining $245 million,
$153 million is subject to limitation as a result of the
change in stock ownership in May 2006. This limitation is not
expected to have a material impact on utilization of the net
operating loss carryforwards.
The Company also had foreign net operating loss carryforwards as
of December 31, 2008 of approximately $435 million for
China, Germany, Mexico and other foreign jurisdictions with
various expiration dates. Net operating losses in China have
various carryforward periods and begin expiring in 2011. Net
operating losses in Germany have no expiration date. Net
operating losses in Mexico have a ten year carryforward period
and begin to expire in 2009. However, these losses are not
available for use under the new IETU tax regulations in Mexico.
As the IETU is the primary system upon which the Company will be
subject to tax in future periods, no deferred tax asset has been
reflected in the consolidated balance sheets as of
December 31, 2008 for these income tax loss carryforwards.
The Company adopted the provisions of FIN 48 effective
January 1, 2007. FIN 48 clarifies the accounting for
income taxes by prescribing a minimum recognition threshold a
tax benefit is required to meet before being recognized in the
financial statements. FIN 48 also provides guidance on
derecognition, measurement, classification, interest and
penalties, accounting in interim periods, disclosure and
transition. As a result of the implementation of FIN 48,
the Company increased Retained earnings by $14 million and
decreased Goodwill by $2 million. In addition, certain tax
liabilities for unrecognized tax benefits, as well as related
potential penalties and interest, were reclassified from current
liabilities to noncurrent liabilities. Liabilities for
unrecognized tax benefits as of December 31, 2008 relate to
various US and foreign jurisdictions.
A reconciliation of the beginning and ending amount of
unrecognized tax benefits is as follows:
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
|
(In $ millions)
|
|
|
Balance as of January 1, 2008
|
|
|
200
|
|
|
|
193
|
|
Increases in tax positions for the current year
|
|
|
|
|
|
|
2
|
|
Increases in tax positions for prior years
|
|
|
7
|
|
|
|
28
|
|
Decreases in tax positions of prior years
|
|
|
(10
|
)
|
|
|
(21
|
)
|
Settlements
|
|
|
(2
|
)
|
|
|
(2
|
)
|
|
|
|
|
|
|
|
|
|
Balance as of December 31, 2008
|
|
|
195
|
|
|
|
200
|
|
|
|
|
|
|
|
|
|
|
Included in the unrecognized tax benefits as of
December 31, 2008 and 2007 are $71 million and
$56 million, respectively, of tax benefits that, if
recognized, would reduce the Companys effective tax rate.
The Company recognizes interest and penalties related to
unrecognized tax benefits in the provision for income taxes. As
of December 31, 2008 and 2007, the Company has recorded a
liability of approximately $38 million and
$36 million, respectively, for interest and penalties. This
amount includes an increase of approximately $2 million and
$13 million for the years ended December 31, 2008 and
2007, respectively.
The Company operates in the US (including multiple state
jurisdictions), Germany and approximately 40 other foreign
jurisdictions including Canada, China, France, Mexico and
Singapore. Examinations are ongoing in a number of those
jurisdictions including, most significantly, in Germany for the
years 2001 to 2004. During the
F-40
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
quarter ended March 31, 2007, the Company received final
assessments in Germany for the prior examination period, 1997 to
2000. The effective settlement of those examinations resulted in
a reduction to Goodwill of approximately $42 million with a
net expected cash outlay of $29 million. The Companys
US federal income tax returns for 2003 and beyond are open tax
years not currently under examination. Unrecognized tax benefits
are not expected to change significantly over the next
12 months.
The tax provision (benefit) amounts allocated to other
comprehensive income (loss), net, were $5 million,
$10 million and $11 million for the years ended
December 31, 2008, 2007 and 2006 respectively. Of these
amounts, $5 million, $10 million and $11 million
were attributable to the pension and postretirement benefits
component of other comprehensive income (loss), net. The income
tax provision (benefit) associated with Accumulated other
comprehensive income (loss), net is dependent upon the tax
jurisdiction in which the items arise and accordingly could
result in an effective tax rate that is different from the
overall consolidated effective income tax rate on the
consolidated statements of operations.
|
|
20.
|
Stock-Based
and Other Management Compensation Plans
|
In December 2004, the Company approved a stock incentive plan
for executive officers, key employees and directors, a deferred
compensation plan for executive officers and key employees as
well as other management incentive programs.
The stock incentive plan allows for the issuance or delivery of
up to 16,250,000 shares of the Companys Series A
common stock through the award of stock options, restricted
stock units (RSUs) and other stock-based awards as
may be approved by the Companys Compensation Committee of
the Board of Directors.
Deferred
Compensation
The 2004 deferred compensation plan provides an aggregate
maximum amount payable of $196 million. The initial
component of the deferred compensation plan vested in 2004 and
was paid in the first quarter of 2005. In May 2007, the Original
Shareholders sold their remaining equity interest in the Company
triggering an Exit Event, as defined by the plan. Cash
compensation of $74 million, representing the
participants 2005 and 2006 contingent benefits, was paid
to the participants during the year ended December 31,
2007. Participants continuing in the 2004 deferred compensation
plan (see below for discussion regarding certain
participants decision to participate in a revised program)
continue to vest in their 2008 and 2009 time-based and
performance-based entitlements as defined in the deferred
compensation plan. During the years ended December 31,
2008, 2007 and 2006, the Company recorded compensation expense
of $3 million, $84 million and $19 million,
respectively, associated with this plan. The remaining amount
payable under the plan is $1 million.
On April 2, 2007, certain participants in the
Companys deferred compensation plan elected to participate
in a revised program, which includes both cash awards and
restricted stock units (see Restricted Stock Units below). Under
the revised program, participants relinquished their cash awards
of up to $30 million that would have contingently accrued
from
2007-2009
under the original plan. In lieu of these awards, the revised
deferred compensation program provides for a future cash award
in an amount equal to 90% of the maximum potential payout under
the original plan, plus growth pursuant to one of three
participant-selected notional investment vehicles, as defined in
the associated agreements. Participants must remain employed
through 2010 to vest in the new award. The Company will make
award payments under the revised program in the first quarter of
2011, unless participants elect to further defer the payment of
their individual awards. Based on current participation in the
revised program, the awards aggregate to approximately
$27 million plus notional earnings and will be recognized
as expense through December 31, 2010. The Company expensed
$8 million and $6 million during the years ended
December 31, 2008 and 2007, respectively, related to the
revised program.
In December 2007, the Company adopted a deferred compensation
plan whereby certain of the Companys senior employees and
directors were offered the opportunity to defer a portion of
their compensation in exchange for a future payment amount equal
to their deferments plus or minus certain amounts based upon the
market-
F-41
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
performance of specified measurement funds selected by the
participant. Participants are required to make deferral
elections under the plan prior to January 1 of the year
such deferrals will be withheld from their compensation. The
Company expensed $1 million during the year ended
December 31, 2008 related to this plan.
In December 2008, the Company granted time-vesting cash awards
of $22 million with the Companys executive officers
and certain other key employees. Each award of cash vests 30% on
October 14, 2009, 30% on October 14, 2010 and 40% on
October 14, 2011. In its sole discretion, the compensation
committee of the Board of Directors may at any time convert all
or a portion of the cash award to an award of time-vesting
restricted stock units.
Long-Term
Incentive Plan
Effective January 1, 2004, the Company adopted a long-term
incentive plan (the LTIP Plan) which covers certain
members of management and other key employees of the Company.
The LTIP Plan is a three-year cash based plan in which awards
are based on annual and three-year cumulative targets (as
defined in the LTIP Plan). In February 2007, $26 million
was paid to the LTIP plan participants. During the year ended
December 31, 2006, the Company recorded expense of
$19 million related to the LTIP Plan. There are no
additional amounts due under the LTIP Plan.
Stock
Options
The Company adopted the provisions of SFAS No. 123(R),
Share-Based Payments (SFAS No. 123(R)), on
January 1, 2006. The Company elected the modified
prospective transition method under which compensation costs are
recognized for all stock-based payments granted prior to, but
not yet vested as of January 1, 2006 and all stock-based
payments granted subsequent to January 1, 2006.
Compensation costs are based on the grant-date fair value
estimated in accordance with SFAS No. 123(R).
The Company has a stock-based compensation plan that makes
awards of stock options to certain employees. It is the
Companys current policy to grant options with an exercise
price equal to the average of the high and low price of the
Companys Series A common stock on the grant date. The
options issued have a ten-year term and vest on a graded basis
over periods ranging from one to five years. The estimated value
of the Companys stock-based awards less expected
forfeitures is amortized over the awards respective
vesting period on a straight-line basis.
The fair value of each option granted is estimated on the grant
date using the Black-Scholes option pricing method. The weighted
average assumptions used in the model are outlined in the
following table:
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
Risk-free interest rate
|
|
|
3.3
|
%
|
|
|
4.6
|
%
|
Estimated life in years
|
|
|
7.7
|
|
|
|
6.8
|
|
Dividend yield
|
|
|
0.38
|
%
|
|
|
0.42
|
%
|
Volatility
|
|
|
31.4
|
%
|
|
|
27.5
|
%
|
The computation of the expected volatility assumption used in
the Black-Scholes calculations for new grants is based on the
Companys historical volatilities and volatilities of peer
companies. When establishing the expected life assumptions, the
Company reviews annual historical employee exercise behavior of
option grants with similar vesting periods and the expected life
assumptions of peer companies. The Company utilizes the review
of peer companies based on its own lack of extensive history.
F-42
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
A summary of changes in stock options outstanding is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31, 2008
|
|
|
|
|
|
|
Weighted-
|
|
|
Weighted-
|
|
|
|
|
|
|
|
|
|
Average
|
|
|
Average
|
|
|
|
|
|
|
|
|
|
Grant
|
|
|
Remaining
|
|
|
Aggregate
|
|
|
|
Number of
|
|
|
Price in
|
|
|
Contractual
|
|
|
Intrinsic
|
|
|
|
Options
|
|
|
$
|
|
|
Term
|
|
|
Value
|
|
|
|
(In millions)
|
|
|
|
|
|
(In years)
|
|
|
(In $ millions)
|
|
|
Outstanding at beginning of year
|
|
|
8.1
|
|
|
|
18.72
|
|
|
|
7.5
|
|
|
|
192
|
|
Granted
|
|
|
0.2
|
|
|
|
42.12
|
|
|
|
|
|
|
|
|
|
Exercised
|
|
|
(1.1
|
)
|
|
|
17.35
|
|
|
|
|
|
|
|
|
|
Forfeited
|
|
|
(0.2
|
)
|
|
|
22.72
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding at end of year
|
|
|
7.0
|
|
|
|
19.35
|
|
|
|
6.6
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options exercisable at end of year
|
|
|
5.3
|
|
|
|
16.41
|
|
|
|
6.2
|
|
|
|
|
|
The weighted-average grant-date fair value of stock options
granted during the years ended December 31, 2008 and 2007
was $16.78 and $14.42, respectively, per option. As of
December 31, 2008, the Company had approximately
$12 million of total unrecognized compensation expense
related to stock options, excluding estimated forfeitures, to be
recognized over the remaining vesting periods of the options.
Cash received from stock option exercises was $18 million
during the year ended December 31, 2008. There was no tax
benefit realized from stock option exercises during the year
ended December 31, 2008.
Restricted
Stock Units
Performance-based RSUs. Participants in the
revised deferred compensation program also received an award of
RSUs. The RSUs, which were granted in April 2007, cliff vest on
December 31, 2010 and have a fair value of $23.63 per unit.
The number of RSUs that ultimately vest depends on market
performance targets measured by comparison of the Companys
stock performance versus a defined peer group. The ultimate
award will range from zero to 263,030 RSUs, based on the market
performance measurement at the cliff vesting date. The market
performance feature is factored into the estimated fair value
per unit, and compensation expense for the award is based on the
maximum RSUs of 263,030. Dividends on RSUs are earned in
accordance with the Companys common stock dividend policy
and are reinvested in additional RSUs.
In addition, under the 2007 Long-term Performance Program, the
Company granted RSUs with a fair value of $21.30 per unit to
certain employees. The RSUs vest annually in equal tranches
beginning September 30, 2008 through September 30,
2011. The RSUs contain the same market performance criteria as
those described above, with an ultimate award that will range
from zero to 947,361 RSUs. The awards include a
catch-up
provision that provides for vesting on September 30, 2012
of previously unvested amounts, subject to certain maximums.
Dividends on RSUs are earned in accordance with the
Companys common stock dividend policy and are reinvested
in additional RSUs.
F-43
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
A summary of changes in RSUs outstanding under the revised
deferred compensation program and the 2007 Long-term Performance
Program during the year ended December 31, 2008 is
presented as follows:
|
|
|
|
|
|
|
|
|
|
|
Performance-based RSUs
|
|
|
|
|
|
|
Weighted
|
|
|
|
|
|
|
Average
|
|
|
|
Number of
|
|
|
Fair Value in
|
|
|
|
Units
|
|
|
$
|
|
|
|
(Units in thousands)
|
|
|
Nonvested at beginning of year
|
|
|
1,119
|
|
|
|
21.84
|
|
Granted
|
|
|
|
|
|
|
|
|
Vested
|
|
|
(143
|
)
|
|
|
21.30
|
|
Forfeited
|
|
|
(85
|
)
|
|
|
21.30
|
|
|
|
|
|
|
|
|
|
|
Nonvested at end of year
|
|
|
891
|
|
|
|
21.98
|
|
|
|
|
|
|
|
|
|
|
In December 2008, the Company granted RSUs to certain employees
with a fair value of $12.65 per unit. The RSUs vest on
October 14, 2011. The number of RSUs that ultimately vest
is dependent upon the achievement of 1) internal
profitability targets and 2) market performance targets
measured by the comparison of the Companys stock
performance versus a defined peer group. The ultimate award will
range from zero to 669,150 RSUs. The market performance feature
is factored into the estimated fair value per unit.
The Company also made a grant in December 2008 of 200,000
performance units to be settled in cash to the Companys
Chief Executive Officer. The terms of the performance units are
substantially similar to the performance-based RSUs granted in
December 2008. The value of the performance units is equivalent
to the value of one share of the Companys Series A
common stock and any amounts that may vest under the performance
unit award agreement are to be settled in cash, rather than
shares of the Companys Series A common stock. The
compensation committee of the Board of Directors may elect to
convert all or any portion of the performance units award to an
award of an equivalent value of performance-based RSUs.
Fair value for the Companys performance-based RSUs was
estimated at the grant date using a Monte Carlo simulation
approach. Monte Carlo simulation was utilized to randomly
generate future stock returns for the Company and each company
in the designated peer group for each grant based on
company-specific dividend yields, volatilities and stock return
correlations. These returns were used to calculate future RSU
vesting percentages and the simulated values of the vested RSUs
were then discounted to present value using a risk-free rate,
yielding the expected value of these RSUs.
The range of assumptions used in the Monte Carlo simulation
approach is outlined in the following table:
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
Risk-free interest rate
|
|
|
1.05
|
%
|
|
|
4.53 4.55
|
%
|
Dividend yield
|
|
|
0.00 12.71
|
%
|
|
|
0.00 2.76
|
%
|
Volatility
|
|
|
20 70
|
%
|
|
|
20 45
|
%
|
Time-based RSUs. During 2007 and 2008, the
Company granted non-employee Directors time-based RSUs that
generally vest one year after grant. During 2008, the Company
granted time-based RSUs to certain employees that vest ratably
over time intervals ranging from one to four years. The fair
value of the time-based RSUs was equal to the average of the
high and low price of the Companys Series A common
stock on the grant date.
F-44
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
A summary of changes in time-based RSUs outstanding during the
year ended December 31, 2008 is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Employee Time-based RSUs
|
|
|
Director Time-Based RSUs
|
|
|
|
|
|
|
Weighted
|
|
|
|
|
|
Weighted
|
|
|
|
|
|
|
Average
|
|
|
|
|
|
Average
|
|
|
|
Number of
|
|
|
Fair Value in
|
|
|
Number of
|
|
|
Fair Value in
|
|
|
|
Units
|
|
|
$
|
|
|
Units
|
|
|
$
|
|
|
|
|
|
|
Shares in 000s
|
|
|
|
|
|
Nonvested at beginning of year
|
|
|
|
|
|
|
|
|
|
|
23
|
|
|
|
32.61
|
|
Granted
|
|
|
106
|
|
|
|
39.35
|
|
|
|
15
|
|
|
|
44.02
|
|
Vested
|
|
|
|
|
|
|
|
|
|
|
(23
|
)
|
|
|
32.61
|
|
Forfeited
|
|
|
(1
|
)
|
|
|
39.53
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nonvested at end of year
|
|
|
105
|
|
|
|
39.34
|
|
|
|
15
|
|
|
|
44.02
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of December 31, 2008, there was approximately
$19 million of unrecognized compensation cost related to
RSUs, excluding estimated forfeitures, which will be amortized
on a straight-line basis over the remaining vesting periods.
Total rent expense charged to operations under all operating
leases was $96 million, $122 million and
$109 million for the years ended December 31, 2008,
2007 and 2006, respectively. Future minimum lease payments under
non-cancelable rental and lease agreements which have initial or
remaining terms in excess of one year as of December 31,
2008 are as follows:
|
|
|
|
|
|
|
|
|
|
|
Capital
|
|
|
Operating
|
|
|
|
(In $ millions)
|
|
|
2009
|
|
|
38
|
|
|
|
45
|
|
2010
|
|
|
55
|
|
|
|
27
|
|
2011
|
|
|
33
|
|
|
|
21
|
|
2012
|
|
|
33
|
|
|
|
14
|
|
2013
|
|
|
30
|
|
|
|
11
|
|
Later years
|
|
|
228
|
|
|
|
22
|
|
Sublease income
|
|
|
|
|
|
|
(34
|
)
|
|
|
|
|
|
|
|
|
|
Minimum lease commitments
|
|
|
417
|
|
|
|
106
|
|
|
|
|
|
|
|
|
|
|
Less amounts representing interest
|
|
|
206
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Present value of net minimum lease obligations
|
|
|
211
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The Company expects that, in the normal course of business,
leases that expire will be renewed or replaced by other leases.
|
|
22.
|
Financial
Instruments
|
Interest
Rate Risk Management
To reduce the interest rate risk inherent in the Companys
variable rate debt, the Company utilizes interest rate swap
agreements to convert a portion of the variable rate debt to a
fixed rate obligation. These interest rate swap agreements are
designated as cash flow hedges. If an interest rate swap
agreement is terminated prior to its maturity, the amount
previously recorded in Accumulated other comprehensive income
(loss), net is recognized into earnings over the period that the
hedged transaction impacts earnings. If the hedging relationship
is discontinued because it is probable that the forecasted
transaction will not occur according to the original strategy,
any related amounts previously recorded in Accumulated other
comprehensive income (loss), net are recognized into earnings
immediately.
F-45
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
As of December 31, 2006, the Company had an interest rate
swap agreement in place with a notional value of
$300 million. On March 29, 2007, in connection with
the April 2007 debt refinancing, the Company terminated this
interest rate swap agreement and recognized a gain of
$2 million related to amounts previously recorded in
Accumulated other comprehensive income (loss), net.
In March 2007, in anticipation of the April 2007 debt
refinancing, the Company entered into various US dollar and Euro
interest rate swap agreements, which became effective on
April 2, 2007, with notional amounts of $1.6 billion
and 150 million, respectively. The notional amount of
the $1.6 billion US dollar interest rate swaps decreased by
$400 million effective January 2, 2008 and decreased
by another $200 million effective January 2, 2009. To
offset the declines, the Company entered into US dollar interest
rate swaps with a combined notional amount of $400 million
which became effective on January 2, 2008 and an additional
US dollar interest rate swap with a notional amount of
$200 million which will become effective April 2, 2009.
The Company recognized interest (expense) income from hedging
activities relating to interest rate swaps of
($18) million, $6 million and $1 million for the
years ended December 31, 2008, 2007 and 2006, respectively.
The Company recorded a net loss of less than $1 million to
Other income (expense), net for the ineffective portion of the
interest rate swap agreements for each of the years ended
December 31, 2008, 2007 and 2006. The Company recorded an
unrealized loss on interest rate swaps of $79 million
during the year ended December 31, 2008.
Foreign
Exchange Risk Management
Certain entities have receivables and payables denominated in
currencies other than their respective functional currencies,
which creates foreign exchange risk. The Company enters into
foreign currency forwards and swaps to minimize its exposure to
foreign currency fluctuations. The currently outstanding foreign
currency contracts are hedging booked exposure, however the
Company may from time to time hedge its currency exposure
related to forecasted transactions. Forward contracts are not
designated as hedges under SFAS No. 133.
The following table indicates the total US dollar equivalents of
net foreign exchange exposure related to (short) long foreign
exchange forward contracts outstanding by currency. All of the
contracts included in the table below will have approximately
offsetting effects from actual underlying payables, receivables,
intercompany loans or other assets or liabilities subject to
foreign exchange remeasurement.
|
|
|
|
|
|
|
2009 Maturity
|
|
|
|
(In $ millions)
|
|
|
Currency
|
|
|
|
|
Euro
|
|
|
145
|
|
British pound sterling
|
|
|
(115
|
)
|
Mexican peso
|
|
|
80
|
|
Singapore dollar
|
|
|
26
|
|
Canadian dollar
|
|
|
21
|
|
Japanese yen
|
|
|
9
|
|
Brazilian real
|
|
|
(7
|
)
|
Swedish krona
|
|
|
6
|
|
Hungarian forint
|
|
|
(5
|
)
|
Other
|
|
|
(3
|
)
|
|
|
|
|
|
Total
|
|
|
157
|
|
|
|
|
|
|
To protect the foreign currency exposure of a net investment in
a foreign operation, the Company entered into cross currency
swaps with certain financial institutions in 2004. The cross
currency swaps and the Euro-denominated portion of the senior
term loan were designated as a hedge of a net investment of a
foreign operation. The Company dedesignated the net investment
hedge due to the debt refinancing in April 2007 and redesignated
the
F-46
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
cross currency swaps and new senior Euro term loan in July 2007.
As a result, the Company recorded $26 million of
mark-to-market losses related to the cross currency swaps and
the new senior Euro term loan during this period.
Under the terms of the cross currency swap arrangements, the
Company paid approximately 13 million in interest and
received approximately $16 million in interest on June 15
and December 15 of each year. The fair value of the net
obligation under the cross currency swaps was included in
current Other liabilities in the consolidated balance sheets as
of December 31, 2007. Upon maturity of the cross currency
swap agreements in June 2008, the Company owed
276 million ($426 million) and was owed
$333 million. In settlement of the obligation, the Company
paid $93 million (net of interest of $3 million) in
June 2008.
During the year ended December 31, 2008, the Company
dedesignated 385 million of the 400
Euro-denominated portion of the term loan, previously designated
as a hedge of a net investment of a foreign operation. Prior to
this dedesignation, the Company had been using external
derivative contracts to offset foreign currency exposures on
intercompany loans. The foreign currency exposure resulting from
dedesignation of 385 million of the hedge of a net
investment of a foreign operation is expected to offset the
foreign currency exposure on certain intercompany loans,
decreasing the need for external derivative contracts and
reducing the Companys exposure to external counterparties.
The remaining 15 million Euro-denominated portion of
the term loan continues to be designated as a hedge of a net
investment of a foreign operation.
The effective portion of the gain (loss) on the derivative
(cross currency swaps) is recorded in Accumulated other
comprehensive income (loss), net. For the years ended
December 31, 2008, 2007 and 2006, the amount charged to
Accumulated other comprehensive income (loss), net was
$(19) million, $(19) million and $(23) million,
respectively. The gain (loss) related to items excluded from the
assessment of hedge effectiveness of the cross currency swaps
are recorded to Other income (expense), net in the consolidated
statements of operations. For the years ended December 31,
2008, 2007 and 2006, the amount charged to Other income
(expense), net in the consolidated statements of operations was
$1 million, $(6) million and $5 million,
respectively.
Commodity
Risk Management
The Company has exposure to the prices of commodities in its
procurement of certain raw materials. The Company manages its
exposure primarily through the use of long-term supply
agreements and derivative instruments. The Company regularly
assesses its practice of purchasing a portion of its commodity
requirements forward and utilization of other raw material
hedging instruments, in addition to forward purchase contracts,
in accordance with changes in market conditions. Forward
purchases and swap contracts for raw materials are principally
settled through actual delivery of the physical commodity. For
qualifying contracts, the Company has elected to apply the
normal purchases and normal sales exception of
SFAS No. 133, as amended, as it was probable at the
inception and throughout the term of the contract that they
would not settle net and would result in physical delivery. As
such, realized gains and losses on these contracts are included
in the cost of the commodity upon the settlement of the contract.
In addition, the Company occasionally enters into financial
derivatives to hedge a component of a raw material or energy
source. Typically, these types of transactions do not qualify
for hedge accounting. These instruments are marked to market at
each reporting period and gains (losses) are included in Cost of
sales in the consolidated statements of operations. The Company
recognized no gain or loss from these types of contracts during
the year ended December 31, 2008 and less than
$1 million during each of the years ended December 31,
2007 and 2006, respectively. As of December 31, 2008, the
Company did not have any open financial derivative contracts for
commodities.
Fair
Value of Financial Instruments
As discussed in Note 2, the Company adopted certain provisions
of SFAS No. 157 on January 1, 2008.
SFAS No. 157 establishes a three-tiered fair value
hierarchy that prioritizes inputs to valuation techniques used
in fair value calculations. The three levels of inputs are
defined as follows:
Level 1 unadjusted quoted prices for identical
assets or liabilities in active markets accessible by the Company
F-47
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Level 2 inputs that are observable in the
marketplace other than those inputs classified as Level 1
Level 3 inputs that are unobservable in the
marketplace and significant to the valuation
SFAS No. 157 requires the Company to maximize the use
of observable inputs and minimize the use of unobservable
inputs. If a financial instrument uses inputs that fall in
different levels of the hierarchy, the instrument will be
categorized based upon the lowest level of input that is
significant to the fair value calculation.
The Companys financial assets and liabilities are measured
at fair value on a recurring basis and include securities
available for sale and derivative financial instruments.
Securities available for sale include US government and
corporate bonds, mortgage-backed securities and equity
securities. Derivative financial instruments include interest
rate swaps and foreign currency forwards and swaps.
Marketable Securities. Where possible, the
Company utilizes quoted prices in active markets to measure debt
and equity securities; such items are classified as Level 1
in the hierarchy and include equity securities and US government
bonds. When quoted market prices for identical assets are
unavailable, varying valuation techniques are used. Common
inputs in valuing these assets include, among others, benchmark
yields, issuer spreads, forward mortgage-backed securities trade
prices and recently reported trades. Such assets are classified
as Level 2 in the hierarchy and typically include
mortgage-backed securities, corporate bonds and other US
government securities.
Derivatives. Derivative financial instruments
are valued in the market using discounted cash flow techniques.
These techniques incorporate Level 1 and Level 2
inputs such as interest rates and foreign currency exchange
rates. These market inputs are utilized in the discounted cash
flow calculation considering the instruments term,
notional amount, discount rate and credit risk. Significant
inputs to the derivative valuation for interest rate swaps and
foreign currency forwards and swaps are observable in the active
markets and are classified as Level 2 in the hierarchy.
The following fair value hierarchy table presents information
about the Companys assets and liabilities measured at fair
value on a recurring basis:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair Value Measurement as of
|
|
|
|
|
|
|
December 31, 2008 Using
|
|
|
|
|
|
|
Quoted Prices in
|
|
|
|
|
|
|
|
|
|
Active Markets for
|
|
|
Significant Other
|
|
|
As of
|
|
|
|
Identical Assets
|
|
|
Observable Inputs
|
|
|
December 31,
|
|
|
|
(Level 1)
|
|
|
(Level 2)
|
|
|
2008
|
|
|
|
(In $ millions)
|
|
|
Assets
|
|
|
|
|
|
|
|
|
|
|
|
|
Marketable securities
|
|
|
42
|
|
|
|
58
|
|
|
|
100
|
|
Current derivatives (included in Non-trade receivables)
|
|
|
|
|
|
|
54
|
|
|
|
54
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
|
42
|
|
|
|
112
|
|
|
|
154
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities
|
|
|
|
|
|
|
|
|
|
|
|
|
Current derivatives (included in current Other liabilities)
|
|
|
|
|
|
|
(65
|
)
|
|
|
(65
|
)
|
Noncurrent derivatives (included in noncurrent Other liabilities)
|
|
|
|
|
|
|
(76
|
)
|
|
|
(76
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total liabilities
|
|
|
|
|
|
|
(141
|
)
|
|
|
(141
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
F-48
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Summarized below are the carrying values and estimated fair
values of financial instruments that are not carried at fair
value on our consolidated balance sheets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
|
Carrying
|
|
|
Fair
|
|
|
Carrying
|
|
|
Fair
|
|
|
|
Amount
|
|
|
Value
|
|
|
Amount
|
|
|
Value
|
|
|
|
(In $ millions)
|
|
|
Cost investments
|
|
|
184
|
|
|
|
|
|
|
|
189
|
|
|
|
|
|
Insurance contracts in nonqualified pension trusts
|
|
|
67
|
|
|
|
67
|
|
|
|
74
|
|
|
|
74
|
|
Long-term debt, including current installments of long-term debt
|
|
|
3,381
|
|
|
|
2,404
|
|
|
|
3,328
|
|
|
|
3,211
|
|
In general, the cost investments included in the table above are
not publicly traded and their fair values are not readily
determinable; however, the Company believes the carrying values
approximate or are less than the fair values.
As of December 31, 2008 and 2007, the fair values of cash
and cash equivalents, receivables, trade payables, short-term
debt and the current installments of long-term debt approximate
carrying values due to the short-term nature of these
instruments. These items have been excluded from the table.
Additionally, certain noncurrent receivables, principally
insurance recoverables, are carried at net realizable value.
The fair value of long-term debt and debt-related financial
instruments is based upon valuations from third-party banks and
market quotations.
23. Commitments
and Contingencies
The Company is involved in a number of legal proceedings,
lawsuits and claims incidental to the normal conduct of
business, relating to such matters as product liability,
antitrust, past waste disposal practices and release of
chemicals into the environment. While it is impossible at this
time to determine with certainty the ultimate outcome of these
proceedings, lawsuits and claims, the Company is actively
defending those matters where the Company is named as a
defendant. Additionally, the Company believes it has determined
its best estimate, based on the advice of legal counsel, that
adequate reserves have been made and that the ultimate outcomes
will not have a material adverse effect on the financial
position of the Company; however, the ultimate outcome of any
given matter may have a material impact on the results of
operations or cash flows of the Company in any given reporting
period.
Plumbing
Actions
CNA Holdings, Inc. (CNA Holdings), a US subsidiary
of the Company, which included the US business now conducted by
the Ticona business which is included in the Advanced Engineered
Materials segment, along with Shell Oil Company
(Shell), E.I. DuPont de Nemours and Company
(DuPont) and others, has been a defendant in a
series of lawsuits, including a number of class actions,
alleging that plastics manufactured by these companies that were
utilized in the production of plumbing systems for residential
property were defective or caused such plumbing systems to fail.
Based on, among other things, the findings of outside experts
and the successful use of Ticonas acetal copolymer in
similar applications, CNA Holdings does not believe
Ticonas acetal copolymer was defective or caused the
plumbing systems to fail. In many cases CNA Holdings
potential future exposure may be limited by invocation of the
statute of limitations since CNA Holdings ceased selling the
resin for use in the plumbing systems in site-built homes during
1986 and in manufactured homes during 1990.
In November 1995, CNA Holdings, DuPont and Shell entered into
national class action settlements which called for the
replacement of plumbing systems of claimants who have had
qualifying leaks, as well as reimbursements for certain leak
damage. In connection with such settlement, the three companies
had agreed to fund these replacements and reimbursements up to
an aggregate amount of $950 million. As of
December 31,
F-49
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
2008, the aggregate funding is $1,103 million, due to
additional contributions and funding commitments made primarily
by other parties.
During the period between 1995 and 2001, CNA Holdings was also
named as a defendant in the following putative class actions:
|
|
|
|
|
Cox, et al. v. Hoechst Celanese Corporation, et al.,
No. 94-0047
(Chancery Ct., Obion County, Tennessee) (class was certified).
|
|
|
|
Couture, et al. v. Shell Oil Company, et al.,
No. 200-06-000001-985
(Quebec Superior Court, Canada).
|
|
|
|
Dilday, et al. v. Hoechst Celanese Corporation, et al.,
No. 15187 (Chancery Ct., Weakley County, Tennessee).
|
|
|
|
Furlan v. Shell Oil Company, et al.,
No. C967239 (British Columbia Supreme Court, Vancouver
Registry, Canada).
|
|
|
|
Gariepy, et al. v. Shell Oil Company, et al.,
No. 30781/99 (Ontario Court General Division, Canada).
|
|
|
|
Shelter General Insurance Co., et al. v. Shell Oil
Company, et al., No. 16809 (Chancery Ct., Weakley
County, Tennessee).
|
|
|
|
St. Croix Ltd., et al. v. Shell Oil Company, et al.,
No. 1997/467 (Territorial Ct., St. Croix Division, the
US Virgin Islands).
|
|
|
|
Tranter v. Shell Oil Company, et al.,
No. 46565/97 (Ontario Court General Division, Canada).
|
In addition, between 1994 and 2008 CNA Holdings was named as a
defendant in numerous non-class actions filed in Arizona,
Florida, Georgia, Louisiana, Mississippi, New Jersey, Tennessee
and Texas, the US Virgin Islands and Canada of which ten are
currently pending. In all of these actions, the plaintiffs have
sought recovery for alleged damages caused by leaking
polybutylene plumbing. Damage amounts have generally not been
specified but these cases generally do not involve (either
individually or in the aggregate) a large number of homes.
As of December 31, 2008, the Company had remaining accruals
of $64 million, of which $2 million is included in
current Other liabilities in the consolidated balance sheets. As
of December 31, 2007, the Company had remaining accruals of
$65 million, of which $3 million was included in
current Other liabilities in the consolidated balance sheets.
The Company reached settlements with CNA Holdings insurers
specifying their responsibility for these claims. During the
year ended December 31, 2007, the Company received $23
million of insurance proceeds from various CNA Holdings
insurers as full satisfaction for their responsibility for these
claims.
Plumbing
Insurance Indemnifications
Celanese GmbH entered into agreements with insurance companies
related to product liability settlements associated with
Celcon®
plumbing claims. These agreements, except those with insolvent
insurance companies, require the Company to indemnify
and/or
defend these insurance companies in the event that third parties
seek additional monies for matters released in these agreements.
The indemnifications in these agreements do not provide for time
limitations.
In certain of the agreements, Celanese GmbH received a fixed
settlement amount. The indemnities under these agreements
generally are limited to, but in some cases are greater than,
the amount received in settlement from the insurance company.
The maximum exposure under these indemnifications is
$95 million. Other settlement agreements have no stated
limits.
F-50
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
There are other agreements whereby the settling insurer agreed
to pay a fixed percentage of claims that relate to that
insurers policies. The Company has provided
indemnifications to the insurers for amounts paid in excess of
the settlement percentage. These indemnifications do not provide
for monetary or time limitations.
Sorbates
Antitrust Actions
In May 2002, the European Commission informed Hoechst AG
(Hoechst) of its intent to officially investigate
the sorbates industry. In early January 2003, the European
Commission served Hoechst, Nutrinova, Inc., a US subsidiary of
Nutrinova Nutrition Specialties & Food Ingredients
GmbH and previously a wholly owned subsidiary of Hoechst
(Nutrinova), and a number of competitors of
Nutrinova with a statement of objections alleging unlawful,
anticompetitive behavior affecting the European sorbates market.
In October 2003, the European Commission ruled that Hoechst,
Chisso Corporation, Daicel Chemical Industries Ltd.
(Daicel), The Nippon Synthetic Chemical Industry Co.
Ltd. and Ueno Fine Chemicals Industry Ltd. operated a cartel in
the European sorbates market between 1979 and 1996. The European
Commission imposed a total fine of 138 million on
such companies, of which 99 million was assessed
against Hoechst and its legal successors. The case against
Nutrinova was closed. Pursuant to the Demerger Agreement with
Hoechst, Celanese GmbH was assigned the obligation related to
the sorbates antitrust matter; however, Hoechst, and its legal
successors, agreed to indemnify Celanese GmbH for 80% of any
costs Celanese GmbH incurred relative to this matter.
Accordingly, Celanese GmbH recognized a receivable from Hoechst
from this indemnification. In June 2008, the Court of First
Instance of the European Communities (Fifth Chamber) reduced the
fine against Hoechst to 74.25 million and in July
2008, Hoechst paid the 74.25 million fine. In August
2008, the Company paid Hoechst 17 million, including
interest of 2 million, in satisfaction of its 20%
obligation with respect to the fine.
Based on the advice of external counsel and a review of the
existing facts and circumstances relating to the sorbates
antitrust matters, including the settlement of the European
Unions investigation, as well as civil claims filed and
settled, the Company released its accruals related to the
settled sorbates antitrust matters and the indemnification
receivables resulting in a gain of $8 million, net,
included in Other (charges) gains, net, in the consolidated
statements of operations. As of December 31, 2007, the
Company had indemnification receivables of $137 million
included in current Other assets and accruals of
$170 million included in current Other liabilities in the
consolidated balance sheets.
In addition, in 2004 a civil antitrust action styled Freeman
Industries LLC v. Eastman Chemical Co., et. al. was
filed against Hoechst and Nutrinova, Inc. in the Law Court for
Sullivan County in Kingsport, Tennessee. The plaintiff sought
monetary damages and other relief for alleged conduct involving
the sorbates industry. The trial court dismissed the
plaintiffs claims and upon appeal the Supreme Court of
Tennessee affirmed the dismissal of the plaintiffs claims.
In December 2005, the plaintiff lost an attempt to amend its
complaint and the entire action was dismissed with prejudice by
the trial court. Plaintiffs counsel has subsequently filed
a new complaint with new class representatives in the District
Court of the District of Tennessee. The Companys motion to
strike the class allegations was granted in April 2008 and the
plaintiffs appeal of such ruling is currently pending.
Acetic
Acid Patent Infringement Matters
On May 9, 1999, Celanese International Corporation filed a
private criminal action styled Celanese International
Corporation v. China Petrochemical Development Corporation
against China Petrochemical Development Corporation
(CPDC) in the Taiwan Kaoshiung District Court
alleging that CPDC infringed Celanese International
Corporations patent covering the manufacture of acetic
acid. Celanese International Corporation also filed a
supplementary civil brief which, in view of changes in Taiwanese
patent laws, was subsequently converted to a civil action
alleging damages against CPDC based on a period of infringement
of ten years,
1991-2000,
and based on CPDCs own data which was reported to the
Taiwanese securities and exchange commission. Celanese
International Corporations patent was held valid by the
Taiwanese patent office. On August 31, 2005, the District
Court held that CPDC infringed Celanese International
Corporations acetic acid patent and awarded Celanese
International Corporation approximately $28 million (plus
interest) for the period of 1995 through 1999. In October 2008,
the High Court, on appeal, reversed the District Courts
$28 million award to the Company. The Company is appealing. On
January 16, 2006, the District Court
F-51
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
awarded Celanese International Corporation $800,000 (plus
interest) for the year 1990. In January 2009, the High
Court, on appeal, affirmed the District Courts award and
CPDC appealed on February 5, 2009. On June 29, 2007,
the District Court awarded Celanese International Corporation
$60 million (plus interest) for the period of 2000 through
2005. CPDC is appealing this award.
Domination
Agreement
On October 1, 2004, a Domination Agreement between Celanese
GmbH and the Purchaser became operative. When the Domination
Agreement became operative, the Purchaser became obligated to
offer to acquire all outstanding Celanese GmbH shares from the
minority shareholders of Celanese GmbH in return for payment of
fair cash compensation. The amount of this fair cash
compensation was determined to be 41.92 per share, plus
interest, in accordance with applicable German law. Until the
Squeeze-Out was registered in the commercial register in Germany
on December 22, 2006, any minority shareholder who elected
not to sell its shares to the Purchaser was entitled to remain a
shareholder of Celanese GmbH and to receive from the Purchaser a
gross guaranteed annual payment on its shares of 3.27 per
Celanese GmbH share less certain corporate taxes in lieu of any
dividend. For the year ended December 31, 2006, a charge of
3 million ($4 million) was recorded to Other
income (expense), net for the anticipated guaranteed annual
payment.
On June 1, 2006, the guaranteed annual payment for the
fiscal year ended September 30, 2005, which amounted to
3 million, was paid. In addition, pursuant to a
settlement agreement entered into with plaintiff shareholders in
March 2006, the Purchaser paid 1 million on
June 30, 2006, the guaranteed annual payment for the fiscal
year ended September 30, 2006, to those shareholders who
signed a letter waiving any further rights with respect to such
guaranteed annual payment that ordinarily would become due and
payable after the 2007 annual general meeting. Between
June 30, 2006, and January 17, 2007, the Purchaser
paid a total amount of less than 1 million to
minority shareholders who required early payment of the
guaranteed annual payment for the fiscal year ended
September 30, 2006, by submitting such waiver letter after
June 30, 2006.
On January 17, 2007, the Purchaser made, pursuant to a
settlement agreement entered into with plaintiff shareholders in
December 2006, the following guaranteed annual payments:
(i) a total amount of 1 million was paid to all
minority shareholders who had not yet requested early payment of
the guaranteed annual payment for the fiscal year ended on
September 30, 2006, and (ii) a total amount of
1 million representing the pro rata share of the
guaranteed annual payment for the first five months of the
fiscal year ending September 30, 2007 was paid to all
minority shareholders.
The Domination Agreement cannot be terminated by the Purchaser
in the ordinary course of business until September 30,
2009. The Companys subsidiaries, Celanese International
Holdings Luxembourg S.à r.l. (CIH), formerly
Celanese Caylux Holdings Luxembourg S.C.A., and Celanese US,
have each agreed to provide the Purchaser with financing to
strengthen the Purchasers ability to fulfill its
obligations under, or in connection with, the Domination
Agreement and to ensure that the Purchaser will perform all of
its obligations under, or in connection with, the Domination
Agreement when such obligations become due, including, without
limitation, the obligation to compensate Celanese GmbH for any
statutory annual loss incurred by Celanese GmbH during the term
of the Domination Agreement. If CIH
and/or
Celanese US are obligated to make payments under such guarantees
or other security to the Purchaser, the Company may not have
sufficient funds for payments on its indebtedness when due. The
Company has not had to compensate Celanese GmbH for an annual
loss for any period during which the Domination Agreement has
been in effect.
The amounts of the fair cash compensation and of the guaranteed
annual payment offered under the Domination Agreement are under
court review in special award proceedings. As a result of these
proceedings, either amount could be increased by the court so
that all former Celanese GmbH shareholders, including those who
have already tendered their shares into the mandatory offer and
have received the fair cash compensation could claim the
respective higher amounts. Certain former Celanese GmbH
shareholders may initiate such proceedings also with respect to
the Squeeze-Out compensation. In this case, former Celanese GmbH
shareholders who ceased to be shareholders of Celanese
F-52
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
GmbH due to the Squeeze-Out are entitled, pursuant to a
settlement agreement between the Purchaser and certain former
Celanese GmbH shareholders, to claim for their shares the higher
of the compensation amounts determined by the court in these
different proceedings. Payments these shareholders already
received as compensation for their shares will be offset so that
those shareholders who ceased to be shareholders of Celanese
GmbH due to the Squeeze-Out are not entitled to more than the
higher of the amount set in the two court proceedings.
Shareholder
Litigation
The amounts of the fair cash compensation and of the guaranteed
annual payment offered under the Domination Agreement may be
increased in special award proceedings initiated by minority
shareholders, which may further reduce the funds the Purchaser
can otherwise make available to the Company. As of
March 30, 2005, several minority shareholders of Celanese
GmbH had initiated special award proceedings seeking the
courts review of the amounts of the fair cash compensation
and of the guaranteed annual payment offered under the
Domination Agreement. As a result of these proceedings, the
amount of the fair cash consideration and the guaranteed annual
payment offered under the Domination Agreement could be
increased by the court so that all minority shareholders,
including those who have already tendered their shares into the
mandatory offer and have received the fair cash compensation
could claim the respective higher amounts. The court dismissed
all of these proceedings in March 2005 on the grounds of
inadmissibility. Thirty-three plaintiffs appealed the dismissal,
and in January 2006, twenty-three of these appeals were
granted by the court. They were remanded back to the court of
first instance, where the valuation will be further reviewed. On
December 12, 2006, the court of first instance appointed an
expert to help determine the value of Celanese GmbH. In the
first quarter of 2007, certain minority shareholders that
received 66.99 per share as fair cash compensation also
filed award proceedings challenging the amount they received as
fair cash compensation.
As a result of the special proceedings discussed above, amounts
paid as fair cash compensation to certain minority shareholders
of Celanese GmbH could be increased by the court such that
minority shareholders could be awarded amounts in excess of the
fair cash compensation they have previously received.
The Company received applications for the commencement of award
proceedings filed by 79 shareholders against the Purchaser
with the Frankfurt District Court requesting the court to set a
higher amount for the Squeeze-Out compensation. The motions are
based on various alleged shortcomings and mistakes in the
valuation of Celanese GmbH done for purposes of the Squeeze-Out.
On May 11, 2007, the court of first instance appointed a
common representative for those shareholders that have not filed
an application on their own.
Polyester
Staple Antitrust Litigation
CNA Holdings, the successor in interest to Hoechst Celanese
Corporation (HCC), Celanese Americas Corporation and
Celanese GmbH (collectively, the Celanese Entities)
and Hoechst, the former parent of HCC, were named as defendants
in two actions (involving 25 individual participants) filed in
September 2006 by US purchasers of polyester staple fibers
manufactured and sold by HCC. The actions allege that the
defendants participated in a conspiracy to fix prices, rig bids
and allocate customers of polyester staple sold in the United
States. These actions were consolidated in a proceeding by a
Multi-District Litigation Panel in the United States District
Court for the Western District of North Carolina styled In re
Polyester Staple Antitrust Litigation, MDL 1516. On
June 12, 2008 the court dismissed these actions against all
Celanese Entities in consideration of a payment by the Company
of $107 million. This proceeding related to sales by the
polyester staple fibers business which Hoechst AG sold to KoSa,
Inc. in 1998. Accordingly, the impact of this settlement is
reflected within discontinued operations in the consolidated
statements of operations. The Company also previously entered
into tolling arrangements with four other alleged US purchasers
of polyester staple fibers manufactured and sold by the Celanese
Entities. These purchasers were not included in the settlement
and one such company filed suit against the Company in December
2008 in the Western District of North Carolina entitled
Milliken & Company v. CNA Holdings, Inc., Celanese
Americas Corporation and Hoechst AG (No. 8-CV-00578).
F-53
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
In 1998, HCC sold its polyester staple business as part of the
sale of its Film & Fibers Division to KoSa B.V., f/k/a
Arteva B.V. and a subsidiary of Koch Industries, Inc.
(KoSa). In March 2001 the US Department of Justice
(DOJ) commenced an investigation of possible price
fixing regarding the sales of polyester staple fibers in the US
subsequent to the period the Celanese Entities were engaged in
the polyester staple fiber business. The Celanese Entities were
never named in these DOJ actions. As a result of the DOJ action,
during August of 2002, Arteva Specialties, S.a.r.l., a
subsidiary of KoSa, (Arteva Specialties) pled guilty
to criminal violation of the Sherman Act related to
anti-competitive conduct occurring after the 1998 sale of the
polyester staple fiber business and paid a fine of
$29 million. In a complaint pending against the Celanese
Entities and Hoechst in the United States District Court for the
Southern District of New York, Koch Industries, Inc., KoSa,
Arteva Specialties and Arteva Services S.a.r.l. seek damages in
excess of $371 million which includes indemnification for
all damages related to the defendants alleged
participation in, and failure to disclose, the alleged
conspiracy.
Guarantees
The Company has agreed to guarantee or indemnify third parties
for environmental and other liabilities pursuant to a variety of
agreements, including asset and business divestiture agreements,
leases, settlement agreements and various agreements with
affiliated companies. Although many of these obligations contain
monetary
and/or time
limitations, others do not provide such limitations.
As indemnification obligations often depend on the occurrence of
unpredictable future events, the future costs associated with
them cannot be determined at this time.
The Company has accrued for all probable and reasonably
estimable losses associated with all known matters or claims
that have been brought to its attention. These known obligations
include the following:
Demerger Obligations
The Company has obligations to indemnify Hoechst, and its legal
successors, for various liabilities under the Demerger
Agreement, including for environmental liabilities associated
with contamination arising under 19 divestiture agreements
entered into by Hoechst prior to the demerger.
The Companys obligation to indemnify Hoechst, and its
legal successors, is subject to the following thresholds:
|
|
|
|
|
The Company will indemnify Hoechst, and its legal successors,
against those liabilities up to 250 million;
|
|
|
|
Hoechst, and its legal successors, will bear those liabilities
exceeding 250 million, however the Company will
reimburse Hoechst, and its legal successors, for one-third of
those liabilities for amounts that exceed 750 million
in the aggregate.
|
The aggregate maximum amount of environmental indemnifications
under the remaining divestiture agreements that provide for
monetary limits is approximately 750 million. Three
of the divestiture agreements do not provide for monetary limits.
Based on the estimate of the probability of loss under this
indemnification, the Company had reserves of $27 million
and $27 million as of December 31, 2008 and 2007,
respectively, for this contingency. Where the Company is unable
to reasonably determine the probability of loss or estimate such
loss under an indemnification, the Company has not recognized
any related liabilities.
The Company has also undertaken in the Demerger Agreement to
indemnify Hoechst and its legal successors for liabilities that
Hoechst is required to discharge, including tax liabilities,
which are associated with businesses that were included in the
demerger but were not demerged due to legal restrictions on the
transfers of such items. These indemnities do not provide for
any monetary or time limitations. The Company has not provided
for any reserves associated with this indemnification as it is
not probable or estimable. The Company has not made any
F-54
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
payments to Hoechst or its legal successors during the years
ended December 31, 2008 and 2007, respectively, in
connection with this indemnification.
Divestiture Obligations
The Company and its predecessor companies agreed to indemnify
third-party purchasers of former businesses and assets for
various pre-closing conditions, as well as for breaches of
representations, warranties and covenants. Such liabilities also
include environmental liability, product liability, antitrust
and other liabilities. These indemnifications and guarantees
represent standard contractual terms associated with typical
divestiture agreements and, other than environmental
liabilities, the Company does not believe that they expose the
Company to any significant risk.
The Company has divested numerous businesses, investments and
facilities through agreements containing indemnifications or
guarantees to the purchasers. Many of the obligations contain
monetary
and/or time
limitations, ranging from one year to thirty years. The
aggregate amount of guarantees provided for under these
agreements is approximately $2.3 billion as of
December 31, 2008. Other agreements do not provide for any
monetary or time limitations.
Based on historical claims experience and its knowledge of the
sites and businesses involved, the Company believes that it is
adequately reserved for these matters. As of December 31,
2008 and 2007, the Company has reserves in the aggregate of
$33 million and $27 million, respectively, for these
matters.
Other Obligations
The Company is secondarily liable under a lease agreement that
the Company assigned to a third party. The lease expires on
April 30, 2012. The lease liability for the period from
January 1, 2009 to April 30, 2012 is estimated to be
approximately $26 million.
The Company has agreed to indemnify various insurance carriers
for amounts not in excess of the settlements received from
claims made against these carriers subsequent to the settlement.
The aggregate amount of guarantees under these settlements which
is limited in term is approximately $10 million.
Asbestos
Claims
As of December 31, 2008, Celanese Ltd. and/or CNA Holdings,
Inc., both US subsidiaries of the Company, are defendants in
approximately 559 asbestos cases. During the year ended
December 31, 2008, 66 new cases were filed against the
Company, 137 cases were resolved, and 4 cases were added after
further analysis by outside counsel. Because many of these cases
involve numerous plaintiffs, the Company is subject to claims
significantly in excess of the number of actual cases. The
Company has reserves for defense costs related to claims arising
from these matters. The Company believes that there is no
significant exposure related to these matters.
Purchase
Obligations
In the normal course of business, the Company enters into
commitments to purchase goods and services over a fixed period
of time. The Company maintains a number of
take-or-pay contracts for purchases of raw materials
and utilities. As of December 31, 2008, there were
outstanding future commitments of $2,291 million under
take-or-pay contracts. The Company does not expect to incur any
losses under these contractual arrangements and historically has
not incurred any material losses related to these contracts.
Additionally, as of December 31, 2008, there were
outstanding commitments relating to capital projects of
$33 million.
F-55
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
24.
|
Supplemental
Cash Flow Information
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
|
(In $ millions)
|
|
|
Cash paid for:
|
|
|
|
|
|
|
|
|
|
|
|
|
Taxes, net of refunds
|
|
|
98
|
|
|
|
181
|
|
|
|
101
|
|
Interest, net of amounts
capitalized(1)
|
|
|
259
|
|
|
|
414
|
|
|
|
239
|
|
Noncash investing and financing activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair value adjustment to securities available for sale, net of
tax
|
|
|
(25
|
)
|
|
|
17
|
|
|
|
13
|
|
Capital lease obligations
|
|
|
103
|
|
|
|
80
|
|
|
|
5
|
|
Accrued capital expenditures
|
|
|
(7
|
)
|
|
|
18
|
|
|
|
|
|
Asset retirement obligations
|
|
|
8
|
|
|
|
4
|
|
|
|
10
|
|
Accrued Ticona Kelsterbach plant relocation costs
|
|
|
17
|
|
|
|
19
|
|
|
|
|
|
|
|
|
(1) |
|
Amount includes premiums paid on early redemption of debt and
related issuance costs, net of amounts capitalized, of
$217 million for the year ended December 31, 2007. |
|
|
25.
|
Business
and Geographical Segments
|
The Company operates through the following business segments:
Advanced
Engineered Materials
The Companys Advanced Engineered Materials segment
develops, produces and supplies a broad portfolio of high
performance technical polymers for application in automotive and
electronics products as well as other consumer and industrial
applications. Together with the Companys strategic
affiliates, we are a leading participant in the global technical
polymers industry. The primary products of Advanced Engineered
Materials are used in a broad range of products including
automotive components, electronics, appliances, industrial
applications, battery separators, conveyor belts, filtration
equipment, coatings, medical devices, electrical and electronics.
Consumer
Specialties
The Companys Consumer Specialties segment consists of the
Acetate Products and Nutrinova businesses. The Acetate Products
business primarily produces and supplies acetate tow, which is
used in the production of filter products. We also produce
acetate flake which is processed into acetate fiber in the form
of a tow band. Our Nutrinova business produces and sells
Sunett®,
a high intensity sweetener, and food protection ingredients,
such as sorbates, for the food, beverage and pharmaceuticals
industries.
Industrial
Specialties
The Companys Industrial Specialties segment includes our
Emulsions, PVOH and AT Plastics businesses. Our Emulsions
business is a global leader which produces a broad product
portfolio, specializing in vinyl acetate ethylene emulsions, and
is a recognized authority on low VOC (volatile organic
compounds), an environmentally-friendly technology. As a global
leader, our PVOH business produces a broad portfolio of
performance PVOH chemicals engineered to meet specific customer
requirements. Our emulsions and PVOH products are used in a wide
array of applications including paints and coatings, adhesives,
building and construction, glass fiber, textiles and paper. AT
Plastics offers a complete line of low-density polyethylene and
specialty ethylene vinyl acetate resins and compounds. AT
Plastics products are used in many applications including
flexible packaging films, lamination film products, hot melt
adhesives, medical tubing, automotive carpeting and solar cell
encapsulation films.
F-56
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Acetyl
Intermediates
The Companys Acetyl Intermediates segment produces and
supplies acetyl products, including acetic acid, VAM, acetic
anhydride and acetate esters. These products are generally used
as starting materials for colorants, paints, adhesives,
coatings, medicines and more. Other chemicals produced in this
segment are organic solvents and intermediates for
pharmaceutical, agricultural and chemical products.
Other
Activities
Other Activities primarily consists of corporate center costs,
including financing and administrative activities such as legal,
accounting and treasury functions and interest income or expense
associated with financing activities of the Company, and the
captive insurance companies.
The segment management reporting and controlling systems are
based on the same accounting policies as those described in the
summary of significant accounting policies in Note 2. The
Company evaluates performance based on operating profit, net
earnings (loss), cash flows and other measures of financial
performance reported in accordance with US GAAP.
F-57
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Sales and revenues related to transactions between segments are
generally recorded at values that approximate third-party
selling prices.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Advanced
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Engineered
|
|
|
Consumer
|
|
|
Industrial
|
|
|
Acetyl
|
|
|
Other
|
|
|
|
|
|
|
|
|
|
Materials
|
|
|
Specialties
|
|
|
Specialties
|
|
|
Intermediates
|
|
|
Activities
|
|
|
Eliminations
|
|
|
Consolidated
|
|
|
|
(In $ millions)
|
|
|
As of and for the year ended December 31, 2008:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net sales
|
|
|
1,061
|
|
|
|
1,155
|
|
|
|
1,406
|
|
|
|
3,875
|
(1)
|
|
|
2
|
|
|
|
(676
|
)
|
|
|
6,823
|
|
Other (charges) gains, net
|
|
|
(29
|
)
|
|
|
(2
|
)
|
|
|
(3
|
)
|
|
|
(78
|
)
|
|
|
4
|
|
|
|
|
|
|
|
(108
|
)
|
Equity in net earnings of affiliates
|
|
|
37
|
|
|
|
|
|
|
|
|
|
|
|
3
|
|
|
|
14
|
|
|
|
|
|
|
|
54
|
|
Earnings (loss) from continuing operations before tax and
minority interests
|
|
|
69
|
|
|
|
237
|
|
|
|
47
|
|
|
|
434
|
|
|
|
(353
|
)
|
|
|
|
|
|
|
434
|
|
Depreciation and amortization
|
|
|
76
|
|
|
|
53
|
|
|
|
62
|
|
|
|
150
|
|
|
|
9
|
|
|
|
|
|
|
|
350
|
|
Capital
expenditures(2)
|
|
|
55
|
|
|
|
49
|
|
|
|
67
|
|
|
|
86
|
|
|
|
10
|
|
|
|
|
|
|
|
267
|
|
Goodwill and intangible assets
|
|
|
398
|
|
|
|
309
|
|
|
|
73
|
|
|
|
363
|
|
|
|
|
|
|
|
|
|
|
|
1,143
|
|
Total assets
|
|
|
1,867
|
|
|
|
995
|
|
|
|
903
|
|
|
|
2,197
|
|
|
|
1,204
|
|
|
|
|
|
|
|
7,166
|
|
As of and for the year ended December 31, 2007:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net sales
|
|
|
1,030
|
|
|
|
1,111
|
|
|
|
1,346
|
|
|
|
3,615
|
(1)
|
|
|
2
|
|
|
|
(660
|
)
|
|
|
6,444
|
|
Other (charges) gains, net
|
|
|
(4
|
)
|
|
|
(4
|
)
|
|
|
(23
|
)
|
|
|
72
|
|
|
|
(64
|
)
|
|
|
(35
|
)(3)
|
|
|
(58
|
)
|
Equity in net earnings of affiliates
|
|
|
55
|
|
|
|
3
|
|
|
|
|
|
|
|
6
|
|
|
|
18
|
|
|
|
|
|
|
|
82
|
|
Earnings (loss) from continuing operations before tax and
minority interests
|
|
|
189
|
|
|
|
235
|
|
|
|
28
|
|
|
|
694
|
|
|
|
(699
|
)
|
|
|
|
|
|
|
447
|
|
Depreciation and amortization
|
|
|
69
|
|
|
|
51
|
|
|
|
59
|
|
|
|
106
|
|
|
|
6
|
|
|
|
|
|
|
|
291
|
|
Capital
expenditures(2)
|
|
|
59
|
|
|
|
43
|
|
|
|
63
|
|
|
|
130
|
|
|
|
11
|
|
|
|
|
|
|
|
306
|
|
Goodwill and intangible assets
|
|
|
445
|
|
|
|
339
|
|
|
|
97
|
|
|
|
410
|
|
|
|
|
|
|
|
|
|
|
|
1,291
|
|
Total assets
|
|
|
1,734
|
|
|
|
1,137
|
|
|
|
963
|
|
|
|
2,542
|
|
|
|
1,682
|
|
|
|
|
|
|
|
8,058
|
|
As of and for the year ended December 31, 2006:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net sales
|
|
|
915
|
|
|
|
876
|
|
|
|
1,281
|
|
|
|
3,351
|
(1)
|
|
|
22
|
|
|
|
(667
|
)
|
|
|
5,778
|
|
Other (charges) gains, net
|
|
|
6
|
|
|
|
|
|
|
|
(11
|
)
|
|
|
|
|
|
|
(5
|
)
|
|
|
|
|
|
|
(10
|
)
|
Equity in net earnings of affiliates
|
|
|
53
|
|
|
|
3
|
|
|
|
|
|
|
|
8
|
|
|
|
12
|
|
|
|
|
|
|
|
76
|
|
Earnings (loss) from continuing operations before tax and
minority interests
|
|
|
201
|
|
|
|
185
|
|
|
|
43
|
|
|
|
519
|
|
|
|
(422
|
)
|
|
|
|
|
|
|
526
|
|
Depreciation and amortization
|
|
|
65
|
|
|
|
39
|
|
|
|
59
|
|
|
|
101
|
|
|
|
5
|
|
|
|
|
|
|
|
269
|
|
Capital expenditures
|
|
|
27
|
|
|
|
75
|
|
|
|
30
|
|
|
|
105
|
|
|
|
7
|
|
|
|
|
|
|
|
244
|
|
|
|
|
(1) |
|
Includes $676 million, $660 million and
$667 million of intersegment sales eliminated in
consolidation for the years ended December 31, 2008, 2007
and 2006, respectively. |
|
(2) |
|
Excludes expenditures related to the relocation of the
Companys Ticona plant in Kelsterbach and includes a
decrease in accrued capital expenditures of $7 million and
an increase of $18 million for the years ended December 31,
2008 and 2007, respectively (Note 24). |
|
(3) |
|
Represents insurance recoveries received from the Companys
captive insurance companies related to the Clear Lake, Texas
facility (Note 29) that eliminates in consolidation. |
F-58
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Geographical
Segments
Revenues and noncurrent assets are presented based on the
location of the business. The following table presents financial
information based on the geographic location of the
Companys facilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
|
(In $ millions)
|
|
|
Net sales
|
|
|
|
|
|
|
|
|
|
|
|
|
United States
|
|
|
1,719
|
|
|
|
1,754
|
|
|
|
1,803
|
|
Non-United
States
|
|
|
5,104
|
|
|
|
4,690
|
|
|
|
3,975
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
6,823
|
|
|
|
6,444
|
|
|
|
5,778
|
|
Significant
Non-United
States net sales sources include:
|
|
|
|
|
|
|
|
|
|
|
|
|
Germany
|
|
|
2,469
|
|
|
|
2,348
|
|
|
|
1,974
|
|
Singapore
|
|
|
783
|
|
|
|
762
|
|
|
|
771
|
|
Belgium
|
|
|
478
|
|
|
|
295
|
|
|
|
228
|
|
Mexico
|
|
|
391
|
|
|
|
349
|
|
|
|
303
|
|
China
|
|
|
393
|
|
|
|
182
|
|
|
|
14
|
|
|
|
|
|
|
|
|
|
|
|
|
As of December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
|
(In $ millions)
|
|
|
Property, plant and equipment, net
|
|
|
|
|
|
|
|
|
United States
|
|
|
733
|
|
|
|
788
|
|
Non-United
States
|
|
|
1,739
|
|
|
|
1,574
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
2,472
|
|
|
|
2,362
|
|
Significant
Non-United
States property, plant and equipment, net sources include:
|
|
|
|
|
|
|
|
|
Germany
|
|
|
682
|
|
|
|
493
|
|
Singapore
|
|
|
111
|
|
|
|
91
|
|
Canada
|
|
|
117
|
|
|
|
126
|
|
Mexico
|
|
|
105
|
|
|
|
133
|
|
China
|
|
|
493
|
|
|
|
383
|
|
F-59
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
26.
|
Transactions
and Relationships with Affiliates and Related Parties
|
The Company is a party to various transactions with affiliated
companies. Entities in which the Company has an investment
accounted for under the cost or equity method of accounting, are
considered affiliates; any transactions or balances with such
companies are considered affiliate transactions. The following
tables represent the Companys transactions and balances
with affiliates for the periods presented:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
|
(In $ millions)
|
|
|
Statements of Operations
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchases from
affiliates(1)(2)
|
|
|
131
|
|
|
|
126
|
|
|
|
159
|
|
Sales to
affiliates(1)
|
|
|
36
|
|
|
|
126
|
|
|
|
290
|
|
Interest income from affiliates
|
|
|
2
|
|
|
|
1
|
|
|
|
1
|
|
Interest expense to affiliates
|
|
|
9
|
|
|
|
7
|
|
|
|
5
|
|
|
|
|
(1) |
|
Purchases and sales from/to affiliates are accounted for at
prices which, in the opinion of the Company, approximate those
charged to third-party customers for similar goods or services. |
|
(2) |
|
Primarily includes utilities and services purchased from
InfraServ Hoechst. |
Refer to Note 8 for additional information related to
dividends received from affiliates.
|
|
|
|
|
|
|
|
|
|
|
As of December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
|
(In $ millions)
|
|
|
Balance Sheets
|
|
|
|
|
|
|
|
|
Trade and other receivables from affiliates
|
|
|
8
|
|
|
|
15
|
|
Current notes receivable (including interest) from affiliates
|
|
|
9
|
|
|
|
15
|
|
Noncurrent notes receivable (including interest) from affiliates
|
|
|
9
|
|
|
|
7
|
|
|
|
|
|
|
|
|
|
|
Total receivables from affiliates
|
|
|
26
|
|
|
|
37
|
|
|
|
|
|
|
|
|
|
|
Accounts payable and other liabilities due affiliates
|
|
|
18
|
|
|
|
22
|
|
Short-term borrowings from affiliates
|
|
|
103
|
|
|
|
200
|
|
|
|
|
|
|
|
|
|
|
Total due affiliates
|
|
|
121
|
|
|
|
222
|
|
|
|
|
|
|
|
|
|
|
The Company has agreements with certain affiliates, primarily
InfraServ entities, whereby excess affiliate cash is lent to and
managed by the Company, at variable interest rates governed by
those agreements.
For the year ended 2007, the Company made payments to the
Advisor of $7 million in accordance with the sponsor
services agreement dated January 26, 2005, as amended.
These payments were related primarily to the sale of the oxo
products and derivatives businesses and the acquisition of APL
(Note 4).
F-60
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
27.
|
Earnings
(Loss) Per Share
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
|
Basic
|
|
|
Diluted
|
|
|
Basic
|
|
|
Diluted
|
|
|
Basic
|
|
|
Diluted
|
|
|
|
|
|
|
(In $ millions, except for share and per share data)
|
|
|
|
|
|
Earnings (loss) from continuing operations
|
|
|
372
|
|
|
|
372
|
|
|
|
336
|
|
|
|
336
|
|
|
|
319
|
|
|
|
319
|
|
Earnings (loss) from discontinued operations
|
|
|
(90
|
)
|
|
|
(90
|
)
|
|
|
90
|
|
|
|
90
|
|
|
|
87
|
|
|
|
87
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net earnings (loss)
|
|
|
282
|
|
|
|
282
|
|
|
|
426
|
|
|
|
426
|
|
|
|
406
|
|
|
|
406
|
|
Less: cumulative preferred stock dividend
|
|
|
(10
|
)
|
|
|
|
|
|
|
(10
|
)
|
|
|
|
|
|
|
(10
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net earnings (loss) available to common shareholders
|
|
|
272
|
|
|
|
282
|
|
|
|
416
|
|
|
|
426
|
|
|
|
396
|
|
|
|
406
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares basic
|
|
|
148,350,273
|
|
|
|
148,350,273
|
|
|
|
154,475,020
|
|
|
|
154,475,020
|
|
|
|
158,597,424
|
|
|
|
158,597,424
|
|
Dilutive stock options
|
|
|
|
|
|
|
2,559,268
|
|
|
|
|
|
|
|
4,344,644
|
|
|
|
|
|
|
|
1,205,413
|
|
Dilutive restricted stock
|
|
|
|
|
|
|
504,439
|
|
|
|
|
|
|
|
362,130
|
|
|
|
|
|
|
|
|
|
Assumed conversion of preferred stock
|
|
|
|
|
|
|
12,057,893
|
|
|
|
|
|
|
|
12,046,203
|
|
|
|
|
|
|
|
12,004,762
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares diluted
|
|
|
148,350,273
|
|
|
|
163,471,873
|
|
|
|
154,475,020
|
|
|
|
171,227,997
|
|
|
|
158,597,424
|
|
|
|
171,807,599
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings (loss) from continuing operations
|
|
|
2.44
|
|
|
|
2.28
|
|
|
|
2.11
|
|
|
|
1.96
|
|
|
|
1.95
|
|
|
|
1.86
|
|
Earnings (loss) from discontinued operations
|
|
|
(0.61
|
)
|
|
|
(0.55
|
)
|
|
|
0.58
|
|
|
|
0.53
|
|
|
|
0.55
|
|
|
|
0.50
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net earnings (loss)
|
|
|
1.83
|
|
|
|
1.73
|
|
|
|
2.69
|
|
|
|
2.49
|
|
|
|
2.50
|
|
|
|
2.36
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The following securities were not included in the computation of
diluted net earnings per share as their effect would have been
antidilutive:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
Stock options
|
|
|
2,298,159
|
|
|
|
336,133
|
|
|
|
1,915,289
|
|
Restricted stock units
|
|
|
90,625
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
2,388,784
|
|
|
|
336,133
|
|
|
|
1,915,289
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
28.
|
Ticona
Kelsterbach Plant Relocation
|
On November 29, 2006, the Company reached a settlement with
the Frankfurt, Germany, Airport (Fraport) to
relocate its Kelsterbach, Germany, business, resolving several
years of legal disputes related to the planned Frankfurt airport
expansion. The final settlement agreement was approved by the
Fraport supervisory board on May 8, 2007 at an
extraordinary board meeting. The final settlement agreement was
signed on June 12, 2007. In July 2007, the Company
announced that it would relocate the Kelsterbach, Germany,
business to the Hoechst Industrial Park in the Rhine Main area
by mid-2011. Over a five-year period, Fraport will pay Ticona a
total of 670 million to
F-61
CELANESE
CORPORATION AND SUBSIDIARIES
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
offset the costs associated with the transition of the business
from its current location and the closure of the Kelsterbach
plant. The payment amount was increased by 20 million
to 670 million in consideration of the Companys
agreement to waive certain obligations of Fraport set forth in
the settlement agreement. In June 2008, the Company received
200 million ($311 million) from Fraport under
this agreement. Amounts received from Fraport are accounted for
as deferred proceeds and are included in noncurrent Other
liabilities in the consolidated balance sheets. See Note 30
for a description of proceeds received in advance of the
original terms of the agreement.
Below is a summary of the financial statement impact associated
with the Ticona Kelsterbach plant relocation:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended
|
|
|
Total From
|
|
|
|
December 31,
|
|
|
Inception Through
|
|
|
|
2008
|
|
|
2007
|
|
|
December 31, 2008
|
|
|
|
(In $ millions)
|
|
|
Proceeds received from Fraport
|
|
|
311
|
|
|
|
|
|
|
|
337
|
|
Costs expensed
|
|
|
12
|
|
|
|
5
|
|
|
|
17
|
|
Costs
capitalized(1)
|
|
|
202
|
|
|
|
40
|
|
|
|
243
|
|
|
|
|
(1) |
|
Includes increase in accrued capital expenditures of
$17 million and $19 million for the years ended
December 31, 2008 and 2007, respectively. |
In May 2007, the Company announced that it had an unplanned
outage at its Clear Lake, Texas acetic acid facility. At that
time, the Company originally expected the outage to last until
the end of May. Upon restart of the facility, additional
operating issues were identified which necessitated an extension
of the outage for further, more extensive repairs. In July 2007,
the Company announced that the further repairs were unsuccessful
on restart of the unit. All repairs were completed in early
August 2007 and normal production capacity resumed. During the
years ended December 31, 2008 and 2007, the Company
recorded $38 million and $40 million, respectively, of
insurance recoveries from its reinsurers in partial satisfaction
of claims that the Company made based on losses resulting from
the outage. These insurances recoveries are included in Other
(charges) gains, net in the consolidated statements of
operations (Note 18).
In October 2008, the Company declared force majeure on its
specialty polymers products produced at its AT Plastics facility
in Edmonton, Alberta, Canada as a result of certain events and
subsequent cessation of production. The Company intends to
replace damaged long-lived assets. Any contingent liabilities
associated with the outage may be mitigated by the
Companys insurance policies.
On January 5, 2009, the Company declared a cash dividend of
$0.265625 per share on its 4.25% convertible perpetual preferred
stock amounting to $3 million and a cash dividend of $0.04
per share on its Series A common stock amounting to
$6 million. Both cash dividends are for the period
November 1, 2008 to January 31, 2009 and were paid on
February 1, 2009 to holders of record as of
January 15, 2009.
On February 2, 2009, the Company announced the Fraport
supervisory board approved the acceleration of the 2009 and 2010
payments of 200 million and 140 million,
respectively, required by the settlement agreement signed in
June 2007. On February 5, 2009, the Company received a
discounted amount of approximately 322 million, excluding
value-added tax of 59 million.
On February 12, 2009, the Company announced it will shut
down its VAM production unit in Cangrejera, Mexico and cease VAM
production at Cangrejera effective the end of February 2009. The
Company believes this capacity reduction is necessitated by the
significant change in the global economic environment, the cost
structure of its VAM unit operations in Cangrejera and
anticipated lower demand. The Company recorded an impairment
loss as it relates to the Cangrejera VAM production unit of
$4 million for the three months ended December 31,
2008.
F-62
INDEX TO
EXHIBITS
Exhibits will be furnished upon request for a nominal fee,
limited to reasonable expenses.
|
|
|
Exhibit
|
|
|
Number
|
|
Description
|
|
3.1
|
|
Second Amended and Restated Certificate of Incorporation
(Incorporated by reference to Exhibit 3.1 to the Current
Report on
Form 8-K
filed on January 28, 2005).
|
3.2
|
|
Third Amended and Restated By-laws, effective as of
October 23, 2008 (Incorporated by reference to
Exhibit 3.1 to the Current Report on
Form 8-K
filed on October 29, 2008).
|
3.3
|
|
Certificate of Designations of 4.25% Convertible Perpetual
Preferred Stock (Incorporated by reference to Exhibit 3.2
to the Current Report on
Form 8-K
filed on January 28, 2005).
|
4.1
|
|
Form of certificate of Series A Common Stock (Incorporated
by reference to Exhibit 4.1 to the Registration Statement
on
Form S-1
(File
No. 333-120187),
filed on January 13, 2005).
|
4.2
|
|
Form of certificate of 4.25% Convertible Perpetual
Preferred Stock (Incorporated by reference to Exhibit 4.2
to the Registration Statement on
Form S-1
(File
No. 333-120187)
filed on January 13, 2005).
|
10.1
|
|
Credit Agreement, dated April 2, 2007, among Celanese
Holdings LLC, Celanese US Holdings LLC, the subsidiaries of
Celanese US Holdings LLC from time to time party thereto as
borrowers, the Lenders party thereto, Deutsche Bank AG, New York
Branch, as administrative agent and as collateral agent, Merrill
Lynch Capital Corporation as syndication agent, ABN AMRO Bank
N.V., Bank of America, N.A., Citibank NA, and JP Morgan Chase
Bank NA, as co-documentation agents (incorporated by reference
to Exhibit 10.1 to the Current Report on
Form 8-K
filed with the SEC on April 5, 2007).
|
10.2
|
|
Guarantee and Collateral Agreement, dated April 2, 2007, by
and among Celanese Holdings LLC, Celanese US Holdings LLC,
certain subsidiaries of Celanese US Holdings LLC and Deutsche
Bank AG, New York Branch (incorporated by reference to
Exhibit 10.2 to the Current Report on
Form 8-K
filed with the SEC on April 5, 2007).
|
10.3
|
|
Celanese Corporation 2004 Stock Incentive Plan (Incorporated by
reference to Exhibit 10.7 to the Current Report on
Form 8-K
filed on January 28, 2005).
|
10.4
|
|
Celanese Corporation Deferred Compensation Plan (Incorporated by
reference to Exhibit 10.21 to the Registration Statement on
Form S-1
(File
No. 333-120187)
filed on January 3, 2005).
|
10.5
|
|
Amendment to Celanese Corporation Deferred Compensation Plan
(incorporated by reference to Exhibit 10.2 to the Current
Report on
Form 8-K
filed with the SEC on April 3, 2007).
|
10.6
|
|
Deferred Compensation Plan-Master Plan Document adopted
December 7, 2007 (Incorporated by reference to
Exhibit 10.6 to the Annual Report on
Form 10-K
filed on February 29, 2008).
|
10.7
|
|
Form of Nonqualified Stock Option Agreement (for employees)
(Incorporated by reference to Exhibit 10.5 to the Current
Report on
Form 8-K
filed on January 28, 2005).
|
10.8
|
|
Form of Amendment Two to Nonqualified Stock Option Agreement
(for executive officers), dated January 20, 2009,
(Incorporated by reference to Exhibit 10.1 to the Current
Report on
Form 8-K
filed on January 26, 2009).
|
10.9
|
|
Form of Nonqualified Stock Option Agreement (for non-employee
directors) (Incorporated by reference to Exhibit 10.6 to
the Current Report on
Form 8-K
filed on January 28, 2005).
|
10.10
|
|
Form of Director Performance-Based Restricted Stock Unit
Agreement between Celanese Corporation and award recipient
(Incorporated by reference to Exhibit 10.1 to the Quarterly
Report on
Form 10-Q
filed on July 27, 2007).
|
10.11
|
|
Form of 2007 Deferral Agreement between Celanese Corporation and
award recipient, dated as of April 2, 2007 (incorporated by
reference to Exhibit 10.1 to the Current Report on
Form 8-K
filed with the SEC on April 3, 2007).
|
10.12
|
|
Form of Performance-Based Restricted Stock Unit Agreement
between Celanese Corporation and award recipient, dated as of
April 2, 2007 (incorporated by reference to
Exhibit 10.3 to the Current Report on
Form 8-K
filed with the SEC on April 3, 2007).
|
10.13
|
|
Form of Performance-Vesting Restricted Stock Unit Award
Agreement, together with a schedule identifying substantially
identical agreements between the Company and each of its
executive officers identified thereon (Incorporated by reference
to Exhibit 10.1 to the Current Report on
Form 8-K
filed on January 26, 2009).
|
|
|
|
Exhibit
|
|
|
Number
|
|
Description
|
|
10.14
|
|
Form of Time-Vesting Cash Award Agreement, together with a
schedule identifying substantially identical agreements between
the Company and each of its executive officers identified
thereon (Incorporated by reference to Exhibit 10.3 to the
Current Report on
Form 8-K
filed on January 26, 2009).
|
10.15
|
|
Summary of pension benefits for David N. Weidman (Incorporated
by reference to Exhibit 10.34 to the Annual Report of
Form 10-K
filed on March 31, 2005).
|
10.16
|
|
Separation Agreement, dated as of July 5, 2007, between
Celanese Corporation and Lyndon B. Cole (Incorporated by
reference to Exhibit 10.2 to the Quarterly Report on
Form 10-Q
filed on July 27, 2007).
|
10.17
|
|
Offer letter agreement, effective April 18, 2005 between
Curtis S. Shaw and Celanese Corporation (Incorporated by
reference to Exhibit 10.23 to the Quarterly Report on
Form 10-Q
filed on May 16, 2005.
|
10.18
|
|
Offer Letter Agreement, dated June 27, 2007, between
Celanese Corporation and Sandra Beach Lin (Incorporated by
reference to Exhibit 10.3 to the Quarterly Report on
Form 10-Q
filed on July 27, 2007).
|
10.19
|
|
Offer Letter Agreement, dated May 21, 2008, between the
Company and Michael L. Summers (Incorporated by reference to
Exhibit 10.2 to the Quarterly Report on
Form 10-Q
filed on July 23, 2008).
|
10.20
|
|
Amended and Restated Employment Agreement, dated as of
July 26, 2007 between Celanese Corporation and John J.
Gallagher III (Incorporated by reference to
Exhibit 10.1 to the Quarterly Report on
Form 10-Q
filed on October 24, 2007).
|
10.21
|
|
Nonqualified Stock Option Agreement, dated as of
January 25, 2005, between Celanese Corporation and
Blackstone Management Partners IV L.L.C. (Incorporated by
reference from Exhibit 10.23 to the Annual Report on
Form 10-K
filed on March 31, 2005).
|
10.22
|
|
Share Purchase and Transfer Agreement and Settlement Agreement,
dated August 19, 2005 between Celanese Europe Holding
GmbH & Co. KG, as purchaser, and Paulson &
Co. Inc., and Arnhold and S. Bleichroeder Advisers, LLC, each on
behalf of its own and with respect to shares owned by the
investment funds and separate accounts managed by it, as the
sellers (Incorporated by reference to Exhibit 10.1 to the
Current Report on
Form 8-K
filed on August 19, 2005).
|
10.23
|
|
Translation of Letter of Intent, dated November 29, 2006,
among Celanese AG, Ticona GmbH and Fraport AG (Incorporated by
reference to Exhibit 99.2 to the Current Report on
Form 8-K
filed November 29, 2006).
|
10.24
|
|
Purchase Agreement dated as of December 12, 2006 by and
among Celanese Ltd. and certain of its affiliates named therein
and Advent Oxo (Cayman) Limited, Oxo Titan US Corporation,
Drachenfelssee 520. V V GMBH and Drachenfelssee 521. V V GMBH
(Incorporated by reference to Exhibit 10.27 to the Annual
Report of
Form 10-K
filed on February 21, 2007).
|
10.25
|
|
First Amendment to Purchase Agreement dated February 28,
2007, by and among Advent Oxea Cayman Ltd., Oxea Corporation,
Drachenfelssee 520. V V GmbH, Drachenfelssee 521. V V GmbH,
Celanese Ltd., Ticona Polymers Inc. and Celanese Chemicals
Europe GmbH (Incorporated by reference to Exhibit 10.6 to
the Quarterly Report on
Form 10-Q
filed on May 9, 2007).
|
10.26
|
|
Second Amendment to Purchase Agreement effective as of
July 1, 2007 by and among Advent Oxea Cayman Ltd., Oxea
Corporation, Oxea Holdings GmbH, Oxea Deutschland GmbH, Oxea
Bishop, LLC, Oxea Japan KK, Oxea UK Ltd., Celanese Ltd., and
Celanese Chemicals Europe GmbH (Incorporated by reference to
Exhibit 10.2 to the Quarterly Report on
Form 10-Q
filed on October 24, 2007).
|
10.27
|
|
Compensation Letter Agreement, dated March 27, 2007 by and
between Jim Alder and Celanese Corporation (Incorporated by
reference to Exhibit 10.31 to the Annual Report on
Form 10-K
filed on February 29, 2008
|
10.28
|
|
Change in Control Agreement, dated April 1, 2008, between
the Company and David N. Weidman, together with a schedule
identifying other substantially identical agreements between the
Company and each of its name executive officers identified
thereon and identifying the material differences between each of
those agreements and the filed Changed of Control Agreement
(Incorporated by reference to Exhibit 10.1 to the Current
Report on
Form 8-K
filed on April 7, 2008).
|
10.29
|
|
Change in Control Agreement, dated April 1, 2008 between
the Company and Sandra Beach Lin, together with a schedule
identifying other substantially identical agreements between the
Company and each of its executive officers identified thereon
and identifying the material differences between each of those
agreements and the filed Change of Control Agreement
(Incorporated by reference to Exhibit 10.2 to the Quarterly
Report on
Form 10-Q
filed on April 23, 2008).
|
|
|
|
Exhibit
|
|
|
Number
|
|
Description
|
|
10.30
|
|
Change in Control Agreement, dated April 1, 2008, between
the Company and Curtis S. Shaw (Incorporated by reference to
Exhibit 10.3 to the Quarterly Report on
Form 10-Q
filed on April 23, 2008).
|
10.31
|
|
Change in Control Agreement, dated May 1, 2008, between the
Company and Christopher W. Jensen (Incorporated by reference to
Exhibit 10.1 to the Quarterly Report on
Form 10-Q
filed on July 23, 2008).
|
10.32
|
|
Change in Control Agreement, dated June 5, 2008, between
the Company and Michael L. Summers (Incorporated by reference to
Exhibit 10.1 to the Quarterly Report on
Form 10-Q
filed on October 22, 2008).
|
10.33
|
|
Agreement and General Release, dated September 25, 2008,
between the Company and Curtis S. Shaw (Incorporated by
reference to Exhibit 10.2 to the Quarterly Report on
Form 10-Q
filed on October 22, 2008).
|
10.34
|
|
Agreement and General Release, dated March 28, 2008,
between the Company and William P. Antonace (Incorporated by
reference to Exhibit 10.4 to the Quarterly Report on
Form 10-Q
filed on October 22, 2008).
|
10.35
|
|
Form of Long-Term Incentive Claw-Back Agreement (Incorporated by
reference to Exhibit 10.1 to the Current Report on
Form 8-K
filed on January 26, 2009).
|
21.1*
|
|
List of subsidiaries of Celanese Corporation
|
23.1*
|
|
Report on Financial Statement Schedule and Consent of
Independent Registered Public Accounting Firm, KPMG LLP
|
31.1*
|
|
Certification of Chief Executive Officer pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002
|
31.2*
|
|
Certification of Chief Financial Officer pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002
|
32.1*
|
|
Certification of Chief Executive Officer pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002
|
32.2*
|
|
Certification of Chief Financial Officer pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002
|
99.1*
|
|
Financial Statement schedule regarding Valuation and Qualifying
Accounts
|
|
|
|
* |
|
Filed herewith |
|
|
|
Portions of this exhibit have been omitted pursuant to a request
for confidential treatment filed with the Securities and
Exchange Commission under
Rule 24b-2
of the Securities Exchange Act of 1934, as amended. The omitted
portions of this exhibit have been separately filed with the
Securities and Exchange Commission. |